Biotech RadarJobs updated

Funding and NIH signals

In the last 12 months: 381 companies with 453 SEC Form D filings, and 569 companies with 796 NIH awards (909 companies in all). Another 61 Form D filings are shown as backing on raises the companies announced. Every row links to its SEC EDGAR filing or NIH RePORTER record and gives its date.

How we count and match filings

A Form D is the notice a company files with the SEC after selling securities in a private offering; the amount is the “Total Amount Sold” the company reported. When the company also announced a raise in a press release, Radar shows that round once (the press release, with “Form D filed <date>” as backing) instead of a second row here if the Form D was filed: within 14 days of the announcement and the announcement gives no amount or the security type matches (equity or debt); 15 to 45 days apart, the security type matches and the Form D amount sold or offered is within 10% of the announced amount or between 50% and 110% of it; or 46 to 90 days apart, the security type matches and the Form D amount is within 10%. When the announcement gives an “up to” amount, the Form D is compared with that amount too. Otherwise the Form D is listed here as its own row. A Form D whose first sale was more than a year before it was filed reports a cumulative amount sold over several years: such rows say “Form D reports $X sold since <year>”, not “Raised”, unless the filing itemises its rounds, in which case the latest round is shown. When a Form D total includes money the company would receive only if warrants are exercised later, the row says “Form D reports $X, incl. warrant exercise value”, not “Raised”; when the whole amount is that value, it says “Form D reports $X in warrant exercise value”. “Amended <date>” means the amount is from that amendment. Form Ds that report stock-option or RSU grants, or only stock options with nothing sold (equity compensation), are not counted, nor are Form Ds with nothing sold that only report shares issued for a licence, acquisition or services (non-cash share issuance). NIH awards are government grants, never counted as money raised; each says whether it is a new award or a continuation. “Since then posted” counts only jobs Radar can show were first posted after the filing or award date; otherwise the row says how many roles are open. A raise or grant next to open jobs does not mean one caused the other.

Data checked Oct 18, 2026. Trial and FDA signals · All dated changes.

SEC Form D raise: 381 companies

CompanySignalEvent dateSource
Cadrenal TherapeuticsForm D reports $8.84M in warrant exercise value (filed Jul 15, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • Jul 15, 2026 · SEC Form D 0001213900-26-078373
    Name of Issuer: Cadrenal Therapeutics, Inc.; CIK: 1937993; Address: Ponte Vedra, FL; Submission type: D; Filing date: 2026-07-15; Industry Group: Biotechnology; Date of First Sale: 2026-06-30; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 8843849; Total Amount Sold: 8843849; Federal exemptions: 06b
  • Apr 6, 2026 · SEC Form D 0001213900-26-040457
    Name of Issuer: Cadrenal Therapeutics, Inc.; CIK: 1937993; Address: Ponte Vedra, FL; Submission type: D; Filing date: 2026-04-06; Industry Group: Biotechnology; Date of First Sale: 2026-04-01; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 7923235; Total Amount Sold: 7923235; Federal exemptions: 06b
  • Dec 31, 2025 · SEC Form D 0001213900-25-127129
    Name of Issuer: Cadrenal Therapeutics, Inc.; CIK: 1937993; Address: Ponte Vedra, FL; Submission type: D; Filing date: 2025-12-31; Industry Group: Biotechnology; Date of First Sale: 2025-12-16; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4396329; Total Amount Sold: 4396329; Federal exemptions: 06b
Jul 15, 2026SEC Form D 0001213900-26-078373
GenialisRaised $700K in debt securities (Form D filed Dec 31, 2025).
Evidence (1 event)
  • Dec 31, 2025 · SEC Form D 0001948756-25-000002
    Name of Issuer: Genialis, Inc.; CIK: 1948756; Address: Boston, MA; Submission type: D; Filing date: 2025-12-31; Industry Group: Biotechnology; Date of First Sale: 2025-12-17; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 700000; Federal exemptions: 06b
Dec 31, 2025SEC Form D 0001948756-25-000002
Alume Biosciences, Inc.Raised $2.16M (Form D filed Apr 6, 2026; amended May 8, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Apr 6, 2026 · SEC Form D 0001782348-26-000005
    Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D; Filing date: 2026-04-06; Industry Group: Biotechnology; Date of First Sale: 2026-03-24; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 110000; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2026-05-08; Industry Group: Biotechnology; Date of First Sale: 2026-03-24; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 2160000; Federal exemptions: 06b
  • Oct 31, 2025 · SEC Form D 0001782348-25-000003
    Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D; Filing date: 2025-10-31; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 3055500; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2025-11-12; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 3611116; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2025-12-31; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 5316105; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2026-01-30; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 5967305; Federal exemptions: 06b || Name of Issuer: Alume Biosciences Inc; CIK: 1782348; Address: LA Jolla, CA; Submission type: D/A; Filing date: 2026-02-19; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23499998; Total Amount Sold: 6853305; Federal exemptions: 06b
Apr 6, 2026SEC Form D 0001782348-26-000005
Healionics CorporationRaised $1.96M (Form D filed Dec 31, 2025).
Evidence (1 event)
  • Dec 31, 2025 · SEC Form D 0001413969-25-000002
    Name of Issuer: Healionics CORP; CIK: 1413969; Address: Seattle, WA; Submission type: D; Filing date: 2025-12-31; Industry Group: Other; Date of First Sale: 2025-12-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 1964221; Federal exemptions: 06b
Dec 31, 2025SEC Form D 0001413969-25-000002
DMC Biotechnologies, Inc.Raised $1.41M (Form D filed Dec 30, 2025); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Dec 30, 2025 · SEC Form D 0001231919-25-000673
    Name of Issuer: DMC Biotechnologies, Inc.; CIK: 1728411; Address: Boulder, CO; Submission type: D; Filing date: 2025-12-30; Industry Group: Biotechnology; Date of First Sale: 2025-12-16; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired, Other (Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1414267; Federal exemptions: 06b
  • Dec 30, 2025 · SEC Form D 0001231919-25-000671
    Name of Issuer: DMC Biotechnologies, Inc.; CIK: 1728411; Address: Boulder, CO; Submission type: D; Filing date: 2025-12-30; Industry Group: Biotechnology; Date of First Sale: 2025-10-31; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired, Other (Promissory notes convertible into equity securities of the Issuer and the equity securities to be issued upon such conversion); Business combination transaction: false; Total Offering Amount: 1658250; Total Amount Sold: 904500; Federal exemptions: 06b
Dec 30, 2025SEC Form D 0001231919-25-000673
Nacuity PharmaceuticalsRaised $8.39M (Form D filed Dec 30, 2025).
Evidence (1 event)
  • Dec 30, 2025 · SEC Form D 0001690279-25-000002
    Name of Issuer: Nacuity Pharmaceuticals, Inc.; CIK: 1690279; Address: Fort Worth, TX; Submission type: D; Filing date: 2025-12-30; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-11; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired, Other (Convertible Promissory Notes convertible into preferred stock or common stock, Common Stock Purchase Warrants, Common Stock issued for Warrant Conversion); Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 8393350; Federal exemptions: 06b
Dec 30, 2025SEC Form D 0001690279-25-000002
Phenomix SciencesRaised $2.5M (Form D filed Dec 29, 2025).
Evidence (1 event)
  • Dec 29, 2025 · SEC Form D 0001966746-25-000002
    Name of Issuer: Phenomix Sciences, Inc.; CIK: 1966746; Address: Menlo Park, CA; Submission type: D; Filing date: 2025-12-29; Industry Group: Other Health Care; Date of First Sale: 2025-12-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000004; Total Amount Sold: 2500002; Federal exemptions: 06b
Dec 29, 2025SEC Form D 0001966746-25-000002
GlycologixRaised $800K (Form D filed Dec 29, 2025).
Evidence (1 event)
  • Dec 29, 2025 · SEC Form D 0001903671-25-000002
    Name of Issuer: Glycologix, Inc.; CIK: 1903671; Address: Beverly, MA; Submission type: D; Filing date: 2025-12-29; Industry Group: Other Technology; Date of First Sale: 2025-12-12; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 800000; Federal exemptions: 06b
Dec 29, 2025SEC Form D 0001903671-25-000002
Slam BioTherapeuticsRaised $1M in debt securities (Form D filed Dec 29, 2025).
Evidence (1 event)
  • Dec 29, 2025 · SEC Form D 0001983523-25-000004
    Name of Issuer: SLAM BioTherapeutics, Inc.; CIK: 1983523; Address: Westlake Village, CA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-12-19; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1000000; Federal exemptions: 06b
Dec 29, 2025SEC Form D 0001983523-25-000004
Aprea TherapeuticsRaised $3.06M (Form D filed Dec 29, 2025).
Evidence (1 event)
  • Dec 29, 2025 · SEC Form D 0001781983-25-000003
    Name of Issuer: Aprea Therapeutics, Inc.; CIK: 1781983; Address: Doylestown, PA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-12-10; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5783766; Total Amount Sold: 3055822; Federal exemptions: 06b
Dec 29, 2025SEC Form D 0001781983-25-000003
GEn1E LifesciencesRaised $5.52M (Form D filed Dec 29, 2025).
Evidence (1 event)
  • Dec 29, 2025 · SEC Form D 0001752886-25-000002
    Name of Issuer: GEN1E LIFESCIENCES INC.; CIK: 1752886; Address: Palo Alto, CA; Submission type: D; Filing date: 2025-12-29; Industry Group: Biotechnology; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11887377; Total Amount Sold: 5520803; Federal exemptions: 06b
Dec 29, 2025SEC Form D 0001752886-25-000002
Enveric BiosciencesRaised $5M (Form D filed May 4, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • May 4, 2026 · SEC Form D 0000890821-26-000002
    Name of Issuer: Enveric Biosciences, Inc.; CIK: 890821; Address: Cambridge, MA; Submission type: D; Filing date: 2026-05-04; Industry Group: Biotechnology; Date of First Sale: 2026-04-17; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 5000002; Total Amount Sold: 5000002; Federal exemptions: 06b
  • Feb 11, 2026 · SEC Form D 0000890821-26-000001
    Name of Issuer: Enveric Biosciences, Inc.; CIK: 890821; Address: Cambridge, MA; Submission type: D; Filing date: 2026-02-11; Industry Group: Biotechnology; Date of First Sale: 2026-01-28; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 1450017; Total Amount Sold: 1450017; Federal exemptions: 06b
  • Dec 23, 2025 · SEC Form D 0000890821-25-000006
    Name of Issuer: Enveric Biosciences, Inc.; CIK: 890821; Address: Cambridge, MA; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-12; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 106598; Total Amount Sold: 106598; Federal exemptions: 06b
May 4, 2026SEC Form D 0000890821-26-000002
Nature's ToolboxRaised $10.37M (Form D filed Dec 23, 2025; amended Feb 4, 2026).
Evidence (1 event)
  • Dec 23, 2025 · SEC Form D 0001798793-25-000004
    Name of Issuer: Nature's Toolbox, Inc.; CIK: 1798793; Address: Rio Rancho, NM; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-11-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15001975; Total Amount Sold: 9965162; Federal exemptions: 06b || Name of Issuer: Nature's Toolbox, Inc.; CIK: 1798793; Address: Rio Rancho, NM; Submission type: D/A; Filing date: 2026-02-04; Industry Group: Biotechnology; Date of First Sale: 2025-11-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15001975; Total Amount Sold: 10365162; Federal exemptions: 06b
Dec 23, 2025SEC Form D 0001798793-25-000004
Aethlon Medical, Inc.Raised $2.15M (Form D filed Dec 23, 2025).
Evidence (1 event)
  • Dec 23, 2025 · SEC Form D 0000882291-25-000004
    Name of Issuer: AETHLON MEDICAL INC; CIK: 882291; Address: San Diego, CA; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-08; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2153700; Total Amount Sold: 2153700; Federal exemptions: 06b
Dec 23, 2025SEC Form D 0000882291-25-000004
Koios MedicalFiled a Form D, amount not stated (filed Dec 23, 2025); 1 role open.
Evidence (1 event)
  • Dec 23, 2025 · SEC Form D 0001764417-25-000003
    Name of Issuer: Koios Medical, Inc.; CIK: 1764417; Address: New York, NY; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 0; Federal exemptions: 06c
Dec 23, 2025SEC Form D 0001764417-25-000003
Cytogel PharmaFiled a Form D for an offering of up to $16M, no sales reported yet (filed Dec 23, 2025; amended Mar 26, 2026).
Evidence (1 event)
  • Dec 23, 2025 · SEC Form D 0001213900-25-124742
    Name of Issuer: Cytogel Pharma, LLC; CIK: 1491841; Address: Darien, CT; Submission type: D; Filing date: 2025-12-23; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 16000000; Total Amount Sold: 0; Federal exemptions: 06b || Name of Issuer: Cytogel Pharma, LLC; CIK: 1491841; Address: Darien, CT; Submission type: D/A; Filing date: 2025-12-23; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-14; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 250000; Federal exemptions: 06b || Name of Issuer: Cytogel Pharma, LLC; CIK: 1491841; Address: Darien, CT; Submission type: D/A; Filing date: 2026-03-26; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 16000000; Total Amount Sold: 0; Federal exemptions: 06b
Dec 23, 2025SEC Form D 0001213900-25-124742
Mediar TherapeuticsRaised $37.85M (Form D filed Dec 23, 2025).
Evidence (1 event)
  • Dec 23, 2025 · SEC Form D 0001766784-25-000002
    Name of Issuer: Mediar Therapeutics, Inc.; CIK: 1766784; Address: Boston, MA; Submission type: D; Filing date: 2025-12-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 75699630; Total Amount Sold: 37849815; Federal exemptions: 06b
Dec 23, 2025SEC Form D 0001766784-25-000002
OrthoPreserveRaised $157K in debt securities (Form D filed Dec 23, 2025).
Evidence (1 event)
  • Dec 23, 2025 · SEC Form D 0002034639-25-000003
    Name of Issuer: OrthoPreserve, Inc.; CIK: 2034639; Address: Henrico, VA; Submission type: D; Filing date: 2025-12-23; Industry Group: Other Health Care; Date of First Sale: 2025-12-04; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 157000; Federal exemptions: 06b
Dec 23, 2025SEC Form D 0002034639-25-000003
Aeovian PharmaceuticalsRaised $55M (Form D filed Dec 22, 2025).
Evidence (1 event)
  • Dec 22, 2025 · SEC Form D 0000905148-25-004456
    Name of Issuer: Aeovian Pharmaceuticals, Inc.; CIK: 1710088; Address: Berkeley, CA; Submission type: D; Filing date: 2025-12-22; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 54999996; Total Amount Sold: 54999996; Federal exemptions: 06b
Dec 22, 2025SEC Form D 0000905148-25-004456
Amphix Bio, Inc.Raised $10.3M (Form D filed Dec 19, 2025).
Evidence (1 event)
  • Dec 19, 2025 · SEC Form D 0002101704-25-000001
    Name of Issuer: Amphix Bio, Inc.; CIK: 2101704; Address: Chicago, IL; Submission type: D; Filing date: 2025-12-19; Industry Group: Biotechnology; Date of First Sale: 2025-12-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 12500000; Total Amount Sold: 10300000; Federal exemptions: 06b
Dec 19, 2025SEC Form D 0002101704-25-000001
OXOS MedicalRaised $10.71M (Form D filed Dec 19, 2025).
Evidence (1 event)
  • Dec 19, 2025 · SEC Form D 0001694304-25-000002
    Name of Issuer: OXOS MEDICAL, INC.; CIK: 1694304; Address: Atlanta, GA; Submission type: D; Filing date: 2025-12-19; Industry Group: Other Technology; Date of First Sale: 2025-12-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 28207000; Total Amount Sold: 10706990; Federal exemptions: 06b
Dec 19, 2025SEC Form D 0001694304-25-000002
Lexaria Bioscience Corp.Raised $113K (Form D filed Sep 21, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Sep 21, 2026 · SEC Form D 0001348362-26-000002
    Name of Issuer: Lexaria Bioscience Corp.; CIK: 1348362; Address: British Columbia, Canada; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-09-09; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 113492; Total Amount Sold: 113492; Federal exemptions: 06b
  • Dec 19, 2025 · SEC Form D 0001348362-25-000018
    Name of Issuer: Lexaria Bioscience Corp.; CIK: 1348362; Address: British Columbia, Canada; Submission type: D; Filing date: 2025-12-19; Industry Group: Biotechnology; Date of First Sale: 2025-12-16; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 3500004; Total Amount Sold: 3500004; Federal exemptions: 06b
Sep 21, 2026SEC Form D 0001348362-26-000002
InSitu BiologicsRaised $1.25M in debt securities (Form D filed Aug 10, 2026; amended Oct 14, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Aug 10, 2026 · SEC Form D 0001723443-26-000005
    Name of Issuer: InSitu Biologics, Inc.; CIK: 1723443; Address: Oakdale, MN; Submission type: D; Filing date: 2026-08-10; Industry Group: Biotechnology; Date of First Sale: 2026-08-04; Types of Securities Offered: Debt, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1250000; Federal exemptions: 06b || Name of Issuer: InSitu Biologics, Inc.; CIK: 1723443; Address: Oakdale, MN; Submission type: D/A; Filing date: 2026-10-14; Industry Group: Biotechnology; Date of First Sale: 2026-08-04; Types of Securities Offered: Debt, Option/warrant, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 3375000; Total Amount Sold: 1250000; Federal exemptions: 06b
  • Dec 18, 2025 · SEC Form D 0001723443-25-000003
    Name of Issuer: InSitu Biologics, Inc; CIK: 1723443; Address: Oakdale, MN; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-11-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 3950000; Federal exemptions: 06b
Aug 10, 2026SEC Form D 0001723443-26-000005
Paulex BioRaised $18.52M (Form D filed Dec 18, 2025).
Evidence (1 event)
  • Dec 18, 2025 · SEC Form D 0001493152-25-028344
    Name of Issuer: Paulex Bio Inc.; CIK: 2071082; Address: LA Jolla, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-21; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 22500000; Total Amount Sold: 18516040; Federal exemptions: 06c
Dec 18, 2025SEC Form D 0001493152-25-028344
NeOnc TechnologiesRaised $5M (Form D filed Jun 25, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Jun 25, 2026 · SEC Form D 0001829126-26-006874
    Name of Issuer: NEONC TECHNOLOGIES HOLDINGS, INC.; CIK: 1979414; Address: Calabasas, CA; Submission type: D; Filing date: 2026-06-25; Industry Group: Biotechnology; Date of First Sale: 2026-06-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
  • Dec 18, 2025 · SEC Form D 0001979414-25-000006
    Name of Issuer: NEONC TECHNOLOGIES HOLDINGS, INC.; CIK: 1979414; Address: Calabasas, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 1000000; Federal exemptions: 06b
Jun 25, 2026SEC Form D 0001829126-26-006874
Kazia Therapeutics LimitedForm D reports $55.25M, incl. warrant exercise value (filed Dec 18, 2025).
Evidence (1 event)
  • Dec 18, 2025 · SEC Form D 0001470831-25-000435
    Name of Issuer: KAZIA THERAPEUTICS LTD; CIK: 1075880; Address: Sydney Nsw, Australia; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-12-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 55251088; Total Amount Sold: 55251088; Federal exemptions: 06b
Dec 18, 2025SEC Form D 0001470831-25-000435
DELFI DiagnosticsRaised $34.33M in debt securities (Form D filed Dec 18, 2025); since then posted 6 roles.
Evidence (1 event)
  • Dec 18, 2025 · SEC Form D 0000905148-25-004422
    Name of Issuer: Delfi Diagnostics, Inc.; CIK: 1783735; Address: Palo Alto, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 34333315; Federal exemptions: 06b
Dec 18, 2025SEC Form D 0000905148-25-004422
Ceretype NeuromedicineForm D reports $400K sold since 2024 (filed Dec 18, 2025).
Evidence (1 event)
  • Dec 18, 2025 · SEC Form D 0001884863-25-000004
    Name of Issuer: Ceretype Neuromedicine, Inc.; CIK: 1884863; Address: Cambridge, MA; Submission type: D; Filing date: 2025-12-18; Industry Group: Biotechnology; Date of First Sale: 2024-08-06; Types of Securities Offered: Security to be acquired; Business combination transaction: false; Total Offering Amount: 400000; Total Amount Sold: 400000; Federal exemptions: 06b
Dec 18, 2025SEC Form D 0001884863-25-000004
Innovaprep LLCRaised $100K in debt securities (Form D filed Dec 17, 2025).
Evidence (1 event)
  • Dec 17, 2025 · SEC Form D 0001753878-25-000002
    Name of Issuer: INNOVAPREP INC.; CIK: 1753878; Address: Drexel, MO; Submission type: D; Filing date: 2025-12-17; Industry Group: Biotechnology; Date of First Sale: 2025-12-05; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 100000; Federal exemptions: 06b
Dec 17, 2025SEC Form D 0001753878-25-000002
NovilyticRaised $531K (Form D filed Dec 15, 2025).
Evidence (1 event)
  • Dec 15, 2025 · SEC Form D 0001850261-25-000002
    Name of Issuer: Novilytic, LLC; CIK: 1850261; Address: West Lafayette, IN; Submission type: D; Filing date: 2025-12-15; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 530800; Federal exemptions: 06b
Dec 15, 2025SEC Form D 0001850261-25-000002
Telos BiotechRaised $725K (Form D filed Dec 12, 2025).
Evidence (1 event)
  • Dec 12, 2025 · SEC Form D 0001815708-25-000002
    Name of Issuer: Telos Biotech Inc.; CIK: 1815708; Address: Dallas, TX; Submission type: D; Filing date: 2025-12-12; Industry Group: Biotechnology; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2250000; Total Amount Sold: 724999; Federal exemptions: 06b
Dec 12, 2025SEC Form D 0001815708-25-000002
Consano Bio, Inc.Raised $34.82M (Form D filed Mar 20, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Mar 20, 2026 · SEC Form D 0001981285-26-000001
    Name of Issuer: Consano Bio, Inc.; CIK: 1981285; Address: Burlington, MA; Submission type: D; Filing date: 2026-03-20; Industry Group: Biotechnology; Date of First Sale: 2026-03-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 48858795; Total Amount Sold: 34824466; Federal exemptions: 06b
  • Dec 12, 2025 · SEC Form D 0001981285-25-000005
    Name of Issuer: Consano Bio, Inc.; CIK: 1981285; Address: Burlington, MA; Submission type: D; Filing date: 2025-12-12; Industry Group: Biotechnology; Date of First Sale: 2024-10-15; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 16840000; Total Amount Sold: 16840000; Federal exemptions: 06b
Mar 20, 2026SEC Form D 0001981285-26-000001
Oncotelic TherapeuticsRaised $275K (Form D filed Dec 11, 2025).
Evidence (1 event)
  • Dec 11, 2025 · SEC Form D 0001493152-25-027270
    Name of Issuer: Oncotelic Therapeutics, Inc.; CIK: 908259; Address: Agoura Hills, CA; Submission type: D; Filing date: 2025-12-11; Industry Group: Biotechnology; Date of First Sale: 2025-12-04; Types of Securities Offered: Equity, Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12500000; Total Amount Sold: 275000; Federal exemptions: 06b
Dec 11, 2025SEC Form D 0001493152-25-027270
NeuroBionicsRaised $4.25M (Form D filed Dec 10, 2025).
Evidence (1 event)
  • Dec 10, 2025 · SEC Form D 0002100415-25-000001
    Name of Issuer: NeuroBionics Inc.; CIK: 2100415; Address: Somerville, MA; Submission type: D; Filing date: 2025-12-10; Industry Group: Other Technology; Date of First Sale: 2025-11-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4249990; Total Amount Sold: 4249990; Federal exemptions: 06b
Dec 10, 2025SEC Form D 0002100415-25-000001
Minnesota Medical TechnologiesRaised $8.28M (Form D filed Dec 10, 2025).
Evidence (1 event)
  • Dec 10, 2025 · SEC Form D 0000912282-25-001382
    Name of Issuer: Minnesota Medical Technologies Corp; CIK: 1736524; Address: Stewartville, MN; Submission type: D; Filing date: 2025-12-10; Industry Group: Other Health Care; Date of First Sale: 2025-12-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 16999964; Total Amount Sold: 8279547; Federal exemptions: 06b
Dec 10, 2025SEC Form D 0000912282-25-001382
Invea TherapeuticsRaised $120K (Form D filed Dec 10, 2025).
Evidence (1 event)
  • Dec 10, 2025 · SEC Form D 0001906425-25-000004
    Name of Issuer: Invea Therapeutics, Inc; CIK: 1906425; Address: Guilford, CT; Submission type: D; Filing date: 2025-12-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-31; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 120250; Total Amount Sold: 120250; Federal exemptions: 06b
Dec 10, 2025SEC Form D 0001906425-25-000004
Relation TherapeuticsRaised $36.18M in debt securities (Form D filed Dec 9, 2025); since then posted 14 roles.
Evidence (1 event)
  • Dec 9, 2025 · SEC Form D 0001876828-25-000003
    Name of Issuer: Relation Therapeutics Inc.; CIK: 1876828; Address: Miami Beach, FL; Submission type: D; Filing date: 2025-12-09; Industry Group: Biotechnology; Date of First Sale: 2025-11-21; Types of Securities Offered: Debt, Security to be acquired, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 36175000; Total Amount Sold: 36175000; Federal exemptions: 06b
Dec 9, 2025SEC Form D 0001876828-25-000003
CresilonRaised $29M in debt securities (Form D filed Apr 29, 2026; amended Jun 26, 2026); +1 other Form D filing in the last 12 months; 7 roles open.
Evidence (2 events)
  • Apr 29, 2026 · SEC Form D 0001728054-26-000001
    Name of Issuer: Cresilon, Inc.; CIK: 1728054; Address: Brooklyn, NY; Submission type: D; Filing date: 2026-04-29; Industry Group: Biotechnology; Date of First Sale: 2026-04-24; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 25000000; Total Amount Sold: 4997000; Federal exemptions: 06b || Name of Issuer: Cresilon, Inc.; CIK: 1728054; Address: Brooklyn, NY; Submission type: D/A; Filing date: 2026-06-26; Industry Group: Biotechnology; Date of First Sale: 2026-04-24; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 29000000; Total Amount Sold: 28999199; Federal exemptions: 06c
  • Dec 8, 2025 · SEC Form D 0001728054-25-000004
    Name of Issuer: Cresilon, Inc.; CIK: 1728054; Address: Brooklyn, NY; Submission type: D; Filing date: 2025-12-08; Industry Group: Biotechnology; Date of First Sale: 2025-11-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6716808; Total Amount Sold: 6683401; Federal exemptions: 06c
Apr 29, 2026SEC Form D 0001728054-26-000001
Armonica Technologies, Inc.Raised $4.21M (Form D filed Dec 8, 2025).
Evidence (1 event)
  • Dec 8, 2025 · SEC Form D 0001714729-25-000002
    Name of Issuer: Armonica Technologies, Inc.; CIK: 1714729; Address: Albuquerque, NM; Submission type: D; Filing date: 2025-12-08; Industry Group: Biotechnology; Date of First Sale: 2025-11-20; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5714702; Total Amount Sold: 4214700; Federal exemptions: 06b
Dec 8, 2025SEC Form D 0001714729-25-000002
MedicovestorRaised $3.16M (Form D filed Dec 5, 2025).
Evidence (1 event)
  • Dec 5, 2025 · SEC Form D 0002099357-25-000001
    Name of Issuer: Medicovestor, Inc.; CIK: 2099357; Address: New York, NY; Submission type: D; Filing date: 2025-12-05; Industry Group: Biotechnology; Date of First Sale: 2025-11-05; Types of Securities Offered: Equity, Other (Simple Agreements for Future Equity); Business combination transaction: false; Total Offering Amount: 4064834; Total Amount Sold: 3164834; Federal exemptions: 06b
Dec 5, 2025SEC Form D 0002099357-25-000001
Zeo ScientifixRaised $500K (Form D filed Dec 5, 2025).
Evidence (1 event)
  • Dec 5, 2025 · SEC Form D 0001829126-25-009746
    Name of Issuer: Zeo ScientifiX, Inc.; CIK: 1557376; Address: Davie, FL; Submission type: D; Filing date: 2025-12-05; Industry Group: Biotechnology; Date of First Sale: 2025-11-30; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 500000; Federal exemptions: 06b
Dec 5, 2025SEC Form D 0001829126-25-009746
MindImmune TherapeuticsRaised $15.22M (Form D filed Dec 5, 2025; amended Mar 5, 2026).
Evidence (1 event)
  • Dec 5, 2025 · SEC Form D 0001792522-25-000002
    Name of Issuer: MindImmune Therapeutics, Inc.; CIK: 1792522; Address: Kingston, RI; Submission type: D; Filing date: 2025-12-05; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-24; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 10203858; Federal exemptions: 06b || Name of Issuer: MindImmune Therapeutics, Inc.; CIK: 1792522; Address: Kingston, RI; Submission type: D/A; Filing date: 2026-03-05; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-24; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 17014485; Total Amount Sold: 15218343; Federal exemptions: 06b
Dec 5, 2025SEC Form D 0001792522-25-000002
Aminex TherapeuticsForm D reports $15.08M sold since 2022 (filed Dec 5, 2025).
Evidence (1 event)
  • Dec 5, 2025 · SEC Form D 0001470831-25-000383
    Name of Issuer: Aminex Therapeutics, Inc.; CIK: 1613386; Address: Kenmore, WA; Submission type: D; Filing date: 2025-12-05; Industry Group: Biotechnology; Date of First Sale: 2022-10-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 30000030; Total Amount Sold: 15084670; Federal exemptions: 06b
Dec 5, 2025SEC Form D 0001470831-25-000383
A-Synaptic PharmaRaised $533K (Form D filed Dec 4, 2025).
Evidence (1 event)
  • Dec 4, 2025 · SEC Form D 0001913553-25-000004
    Name of Issuer: A-SYNAPTIC CORP.; CIK: 1913553; Address: Ontario, Canada; Submission type: D; Filing date: 2025-12-04; Industry Group: Other; Date of First Sale: 2025-11-21; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 533100; Federal exemptions: 06b
Dec 4, 2025SEC Form D 0001913553-25-000004
VahatiCorRaised $21.18M (Form D filed Dec 4, 2025).
Evidence (1 event)
  • Dec 4, 2025 · SEC Form D 0002042118-25-000002
    Name of Issuer: VahatiCor, Inc.; CIK: 2042118; Address: Santa Clara, CA; Submission type: D; Filing date: 2025-12-04; Industry Group: Other Health Care; Date of First Sale: 2025-11-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 32383479; Total Amount Sold: 21183479; Federal exemptions: 06b
Dec 4, 2025SEC Form D 0002042118-25-000002
Odyssey Therapeutics (2)Raised $214.03M (Form D filed Dec 4, 2025).
Evidence (1 event)
  • Dec 4, 2025 · SEC Form D 0001104659-25-118426
    Name of Issuer: Odyssey Therapeutics, Inc.; CIK: 1882782; Address: Boston, MA; Submission type: D; Filing date: 2025-12-04; Industry Group: Biotechnology; Date of First Sale: 2025-06-16; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 214025200; Total Amount Sold: 214025200; Federal exemptions: 06b
Dec 4, 2025SEC Form D 0001104659-25-118426
TRIANA Biomedicines, Inc.Raised $120.06M (Form D filed Dec 4, 2025).
Evidence (1 event)
  • Dec 4, 2025 · SEC Form D 0001815337-25-000003
    Name of Issuer: Triana Biomedicines, Inc.; CIK: 1815337; Address: Lexington, MA; Submission type: D; Filing date: 2025-12-04; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120061960; Total Amount Sold: 120061960; Federal exemptions: 06b
Dec 4, 2025SEC Form D 0001815337-25-000003
Adial PharmaceuticalsForm D reports $4.29M in warrant exercise value (filed Dec 3, 2025).
Evidence (1 event)
  • Dec 3, 2025 · SEC Form D 0001213900-25-117804
    Name of Issuer: ADIAL PHARMACEUTICALS, INC.; CIK: 1513525; Address: Glen Allen, VA; Submission type: D; Filing date: 2025-12-03; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-28; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4285289; Total Amount Sold: 4285289; Federal exemptions: 06b
Dec 3, 2025SEC Form D 0001213900-25-117804
Akura MedicalRaised $51.45M (Form D filed Dec 3, 2025).
Evidence (1 event)
  • Dec 3, 2025 · SEC Form D 0000905148-25-004216
    Name of Issuer: Akura Medical, Inc.; CIK: 1902758; Address: Campbell, CA; Submission type: D; Filing date: 2025-12-03; Industry Group: Other Health Care; Date of First Sale: 2025-11-12; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 71999999; Total Amount Sold: 51449999; Federal exemptions: 06b
Dec 3, 2025SEC Form D 0000905148-25-004216
Ophthalmic Therapeutic InnovationRaised $100K (Form D filed Dec 2, 2025).
Evidence (1 event)
  • Dec 2, 2025 · SEC Form D 0002098204-25-000001
    Name of Issuer: Ophthalmic Therapeutic Innovation LLC; CIK: 2098204; Address: Watertown, MA; Submission type: D; Filing date: 2025-12-02; Industry Group: Biotechnology; Date of First Sale: 2025-11-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 100000; Federal exemptions: 06b
Dec 2, 2025SEC Form D 0002098204-25-000001
Okami MedicalRaised $28.94M (Form D filed Dec 1, 2025).
Evidence (1 event)
  • Dec 1, 2025 · SEC Form D 0001675564-25-000002
    Name of Issuer: Okami Medical, Inc.; CIK: 1675564; Address: Aliso Viejo, CA; Submission type: D; Filing date: 2025-12-01; Industry Group: Other Technology; Date of First Sale: 2025-11-18; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 46735000; Total Amount Sold: 28936718; Federal exemptions: 06b
Dec 1, 2025SEC Form D 0001675564-25-000002
BTB TherapeuticsRaised $8.9M (Form D filed Dec 1, 2025; amended Aug 12, 2026).
Evidence (1 event)
  • Dec 1, 2025 · SEC Form D 0002055053-25-000003
    Name of Issuer: BTB Therapeutics, Inc.; CIK: 2055053; Address: Escondido, CA; Submission type: D; Filing date: 2025-12-01; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 7402704; Total Amount Sold: 3402704; Federal exemptions: 06b || Name of Issuer: BTB Therapeutics, Inc.; CIK: 2055053; Address: Escondido, CA; Submission type: D/A; Filing date: 2026-08-12; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10402704; Total Amount Sold: 8902204; Federal exemptions: 06b
Dec 1, 2025SEC Form D 0002055053-25-000003
Allurion TechnologiesRaised $5M (Form D filed Nov 26, 2025).
Evidence (1 event)
  • Nov 26, 2025 · SEC Form D 0001964979-25-000003
    Name of Issuer: ALLURION TECHNOLOGIES, INC.; CIK: 1964979; Address: Natick, MA; Submission type: D; Filing date: 2025-11-26; Industry Group: Other Health Care; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
Nov 26, 2025SEC Form D 0001964979-25-000003
Huxley MedicalRaised $11.02M in debt securities (Form D filed Sep 30, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • Sep 30, 2026 · SEC Form D 0001869701-26-000004
    Name of Issuer: Huxley Medical, Inc.; CIK: 1869701; Address: Atlanta, GA; Submission type: D; Filing date: 2026-09-30; Industry Group: Other Health Care; Date of First Sale: 2026-09-16; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 11700000; Total Amount Sold: 11019335; Federal exemptions: 06b
  • Apr 27, 2026 · SEC Form D 0001869701-26-000002
    Name of Issuer: Huxley Medical, Inc.; CIK: 1869701; Address: Atlanta, GA; Submission type: D; Filing date: 2026-04-27; Industry Group: Other Health Care; Date of First Sale: 2026-04-17; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2774482; Federal exemptions: 06b || Name of Issuer: Huxley Medical, Inc.; CIK: 1869701; Address: Atlanta, GA; Submission type: D/A; Filing date: 2026-06-12; Industry Group: Other Health Care; Date of First Sale: 2026-04-17; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2999568; Federal exemptions: 06b
  • Nov 26, 2025 · SEC Form D 0001869701-25-000004
    Name of Issuer: Huxley Medical, Inc.; CIK: 1869701; Address: Atlanta, GA; Submission type: D; Filing date: 2025-11-26; Industry Group: Other Health Care; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 5904105; Federal exemptions: 06b || Name of Issuer: Huxley Medical, Inc.; CIK: 1869701; Address: Atlanta, GA; Submission type: D/A; Filing date: 2026-02-12; Industry Group: Other Health Care; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 9983145; Federal exemptions: 06b
Sep 30, 2026SEC Form D 0001869701-26-000004
Enrich BiosystemsRaised $1.45M in debt securities (Form D filed Nov 26, 2025).
Evidence (1 event)
  • Nov 26, 2025 · SEC Form D 0001931770-25-000002
    Name of Issuer: ENRICH BIOSYSTEMS INC.; CIK: 1931770; Address: Branford, CT; Submission type: D; Filing date: 2025-11-26; Industry Group: Biotechnology; Date of First Sale: 2025-11-13; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1450000; Federal exemptions: 06b
Nov 26, 2025SEC Form D 0001931770-25-000002
Ablative SolutionsRaised $10.41M (Form D filed Nov 26, 2025).
Evidence (1 event)
  • Nov 26, 2025 · SEC Form D 0002080612-25-000020
    Name of Issuer: Ablative Solutions, Inc.; CIK: 1535723; Address: Wakefield, MA; Submission type: D; Filing date: 2025-11-26; Industry Group: Other Health Care; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 45000000; Total Amount Sold: 10407500; Federal exemptions: 06b
Nov 26, 2025SEC Form D 0002080612-25-000020
Repair BiotechnologiesRaised $5.26M (Form D filed Nov 25, 2025).
Evidence (1 event)
  • Nov 25, 2025 · SEC Form D 0001750699-25-000002
    Name of Issuer: Repair Biotechnologies, Inc.; CIK: 1750699; Address: Syracuse, NY; Submission type: D; Filing date: 2025-11-25; Industry Group: Biotechnology; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11000000; Total Amount Sold: 5258906; Federal exemptions: 06b
Nov 25, 2025SEC Form D 0001750699-25-000002
Tenon MedicalRaised $4.31M (Form D filed Sep 21, 2026); +3 other Form D filings in the last 12 months.
Evidence (4 events)
  • Sep 21, 2026 · SEC Form D 0001213900-26-101515
    Name of Issuer: Tenon Medical, Inc.; CIK: 1560293; Address: Los Gatos, CA; Submission type: D; Filing date: 2026-09-21; Industry Group: Other Health Care; Date of First Sale: 2026-09-11; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4308510; Total Amount Sold: 4308510; Federal exemptions: 06b
  • Sep 4, 2026 · SEC Form D 0001213900-26-097552
    Name of Issuer: Tenon Medical, Inc.; CIK: 1560293; Address: Los Gatos, CA; Submission type: D; Filing date: 2026-09-04; Industry Group: Other Health Care; Date of First Sale: 2026-08-27; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b
  • Mar 18, 2026 · SEC Form D 0001213900-26-029368
    Name of Issuer: Tenon Medical, Inc.; CIK: 1560293; Address: Los Gatos, CA; Submission type: D; Filing date: 2026-03-18; Industry Group: Other Health Care; Date of First Sale: 2026-03-11; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4300000; Total Amount Sold: 4300000; Federal exemptions: 06b || Name of Issuer: Tenon Medical, Inc.; CIK: 1560293; Address: Los Gatos, CA; Submission type: D/A; Filing date: 2026-03-19; Industry Group: Other Health Care; Date of First Sale: 2026-03-11; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4300000; Total Amount Sold: 4300000; Federal exemptions: 06b
  • Nov 25, 2025 · SEC Form D 0001213900-25-114408
    Name of Issuer: Tenon Medical, Inc.; CIK: 1560293; Address: Los Gatos, CA; Submission type: D; Filing date: 2025-11-25; Industry Group: Other Health Care; Date of First Sale: 2025-11-10; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2850000; Total Amount Sold: 2850000; Federal exemptions: 06b
Sep 21, 2026SEC Form D 0001213900-26-101515
Solve TherapeuticsRaised $48.21M (Form D filed Nov 25, 2025).
Evidence (1 event)
  • Nov 25, 2025 · SEC Form D 0001231919-25-000548
    Name of Issuer: Solve Therapeutics, Inc.; CIK: 1905252; Address: Belmont, CA; Submission type: D; Filing date: 2025-11-25; Industry Group: Biotechnology; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120535618; Total Amount Sold: 48214232; Federal exemptions: 06b
Nov 25, 2025SEC Form D 0001231919-25-000548
Pelage PharmaceuticalsRaised $120M (Form D filed Nov 24, 2025).
Evidence (1 event)
  • Nov 24, 2025 · SEC Form D 0001982875-25-000002
    Name of Issuer: Pelage Pharmaceuticals, Inc.; CIK: 1982875; Address: Los Angeles, CA; Submission type: D; Filing date: 2025-11-24; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 119999987; Total Amount Sold: 119999987; Federal exemptions: 06b
Nov 24, 2025SEC Form D 0001982875-25-000002
Strategikon PharmaRaised $2.29M in debt securities (Form D filed Nov 21, 2025).
Evidence (1 event)
  • Nov 21, 2025 · SEC Form D 0001722200-25-000002
    Name of Issuer: Strategikon Pharma, Inc.; CIK: 1722200; Address: San Francisco, CA; Submission type: D; Filing date: 2025-11-21; Industry Group: Other Technology; Date of First Sale: 2025-05-08; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2291885; Federal exemptions: 06b
Nov 21, 2025SEC Form D 0001722200-25-000002
Iambic TherapeuticsRaised $65.97M in debt securities (Form D filed Sep 9, 2026); +2 other Form D filings in the last 12 months; since then posted 16 roles.
Evidence (3 events)
  • Sep 9, 2026 · SEC Form D 0001997038-26-000002
    Name of Issuer: Iambic Therapeutics, Inc.; CIK: 1997038; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-09; Industry Group: Biotechnology; Date of First Sale: 2026-08-14; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 66500000; Total Amount Sold: 65965000; Federal exemptions: 06b
  • Apr 8, 2026 · SEC Form D 0001997038-26-000001
    Name of Issuer: Iambic Therapeutics, Inc.; CIK: 1997038; Address: San Diego, CA; Submission type: D; Filing date: 2026-04-08; Industry Group: Biotechnology; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 49999996; Total Amount Sold: 27769668; Federal exemptions: 06b
  • Nov 21, 2025 · SEC Form D 0001997038-25-000002
    Name of Issuer: Iambic Therapeutics, Inc.; CIK: 1997038; Address: San Diego, CA; Submission type: D; Filing date: 2025-11-21; Industry Group: Biotechnology; Date of First Sale: 2025-11-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 124999970; Total Amount Sold: 99269270; Federal exemptions: 06b
Sep 9, 2026SEC Form D 0001997038-26-000002
SpineologyRaised $12.64M (Form D filed Nov 19, 2025; amended Jun 17, 2026).
Evidence (1 event)
  • Nov 19, 2025 · SEC Form D 0001165842-25-000003
    Name of Issuer: SPINEOLOGY INC; CIK: 1165842; Address: St. Paul, MN; Submission type: D; Filing date: 2025-11-19; Industry Group: Biotechnology; Date of First Sale: 2025-11-07; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10522826; Total Amount Sold: 8755306; Federal exemptions: 06b || Name of Issuer: SPINEOLOGY INC; CIK: 1165842; Address: St. Paul, MN; Submission type: D/A; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2025-11-07; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 14079337; Total Amount Sold: 12641849; Federal exemptions: 06b
Nov 19, 2025SEC Form D 0001165842-25-000003
Pelthos TherapeuticsRaised $18M (Form D filed Nov 19, 2025); 12 roles open.
Evidence (1 event)
  • Nov 19, 2025 · SEC Form D 0001919246-25-000006
    Name of Issuer: Pelthos Therapeutics Inc.; CIK: 1919246; Address: Durham, NC; Submission type: D; Filing date: 2025-11-19; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-06; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Senior secured convertible notes, which are convertible into shares of the Company's common stock, par value $0.0001 per share.); Business combination transaction: false; Total Offering Amount: 18000000; Total Amount Sold: 18000000; Federal exemptions: 06b
Nov 19, 2025SEC Form D 0001919246-25-000006
VST BioRaised $31.89M (Form D filed Nov 18, 2025; amended Apr 24, 2026).
Evidence (1 event)
  • Nov 18, 2025 · SEC Form D 0001231919-25-000520
    Name of Issuer: VST BIO Corp; CIK: 2093250; Address: San Diego, CA; Submission type: D; Filing date: 2025-11-18; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 28888146; Total Amount Sold: 28888146; Federal exemptions: 06b || Name of Issuer: VST BIO Corp; CIK: 2093250; Address: San Diego, CA; Submission type: D/A; Filing date: 2026-04-24; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31888146; Total Amount Sold: 31888146; Federal exemptions: 06b
Nov 18, 2025SEC Form D 0001231919-25-000520
Dualitas TherapeuticsRaised $32.6M (Form D filed Nov 18, 2025); since then posted 4 roles.
Evidence (1 event)
  • Nov 18, 2025 · SEC Form D 0001231919-25-000517
    Name of Issuer: Dualitas Therapeutics, Inc.; CIK: 2091994; Address: South San Francisco, CA; Submission type: D; Filing date: 2025-11-18; Industry Group: Biotechnology; Date of First Sale: 2025-07-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 66599990; Total Amount Sold: 32599997; Federal exemptions: 06b
Nov 18, 2025SEC Form D 0001231919-25-000517
Qlaris BioRaised $3.95M in debt securities (Form D filed Jun 17, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Jun 17, 2026 · SEC Form D 0001786717-26-000002
    Name of Issuer: Qlaris Bio, Inc.; CIK: 1786717; Address: Dedham, MA; Submission type: D; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2026-06-12; Types of Securities Offered: Debt, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 3946659; Total Amount Sold: 3946659; Federal exemptions: 06b
  • Nov 17, 2025 · SEC Form D 0001786717-25-000002
    Name of Issuer: Qlaris Bio, Inc.; CIK: 1786717; Address: Dedham, MA; Submission type: D; Filing date: 2025-11-17; Industry Group: Biotechnology; Date of First Sale: 2025-11-13; Types of Securities Offered: Debt, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 5641600; Total Amount Sold: 5641600; Federal exemptions: 06b
Jun 17, 2026SEC Form D 0001786717-26-000002
NeuropathixFiled a Form D for an offering of up to $50M, no sales reported yet (filed Nov 17, 2025).
Evidence (1 event)
  • Nov 17, 2025 · SEC Form D 0001615999-25-000003
    Name of Issuer: NEUROPATHIX, INC.; CIK: 1615999; Address: Doylestown, PA; Submission type: D; Filing date: 2025-11-17; Industry Group: Biotechnology; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 50000000; Total Amount Sold: 0; Federal exemptions: 06c
Nov 17, 2025SEC Form D 0001615999-25-000003
LifeLens TechnologiesRaised $21.1M (Form D filed Nov 17, 2025; amended Sep 8, 2026).
Evidence (1 event)
  • Nov 17, 2025 · SEC Form D 0001782780-25-000002
    Name of Issuer: LifeLens Technologies, Inc.; CIK: 1782780; Address: Ivyland, PA; Submission type: D; Filing date: 2025-11-17; Industry Group: Other Technology; Date of First Sale: 2025-11-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 23171697; Total Amount Sold: 15079197; Federal exemptions: 06b || Name of Issuer: LifeLens Technologies, Inc.; CIK: 1782780; Address: Ivyland, PA; Submission type: D/A; Filing date: 2026-09-08; Industry Group: Other Technology; Date of First Sale: 2025-11-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 21104217; Federal exemptions: 06b
Nov 17, 2025SEC Form D 0001782780-25-000002
FemasysRaised $30M (Form D filed Aug 20, 2026).
Evidence (1 event)
  • Aug 20, 2026 · SEC Form D 0000945621-26-001085
    Name of Issuer: FEMASYS INC; CIK: 1339005; Address: Suwanee, GA; Submission type: D; Filing date: 2026-08-20; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 30000000; Federal exemptions: 06b
Aug 20, 2026SEC Form D 0000945621-26-001085
Model MedicinesRaised $3.26M (Form D filed Nov 14, 2025).
Evidence (1 event)
  • Nov 14, 2025 · SEC Form D 0001892786-25-000008
    Name of Issuer: Model Medicines, Inc.; CIK: 1892786; Address: San Deigo, CA; Submission type: D; Filing date: 2025-11-14; Industry Group: Other; Date of First Sale: 2025-10-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 3260000; Federal exemptions: 06b
Nov 14, 2025SEC Form D 0001892786-25-000008
Carolina MolecularRaised $1.13M (Form D filed Nov 13, 2025).
Evidence (1 event)
  • Nov 13, 2025 · SEC Form D 0002096691-25-000001
    Name of Issuer: Carolina Molecular Inc.; CIK: 2096691; Address: Morrisville, NC; Submission type: D; Filing date: 2025-11-13; Industry Group: Biotechnology; Date of First Sale: 2025-09-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1700000; Total Amount Sold: 1125000; Federal exemptions: 06b
Nov 13, 2025SEC Form D 0002096691-25-000001
Elixirgen TherapeuticsRaised $4M in debt securities (Form D filed Nov 13, 2025).
Evidence (1 event)
  • Nov 13, 2025 · SEC Form D 0001744333-25-000004
    Name of Issuer: ELIXIRGEN THERAPEUTICS, INC.; CIK: 1744333; Address: Baltimore, MD; Submission type: D; Filing date: 2025-11-13; Industry Group: Biotechnology; Date of First Sale: 2025-10-30; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b
Nov 13, 2025SEC Form D 0001744333-25-000004
Levee MedicalRaised $12.5M in debt securities (Form D filed Nov 12, 2025; amended May 5, 2026).
Evidence (1 event)
  • Nov 12, 2025 · SEC Form D 0001877814-25-000002
    Name of Issuer: Levee Medical, Inc.; CIK: 1877814; Address: Durham, NC; Submission type: D; Filing date: 2025-11-12; Industry Group: Other Health Care; Date of First Sale: 2025-10-31; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4458934; Federal exemptions: 06b || Name of Issuer: Levee Medical, Inc.; CIK: 1877814; Address: Durham, NC; Submission type: D/A; Filing date: 2026-05-05; Industry Group: Other Health Care; Date of First Sale: 2025-10-31; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 12500000; Total Amount Sold: 12500000; Federal exemptions: 06b
Nov 12, 2025SEC Form D 0001877814-25-000002
Phio PharmaceuticalsRaised $1.42M (Form D filed Nov 12, 2025).
Evidence (1 event)
  • Nov 12, 2025 · SEC Form D 0001123292-25-000633
    Name of Issuer: Phio Pharmaceuticals Corp.; CIK: 1533040; Address: King OF Prussia, PA; Submission type: D; Filing date: 2025-11-12; Industry Group: Biotechnology; Date of First Sale: 2025-11-04; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 25931342; Total Amount Sold: 1415796; Federal exemptions: 06b
Nov 12, 2025SEC Form D 0001123292-25-000633
Saluda MedicalRaised $30M (Form D filed Nov 12, 2025); 28 roles open.
Evidence (1 event)
  • Nov 12, 2025 · SEC Form D 0001973574-25-000002
    Name of Issuer: Saluda Medical, Inc.; CIK: 1973574; Address: Bloomington, MN; Submission type: D; Filing date: 2025-11-12; Industry Group: Other Health Care; Date of First Sale: 2025-10-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 29999995; Total Amount Sold: 29999995; Federal exemptions: 06b
Nov 12, 2025SEC Form D 0001973574-25-000002
BioLoomicsRaised $450K (Form D filed Nov 10, 2025).
Evidence (1 event)
  • Nov 10, 2025 · SEC Form D 0001776021-25-000003
    Name of Issuer: BioLoomics, Inc.; CIK: 1776021; Address: Boulder, CO; Submission type: D; Filing date: 2025-11-10; Industry Group: Other; Date of First Sale: 2025-08-11; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 450000; Federal exemptions: 06b
Nov 10, 2025SEC Form D 0001776021-25-000003
TuHURA BiosciencesRaised $1.5M (Form D filed Nov 10, 2025).
Evidence (1 event)
  • Nov 10, 2025 · SEC Form D 0001498382-25-000004
    Name of Issuer: TuHURA Biosciences, Inc./NV; CIK: 1498382; Address: Tampa, FL; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-27; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1500000; Federal exemptions: 06b
Nov 10, 2025SEC Form D 0001498382-25-000004
EpalexRaised $1.2M (Form D filed Nov 10, 2025).
Evidence (1 event)
  • Nov 10, 2025 · SEC Form D 0001755010-25-000003
    Name of Issuer: EPALEX Corp; CIK: 1755010; Address: Mountain View, CA; Submission type: D; Filing date: 2025-11-10; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3199991; Total Amount Sold: 1200000; Federal exemptions: 06b
Nov 10, 2025SEC Form D 0001755010-25-000003
Artelo BiosciencesRaised $315K in debt securities (Form D filed Mar 27, 2026); +4 other Form D filings in the last 12 months.
Evidence (5 events)
  • Mar 27, 2026 · SEC Form D 0001621221-26-000004
    Name of Issuer: ARTELO BIOSCIENCES, INC.; CIK: 1621221; Address: Solana Beach, CA; Submission type: D; Filing date: 2026-03-27; Industry Group: Biotechnology; Date of First Sale: 2026-03-20; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 315000; Total Amount Sold: 315000; Federal exemptions: 06b
  • Mar 27, 2026 · SEC Form D 0001621221-26-000003
    Name of Issuer: ARTELO BIOSCIENCES, INC.; CIK: 1621221; Address: Solana Beach, CA; Submission type: D; Filing date: 2026-03-27; Industry Group: Biotechnology; Date of First Sale: 2026-03-12; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 113000; Total Amount Sold: 113000; Federal exemptions: 06b
  • Mar 27, 2026 · SEC Form D 0001621221-26-000002
    Name of Issuer: ARTELO BIOSCIENCES, INC.; CIK: 1621221; Address: Solana Beach, CA; Submission type: D; Filing date: 2026-03-27; Industry Group: Biotechnology; Date of First Sale: 2026-03-12; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 237300; Total Amount Sold: 237300; Federal exemptions: 06b
  • Feb 6, 2026 · SEC Form D 0001621221-26-000001
    Name of Issuer: ARTELO BIOSCIENCES, INC.; CIK: 1621221; Address: Solana Beach, CA; Submission type: D; Filing date: 2026-02-06; Industry Group: Biotechnology; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 50500000; Total Amount Sold: 500000; Federal exemptions: 06b
  • Nov 10, 2025 · SEC Form D 0001640334-25-001998
    Name of Issuer: ARTELO BIOSCIENCES, INC.; CIK: 1621221; Address: Solana Beach, CA; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-28; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3718121; Total Amount Sold: 3718121; Federal exemptions: 06b
Mar 27, 2026SEC Form D 0001621221-26-000004
TearSolutionsRaised $517K (Form D filed Nov 10, 2025).
Evidence (1 event)
  • Nov 10, 2025 · SEC Form D 0001477932-25-008012
    Name of Issuer: TearSolutions, Inc.; CIK: 1611687; Address: Charlottesville, VA; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 517000; Total Amount Sold: 517000; Federal exemptions: 06b
Nov 10, 2025SEC Form D 0001477932-25-008012
Rani TherapeuticsRaised $60.26M (Form D filed Nov 10, 2025).
Evidence (1 event)
  • Nov 10, 2025 · SEC Form D 0001231919-25-000450
    Name of Issuer: Rani Therapeutics Holdings, Inc.; CIK: 1856725; Address: San Jose, CA; Submission type: D; Filing date: 2025-11-10; Industry Group: Biotechnology; Date of First Sale: 2025-10-23; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 60255052; Total Amount Sold: 60255052; Federal exemptions: 06b
Nov 10, 2025SEC Form D 0001231919-25-000450
Shuttle Pharmaceuticals, Inc.Raised $2.5M (Form D filed Nov 7, 2025).
Evidence (1 event)
  • Nov 7, 2025 · SEC Form D 0001757499-25-000003
    Name of Issuer: Shuttle Pharmaceuticals Holdings, Inc.; CIK: 1757499; Address: Gaithersburg, MD; Submission type: D; Filing date: 2025-11-07; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-03; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2500624; Total Amount Sold: 2499998; Federal exemptions: 06b
Nov 7, 2025SEC Form D 0001757499-25-000003
Protein Dynamic SolutionsRaised $1.77M (Form D filed Nov 7, 2025).
Evidence (1 event)
  • Nov 7, 2025 · SEC Form D 0001780775-25-000004
    Name of Issuer: Protein Dynamic Solutions, Inc.; CIK: 1780775; Address: Wilmington, DE; Submission type: D; Filing date: 2025-11-07; Industry Group: Biotechnology; Date of First Sale: 2025-08-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1772369; Federal exemptions: 06b
Nov 7, 2025SEC Form D 0001780775-25-000004
Gut-Brain-Axis Therapeutics Inc.Raised $1.97M (Form D filed Nov 6, 2025).
Evidence (1 event)
  • Nov 6, 2025 · SEC Form D 0001996678-25-000002
    Name of Issuer: Gut-Brain-Axis Therapeutics Inc.; CIK: 1996678; Address: Tempe, AZ; Submission type: D; Filing date: 2025-11-06; Industry Group: Biotechnology; Date of First Sale: 2025-10-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 1965000; Federal exemptions: 06c
Nov 6, 2025SEC Form D 0001996678-25-000002
Osteal TherapeuticsRaised $15.6M (Form D filed Nov 5, 2025).
Evidence (1 event)
  • Nov 5, 2025 · SEC Form D 0001231919-25-000432
    Name of Issuer: Osteal Therapeutics, Inc.; CIK: 1735936; Address: Dallas, TX; Submission type: D; Filing date: 2025-11-05; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 26702156; Total Amount Sold: 15602151; Federal exemptions: 06b
Nov 5, 2025SEC Form D 0001231919-25-000432
Luminary TherapeuticsRaised $1.41M (Form D filed Nov 5, 2025).
Evidence (1 event)
  • Nov 5, 2025 · SEC Form D 0001437749-25-033325
    Name of Issuer: Luminary Therapeutics, Inc.; CIK: 1793860; Address: Minneapolis, MN; Submission type: D; Filing date: 2025-11-05; Industry Group: Biotechnology; Date of First Sale: 2025-10-14; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 12388157; Total Amount Sold: 1406112; Federal exemptions: 06b
Nov 5, 2025SEC Form D 0001437749-25-033325
CelularityRaised $2M (Form D filed Nov 3, 2025); 5 roles open.
Evidence (1 event)
  • Nov 3, 2025 · SEC Form D 0001493152-25-020624
    Name of Issuer: Celularity Inc; CIK: 1752828; Address: Florham Park, NJ; Submission type: D; Filing date: 2025-11-03; Industry Group: Biotechnology; Date of First Sale: 2025-10-24; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 6666667; Total Amount Sold: 2000000; Federal exemptions: 06c
Nov 3, 2025SEC Form D 0001493152-25-020624
BiomeSenseRaised $7.06M (Form D filed Nov 3, 2025).
Evidence (1 event)
  • Nov 3, 2025 · SEC Form D 0001789915-25-000002
    Name of Issuer: BiomeSense, Inc.; CIK: 1789915; Address: Chicago, IL; Submission type: D; Filing date: 2025-11-03; Industry Group: Biotechnology; Date of First Sale: 2025-07-18; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 7250000; Total Amount Sold: 7059599; Federal exemptions: 06b
Nov 3, 2025SEC Form D 0001789915-25-000002
Miach OrthopaedicsRaised $6.5M in debt securities (Form D filed May 7, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • May 7, 2026 · SEC Form D 0001964453-26-000001
    Name of Issuer: Miach Orthopaedics Inc.; CIK: 1964453; Address: Westborough, MA; Submission type: D; Filing date: 2026-05-07; Industry Group: Other Health Care; Date of First Sale: 2026-05-01; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 6500000; Total Amount Sold: 6500000; Federal exemptions: 06b
  • Oct 31, 2025 · SEC Form D 0001964453-25-000002
    Name of Issuer: Miach Orthopaedics Inc.; CIK: 1964453; Address: Westborough, MA; Submission type: D; Filing date: 2025-10-31; Industry Group: Other Health Care; Date of First Sale: 2025-10-16; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 7500000; Federal exemptions: 06b
May 7, 2026SEC Form D 0001964453-26-000001
Vesteck, Inc.Raised $354K (Form D filed Oct 30, 2025).
Evidence (1 event)
  • Oct 30, 2025 · SEC Form D 0001882165-25-000002
    Name of Issuer: VESTECK, INC.; CIK: 1882165; Address: Carlsbad, CA; Submission type: D; Filing date: 2025-10-30; Industry Group: Other Technology; Date of First Sale: 2025-10-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 353578; Federal exemptions: 06b
Oct 30, 2025SEC Form D 0001882165-25-000002
Jabez BiosciencesForm D reports $31K sold since 2024 (filed Mar 26, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • Mar 26, 2026 · SEC Form D 0001213900-26-034473
    Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2026-03-26; Industry Group: Biotechnology; Date of First Sale: 2024-06-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 31200; Federal exemptions: 06b
  • Oct 21, 2025 · SEC Form D 0001213900-25-100745
    Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2025-10-21; Industry Group: Biotechnology; Date of First Sale: 2024-11-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 2550000; Federal exemptions: 06b || Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2025-10-28; Industry Group: Biotechnology; Date of First Sale: 2024-11-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 250510; Federal exemptions: 06b
  • Oct 21, 2025 · SEC Form D 0001213900-25-100637
    Name of Issuer: Jabez Biosciences, Inc.; CIK: 2038185; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2025-10-21; Industry Group: Biotechnology; Date of First Sale: 2024-08-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1326500; Federal exemptions: 06b
Mar 26, 2026SEC Form D 0001213900-26-034473
VeradermicsRaised $30M (Form D filed May 15, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • May 15, 2026 · SEC Form D 0001827635-26-000020
    Name of Issuer: Veradermics, Inc; CIK: 1827635; Address: New Haven, CT; Submission type: D; Filing date: 2026-05-15; Industry Group: Other Health Care; Date of First Sale: 2026-05-01; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 29999997; Total Amount Sold: 29999997; Federal exemptions: 06b
  • Oct 28, 2025 · SEC Form D 0001231919-25-000361
    Name of Issuer: Veradermics, Inc; CIK: 1827635; Address: New Haven, CT; Submission type: D; Filing date: 2025-10-28; Industry Group: Other Health Care; Date of First Sale: 2025-10-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 149999978; Total Amount Sold: 134999978; Federal exemptions: 06b
May 15, 2026SEC Form D 0001827635-26-000020
Alto Neuroscience, Inc.Raised $50M (Form D filed Oct 27, 2025).
Evidence (1 event)
  • Oct 27, 2025 · SEC Form D 0001231919-25-000357
    Name of Issuer: Alto Neuroscience, Inc.; CIK: 1999480; Address: Mountain View, CA; Submission type: D; Filing date: 2025-10-27; Industry Group: Pharmaceuticals; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 49999533; Total Amount Sold: 49999533; Federal exemptions: 06b
Oct 27, 2025SEC Form D 0001231919-25-000357
Antigenix TherapeuticsRaised $3.36M (Form D filed Oct 24, 2025).
Evidence (1 event)
  • Oct 24, 2025 · SEC Form D 0002073993-25-000001
    Name of Issuer: Antigenix Therapeutics, Inc.; CIK: 2073993; Address: Princeton, NJ; Submission type: D; Filing date: 2025-10-24; Industry Group: Other Health Care; Date of First Sale: 2025-10-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8363695; Total Amount Sold: 3363695; Federal exemptions: 06b
Oct 24, 2025SEC Form D 0002073993-25-000001
ENDRA Life SciencesRaised $14.4M (Form D filed Oct 24, 2025).
Evidence (1 event)
  • Oct 24, 2025 · SEC Form D 0001681682-25-000004
    Name of Issuer: ENDRA Life Sciences Inc.; CIK: 1681682; Address: Ann Arbor, MI; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-10-10; Types of Securities Offered: Equity, Other (Prefunded and Common Warrants to purchase shares of Common Stock); Business combination transaction: false; Total Offering Amount: 14402880; Total Amount Sold: 14402880; Federal exemptions: 06c
Oct 24, 2025SEC Form D 0001681682-25-000004
Eliaz TherapeuticsRaised $850K (Form D filed Oct 24, 2025).
Evidence (1 event)
  • Oct 24, 2025 · SEC Form D 0001062993-25-016285
    Name of Issuer: Eliaz Therapeutics Inc.; CIK: 2042609; Address: Santa Rosa, CA; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-03-28; Types of Securities Offered: Other (SAFEs); Business combination transaction: false; Total Offering Amount: 850000; Total Amount Sold: 850000; Federal exemptions: 06b
Oct 24, 2025SEC Form D 0001062993-25-016285
SFC FluidicsRaised $250K (Form D filed Oct 24, 2025).
Evidence (1 event)
  • Oct 24, 2025 · SEC Form D 0001352226-25-000005
    Name of Issuer: SFC FLUIDICS INC.; CIK: 1352226; Address: Fayetteville, AR; Submission type: D; Filing date: 2025-10-24; Industry Group: Other; Date of First Sale: 2025-10-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 650000; Total Amount Sold: 250000; Federal exemptions: 06b
Oct 24, 2025SEC Form D 0001352226-25-000005
NOK TherapeuticsForm D reports $3K sold since 2024 (filed Mar 26, 2026; amended May 1, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • Mar 26, 2026 · SEC Form D 0001213900-26-034315
    Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2026-03-26; Industry Group: Biotechnology; Date of First Sale: 2024-06-27; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1400; Total Amount Sold: 1400; Federal exemptions: 06b || Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2024-06-27; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1400; Total Amount Sold: 1400; Federal exemptions: 06b || Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2026-05-01; Industry Group: Biotechnology; Date of First Sale: 2024-06-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3200; Total Amount Sold: 3200; Federal exemptions: 06b
  • Oct 24, 2025 · SEC Form D 0001213900-25-102039
    Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp, PA; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2024-10-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 250500; Federal exemptions: 06b || Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2024-10-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 500500; Federal exemptions: 06b || Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2026-05-01; Industry Group: Biotechnology; Date of First Sale: 2024-09-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 750500; Federal exemptions: 06b
  • Oct 24, 2025 · SEC Form D 0001213900-25-102036
    Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2024-08-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 750000; Total Amount Sold: 566500; Federal exemptions: 06b || Name of Issuer: Nok Therapeutics, Inc.; CIK: 2038166; Address: Cranberry Twp., PA; Submission type: D/A; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2024-08-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 750000; Total Amount Sold: 649000; Federal exemptions: 06b
Mar 26, 2026SEC Form D 0001213900-26-034315
Epibone, Inc.Raised $4.29M (Form D filed Oct 24, 2025).
Evidence (1 event)
  • Oct 24, 2025 · SEC Form D 0001798436-25-000003
    Name of Issuer: EpiBone, Inc.; CIK: 1798436; Address: New York, NY; Submission type: D; Filing date: 2025-10-24; Industry Group: Other; Date of First Sale: 2025-09-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4300506; Total Amount Sold: 4287429; Federal exemptions: 06b
Oct 24, 2025SEC Form D 0001798436-25-000003
Mercury BioRaised $2.38M (Form D filed Oct 24, 2025).
Evidence (1 event)
  • Oct 24, 2025 · SEC Form D 0001952927-25-000003
    Name of Issuer: Mercury Bio, Inc.; CIK: 1952927; Address: Santa FE, NM; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-09-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 7954094; Total Amount Sold: 2376107; Federal exemptions: 06b
Oct 24, 2025SEC Form D 0001952927-25-000003
Theriva BiologicsForm D reports $13.11M, incl. warrant exercise value (filed Oct 24, 2025).
Evidence (1 event)
  • Oct 24, 2025 · SEC Form D 0001104659-25-101914
    Name of Issuer: Theriva Biologics, Inc.; CIK: 894158; Address: Rockville, MD; Submission type: D; Filing date: 2025-10-24; Industry Group: Biotechnology; Date of First Sale: 2025-10-17; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 13109494; Total Amount Sold: 13109494; Federal exemptions: 06b
Oct 24, 2025SEC Form D 0001104659-25-101914
ReCode TherapeuticsRaised $29.44M in debt securities (Form D filed Oct 23, 2025); 1 role open.
Evidence (1 event)
  • Oct 23, 2025 · SEC Form D 0000905148-25-003655
    Name of Issuer: RECODE THERAPEUTICS, INC.; CIK: 1693764; Address: city not listed;Brien Drive, Menlo Park, CALIFORNIA; Submission type: D; Filing date: 2025-10-23; Industry Group: Biotechnology; Date of First Sale: 2025-09-23; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 29441931; Total Amount Sold: 29441931; Federal exemptions: 06b
Oct 23, 2025SEC Form D 0000905148-25-003655
InstyllaRaised $34.78M (Form D filed Oct 23, 2025; amended Jul 28, 2026); 4 roles open.
Evidence (1 event)
  • Oct 23, 2025 · SEC Form D 0001708696-25-000004
    Name of Issuer: Instylla, Inc.; CIK: 1708696; Address: Bedford, MA; Submission type: D; Filing date: 2025-10-23; Industry Group: Biotechnology; Date of First Sale: 2025-07-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 21734014; Total Amount Sold: 21734014; Federal exemptions: 06b || Name of Issuer: Instylla, Inc.; CIK: 1708696; Address: Bedford, MA; Submission type: D/A; Filing date: 2026-07-28; Industry Group: Biotechnology; Date of First Sale: 2025-07-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 35034025; Total Amount Sold: 34783984; Federal exemptions: 06b
Oct 23, 2025SEC Form D 0001708696-25-000004
Gilgamesh PharmaRaised $2.25M (Form D filed Mar 31, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • Mar 31, 2026 · SEC Form D 0002107396-26-000004
    Name of Issuer: Gilgamesh Pharma Inc.; CIK: 2107396; Address: New York, NY; Submission type: D; Filing date: 2026-03-31; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-27; Types of Securities Offered: Option/warrant, Other (Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.); Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 2250000; Federal exemptions: 06b
  • Mar 24, 2026 · SEC Form D 0002107396-26-000003
    Name of Issuer: Gilgamesh Pharma Inc.; CIK: 2107396; Address: New York, NY; Submission type: D; Filing date: 2026-03-24; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-09; Types of Securities Offered: Equity, Other (Shares of Preferred Stock of Issuer and the shares of capital stock of Issuer into which such shares of Preferred Stock may convert.); Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 60000000; Federal exemptions: 06b
  • Feb 4, 2026 · SEC Form D 0002107396-26-000002
    Name of Issuer: Gilgamesh Pharma Inc.; CIK: 2107396; Address: New York, NY; Submission type: D; Filing date: 2026-02-04; Industry Group: Pharmaceuticals; Date of First Sale: 2026-01-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6090946; Total Amount Sold: 6090946; Federal exemptions: 06b
Mar 31, 2026SEC Form D 0002107396-26-000004
OpZiraRaised $2.03M (Form D filed Sep 15, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Sep 15, 2026 · SEC Form D 0002124535-26-000002
    Name of Issuer: OpZira, Inc.; CIK: 2124535; Address: Middletown, PA; Submission type: D; Filing date: 2026-09-15; Industry Group: Other Technology; Date of First Sale: 2026-09-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 2025000; Federal exemptions: 06b
  • Mar 31, 2026 · SEC Form D 0002124535-26-000001
    Name of Issuer: OpZira, Inc.; CIK: 2124535; Address: Middletown, PA; Submission type: D; Filing date: 2026-03-31; Industry Group: Other Technology; Date of First Sale: 2026-03-17; Types of Securities Offered: Other (Simple Agreement for Future Equity (SAFE)); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1075000; Federal exemptions: 06b
Sep 15, 2026SEC Form D 0002124535-26-000002
Linnaeus TherapeuticsRaised $4.99M (Form D filed Feb 27, 2026; amended Apr 2, 2026).
Evidence (1 event)
  • Feb 27, 2026 · SEC Form D 0001752026-26-000004
    Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D; Filing date: 2026-02-27; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4475000; Federal exemptions: 06b || Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D/A; Filing date: 2026-03-13; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4792000; Federal exemptions: 06b || Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D/A; Filing date: 2026-03-31; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4892000; Federal exemptions: 06b || Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D/A; Filing date: 2026-04-02; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4992000; Federal exemptions: 06b
Feb 27, 2026SEC Form D 0001752026-26-000004
aMBR GenomicsRaised $1.1M (Form D filed Mar 31, 2026).
Evidence (1 event)
  • Mar 31, 2026 · SEC Form D 0002098331-26-000001
    Name of Issuer: aMBR Genomics, Inc.; CIK: 2098331; Address: Madison, WI; Submission type: D; Filing date: 2026-03-31; Industry Group: Other Health Care; Date of First Sale: 2025-10-21; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1100000; Federal exemptions: 06b
Mar 31, 2026SEC Form D 0002098331-26-000001
OmnioxForm D reports $24.07M in debt securities sold since 2016 (filed Mar 30, 2026).
Evidence (1 event)
  • Mar 30, 2026 · SEC Form D 0001553710-26-000004
    Name of Issuer: Omniox, Inc.; CIK: 1553710; Address: San Francisco, CA; Submission type: D; Filing date: 2026-03-30; Industry Group: Other Technology; Date of First Sale: 2016-08-01; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 28063773; Total Amount Sold: 24066235; Federal exemptions: 06b
Mar 30, 2026SEC Form D 0001553710-26-000004
BioLattice Ophthalmics, Inc.Raised $575K (Form D filed Mar 30, 2026).
Evidence (1 event)
  • Mar 30, 2026 · SEC Form D 0002125596-26-000001
    Name of Issuer: BioLattice Ophthalmics, Inc,; CIK: 2125596; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-03-30; Industry Group: Biotechnology; Date of First Sale: 2026-03-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 575000; Federal exemptions: 06b
Mar 30, 2026SEC Form D 0002125596-26-000001
ApnimedRaised $25M (Form D filed Mar 27, 2026).
Evidence (1 event)
  • Mar 27, 2026 · SEC Form D 0001745648-26-000001
    Name of Issuer: Apnimed, Inc.; CIK: 1745648; Address: Cambridge, MA; Submission type: D; Filing date: 2026-03-27; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 24999994; Total Amount Sold: 24999994; Federal exemptions: 06b
Mar 27, 2026SEC Form D 0001745648-26-000001
Jana CareRaised $1.39M (Form D filed Mar 26, 2026).
Evidence (1 event)
  • Mar 26, 2026 · SEC Form D 0001696563-26-000003
    Name of Issuer: Jana Care, Inc.; CIK: 1696563; Address: Watertown, MA; Submission type: D; Filing date: 2026-03-26; Industry Group: Other Health Care; Date of First Sale: 2026-03-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5999995; Total Amount Sold: 1390635; Federal exemptions: 06b
Mar 26, 2026SEC Form D 0001696563-26-000003
Adaptin BioRaised $1.91M (Form D filed Jan 5, 2026; amended Jun 22, 2026).
Evidence (1 event)
  • Jan 5, 2026 · SEC Form D 0001938571-26-000001
    Name of Issuer: ADAPTIN BIO, INC.; CIK: 1938571; Address: Charlotte, NC; Submission type: D; Filing date: 2026-01-05; Industry Group: Biotechnology; Date of First Sale: 2025-12-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1000000; Federal exemptions: 06b || Name of Issuer: ADAPTIN BIO, INC.; CIK: 1938571; Address: Charlotte, NC; Submission type: D/A; Filing date: 2026-02-20; Industry Group: Biotechnology; Date of First Sale: 2025-12-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1297000; Federal exemptions: 06b || Name of Issuer: ADAPTIN BIO, INC.; CIK: 1938571; Address: Charlotte, NC; Submission type: D/A; Filing date: 2026-03-23; Industry Group: Biotechnology; Date of First Sale: 2025-12-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1652000; Federal exemptions: 06b || Name of Issuer: ADAPTIN BIO, INC.; CIK: 1938571; Address: Charlotte, NC; Submission type: D/A; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2025-12-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1912000; Federal exemptions: 06b
Jan 5, 2026SEC Form D 0001938571-26-000001
Affinity BiosensorsRaised $4.9M (Form D filed Mar 23, 2026; amended Oct 14, 2026).
Evidence (1 event)
  • Mar 23, 2026 · SEC Form D 0001424288-26-000001
    Name of Issuer: AFFINITY BIOSENSORS LLC; CIK: 1424288; Address: Santa Barbara, CA; Submission type: D; Filing date: 2026-03-23; Industry Group: Other; Date of First Sale: 2026-03-20; Types of Securities Offered: Equity, Other (SAFE); Business combination transaction: false; Total Offering Amount: 18000000; Total Amount Sold: 1592385; Federal exemptions: 06b || Name of Issuer: AFFINITY BIOSENSORS LLC; CIK: 1424288; Address: Santa Barbara, CA; Submission type: D/A; Filing date: 2026-05-21; Industry Group: Other; Date of First Sale: 2026-03-20; Types of Securities Offered: Equity, Other (SAFE); Business combination transaction: false; Total Offering Amount: 18000000; Total Amount Sold: 2317385; Federal exemptions: 06b || Name of Issuer: AFFINITY BIOSENSORS LLC; CIK: 1424288; Address: Santa Barbara, CA; Submission type: D/A; Filing date: 2026-07-16; Industry Group: Other; Date of First Sale: 2026-03-20; Types of Securities Offered: Equity, Other (SAFE); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 2909771; Federal exemptions: 06b || Name of Issuer: AFFINITY BIOSENSORS LLC; CIK: 1424288; Address: Santa Barbara, CA; Submission type: D/A; Filing date: 2026-07-24; Industry Group: Other; Date of First Sale: 2026-03-20; Types of Securities Offered: Equity, Other (SAFE); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4004771; Federal exemptions: 06b || Name of Issuer: AFFINITY BIOSENSORS LLC; CIK: 1424288; Address: Santa Barbara, CA; Submission type: D/A; Filing date: 2026-09-16; Industry Group: Other; Date of First Sale: 2026-03-20; Types of Securities Offered: Equity, Other (SAFE); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4804771; Federal exemptions: 06b || Name of Issuer: AFFINITY BIOSENSORS LLC; CIK: 1424288; Address: Santa Barbara, CA; Submission type: D/A; Filing date: 2026-10-14; Industry Group: Other; Date of First Sale: 2026-03-20; Types of Securities Offered: Equity, Other (SAFE); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4904771; Federal exemptions: 06b
Mar 23, 2026SEC Form D 0001424288-26-000001
Liquet MedicalRaised $75K in debt securities (Form D filed Mar 23, 2026).
Evidence (1 event)
  • Mar 23, 2026 · SEC Form D 0001887812-26-000004
    Name of Issuer: Liquet Medical Inc.; CIK: 1887812; Address: Glen Allen, VA; Submission type: D; Filing date: 2026-03-23; Industry Group: Other Health Care; Date of First Sale: 2026-03-07; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 75000; Federal exemptions: 06b
Mar 23, 2026SEC Form D 0001887812-26-000004
Imperative CareRaised $111.27M in debt securities (Form D filed Mar 20, 2026; amended Jul 10, 2026); 23 roles open.
Evidence (1 event)
  • Mar 20, 2026 · SEC Form D 0001668962-26-000001
    Name of Issuer: Imperative Care, Inc.; CIK: 1668962; Address: Campbell, CA; Submission type: D; Filing date: 2026-03-20; Industry Group: Other Health Care; Date of First Sale: 2026-03-13; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 100000000; Total Amount Sold: 100000000; Federal exemptions: 06b || Name of Issuer: Imperative Care, Inc.; CIK: 1668962; Address: Campbell, CA; Submission type: D/A; Filing date: 2026-07-10; Industry Group: Other Health Care; Date of First Sale: 2026-03-13; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 111270000; Total Amount Sold: 111270000; Federal exemptions: 06b
Mar 20, 2026SEC Form D 0001668962-26-000001
Waypoint OrthopedicsRaised $300K in debt securities (Form D filed Mar 19, 2026).
Evidence (1 event)
  • Mar 19, 2026 · SEC Form D 0001828399-26-000001
    Name of Issuer: Waypoint Orthopedics, Inc.; CIK: 1828399; Address: Malvern, PA; Submission type: D; Filing date: 2026-03-19; Industry Group: Other Health Care; Date of First Sale: 2026-03-16; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 300000; Federal exemptions: 06b
Mar 19, 2026SEC Form D 0001828399-26-000001
Numerion LabsRaised $19.79M (Form D filed Mar 19, 2026).
Evidence (1 event)
  • Mar 19, 2026 · SEC Form D 0001231919-26-000263
    Name of Issuer: Numerion Labs, Inc.; CIK: 1736153; Address: San Francisco, CA; Submission type: D; Filing date: 2026-03-19; Industry Group: Biotechnology; Date of First Sale: 2026-03-10; Types of Securities Offered: Equity, Other (Offer and sale of Series D Preferred Stock and Common Stock issuable upon conversion thereof. Certain outstanding shares of Common Stock were exchanged for shares of a specific series of Issuer's Preferred Stock for no consideration.); Business combination transaction: false; Total Offering Amount: 35000000; Total Amount Sold: 19794945; Federal exemptions: 06b
Mar 19, 2026SEC Form D 0001231919-26-000263
Terrestrial BioRaised $57.3M (Form D filed Mar 19, 2026); 21 roles open.
Evidence (1 event)
  • Mar 19, 2026 · SEC Form D 0001578117-26-000002
    Name of Issuer: Terrestrial Bio, Inc.; CIK: 1578117; Address: Woburn, MA; Submission type: D; Filing date: 2026-03-19; Industry Group: Biotechnology; Date of First Sale: 2026-03-04; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 83538199; Total Amount Sold: 57301758; Federal exemptions: 06b
Mar 19, 2026SEC Form D 0001578117-26-000002
TelesairRaised $2.96M (Form D filed Mar 18, 2026).
Evidence (1 event)
  • Mar 18, 2026 · SEC Form D 0001964253-26-000003
    Name of Issuer: Telesair, Inc.; CIK: 1964253; Address: Irvine, CA; Submission type: D; Filing date: 2026-03-18; Industry Group: Other Technology; Date of First Sale: 2026-02-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6000000; Total Amount Sold: 2955791; Federal exemptions: 06b
Mar 18, 2026SEC Form D 0001964253-26-000003
Kala Pharmaceuticals, Inc.Raised $1.75M (Form D filed Mar 17, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Mar 17, 2026 · SEC Form D 0001829126-26-002408
    Name of Issuer: KALA BIO, Inc.; CIK: 1479419; Address: Arlington, MA; Submission type: D; Filing date: 2026-03-17; Industry Group: Pharmaceuticals; Date of First Sale: 2026-03-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1753500; Total Amount Sold: 1753500; Federal exemptions: 06b
  • Feb 13, 2026 · SEC Form D 0001829126-26-001292
    Name of Issuer: KALA BIO, Inc.; CIK: 1479419; Address: Arlington, MA; Submission type: D; Filing date: 2026-02-13; Industry Group: Biotechnology; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4200000; Total Amount Sold: 2250600; Federal exemptions: 06b
Mar 17, 2026SEC Form D 0001829126-26-002408
Strand TherapeuticsRaised $108.1M (Form D filed Mar 17, 2026); since then posted 5 roles.
Evidence (1 event)
  • Mar 17, 2026 · SEC Form D 0001231919-26-000259
    Name of Issuer: Strand Therapeutics Inc.; CIK: 1778475; Address: Boston, MA; Submission type: D; Filing date: 2026-03-17; Industry Group: Biotechnology; Date of First Sale: 2025-05-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120099940; Total Amount Sold: 108099927; Federal exemptions: 06b
Mar 17, 2026SEC Form D 0001231919-26-000259
Alphina TherapeuticsRaised $154K (Form D filed Mar 16, 2026).
Evidence (1 event)
  • Mar 16, 2026 · SEC Form D 0001882991-26-000003
    Name of Issuer: Alphina Therapeutics, Inc.; CIK: 1882991; Address: New Haven, CT; Submission type: D; Filing date: 2026-03-16; Industry Group: Biotechnology; Date of First Sale: 2026-02-23; Types of Securities Offered: Option/warrant, Other (Simple Agreements for Future Equity (SAFEs)); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 153715; Federal exemptions: 06b
Mar 16, 2026SEC Form D 0001882991-26-000003
Nocion TherapeuticsRaised $23M (Form D filed Mar 13, 2026).
Evidence (1 event)
  • Mar 13, 2026 · SEC Form D 0001841279-26-000003
    Name of Issuer: Nocion Therapeutics, Inc.; CIK: 1841279; Address: Watertown, MA; Submission type: D; Filing date: 2026-03-13; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 22999999; Total Amount Sold: 22999999; Federal exemptions: 06b
Mar 13, 2026SEC Form D 0001841279-26-000003
BioCyticsRaised $25K (Form D filed Mar 13, 2026).
Evidence (1 event)
  • Mar 13, 2026 · SEC Form D 0001971839-26-000001
    Name of Issuer: BioCytics, Inc.; CIK: 1971839; Address: Huntersville, NC; Submission type: D; Filing date: 2026-03-13; Industry Group: Biotechnology; Date of First Sale: 2026-01-02; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 7000000; Total Amount Sold: 25000; Federal exemptions: 06b
Mar 13, 2026SEC Form D 0001971839-26-000001
Ramona Optics Inc.Raised $26.04M (Form D filed Mar 12, 2026).
Evidence (1 event)
  • Mar 12, 2026 · SEC Form D 0001841317-26-000001
    Name of Issuer: Ramona Optics, Inc.; CIK: 1841317; Address: Durham, NC; Submission type: D; Filing date: 2026-03-12; Industry Group: Biotechnology; Date of First Sale: 2026-02-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31037360; Total Amount Sold: 26037360; Federal exemptions: 06b
Mar 12, 2026SEC Form D 0001841317-26-000001
ThrombolexRaised $32.78M (Form D filed Mar 12, 2026).
Evidence (1 event)
  • Mar 12, 2026 · SEC Form D 0001703764-26-000003
    Name of Issuer: Thrombolex, Inc.; CIK: 1703764; Address: Kingston, NJ; Submission type: D; Filing date: 2026-03-12; Industry Group: Other Health Care; Date of First Sale: 2026-02-26; Types of Securities Offered: Equity, Other (Includes Conversion of Outstanding Notes); Business combination transaction: false; Total Offering Amount: 51105000; Total Amount Sold: 32775000; Federal exemptions: 06b
Mar 12, 2026SEC Form D 0001703764-26-000003
Biosolution DesignsRaised $705K (Form D filed Mar 12, 2026).
Evidence (1 event)
  • Mar 12, 2026 · SEC Form D 0000892251-26-000043
    Name of Issuer: BioSolution Designs, Inc.; CIK: 2110022; Address: Frederick, MD; Submission type: D; Filing date: 2026-03-12; Industry Group: Biotechnology; Date of First Sale: 2026-03-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 705000; Federal exemptions: 06b
Mar 12, 2026SEC Form D 0000892251-26-000043
Slate MedicinesRaised $10M (Form D filed Mar 11, 2026).
Evidence (1 event)
  • Mar 11, 2026 · SEC Form D 0001231919-26-000246
    Name of Issuer: Slate Medicines, Inc.; CIK: 2117806; Address: Boston, MA; Submission type: D; Filing date: 2026-03-11; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 130000000; Total Amount Sold: 9999992; Federal exemptions: 06b
Mar 11, 2026SEC Form D 0001231919-26-000246
AirNexis TherapeuticsRaised $62M (Form D filed Mar 9, 2026).
Evidence (1 event)
  • Mar 9, 2026 · SEC Form D 0002116194-26-000001
    Name of Issuer: AirNexis Therapeutics, Inc.; CIK: 2116194; Address: Palo Alto, CA; Submission type: D; Filing date: 2026-03-09; Industry Group: Biotechnology; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 200000000; Total Amount Sold: 62000000; Federal exemptions: 06b
Mar 9, 2026SEC Form D 0002116194-26-000001
OS TherapiesRaised $5M (Form D filed Aug 25, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • Aug 25, 2026 · SEC Form D 0000921895-26-002306
    Name of Issuer: OS Therapies Inc; CIK: 1795091; Address: Grasonville, MD; Submission type: D; Filing date: 2026-08-25; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 5000000; Federal exemptions: 06b
  • Jul 16, 2026 · SEC Form D 0001795091-26-000003
    Name of Issuer: OS Therapies Inc; CIK: 1795091; Address: Grasonville, MD; Submission type: D; Filing date: 2026-07-16; Industry Group: Biotechnology; Date of First Sale: 2026-06-30; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 9250000; Total Amount Sold: 1600000; Federal exemptions: 06b
  • Mar 6, 2026 · SEC Form D 0001795091-26-000002
    Name of Issuer: OS Therapies Inc; CIK: 1795091; Address: Grasonville, MD; Submission type: D; Filing date: 2026-03-06; Industry Group: Biotechnology; Date of First Sale: 2026-03-04; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 2000000; Federal exemptions: 06b
Aug 25, 2026SEC Form D 0000921895-26-002306
ScienceRaised $230.05M (Form D filed Mar 6, 2026).
Evidence (1 event)
  • Mar 6, 2026 · SEC Form D 0001873836-26-000001
    Name of Issuer: Science Corp; CIK: 1873836; Address: Alameda, CA; Submission type: D; Filing date: 2026-03-06; Industry Group: Other Technology; Date of First Sale: 2026-02-26; Types of Securities Offered: Equity, Other ("Offering of Series C, Series C-1 and Series C-2 Preferred Stock (collectively, ""Series C""), and the underlying shares of Common Stock issuable upon conversion of Series C."); Business combination transaction: false; Total Offering Amount: 250000000; Total Amount Sold: 230049745; Federal exemptions: 06b
Mar 6, 2026SEC Form D 0001873836-26-000001
QureatorRaised $6.68M (Form D filed Mar 6, 2026).
Evidence (1 event)
  • Mar 6, 2026 · SEC Form D 0002109274-26-000001
    Name of Issuer: Qureator, Inc.; CIK: 2109274; Address: San Diego, CA; Submission type: D; Filing date: 2026-03-06; Industry Group: Biotechnology; Date of First Sale: 2025-12-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6881746; Total Amount Sold: 6680994; Federal exemptions: 06b
Mar 6, 2026SEC Form D 0002109274-26-000001
NuvairaRaised $35.76M (Form D filed Mar 4, 2026).
Evidence (1 event)
  • Mar 4, 2026 · SEC Form D 0001461990-26-000003
    Name of Issuer: NUVAIRA, INC.; CIK: 1461990; Address: Minneapolis, MN; Submission type: D; Filing date: 2026-03-04; Industry Group: Other Health Care; Date of First Sale: 2026-02-20; Types of Securities Offered: Equity, Other (Conversion of SAFEs; Conversion of debt); Business combination transaction: false; Total Offering Amount: 63576279; Total Amount Sold: 35764878; Federal exemptions: 06b
Mar 4, 2026SEC Form D 0001461990-26-000003
Aegle TherapeuticsRaised $2.28M (Form D filed Aug 28, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Aug 28, 2026 · SEC Form D 0001797825-26-000007
    Name of Issuer: Aegle Therapeutics Corp; CIK: 1797825; Address: Woburn, MA; Submission type: D; Filing date: 2026-08-28; Industry Group: Biotechnology; Date of First Sale: 2026-08-04; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2277698; Total Amount Sold: 2277698; Federal exemptions: 06b
  • Mar 3, 2026 · SEC Form D 0001231919-26-000232
    Name of Issuer: Aegle Therapeutics Corp; CIK: 1797825; Address: Woburn, MA; Submission type: D; Filing date: 2026-03-03; Industry Group: Biotechnology; Date of First Sale: 2025-12-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 700000; Total Amount Sold: 455695; Federal exemptions: 06b
Aug 28, 2026SEC Form D 0001797825-26-000007
Allyx Therapeutics Inc.Raised $26.43M (Form D filed May 11, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • May 11, 2026 · SEC Form D 0001865257-26-000004
    Name of Issuer: Allyx Therapeutics, Inc.; CIK: 1865257; Address: New Haven, CT; Submission type: D; Filing date: 2026-05-11; Industry Group: Biotechnology; Date of First Sale: 2026-05-04; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 29999999; Total Amount Sold: 26427730; Federal exemptions: 06b
  • Mar 3, 2026 · SEC Form D 0001865257-26-000003
    Name of Issuer: Allyx Therapeutics, Inc.; CIK: 1865257; Address: New Haven, CT; Submission type: D; Filing date: 2026-03-03; Industry Group: Biotechnology; Date of First Sale: 2026-02-23; Types of Securities Offered: Option/warrant, Other (Simple Agreements for Future Equity (SAFEs)); Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 3324918; Federal exemptions: 06b
May 11, 2026SEC Form D 0001865257-26-000004
MultiValent BiotherapiesRaised $10.01M (Form D filed Mar 2, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Mar 2, 2026 · SEC Form D 0002107846-26-000002
    Name of Issuer: MultiValent Biotherapies, Inc.; CIK: 2107846; Address: Los Altos, CA; Submission type: D; Filing date: 2026-03-02; Industry Group: Biotechnology; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 10012500; Federal exemptions: 06b
  • Feb 27, 2026 · SEC Form D 0002107846-26-000001
    Name of Issuer: MultiValent Biotherapies, Inc.; CIK: 2107846; Address: Los Altos, CA; Submission type: D; Filing date: 2026-02-27; Industry Group: Biotechnology; Date of First Sale: 2026-01-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4375; Total Amount Sold: 4375; Federal exemptions: 06b
Mar 2, 2026SEC Form D 0002107846-26-000002
TetraScienceRaised $15M (Form D filed Feb 27, 2026); 20 roles open.
Evidence (1 event)
  • Feb 27, 2026 · SEC Form D 0001855742-26-000003
    Name of Issuer: TetraScience, Inc.; CIK: 1855742; Address: Boston, MA; Submission type: D; Filing date: 2026-02-27; Industry Group: Other; Date of First Sale: 2026-02-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 14999985; Total Amount Sold: 14999985; Federal exemptions: 06b
Feb 27, 2026SEC Form D 0001855742-26-000003
CoRegenRaised $13.5M (Form D filed Feb 26, 2026).
Evidence (1 event)
  • Feb 26, 2026 · SEC Form D 0002012886-26-000003
    Name of Issuer: CoRegen, Inc.; CIK: 2012886; Address: Houston, TX; Submission type: D; Filing date: 2026-02-26; Industry Group: Biotechnology; Date of First Sale: 2025-10-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 13500000; Total Amount Sold: 13500000; Federal exemptions: 06b
Feb 26, 2026SEC Form D 0002012886-26-000003
GeneCaptureRaised $50K in debt securities (Form D filed Feb 26, 2026).
Evidence (1 event)
  • Feb 26, 2026 · SEC Form D 0001559176-26-000003
    Name of Issuer: GeneCapture, Inc.; CIK: 1559176; Address: Huntsville, AL; Submission type: D; Filing date: 2026-02-26; Industry Group: Other; Date of First Sale: 2026-02-25; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 50000; Federal exemptions: 06b
Feb 26, 2026SEC Form D 0001559176-26-000003
CASI PharmaceuticalsRaised $5M in debt securities (Form D filed Apr 28, 2026); +3 other Form D filings in the last 12 months.
Evidence (4 events)
  • Apr 28, 2026 · SEC Form D 0001962738-26-000004
    Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-04-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-17; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
  • Feb 26, 2026 · SEC Form D 0001962738-26-000003
    Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-02-26; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-19; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
  • Jan 28, 2026 · SEC Form D 0001962738-26-000002
    Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-01-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-01-09; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
  • Jan 28, 2026 · SEC Form D 0001962738-26-000001
    Name of Issuer: CASI Pharmaceuticals, Inc.; CIK: 1962738; Address: Beijing, China; Submission type: D; Filing date: 2026-01-28; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-27; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
Apr 28, 2026SEC Form D 0001962738-26-000004
NanoViricidesRaised $6M (Form D filed Feb 25, 2026).
Evidence (1 event)
  • Feb 25, 2026 · SEC Form D 0001104659-26-019284
    Name of Issuer: NANOVIRICIDES, INC.; CIK: 1379006; Address: Shelton, CT; Submission type: D; Filing date: 2026-02-25; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 6000000; Total Amount Sold: 6000000; Federal exemptions: 06b
Feb 25, 2026SEC Form D 0001104659-26-019284
Altesa BioSciencesRaised $75M (Form D filed Feb 23, 2026).
Evidence (1 event)
  • Feb 23, 2026 · SEC Form D 0001960618-26-000003
    Name of Issuer: Altesa BioSciences, Inc.; CIK: 1960618; Address: College Park, GA; Submission type: D; Filing date: 2026-02-23; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 74999986; Total Amount Sold: 74999986; Federal exemptions: 06b
Feb 23, 2026SEC Form D 0001960618-26-000003
ILIAD BiotechnologiesRaised $115.54M (Form D filed Feb 20, 2026).
Evidence (1 event)
  • Feb 20, 2026 · SEC Form D 0002112659-26-000001
    Name of Issuer: ILIAD BIOTECHNOLOGIES, INC.; CIK: 2112659; Address: Weston, FL; Submission type: D; Filing date: 2026-02-20; Industry Group: Biotechnology; Date of First Sale: 2026-02-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 115540057; Total Amount Sold: 115540057; Federal exemptions: 06b
Feb 20, 2026SEC Form D 0002112659-26-000001
Akava TherapeuticsFiled a Form D for an offering of up to $15M, no sales reported yet (filed Feb 19, 2026).
Evidence (1 event)
  • Feb 19, 2026 · SEC Form D 0001966649-26-000001
    Name of Issuer: Akava Therapeutics Inc.; CIK: 1966649; Address: Winnetka, IL; Submission type: D; Filing date: 2026-02-19; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 0; Federal exemptions: 06b
Feb 19, 2026SEC Form D 0001966649-26-000001
Aatru MedicalRaised $700K in debt securities (Form D filed Feb 18, 2026; amended Aug 11, 2026).
Evidence (1 event)
  • Feb 18, 2026 · SEC Form D 0001709493-26-000005
    Name of Issuer: Aatru Medical LLC; CIK: 1709493; Address: Cleveland, OH; Submission type: D; Filing date: 2026-02-18; Industry Group: Other Health Care; Date of First Sale: 2026-02-10; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 150000; Federal exemptions: 06b || Name of Issuer: Aatru Medical LLC; CIK: 1709493; Address: Cleveland, OH; Submission type: D/A; Filing date: 2026-08-11; Industry Group: Other Health Care; Date of First Sale: 2026-02-10; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 700000; Federal exemptions: 06b
Feb 18, 2026SEC Form D 0001709493-26-000005
Lexicon PharmaceuticalsRaised $55.67M (Form D filed Feb 17, 2026).
Evidence (1 event)
  • Feb 17, 2026 · SEC Form D 0001193125-26-054545
    Name of Issuer: LEXICON PHARMACEUTICALS, INC.; CIK: 1062822; Address: The Woodlands, TX; Submission type: D; Filing date: 2026-02-17; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-02; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 59150000; Total Amount Sold: 55668255; Federal exemptions: 06b
Feb 17, 2026SEC Form D 0001193125-26-054545
MedulocRaised $1.84M (Form D filed Aug 6, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Aug 6, 2026 · SEC Form D 0002014714-26-000005
    Name of Issuer: Meduloc, Inc.; CIK: 2014714; Address: Del Mar, CA; Submission type: D; Filing date: 2026-08-06; Industry Group: Other Health Care; Date of First Sale: 2026-07-24; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 1843000; Total Amount Sold: 1843000; Federal exemptions: 06b
  • Feb 17, 2026 · SEC Form D 0002014714-26-000001
    Name of Issuer: Meduloc, LLC; CIK: 2014714; Address: Del Mar, CA; Submission type: D; Filing date: 2026-02-17; Industry Group: Other Health Care; Date of First Sale: 2026-02-06; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2156940; Total Amount Sold: 2156940; Federal exemptions: 06b
Aug 6, 2026SEC Form D 0002014714-26-000005
NexEos Diagnostics, Inc.Raised $3M (Form D filed Feb 17, 2026).
Evidence (1 event)
  • Feb 17, 2026 · SEC Form D 0001783828-26-000001
    Name of Issuer: NexEos Diagnostics, Inc.; CIK: 1783828; Address: Chester Springs, PA; Submission type: D; Filing date: 2026-02-17; Industry Group: Other Health Care; Date of First Sale: 2026-02-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b
Feb 17, 2026SEC Form D 0001783828-26-000001
PAVmed Inc.Raised $30M (Form D filed Feb 17, 2026).
Evidence (1 event)
  • Feb 17, 2026 · SEC Form D 0001094891-26-000056
    Name of Issuer: PAVmed Inc.; CIK: 1624326; Address: New York, NY; Submission type: D; Filing date: 2026-02-17; Industry Group: Other Health Care; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 60000000; Total Amount Sold: 30000000; Federal exemptions: 06b
Feb 17, 2026SEC Form D 0001094891-26-000056
PraeventixRaised $5.6M (Form D filed Feb 13, 2026; amended Sep 10, 2026).
Evidence (1 event)
  • Feb 13, 2026 · SEC Form D 0001952974-26-000002
    Name of Issuer: Praeventix, Inc.; CIK: 1952974; Address: Exton, PA; Submission type: D; Filing date: 2026-02-13; Industry Group: Biotechnology; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 3000000; Federal exemptions: 06b || Name of Issuer: Praeventix, Inc.; CIK: 1952974; Address: Exton, PA; Submission type: D/A; Filing date: 2026-09-10; Industry Group: Biotechnology; Date of First Sale: 2026-02-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5601950; Total Amount Sold: 5601950; Federal exemptions: 06b
Feb 13, 2026SEC Form D 0001952974-26-000002
GeniPhysRaised $3M (Form D filed Feb 13, 2026).
Evidence (1 event)
  • Feb 13, 2026 · SEC Form D 0001955873-26-000001
    Name of Issuer: GeniPhys, Inc.; CIK: 1955873; Address: Indianapolis, IN; Submission type: D; Filing date: 2026-02-13; Industry Group: Other Health Care; Date of First Sale: 2026-01-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5550000; Total Amount Sold: 2999910; Federal exemptions: 06b
Feb 13, 2026SEC Form D 0001955873-26-000001
Ruskid LLCRaised $1.37M (Form D filed Feb 13, 2026).
Evidence (1 event)
  • Feb 13, 2026 · SEC Form D 0002110722-26-000001
    Name of Issuer: RUSKID LLC; CIK: 2110722; Address: Rancho Santa FE, CA; Submission type: D; Filing date: 2026-02-13; Industry Group: Biotechnology; Date of First Sale: 2026-01-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1370000; Federal exemptions: 06b
Feb 13, 2026SEC Form D 0002110722-26-000001
Jupiter BioMedical ResearchRaised $30K (Form D filed Sep 21, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Sep 21, 2026 · SEC Form D 0001079973-26-001264
    Name of Issuer: Jupiter Biomedical Research, Inc.; CIK: 1694280; Address: Palm Beach Gardens, FL; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-09-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 30000; Federal exemptions: 06b, 4a5
  • Feb 13, 2026 · SEC Form D 0001079973-26-000204
    Name of Issuer: Jupiter Biomedical Research, Inc.; CIK: 1694280; Address: Palm Beach Gardens, FL; Submission type: D; Filing date: 2026-02-13; Industry Group: Biotechnology; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 0; Federal exemptions: 06b, 4a5 || Name of Issuer: Jupiter Biomedical Research, Inc.; CIK: 1694280; Address: Palm Beach Gardens, FL; Submission type: D/A; Filing date: 2026-05-05; Industry Group: Biotechnology; Date of First Sale: 2026-02-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 500000; Federal exemptions: 06b, 4a5
Sep 21, 2026SEC Form D 0001079973-26-001264
Eldec PharmaceuticalsRaised $200K in debt securities (Form D filed Feb 12, 2026).
Evidence (1 event)
  • Feb 12, 2026 · SEC Form D 0002110508-26-000001
    Name of Issuer: Eldec Pharmaceuticals, Inc.; CIK: 2110508; Address: Chapel Hill, NC; Submission type: D; Filing date: 2026-02-12; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-11; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 200000; Federal exemptions: 06b
Feb 12, 2026SEC Form D 0002110508-26-000001
Ensho TherapeuticsRaised $7.28M (Form D filed Oct 15, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Oct 15, 2026 · SEC Form D 0002032849-26-000002
    Name of Issuer: Ensho Therapeutics, Inc.; CIK: 2032849; Address: Woodcliff Lake, NJ; Submission type: D; Filing date: 2026-10-15; Industry Group: Biotechnology; Date of First Sale: 2026-10-02; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 15604179; Total Amount Sold: 7281948; Federal exemptions: 06b
  • Feb 9, 2026 · SEC Form D 0002032849-26-000001
    Name of Issuer: Ensho Therapeutics, Inc.; CIK: 2032849; Address: Woodcliff Lake, NJ; Submission type: D; Filing date: 2026-02-09; Industry Group: Biotechnology; Date of First Sale: 2026-01-20; Types of Securities Offered: Equity, Security to be acquired; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 0; Federal exemptions: 06b
Oct 15, 2026SEC Form D 0002032849-26-000002
XDemicsRaised $7.4M (Form D filed Feb 6, 2026).
Evidence (1 event)
  • Feb 6, 2026 · SEC Form D 0002026725-26-000001
    Name of Issuer: XDemics Corp; CIK: 2026725; Address: San Rafael, CA; Submission type: D; Filing date: 2026-02-06; Industry Group: Biotechnology; Date of First Sale: 2025-10-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 7399999; Total Amount Sold: 7399999; Federal exemptions: 06b
Feb 6, 2026SEC Form D 0002026725-26-000001
Atrility MedicalRaised $1M in debt securities (Form D filed Feb 5, 2026).
Evidence (1 event)
  • Feb 5, 2026 · SEC Form D 0001734892-26-000003
    Name of Issuer: Atrility Medical, Inc.; CIK: 1734892; Address: Madison, WI; Submission type: D; Filing date: 2026-02-05; Industry Group: Other Health Care; Date of First Sale: 2025-11-07; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1000000; Federal exemptions: 06b
Feb 5, 2026SEC Form D 0001734892-26-000003
ImmunoMet TherapeuticsRaised $842K (Form D filed Feb 5, 2026).
Evidence (1 event)
  • Feb 5, 2026 · SEC Form D 0002109829-26-000001
    Name of Issuer: Immunomet Therapeutics, Inc.; CIK: 2109829; Address: Houston, TX; Submission type: D; Filing date: 2026-02-05; Industry Group: Biotechnology; Date of First Sale: 2026-01-21; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 842211; Federal exemptions: 06b
Feb 5, 2026SEC Form D 0002109829-26-000001
CompvideRaised $25K (Form D filed Feb 3, 2026).
Evidence (1 event)
  • Feb 3, 2026 · SEC Form D 0002105460-26-000001
    Name of Issuer: Compvide Inc.; CIK: 2105460; Address: Renton, WA; Submission type: D; Filing date: 2026-02-03; Industry Group: Biotechnology; Date of First Sale: 2026-01-05; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 25000; Federal exemptions: 06b
Feb 3, 2026SEC Form D 0002105460-26-000001
CognixionRaised $4.05M in debt securities (Form D filed Feb 3, 2026).
Evidence (1 event)
  • Feb 3, 2026 · SEC Form D 0001749036-26-000001
    Name of Issuer: Cognixion Corp; CIK: 1749036; Address: Santa Barbara, CA; Submission type: D; Filing date: 2026-02-03; Industry Group: Other; Date of First Sale: 2026-01-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 4050000; Total Amount Sold: 4050000; Federal exemptions: 06b
Feb 3, 2026SEC Form D 0001749036-26-000001
PridCor TherapeuticsFiled a Form D for an offering of up to $6.05M, no sales reported yet (filed May 8, 2026; amended Jul 6, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • May 8, 2026 · SEC Form D 0002074593-26-000002
    Name of Issuer: PridCor Therapeutics, LLC; CIK: 2074593; Address: Tuscaloosa, AL; Submission type: D; Filing date: 2026-05-08; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6045000; Total Amount Sold: 0; Federal exemptions: 06c || Name of Issuer: PridCor Therapeutics, LLC; CIK: 2074593; Address: Tuscaloosa, AL; Submission type: D/A; Filing date: 2026-07-06; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6045000; Total Amount Sold: 0; Federal exemptions: 06b
  • Feb 2, 2026 · SEC Form D 0002074593-26-000001
    Name of Issuer: PridCor Therapeutics, LLC; CIK: 2074593; Address: Tuscaloosa, AL; Submission type: D; Filing date: 2026-02-02; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 0; Federal exemptions: 06c
May 8, 2026SEC Form D 0002074593-26-000002
Navega Therapeutics, Inc.Raised $1.3M (Form D filed Jan 30, 2026).
Evidence (1 event)
  • Jan 30, 2026 · SEC Form D 0002107977-26-000001
    Name of Issuer: Navega Therapeutics, Inc.; CIK: 2107977; Address: San Diego, CA; Submission type: D; Filing date: 2026-01-30; Industry Group: Biotechnology; Date of First Sale: 2026-01-02; Types of Securities Offered: Security to be acquired; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1300000; Federal exemptions: 06b
Jan 30, 2026SEC Form D 0002107977-26-000001
Mirum PharmaceuticalsRaised $68.48M (Form D filed Jan 29, 2026); since then posted 71 roles.
Evidence (1 event)
  • Jan 29, 2026 · SEC Form D 0001759425-26-000005
    Name of Issuer: Mirum Pharmaceuticals, Inc.; CIK: 1759425; Address: Foster City, CA; Submission type: D; Filing date: 2026-01-29; Industry Group: Biotechnology; Date of First Sale: 2026-01-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 68480000; Total Amount Sold: 68480000; Federal exemptions: 06c
Jan 29, 2026SEC Form D 0001759425-26-000005
Riverain TechnologiesRaised $8.25M (Form D filed Jan 26, 2026).
Evidence (1 event)
  • Jan 26, 2026 · SEC Form D 0002107191-26-000001
    Name of Issuer: Riverain Technologies, Inc.; CIK: 2107191; Address: Miamisburg, OH; Submission type: D; Filing date: 2026-01-26; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8250000; Total Amount Sold: 8250000; Federal exemptions: 06b
Jan 26, 2026SEC Form D 0002107191-26-000001
iBioRaised $25.99M (Form D filed Jan 22, 2026); 1 role open.
Evidence (1 event)
  • Jan 22, 2026 · SEC Form D 0001104659-26-005775
    Name of Issuer: iBio, Inc.; CIK: 1420720; Address: San Diego, CA; Submission type: D; Filing date: 2026-01-22; Industry Group: Biotechnology; Date of First Sale: 2026-01-08; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 25985431; Total Amount Sold: 25985431; Federal exemptions: 06b
Jan 22, 2026SEC Form D 0001104659-26-005775
Spheryx, Inc.Raised $500K (Form D filed Jan 22, 2026).
Evidence (1 event)
  • Jan 22, 2026 · SEC Form D 0001239944-26-000006
    Name of Issuer: Spheryx, Inc.; CIK: 1630562; Address: New York, NY; Submission type: D; Filing date: 2026-01-22; Industry Group: Other; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2700000; Total Amount Sold: 500400; Federal exemptions: 06b
Jan 22, 2026SEC Form D 0001239944-26-000006
Caldera TherapeuticsRaised $37.5M (Form D filed Jan 21, 2026).
Evidence (1 event)
  • Jan 21, 2026 · SEC Form D 0002069936-26-000001
    Name of Issuer: Caldera Therapeutics, Inc.; CIK: 2069936; Address: Cambridge, MA; Submission type: D; Filing date: 2026-01-21; Industry Group: Biotechnology; Date of First Sale: 2026-01-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 37500000; Total Amount Sold: 37500000; Federal exemptions: 06b
Jan 21, 2026SEC Form D 0002069936-26-000001
Kaida BioPharmaForm D reports $1.6M sold since 2023 (filed Jan 21, 2026; amended Sep 1, 2026).
Evidence (1 event)
  • Jan 21, 2026 · SEC Form D 0001493152-26-003028
    Name of Issuer: Kaida BioPharma Inc.; CIK: 1973954; Address: Fort Lauderdale, FL; Submission type: D; Filing date: 2026-01-21; Industry Group: Biotechnology; Date of First Sale: 2023-10-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1570507; Federal exemptions: 06b || Name of Issuer: Kaida BioPharma Inc.; CIK: 1973954; Address: Fort Lauderdale, FL; Submission type: D/A; Filing date: 2026-09-01; Industry Group: Biotechnology; Date of First Sale: 2023-10-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4100507; Total Amount Sold: 1600507; Federal exemptions: 06b
Jan 21, 2026SEC Form D 0001493152-26-003028
RICOVR Healthcare Inc.Raised $550K (Form D filed Jan 20, 2026).
Evidence (1 event)
  • Jan 20, 2026 · SEC Form D 0001800521-26-000003
    Name of Issuer: Ricovr Healthcare Inc.; CIK: 1800521; Address: Princeton, NJ; Submission type: D; Filing date: 2026-01-20; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 550000; Federal exemptions: 06b
Jan 20, 2026SEC Form D 0001800521-26-000003
TwoStep TherapeuticsRaised $21.11M (Form D filed Jan 20, 2026); 1 role open.
Evidence (1 event)
  • Jan 20, 2026 · SEC Form D 0002015273-26-000002
    Name of Issuer: TwoStep Therapeutics, Inc.; CIK: 2015273; Address: San Carlos, CA; Submission type: D; Filing date: 2026-01-20; Industry Group: Other; Date of First Sale: 2026-01-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 62209510; Total Amount Sold: 21109518; Federal exemptions: 06b
Jan 20, 2026SEC Form D 0002015273-26-000002
PrognomiQRaised $11.87M (Form D filed Jan 16, 2026).
Evidence (1 event)
  • Jan 16, 2026 · SEC Form D 0002034700-26-000001
    Name of Issuer: PrognomIQ, Inc.; CIK: 2034700; Address: San Mateo, CA; Submission type: D; Filing date: 2026-01-16; Industry Group: Other Health Care; Date of First Sale: 2026-01-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11872784; Total Amount Sold: 11872784; Federal exemptions: 06b
Jan 16, 2026SEC Form D 0002034700-26-000001
Omega OphthalmicsRaised $320K (Form D filed Jan 15, 2026).
Evidence (1 event)
  • Jan 15, 2026 · SEC Form D 0001937862-26-000004
    Name of Issuer: Omega Ophthalmics LLC; CIK: 1937862; Address: Versailles, KY; Submission type: D; Filing date: 2026-01-15; Industry Group: Other; Date of First Sale: 2026-01-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 9600000; Total Amount Sold: 320000; Federal exemptions: 06b
Jan 15, 2026SEC Form D 0001937862-26-000004
Iaso TherapeuticsRaised $570K (Form D filed Jan 14, 2026).
Evidence (1 event)
  • Jan 14, 2026 · SEC Form D 0000905729-26-000020
    Name of Issuer: Iaso Therapeutics, Inc.; CIK: 1961165; Address: East Lansing, MI; Submission type: D; Filing date: 2026-01-14; Industry Group: Biotechnology; Date of First Sale: 2026-01-09; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 1800000; Total Amount Sold: 570000; Federal exemptions: 06b
Jan 14, 2026SEC Form D 0000905729-26-000020
Intelligent Bio SolutionsRaised $4.98M (Form D filed Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · SEC Form D 0001725430-26-000002
    Name of Issuer: INTELLIGENT BIO SOLUTIONS INC.; CIK: 1725430; Address: New York, NY; Submission type: D; Filing date: 2026-09-14; Industry Group: Other Health Care; Date of First Sale: 2026-08-31; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 4979631; Total Amount Sold: 4979631; Federal exemptions: 06b
Sep 14, 2026SEC Form D 0001725430-26-000002
ABLi Therapeutics, Inc.Raised $1M (Form D filed Jan 13, 2026).
Evidence (1 event)
  • Jan 13, 2026 · SEC Form D 0002104142-26-000001
    Name of Issuer: ABLi Therapeutics, Inc.; CIK: 2104142; Address: Atlanta, GA; Submission type: D; Filing date: 2026-01-13; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 1000000; Federal exemptions: 06b
Jan 13, 2026SEC Form D 0002104142-26-000001
Immorta BioForm D reports $613K sold since 2024 (filed Oct 16, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Oct 16, 2026 · SEC Form D 0002102665-26-000002
    Name of Issuer: Immorta Bio, Inc.; CIK: 2102665; Address: Miami Beach, FL; Submission type: D; Filing date: 2026-10-16; Industry Group: Biotechnology; Date of First Sale: 2024-11-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 612503; Federal exemptions: 06c
  • Jan 8, 2026 · SEC Form D 0002102665-26-000001
    Name of Issuer: Immorta Bio, Inc.; CIK: 2102665; Address: Miami Beach, FL; Submission type: D; Filing date: 2026-01-08; Industry Group: Biotechnology; Date of First Sale: 2023-11-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 450000; Federal exemptions: 06c
Oct 16, 2026SEC Form D 0002102665-26-000002
VogenxRaised $750K in debt securities (Form D filed Jan 7, 2026).
Evidence (1 event)
  • Jan 7, 2026 · SEC Form D 0001903784-26-000002
    Name of Issuer: Vogenx, Inc.; CIK: 1903784; Address: Raleigh, NC; Submission type: D; Filing date: 2026-01-07; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-10; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 750000; Federal exemptions: 06b
Jan 7, 2026SEC Form D 0001903784-26-000002
Harvard Apparatus Regenerative TechnologyRaised $2.84M (Form D filed Sep 14, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Sep 14, 2026 · SEC Form D 0001437749-26-030242
    Name of Issuer: Harvard Apparatus Regenerative Technology, Inc.; CIK: 1563665; Address: Holliston, MA; Submission type: D; Filing date: 2026-09-14; Industry Group: Biotechnology; Date of First Sale: 2026-09-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2838911; Federal exemptions: 06b
  • Jan 6, 2026 · SEC Form D 0001437749-26-000454
    Name of Issuer: Harvard Apparatus Regenerative Technology, Inc.; CIK: 1563665; Address: Holliston, MA; Submission type: D; Filing date: 2026-01-06; Industry Group: Biotechnology; Date of First Sale: 2025-12-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 700000; Federal exemptions: 06b
Sep 14, 2026SEC Form D 0001437749-26-030242
Spiro MedicalRaised $37.1M (Form D filed Jan 5, 2026).
Evidence (1 event)
  • Jan 5, 2026 · SEC Form D 0001996433-26-000001
    Name of Issuer: Spiro Medical Inc.; CIK: 1996433; Address: Belleair Bluffs, FL; Submission type: D; Filing date: 2026-01-05; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 69095598; Total Amount Sold: 37095655; Federal exemptions: 06b
Jan 5, 2026SEC Form D 0001996433-26-000001
Hyku BiosciencesRaised $8.61M (Form D filed Aug 13, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Aug 13, 2026 · SEC Form D 0001980518-26-000004
    Name of Issuer: HYKU BIOSCIENCES INC.; CIK: 1980518; Address: Concord, MA; Submission type: D; Filing date: 2026-08-13; Industry Group: Other; Date of First Sale: 2026-07-30; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 8612446; Total Amount Sold: 8612446; Federal exemptions: 06b
  • Jan 2, 2026 · SEC Form D 0001980518-26-000001
    Name of Issuer: HYKU BIOSCIENCES INC.; CIK: 1980518; Address: Burlington, MA; Submission type: D; Filing date: 2026-01-02; Industry Group: Other; Date of First Sale: 2025-12-10; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 21000000; Total Amount Sold: 6600000; Federal exemptions: 06b
Aug 13, 2026SEC Form D 0001980518-26-000004
SonoTheraRaised $125.45M (Form D filed Jun 30, 2026); since then posted 2 roles.
Evidence (1 event)
  • Jun 30, 2026 · SEC Form D 0001945154-26-000002
    Name of Issuer: SonoThera, Inc.; CIK: 1945154; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-30; Industry Group: Biotechnology; Date of First Sale: 2026-06-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 125450218; Total Amount Sold: 125450218; Federal exemptions: 06c
Jun 30, 2026SEC Form D 0001945154-26-000002
Rapalogix HealthRaised $19.11M (Form D filed Jun 26, 2026).
Evidence (1 event)
  • Jun 26, 2026 · SEC Form D 0002008372-26-000002
    Name of Issuer: Rapalogix Health, Inc.; CIK: 2008372; Address: Carlsbad, CA; Submission type: D; Filing date: 2026-06-26; Industry Group: Biotechnology; Date of First Sale: 2026-06-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 24999999; Total Amount Sold: 19112746; Federal exemptions: 06b
Jun 26, 2026SEC Form D 0002008372-26-000002
Lycia TherapeuticsRaised $75M (Form D filed Jun 25, 2026); 4 roles open.
Evidence (1 event)
  • Jun 25, 2026 · SEC Form D 0001806540-26-000001
    Name of Issuer: Lycia Therapeutics, Inc.; CIK: 1806540; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-25; Industry Group: Biotechnology; Date of First Sale: 2026-06-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 75000000; Total Amount Sold: 75000000; Federal exemptions: 06b
Jun 25, 2026SEC Form D 0001806540-26-000001
TETmedicalRaised $3.53M (Form D filed Jun 24, 2026).
Evidence (1 event)
  • Jun 24, 2026 · SEC Form D 0002080612-26-000037
    Name of Issuer: TETmedical, Inc.; CIK: 1980705; Address: Fair Haven, NJ; Submission type: D; Filing date: 2026-06-24; Industry Group: Biotechnology; Date of First Sale: 2026-06-12; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 9812108; Total Amount Sold: 3533611; Federal exemptions: 06b
Jun 24, 2026SEC Form D 0002080612-26-000037
EyenukRaised $5.61M (Form D filed Jun 22, 2026).
Evidence (1 event)
  • Jun 22, 2026 · SEC Form D 0001679996-26-000004
    Name of Issuer: Eyenuk, Inc.; CIK: 1679996; Address: Woodland Hills, CA; Submission type: D; Filing date: 2026-06-22; Industry Group: Other Health Care; Date of First Sale: 2026-04-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5648246; Total Amount Sold: 5607046; Federal exemptions: 06b
Jun 22, 2026SEC Form D 0001679996-26-000004
NucleinRaised $9.25M in debt securities (Form D filed Jun 22, 2026; amended Aug 14, 2026).
Evidence (1 event)
  • Jun 22, 2026 · SEC Form D 0001787352-26-000003
    Name of Issuer: Nuclein, LLC; CIK: 1787352; Address: Austin, TX; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2026-06-04; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 11114842; Total Amount Sold: 1295000; Federal exemptions: 06b || Name of Issuer: Nuclein, LLC; CIK: 1787352; Address: Austin, TX; Submission type: D/A; Filing date: 2026-08-14; Industry Group: Biotechnology; Date of First Sale: 2026-06-04; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 16114842; Total Amount Sold: 9253488; Federal exemptions: 06b
Jun 22, 2026SEC Form D 0001787352-26-000003
Aspira Women's HealthRaised $1.49M (Form D filed Jun 22, 2026); 3 roles open.
Evidence (1 event)
  • Jun 22, 2026 · SEC Form D 0001104659-26-076151
    Name of Issuer: Aspira Women's Health Inc.; CIK: 926617; Address: Austin, TX; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2026-06-05; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1485000; Total Amount Sold: 1485000; Federal exemptions: 06b
Jun 22, 2026SEC Form D 0001104659-26-076151
CellanomeRaised $75.93M (Form D filed Jun 22, 2026); since then posted 11 roles.
Evidence (1 event)
  • Jun 22, 2026 · SEC Form D 0000905148-26-003005
    Name of Issuer: Cellanome, Inc.; CIK: 1886462; Address: Foster City, CA; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: 2025-12-23; Types of Securities Offered: Equity, Other (Series C Preferred Stock); Business combination transaction: false; Total Offering Amount: 75930476; Total Amount Sold: 75930476; Federal exemptions: 06b
Jun 22, 2026SEC Form D 0000905148-26-003005
AcuraStemFiled a Form D for an offering of up to $5M, no sales reported yet (filed Jun 22, 2026).
Evidence (1 event)
  • Jun 22, 2026 · SEC Form D 0001745880-26-000001
    Name of Issuer: AcuraStem Inc; CIK: 1745880; Address: Pasadena, CA; Submission type: D; Filing date: 2026-06-22; Industry Group: Biotechnology; Date of First Sale: Yet to Occur; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Convertible promissory note); Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 0; Federal exemptions: 06b
Jun 22, 2026SEC Form D 0001745880-26-000001
Tolerance BioRaised $15.1M (Form D filed Jun 18, 2026).
Evidence (1 event)
  • Jun 18, 2026 · SEC Form D 0001493152-26-029282
    Name of Issuer: Tolerance Bio Inc.; CIK: 2075488; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-06-18; Industry Group: Biotechnology; Date of First Sale: 2026-06-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 15101584; Federal exemptions: 06b
Jun 18, 2026SEC Form D 0001493152-26-029282
Perimeter Medical Imaging AIRaised $4M in debt securities (Form D filed Jun 3, 2026; amended Jun 18, 2026); +1 other Form D filing in the last 12 months; 8 roles open.
Evidence (2 events)
  • Jun 3, 2026 · SEC Form D 0001818286-26-000002
    Name of Issuer: Perimeter Medical Imaging AI, Inc.; CIK: 1818286; Address: Ontario, Canada; Submission type: D; Filing date: 2026-06-03; Industry Group: Other Health Care; Date of First Sale: 2026-04-27; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 2000000; Federal exemptions: 06b || Name of Issuer: Perimeter Medical Imaging AI, Inc.; CIK: 1818286; Address: Ontario, Canada; Submission type: D/A; Filing date: 2026-06-18; Industry Group: Other Health Care; Date of First Sale: 2026-04-27; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b
  • Jun 3, 2026 · SEC Form D 0001818286-26-000001
    Name of Issuer: Perimeter Medical Imaging AI, Inc.; CIK: 1818286; Address: Ontario, Canada; Submission type: D; Filing date: 2026-06-03; Industry Group: Other Health Care; Date of First Sale: 2026-05-05; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1075653; Total Amount Sold: 1075653; Federal exemptions: 06b
Jun 3, 2026SEC Form D 0001818286-26-000002
ScitaraRaised $5M in debt securities (Form D filed Jun 18, 2026).
Evidence (1 event)
  • Jun 18, 2026 · SEC Form D 0001104659-26-075640
    Name of Issuer: Scitara Corp; CIK: 1788003; Address: Marlborough, MA; Submission type: D; Filing date: 2026-06-18; Industry Group: Other Technology; Date of First Sale: 2026-04-24; Types of Securities Offered: Debt, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 5000000; Federal exemptions: 06b
Jun 18, 2026SEC Form D 0001104659-26-075640
EndoSoundRaised $250K (Form D filed Jun 17, 2026).
Evidence (1 event)
  • Jun 17, 2026 · SEC Form D 0001850978-26-000009
    Name of Issuer: EndoSound, Inc.; CIK: 1850978; Address: Portland, OR; Submission type: D; Filing date: 2026-06-17; Industry Group: Other Health Care; Date of First Sale: 2026-06-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 250000; Federal exemptions: 06b
Jun 17, 2026SEC Form D 0001850978-26-000009
Reservoir NeuroscienceRaised $3M (Form D filed Jun 17, 2026).
Evidence (1 event)
  • Jun 17, 2026 · SEC Form D 0001878332-26-000004
    Name of Issuer: Reservoir Neuroscience, Inc.; CIK: 1878332; Address: San Francisco, CA; Submission type: D; Filing date: 2026-06-17; Industry Group: Biotechnology; Date of First Sale: 2026-06-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 2999999; Federal exemptions: 06b
Jun 17, 2026SEC Form D 0001878332-26-000004
CND Life SciencesRaised $6.32M in debt securities (Form D filed Jun 16, 2026; amended Aug 3, 2026).
Evidence (1 event)
  • Jun 16, 2026 · SEC Form D 0001841099-26-000001
    Name of Issuer: CND Life Sciences, Inc.; CIK: 1841099; Address: Scottsdale, AZ; Submission type: D; Filing date: 2026-06-16; Industry Group: Biotechnology; Date of First Sale: 2026-06-09; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 6250000; Total Amount Sold: 4314750; Federal exemptions: 06b || Name of Issuer: CND Life Sciences, Inc.; CIK: 1841099; Address: Scottsdale, AZ; Submission type: D/A; Filing date: 2026-08-03; Industry Group: Biotechnology; Date of First Sale: 2026-06-09; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 6316514; Total Amount Sold: 6316514; Federal exemptions: 06b
Jun 16, 2026SEC Form D 0001841099-26-000001
Nirrin Technologies Inc.Raised $6.7M (Form D filed Jun 15, 2026).
Evidence (1 event)
  • Jun 15, 2026 · SEC Form D 0001889145-26-000001
    Name of Issuer: Nirrin Technologies, Inc.; CIK: 1889145; Address: Billerica, MA; Submission type: D; Filing date: 2026-06-15; Industry Group: Biotechnology; Date of First Sale: 2025-09-23; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 9711196; Total Amount Sold: 6699781; Federal exemptions: 06b
Jun 15, 2026SEC Form D 0001889145-26-000001
Anodyne NanotechRaised $12.6M (Form D filed Jun 11, 2026).
Evidence (1 event)
  • Jun 11, 2026 · SEC Form D 0001818572-26-000003
    Name of Issuer: Anodyne Nanotech, Inc.; CIK: 1818572; Address: Boston, MA; Submission type: D; Filing date: 2026-06-11; Industry Group: Other Health Care; Date of First Sale: 2026-05-27; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 17259023; Total Amount Sold: 12597058; Federal exemptions: 06b
Jun 11, 2026SEC Form D 0001818572-26-000003
Quince TherapeuticsRaised $114.72M (Form D filed Jun 11, 2026).
Evidence (1 event)
  • Jun 11, 2026 · SEC Form D 0000912282-26-000809
    Name of Issuer: Quince Therapeutics, Inc.; CIK: 1662774; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-11; Industry Group: Biotechnology; Date of First Sale: 2026-05-18; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 186422679; Total Amount Sold: 114720542; Federal exemptions: 06b
Jun 11, 2026SEC Form D 0000912282-26-000809
ContralineRaised $55.8M (Form D filed Jun 10, 2026).
Evidence (1 event)
  • Jun 10, 2026 · SEC Form D 0001818752-26-000003
    Name of Issuer: Contraline, Inc.; CIK: 1818752; Address: Charlottesville, VA; Submission type: D; Filing date: 2026-06-10; Industry Group: Biotechnology; Date of First Sale: 2026-05-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 115929658; Total Amount Sold: 55804741; Federal exemptions: 06b
Jun 10, 2026SEC Form D 0001818752-26-000003
Thiogenesis Therapeutics, Inc.Raised $29K (Form D filed Jun 9, 2026).
Evidence (1 event)
  • Jun 9, 2026 · SEC Form D 0001062993-26-003123
    Name of Issuer: Thiogenesis Therapeutics, Corp.; CIK: 1877778; Address: Ontario, Canada; Submission type: D; Filing date: 2026-06-09; Industry Group: Biotechnology; Date of First Sale: 2026-06-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 28964; Total Amount Sold: 28964; Federal exemptions: 06b
Jun 9, 2026SEC Form D 0001062993-26-003123
Infinant HealthRaised $39.25M (Form D filed Jun 8, 2026).
Evidence (1 event)
  • Jun 8, 2026 · SEC Form D 0000905148-26-002831
    Name of Issuer: Infinant Health, Inc.; CIK: 2139235; Address: Sacramento, CA; Submission type: D; Filing date: 2026-06-08; Industry Group: Other Health Care; Date of First Sale: 2026-05-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 118230513; Total Amount Sold: 39247552; Federal exemptions: 06b
Jun 8, 2026SEC Form D 0000905148-26-002831
HCW BiologicsRaised $4M (Form D filed Jun 8, 2026).
Evidence (1 event)
  • Jun 8, 2026 · SEC Form D 0001828673-26-000003
    Name of Issuer: HCW Biologics Inc.; CIK: 1828673; Address: Miramar, FL; Submission type: D; Filing date: 2026-06-08; Industry Group: Biotechnology; Date of First Sale: 2026-05-21; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 4000000; Federal exemptions: 06b
Jun 8, 2026SEC Form D 0001828673-26-000003
Spine BioPharmaRaised $385K (Form D filed Jun 5, 2026).
Evidence (1 event)
  • Jun 5, 2026 · SEC Form D 0001852647-26-000002
    Name of Issuer: Spine BioPharma, Inc.; CIK: 1852647; Address: New York, NY; Submission type: D; Filing date: 2026-06-05; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8500000; Total Amount Sold: 384798; Federal exemptions: 06b
Jun 5, 2026SEC Form D 0001852647-26-000002
Human ContinuumRaised $723K (Form D filed Jun 5, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Jun 5, 2026 · SEC Form D 0002138781-26-000001
    Name of Issuer: Human Continuum Inc.; CIK: 2138781; Address: Jupiter, FL; Submission type: D; Filing date: 2026-06-05; Industry Group: Other; Date of First Sale: 2026-05-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 722500; Total Amount Sold: 722500; Federal exemptions: 06b
  • Jun 5, 2026 · SEC Form D 0002138781-26-000002
    Name of Issuer: Human Continuum Inc.; CIK: 2138781; Address: Jupiter, FL; Submission type: D; Filing date: 2026-06-05; Industry Group: Other; Date of First Sale: 2026-05-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2445000; Total Amount Sold: 2445000; Federal exemptions: 06b
Jun 5, 2026SEC Form D 0002138781-26-000001
Antlia Bioscience, Inc.Raised $6M (Form D filed Jun 5, 2026).
Evidence (1 event)
  • Jun 5, 2026 · SEC Form D 0001829522-26-000003
    Name of Issuer: Antlia Bioscience, Inc.; CIK: 1829522; Address: Encinitas, CA; Submission type: D; Filing date: 2026-06-05; Industry Group: Biotechnology; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 6000000; Federal exemptions: 06b
Jun 5, 2026SEC Form D 0001829522-26-000003
PROTECT3D Inc.Raised $845K in debt securities (Form D filed Jun 4, 2026).
Evidence (1 event)
  • Jun 4, 2026 · SEC Form D 0001792316-26-000002
    Name of Issuer: Protect3d, Inc.; CIK: 1792316; Address: Durham, NC; Submission type: D; Filing date: 2026-06-04; Industry Group: Other Health Care; Date of First Sale: 2026-04-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 845000; Federal exemptions: 06b
Jun 4, 2026SEC Form D 0001792316-26-000002
Bond BiosciencesRaised $7.61M (Form D filed Apr 8, 2026; amended Oct 5, 2026).
Evidence (1 event)
  • Apr 8, 2026 · SEC Form D 0001014108-26-000021
    Name of Issuer: Bond Biosciences, Inc.; CIK: 1824224; Address: Parkville, MO; Submission type: D; Filing date: 2026-04-08; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 5342880; Federal exemptions: 06b || Name of Issuer: Bond Biosciences, Inc.; CIK: 1824224; Address: Parkville, MO; Submission type: D/A; Filing date: 2026-06-04; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 5927939; Federal exemptions: 06b || Name of Issuer: Bond Biosciences, Inc.; CIK: 1824224; Address: Parkville, MO; Submission type: D/A; Filing date: 2026-10-05; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 7614879; Federal exemptions: 06b
Apr 8, 2026SEC Form D 0001014108-26-000021
Illuminare BiotechnologiesRaised $3.65M (Form D filed Jun 4, 2026).
Evidence (1 event)
  • Jun 4, 2026 · SEC Form D 0001701523-26-000003
    Name of Issuer: Illuminare Biotechnologies Inc; CIK: 1701523; Address: Brooklyn, NY; Submission type: D; Filing date: 2026-06-04; Industry Group: Biotechnology; Date of First Sale: 2026-05-07; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 3650000; Federal exemptions: 06b
Jun 4, 2026SEC Form D 0001701523-26-000003
Senti BiosciencesRaised $10M in debt securities (Form D filed Jun 4, 2026).
Evidence (1 event)
  • Jun 4, 2026 · SEC Form D 0001193125-26-256064
    Name of Issuer: Senti Biosciences Holdings, Inc.; CIK: 1854270; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-04; Industry Group: Biotechnology; Date of First Sale: 2026-05-20; Types of Securities Offered: Debt, Other (Guarantee); Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 10000000; Federal exemptions: 06b
Jun 4, 2026SEC Form D 0001193125-26-256064
Biolexis TherapeuticsRaised $1.6M (Form D filed Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · SEC Form D 0001914060-26-000001
    Name of Issuer: Biolexis Therapeutics Inc.; CIK: 1914060; Address: Lehi, UT; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-05-20; Types of Securities Offered: Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 1600000; Federal exemptions: 06b
Jun 3, 2026SEC Form D 0001914060-26-000001
BioStem TechnologiesRaised $3M (Form D filed Oct 9, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Oct 9, 2026 · SEC Form D 0001213900-26-108470
    Name of Issuer: BioStem Technologies, Inc.; CIK: 1658678; Address: Pompano Beach, FL; Submission type: D; Filing date: 2026-10-09; Industry Group: Biotechnology; Date of First Sale: 2026-09-29; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b
  • Sep 21, 2026 · SEC Form D 0001213900-26-101819
    Name of Issuer: BioStem Technologies, Inc.; CIK: 1658678; Address: Pompano Beach, FL; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 0; Federal exemptions: 06b
Oct 9, 2026SEC Form D 0001213900-26-108470
Galaxy DiagnosticsRaised $3.02M (Form D filed Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · SEC Form D 0001462444-26-000002
    Name of Issuer: Galaxy Diagnostics, Inc.; CIK: 1462444; Address: Durham, NC; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-05-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5699460; Total Amount Sold: 3019645; Federal exemptions: 06b
Jun 3, 2026SEC Form D 0001462444-26-000002
Entact BioRaised $10M (Form D filed Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · SEC Form D 0000905148-26-002800
    Name of Issuer: Entact Bio, Inc.; CIK: 2008244; Address: Watertown, MA; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-01-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 9999997; Total Amount Sold: 9999997; Federal exemptions: 06b
Jun 3, 2026SEC Form D 0000905148-26-002800
Optimeos Life Sciences, Inc.Raised $1M in debt securities (Form D filed Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · SEC Form D 0001819114-26-000001
    Name of Issuer: Optimeos Life Sciences, Inc.; CIK: 1819114; Address: Princeton, NJ; Submission type: D; Filing date: 2026-06-03; Industry Group: Biotechnology; Date of First Sale: 2026-05-22; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1000000; Federal exemptions: 06b
Jun 3, 2026SEC Form D 0001819114-26-000001
Channel RoboticsRaised $4.72M (Form D filed Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · SEC Form D 0002045979-26-000002
    Name of Issuer: CHANNEL ROBOTICS, INC.; CIK: 2045979; Address: Del Mar, CA; Submission type: D; Filing date: 2026-06-03; Industry Group: Other Health Care; Date of First Sale: 2026-06-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4718586; Total Amount Sold: 4718586; Federal exemptions: 06b
Jun 3, 2026SEC Form D 0002045979-26-000002
Socrates Health SolutionsFiled a Form D for an offering of up to $1.5M, no sales reported yet (filed Jun 2, 2026).
Evidence (1 event)
  • Jun 2, 2026 · SEC Form D 0001594118-26-000003
    Name of Issuer: Socrates Health Solutions, Inc.; CIK: 1594118; Address: Dallas, TX; Submission type: D; Filing date: 2026-06-02; Industry Group: Other Health Care; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity, Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 0; Federal exemptions: 06b
Jun 2, 2026SEC Form D 0001594118-26-000003
Portal BiotechnologiesRaised $9M (Form D filed May 29, 2026).
Evidence (1 event)
  • May 29, 2026 · SEC Form D 0002049466-26-000004
    Name of Issuer: Portal Biotechnologies, Inc.; CIK: 2049466; Address: Arlington, MA; Submission type: D; Filing date: 2026-05-29; Industry Group: Biotechnology; Date of First Sale: 2026-05-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8999999; Total Amount Sold: 8999999; Federal exemptions: 06b
May 29, 2026SEC Form D 0002049466-26-000004
Fusion Energy Solutions DBA Serva EnergyRaised $2.5M (Form D filed May 29, 2026).
Evidence (1 event)
  • May 29, 2026 · SEC Form D 0001779623-26-000003
    Name of Issuer: SERVA ENERGY, INC.; CIK: 1779623; Address: Tempe, AZ; Submission type: D; Filing date: 2026-05-29; Industry Group: Other Technology; Date of First Sale: 2026-05-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 2500000; Federal exemptions: 06b
May 29, 2026SEC Form D 0001779623-26-000003
ImaginosticsRaised $40K (Form D filed May 29, 2026); +6 other Form D filings in the last 12 months.
Evidence (7 events)
  • May 29, 2026 · SEC Form D 0002122464-26-000008
    Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-05-29; Industry Group: Biotechnology; Date of First Sale: 2026-05-14; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are Simple Agreements for Future Equity (SAFEs), which are convertible into equity securities of the issuer,typically preferred stock,upon the occurrence of specified triggering events including future financingroundS.); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 40000; Federal exemptions: 06b
  • Apr 6, 2026 · SEC Form D 0002122464-26-000004
    Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-04-06; Industry Group: Biotechnology; Date of First Sale: 2021-11-20; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are Simple Agreements for Future Equity (SAFEs), which are convertible into equity securities of the issuer, typically preferred stock, upon the occurrence of specified triggering events, including future financing rounds.); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 500000; Federal exemptions: 06b || Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D/A; Filing date: 2026-04-08; Industry Group: Biotechnology; Date of First Sale: 2021-11-20; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are Simple Agreements for Future Equity (SAFEs), which are convertible into equity securities of the issuer, typically preferred stock, upon the occurrence of specified triggering events, including future financing rounds.); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 50000; Federal exemptions: 06b
  • Apr 6, 2026 · SEC Form D 0002122464-26-000005
    Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-04-06; Industry Group: Biotechnology; Date of First Sale: 2024-02-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are Simple Agreements for Future Equity (SAFEs), which are convertible into equity securities of the issuer, typically preferred stock, upon the occurrence of specified triggering events, including future financing rounds.); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 5353594; Federal exemptions: 06b
  • Apr 6, 2026 · SEC Form D 0002122464-26-000006
    Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-04-06; Industry Group: Biotechnology; Date of First Sale: 2022-09-06; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are convertible promissory notes that may convert into equity securities of the issuer, typically preferred stock, upon the occurrence of specified events, including qualified financing.); Business combination transaction: false; Total Offering Amount: 725274; Total Amount Sold: 725274; Federal exemptions: 06b
  • Apr 3, 2026 · SEC Form D 0002122464-26-000003
    Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-04-03; Industry Group: Biotechnology; Date of First Sale: 2021-02-09; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are Simple Agreements for Future Equity (SAFEs), which are convertible into equity securities of the issuer, typically preferred stock, upon the occurrence of specified triggering events, including future financing rounds.); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 516900; Federal exemptions: 06b
  • Apr 3, 2026 · SEC Form D 0002122464-26-000002
    Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-04-03; Industry Group: Biotechnology; Date of First Sale: 2020-09-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (These securities are Simple Agreements for Future Equity (SAFEs), which are convertible into equity securities of the issuer, typically preferred stock, upon the occurrence of specified triggering events, including future financing rounds.); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 100000; Federal exemptions: 06b
  • Apr 3, 2026 · SEC Form D 0002122464-26-000001
    Name of Issuer: IMAGINOSTICS, INC.; CIK: 2122464; Address: Orlando, FL; Submission type: D; Filing date: 2026-04-03; Industry Group: Biotechnology; Date of First Sale: 2018-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 400000; Federal exemptions: 06b
May 29, 2026SEC Form D 0002122464-26-000008
Oncosynergy, Inc.Raised $6.61M (Form D filed May 26, 2026).
Evidence (1 event)
  • May 26, 2026 · SEC Form D 0001556747-26-000003
    Name of Issuer: ONCOSYNERGY, INC.; CIK: 1556747; Address: Stamford, CT; Submission type: D; Filing date: 2026-05-26; Industry Group: Biotechnology; Date of First Sale: 2026-05-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8208830; Total Amount Sold: 6608832; Federal exemptions: 06b
May 26, 2026SEC Form D 0001556747-26-000003
ViCardia TherapeuticsRaised $700K (Form D filed May 21, 2026).
Evidence (1 event)
  • May 21, 2026 · SEC Form D 0002135564-26-000001
    Name of Issuer: ViCardia Therapeutics, Inc.; CIK: 2135564; Address: San Francisco, CA; Submission type: D; Filing date: 2026-05-21; Industry Group: Biotechnology; Date of First Sale: 2026-05-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 700000; Total Amount Sold: 700000; Federal exemptions: 06b
May 21, 2026SEC Form D 0002135564-26-000001
Reprise BiomedicalRaised $9.25M (Form D filed May 21, 2026; amended Jul 1, 2026).
Evidence (1 event)
  • May 21, 2026 · SEC Form D 0001782236-26-000001
    Name of Issuer: Reprise Biomedical, Inc.; CIK: 1782236; Address: Plymouth, MN; Submission type: D; Filing date: 2026-05-21; Industry Group: Biotechnology; Date of First Sale: 2026-05-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 1450000; Federal exemptions: 06b || Name of Issuer: Reprise Biomedical, Inc.; CIK: 1782236; Address: Plymouth, MN; Submission type: D/A; Filing date: 2026-07-01; Industry Group: Biotechnology; Date of First Sale: 2026-05-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 9246100; Federal exemptions: 06b
May 21, 2026SEC Form D 0001782236-26-000001
Verismo TherapeuticsRaised $28M (Form D filed May 20, 2026).
Evidence (1 event)
  • May 20, 2026 · SEC Form D 0001855431-26-000003
    Name of Issuer: Verismo Therapeutics, Inc.; CIK: 1855431; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-05-20; Industry Group: Other Health Care; Date of First Sale: 2026-04-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 28000000; Total Amount Sold: 28000000; Federal exemptions: 06b
May 20, 2026SEC Form D 0001855431-26-000003
CNS PharmaceuticalsRaised $22.53M (Form D filed May 19, 2026).
Evidence (1 event)
  • May 19, 2026 · SEC Form D 0001683168-26-004126
    Name of Issuer: CNS Pharmaceuticals, Inc.; CIK: 1729427; Address: Houston, TX; Submission type: D; Filing date: 2026-05-19; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-04; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 22525000; Total Amount Sold: 22525000; Federal exemptions: 06b
May 19, 2026SEC Form D 0001683168-26-004126
Remedium BioRaised $1.5M (Form D filed May 18, 2026).
Evidence (1 event)
  • May 18, 2026 · SEC Form D 0001892414-26-000004
    Name of Issuer: Remedium Bio Inc.; CIK: 1892414; Address: Needham, MA; Submission type: D; Filing date: 2026-05-18; Industry Group: Biotechnology; Date of First Sale: 2026-05-06; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 1500000; Federal exemptions: 06b
May 18, 2026SEC Form D 0001892414-26-000004
Trellis BioscienceRaised $6.09M (Form D filed May 15, 2026).
Evidence (1 event)
  • May 15, 2026 · SEC Form D 0000929638-26-001870
    Name of Issuer: Trellis Bioscience, Inc.; CIK: 1162015; Address: Redwood City, CA; Submission type: D; Filing date: 2026-05-15; Industry Group: Biotechnology; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity, Other (Series C Interests); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 6093000; Federal exemptions: 06b
May 15, 2026SEC Form D 0000929638-26-001870
Athos TherapeuticsRaised $10.28M in debt securities (Form D filed May 15, 2026).
Evidence (1 event)
  • May 15, 2026 · SEC Form D 0001885079-26-000001
    Name of Issuer: Athos Therapeutics, Inc.; CIK: 1885079; Address: Torrance, CA; Submission type: D; Filing date: 2026-05-15; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-17; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 10282887; Federal exemptions: 06b
May 15, 2026SEC Form D 0001885079-26-000001
SoliusRaised $3.5M (Form D filed May 14, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • May 14, 2026 · SEC Form D 0001537914-26-000003
    Name of Issuer: Solius Labs, Inc.; CIK: 1537914; Address: Bainbridge Island, WA; Submission type: D; Filing date: 2026-05-14; Industry Group: Other Health Care; Date of First Sale: 2026-04-29; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 17911021; Total Amount Sold: 3500000; Federal exemptions: 06b
  • May 14, 2026 · SEC Form D 0001537914-26-000002
    Name of Issuer: Solius Labs, Inc.; CIK: 1537914; Address: Bainbridge Island, WA; Submission type: D; Filing date: 2026-05-14; Industry Group: Other Health Care; Date of First Sale: 2023-03-14; Types of Securities Offered: Equity, Other (Security to be Acquired upon Conversion); Business combination transaction: false; Total Offering Amount: 23493691; Total Amount Sold: 23493691; Federal exemptions: 06b
May 14, 2026SEC Form D 0001537914-26-000003
SentrimedRaised $250K in debt securities (Form D filed May 13, 2026).
Evidence (1 event)
  • May 13, 2026 · SEC Form D 0002014313-26-000002
    Name of Issuer: Sentrimed, Inc.; CIK: 2014313; Address: Mullica Hill, NJ; Submission type: D; Filing date: 2026-05-13; Industry Group: Biotechnology; Date of First Sale: 2026-05-08; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 250000; Federal exemptions: 06b
May 13, 2026SEC Form D 0002014313-26-000002
Pagari Life ScienceRaised $97K (Form D filed May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · SEC Form D 0001993125-26-000001
    Name of Issuer: Pagari Life Science Corp.; CIK: 1993125; Address: Bethalta, IL; Submission type: D; Filing date: 2026-05-12; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 97494; Federal exemptions: 06b
May 12, 2026SEC Form D 0001993125-26-000001
Virtuoso SurgicalRaised $2.9M (Form D filed May 11, 2026).
Evidence (1 event)
  • May 11, 2026 · SEC Form D 0001742075-26-000004
    Name of Issuer: Virtuoso Surgical, Inc.; CIK: 1742075; Address: Nashville, TN; Submission type: D; Filing date: 2026-05-11; Industry Group: Biotechnology; Date of First Sale: 2026-02-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 2900000; Federal exemptions: 06b
May 11, 2026SEC Form D 0001742075-26-000004
PanGIA BiotechRaised $1.58M in debt securities (Form D filed May 11, 2026).
Evidence (1 event)
  • May 11, 2026 · SEC Form D 0001213900-26-054301
    Name of Issuer: PANGIA BIOTECH, INC.; CIK: 2125789; Address: Delray Beach, FL; Submission type: D; Filing date: 2026-05-11; Industry Group: Biotechnology; Date of First Sale: 2026-04-08; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1580000; Total Amount Sold: 1580000; Federal exemptions: 06c
May 11, 2026SEC Form D 0001213900-26-054301
CytoDynRaised $18.6M (Form D filed May 11, 2026).
Evidence (1 event)
  • May 11, 2026 · SEC Form D 0001175680-26-000003
    Name of Issuer: CytoDyn Inc.; CIK: 1175680; Address: Vancouver, WA; Submission type: D; Filing date: 2026-05-11; Industry Group: Pharmaceuticals; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 18600392; Total Amount Sold: 18600392; Federal exemptions: 06b
May 11, 2026SEC Form D 0001175680-26-000003
Natsar Pharmaceuticals, Inc.Raised $4.22M (Form D filed May 8, 2026).
Evidence (1 event)
  • May 8, 2026 · SEC Form D 0002134002-26-000001
    Name of Issuer: Natsar Pharmaceuticals, Inc.; CIK: 2134002; Address: Ellicott City, MD; Submission type: D; Filing date: 2026-05-08; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 4221000; Federal exemptions: 06b
May 8, 2026SEC Form D 0002134002-26-000001
Illexcor TherapeuticsRaised $13M (Form D filed May 8, 2026).
Evidence (1 event)
  • May 8, 2026 · SEC Form D 0002132799-26-000001
    Name of Issuer: Illexcor Therapeutics, Inc.; CIK: 2132799; Address: Henrico, VA; Submission type: D; Filing date: 2026-05-08; Industry Group: Biotechnology; Date of First Sale: 2026-04-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 69000000; Total Amount Sold: 13000000; Federal exemptions: 06b
May 8, 2026SEC Form D 0002132799-26-000001
Lighthouse PharmaceuticalsRaised $15.21M (Form D filed May 7, 2026).
Evidence (1 event)
  • May 7, 2026 · SEC Form D 0002133359-26-000001
    Name of Issuer: Lighthouse Pharmaceuticals, Inc.; CIK: 2133359; Address: Novato, CA; Submission type: D; Filing date: 2026-05-07; Industry Group: Other; Date of First Sale: 2026-04-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15206800; Total Amount Sold: 15206800; Federal exemptions: 06b
May 7, 2026SEC Form D 0002133359-26-000001
Mitera BiosciencesRaised $1.1M (Form D filed May 6, 2026).
Evidence (1 event)
  • May 6, 2026 · SEC Form D 0002022224-26-000001
    Name of Issuer: Mitera Biosciences Inc.; CIK: 2022224; Address: Bellevue, WA; Submission type: D; Filing date: 2026-05-06; Industry Group: Biotechnology; Date of First Sale: 2026-04-21; Types of Securities Offered: Option/warrant, Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1100000; Federal exemptions: 06b
May 6, 2026SEC Form D 0002022224-26-000001
Inflammasome TherapeuticsRaised $13.16M (Form D filed May 4, 2026).
Evidence (1 event)
  • May 4, 2026 · SEC Form D 0001989925-26-000003
    Name of Issuer: Inflammasome Therapeutics, Inc.; CIK: 1989925; Address: Newton, MA; Submission type: D; Filing date: 2026-05-04; Industry Group: Biotechnology; Date of First Sale: 2026-02-27; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 13155645; Total Amount Sold: 13155645; Federal exemptions: 06b
May 4, 2026SEC Form D 0001989925-26-000003
Preceptis MedicalRaised $2.56M (Form D filed May 1, 2026).
Evidence (1 event)
  • May 1, 2026 · SEC Form D 0000912282-26-000663
    Name of Issuer: Preceptis Medical, Inc.; CIK: 1537953; Address: Golden Valley, MN; Submission type: D; Filing date: 2026-05-01; Industry Group: Other Health Care; Date of First Sale: 2026-04-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6900000; Total Amount Sold: 2561370; Federal exemptions: 06b
May 1, 2026SEC Form D 0000912282-26-000663
Acurx PharmaceuticalsForm D reports $4.59M in warrant exercise value (filed Apr 29, 2026).
Evidence (1 event)
  • Apr 29, 2026 · SEC Form D 0001736243-26-000001
    Name of Issuer: Acurx Pharmaceuticals, Inc.; CIK: 1736243; Address: Staten Island, NY; Submission type: D; Filing date: 2026-04-29; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-15; Types of Securities Offered: Security to be acquired; Business combination transaction: false; Total Offering Amount: 4587473; Total Amount Sold: 4587473; Federal exemptions: 06b
Apr 29, 2026SEC Form D 0001736243-26-000001
Toetal SolutionsRaised $50K (Form D filed Sep 24, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Sep 24, 2026 · SEC Form D 0001888204-26-000002
    Name of Issuer: Toetal Solutions, Inc.; CIK: 1888204; Address: Malvern, PA; Submission type: D; Filing date: 2026-09-24; Industry Group: Other Health Care; Date of First Sale: 2026-09-15; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (Security to be acquired upon exercise.); Business combination transaction: false; Total Offering Amount: 250000; Total Amount Sold: 50000; Federal exemptions: 06b
  • Apr 28, 2026 · SEC Form D 0001888204-26-000001
    Name of Issuer: Toetal Solutions, Inc.; CIK: 1888204; Address: Malvern, PA; Submission type: D; Filing date: 2026-04-28; Industry Group: Other Health Care; Date of First Sale: 2026-04-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 100000; Total Amount Sold: 100000; Federal exemptions: 06b
Sep 24, 2026SEC Form D 0001888204-26-000002
Lungpacer MedicalRaised $7.83M in debt securities (Form D filed Oct 14, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Oct 14, 2026 · SEC Form D 0001708893-26-000005
    Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D; Filing date: 2026-10-14; Industry Group: Other Health Care; Date of First Sale: 2026-09-30; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 7833333; Federal exemptions: 06b
  • Apr 28, 2026 · SEC Form D 0001708893-26-000002
    Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D; Filing date: 2026-04-28; Industry Group: Other Health Care; Date of First Sale: 2026-04-23; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 12000000; Federal exemptions: 06b || Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D/A; Filing date: 2026-07-02; Industry Group: Other Health Care; Date of First Sale: 2026-04-23; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 16000000; Federal exemptions: 06b || Name of Issuer: Lungpacer Medical, Inc.; CIK: 1708893; Address: Exton, PA; Submission type: D/A; Filing date: 2026-10-08; Industry Group: Other Health Care; Date of First Sale: 2026-04-23; Types of Securities Offered: Debt, Other (Unsecured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 12000000; Federal exemptions: 06b
Oct 14, 2026SEC Form D 0001708893-26-000005
Levita MagneticsRaised $30.71M (Form D filed Apr 28, 2026).
Evidence (1 event)
  • Apr 28, 2026 · SEC Form D 0001911389-26-000003
    Name of Issuer: Levita Magnetics International Corp.; CIK: 1911389; Address: Mountain View, CA; Submission type: D; Filing date: 2026-04-28; Industry Group: Other Health Care; Date of First Sale: 2026-02-24; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 57707603; Total Amount Sold: 30707603; Federal exemptions: 06b
Apr 28, 2026SEC Form D 0001911389-26-000003
Novel MicrodevicesRaised $1M in debt securities (Form D filed Apr 27, 2026); 1 role open.
Evidence (1 event)
  • Apr 27, 2026 · SEC Form D 0001837242-26-000002
    Name of Issuer: Novel Microdevices, Inc.; CIK: 1837242; Address: Baltimore, MD; Submission type: D; Filing date: 2026-04-27; Industry Group: Other; Date of First Sale: 2026-03-27; Types of Securities Offered: Debt, Other (Convertible Promissory Note); Business combination transaction: false; Total Offering Amount: 8000000; Total Amount Sold: 1000000; Federal exemptions: 06b
Apr 27, 2026SEC Form D 0001837242-26-000002
Life Biosciences Inc.Raised $31M (Form D filed Apr 24, 2026).
Evidence (1 event)
  • Apr 24, 2026 · SEC Form D 0001751806-26-000003
    Name of Issuer: Life Biosciences LLC; CIK: 1751806; Address: Boston, MA; Submission type: D; Filing date: 2026-04-24; Industry Group: Other; Date of First Sale: 2025-11-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31000002; Total Amount Sold: 31000002; Federal exemptions: 06b
Apr 24, 2026SEC Form D 0001751806-26-000003
BioVentrixRaised $1.2M in debt securities (Form D filed Oct 8, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Oct 8, 2026 · SEC Form D 0001283259-26-000005
    Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D; Filing date: 2026-10-08; Industry Group: Biotechnology; Date of First Sale: 2026-09-29; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1200000; Federal exemptions: 06b
  • Apr 24, 2026 · SEC Form D 0001283259-26-000002
    Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D; Filing date: 2026-04-24; Industry Group: Other; Date of First Sale: 2026-04-16; Types of Securities Offered: Other (Secured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 6000000; Total Amount Sold: 705000; Federal exemptions: 06b || Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D/A; Filing date: 2026-09-01; Industry Group: Other; Date of First Sale: 2026-04-16; Types of Securities Offered: Other (Secured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 2765000; Federal exemptions: 06b || Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D/A; Filing date: 2026-09-09; Industry Group: Other; Date of First Sale: 2026-04-16; Types of Securities Offered: Other (Secured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 2965000; Federal exemptions: 06b
Oct 8, 2026SEC Form D 0001283259-26-000005
Concept MedicalForm D reports $60.04M sold since 2018 (filed Apr 24, 2026); +2 other Form D filings in the last 12 months.
Evidence (3 events)
  • Apr 24, 2026 · SEC Form D 0002108675-26-000003
    Name of Issuer: Concept Medical, Inc.; CIK: 2108675; Address: Tampa, FL; Submission type: D; Filing date: 2026-04-24; Industry Group: Other Health Care; Date of First Sale: 2018-08-15; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 65000000; Total Amount Sold: 60037410; Federal exemptions: 06b
  • Apr 24, 2026 · SEC Form D 0002108675-26-000001
    Name of Issuer: Concept Medical, Inc.; CIK: 2108675; Address: Tampa, FL; Submission type: D; Filing date: 2026-04-24; Industry Group: Other Health Care; Date of First Sale: 2011-08-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 600000; Total Amount Sold: 600000; Federal exemptions: 06b
  • Apr 24, 2026 · SEC Form D 0002108675-26-000002
    Name of Issuer: Concept Medical, Inc.; CIK: 2108675; Address: Tampa, FL; Submission type: D; Filing date: 2026-04-24; Industry Group: Other Health Care; Date of First Sale: 2017-05-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 75000; Total Amount Sold: 75000; Federal exemptions: 04
Apr 24, 2026SEC Form D 0002108675-26-000003
General OncologyRaised $4.81M (Form D filed Apr 23, 2026).
Evidence (1 event)
  • Apr 23, 2026 · SEC Form D 0001658021-26-000006
    Name of Issuer: General Oncology, Inc.; CIK: 1658021; Address: Newton, MA; Submission type: D; Filing date: 2026-04-23; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-15; Types of Securities Offered: Option/warrant, Other (Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.); Business combination transaction: false; Total Offering Amount: 4805299; Total Amount Sold: 4805299; Federal exemptions: 06b
Apr 23, 2026SEC Form D 0001658021-26-000006
Hepion PharmaceuticalsRaised $3.06M (Form D filed Aug 5, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Aug 5, 2026 · SEC Form D 0001493152-26-036216
    Name of Issuer: Hepion Pharmaceuticals, Inc.; CIK: 1583771; Address: Red Bank, NJ; Submission type: D; Filing date: 2026-08-05; Industry Group: Biotechnology; Date of First Sale: 2026-07-31; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3055000; Total Amount Sold: 3055000; Federal exemptions: 06b
  • Apr 22, 2026 · SEC Form D 0001493152-26-018593
    Name of Issuer: Hepion Pharmaceuticals, Inc.; CIK: 1583771; Address: Red Bank, NJ; Submission type: D; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2026-04-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 700000; Total Amount Sold: 700000; Federal exemptions: 06b
Aug 5, 2026SEC Form D 0001493152-26-036216
Corami BiotechRaised $230K (Form D filed Apr 22, 2026).
Evidence (1 event)
  • Apr 22, 2026 · SEC Form D 0002042505-26-000003
    Name of Issuer: Corami Biotech Inc.; CIK: 2042505; Address: Memphis, TN; Submission type: D; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2026-02-04; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 230000; Federal exemptions: 06b
Apr 22, 2026SEC Form D 0002042505-26-000003
Terremoto BiosciencesRaised $40.73M (Form D filed Apr 22, 2026); 1 role open.
Evidence (1 event)
  • Apr 22, 2026 · SEC Form D 0001231919-26-000386
    Name of Issuer: Terremoto Biosciences, Inc.; CIK: 2130748; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2026-04-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 108599999; Total Amount Sold: 40725000; Federal exemptions: 06b
Apr 22, 2026SEC Form D 0001231919-26-000386
TetrousRaised $1.74M (Form D filed Apr 22, 2026).
Evidence (1 event)
  • Apr 22, 2026 · SEC Form D 0002002357-26-000001
    Name of Issuer: Tetrous, Inc.; CIK: 2002357; Address: Sherman Oaks, CA; Submission type: D; Filing date: 2026-04-22; Industry Group: Biotechnology; Date of First Sale: 2026-04-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4000000; Total Amount Sold: 1741024; Federal exemptions: 06b
Apr 22, 2026SEC Form D 0002002357-26-000001
Pearl Diagnostics, Inc.Raised $11.15M (Form D filed Apr 21, 2026).
Evidence (1 event)
  • Apr 21, 2026 · SEC Form D 0001922830-26-000003
    Name of Issuer: Pearl Diagnostics, Inc.; CIK: 1922830; Address: Baltimore, MD; Submission type: D; Filing date: 2026-04-21; Industry Group: Biotechnology; Date of First Sale: 2026-03-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11150000; Total Amount Sold: 11150000; Federal exemptions: 06b
Apr 21, 2026SEC Form D 0001922830-26-000003
Aethl BioRaised $1.64M (Form D filed Apr 17, 2026).
Evidence (1 event)
  • Apr 17, 2026 · SEC Form D 0002116929-26-000001
    Name of Issuer: Aethl Bio, Inc.; CIK: 2116929; Address: Pittsburgh, PA; Submission type: D; Filing date: 2026-04-17; Industry Group: Biotechnology; Date of First Sale: 2025-07-14; Types of Securities Offered: Security to be acquired, Other (Simple Agreement for Future Equity (SAFE)); Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 1635000; Federal exemptions: 06b
Apr 17, 2026SEC Form D 0002116929-26-000001
Bonum TherapeuticsRaised $26.91M (Form D filed Apr 17, 2026).
Evidence (1 event)
  • Apr 17, 2026 · SEC Form D 0001898714-26-000001
    Name of Issuer: Bonum Therapeutics, Inc.; CIK: 1898714; Address: Seattle, WA; Submission type: D; Filing date: 2026-04-17; Industry Group: Biotechnology; Date of First Sale: 2026-04-03; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 32301381; Total Amount Sold: 26907396; Federal exemptions: 06b
Apr 17, 2026SEC Form D 0001898714-26-000001
Spiral TherapeuticsRaised $27.09M (Form D filed Apr 16, 2026).
Evidence (1 event)
  • Apr 16, 2026 · SEC Form D 0001231919-26-000364
    Name of Issuer: Spiral Therapeutics Inc; CIK: 1761906; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-04-16; Industry Group: Pharmaceuticals; Date of First Sale: 2025-09-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 27089842; Total Amount Sold: 27089839; Federal exemptions: 06b
Apr 16, 2026SEC Form D 0001231919-26-000364
CalyxoRaised $40.1M (Form D filed Apr 16, 2026).
Evidence (1 event)
  • Apr 16, 2026 · SEC Form D 0001668653-26-000001
    Name of Issuer: Calyxo, Inc.; CIK: 1668653; Address: Pleasanton, CA; Submission type: D; Filing date: 2026-04-16; Industry Group: Other Health Care; Date of First Sale: 2026-04-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40099963; Total Amount Sold: 40099963; Federal exemptions: 06b
Apr 16, 2026SEC Form D 0001668653-26-000001
Alloy TherapeuticsRaised $30.02M (Form D filed Apr 15, 2026); 15 roles open.
Evidence (1 event)
  • Apr 15, 2026 · SEC Form D 0001851943-26-000001
    Name of Issuer: Alloy Therapeutics, Inc.; CIK: 1851943; Address: Waltham, MA; Submission type: D; Filing date: 2026-04-15; Industry Group: Biotechnology; Date of First Sale: 2026-03-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 39999940; Total Amount Sold: 30020259; Federal exemptions: 06b
Apr 15, 2026SEC Form D 0001851943-26-000001
Allinaire TherapeuticsRaised $700K (Form D filed Apr 14, 2026).
Evidence (1 event)
  • Apr 14, 2026 · SEC Form D 0002113399-26-000001
    Name of Issuer: Allinaire Therapeutics Inc.; CIK: 2113399; Address: Cleveland, OH; Submission type: D; Filing date: 2026-04-14; Industry Group: Other; Date of First Sale: 2026-01-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 700000; Total Amount Sold: 700000; Federal exemptions: 06b
Apr 14, 2026SEC Form D 0002113399-26-000001
GreenMark Biomedical Inc.Filed a Form D for an offering of up to $5M, no sales reported yet (filed Apr 14, 2026).
Evidence (1 event)
  • Apr 14, 2026 · SEC Form D 0001741718-26-000003
    Name of Issuer: GreenMark Biomedical Inc.; CIK: 1741718; Address: East Lansing, MI; Submission type: D; Filing date: 2026-04-14; Industry Group: Biotechnology; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5000000; Total Amount Sold: 0; Federal exemptions: 06b
Apr 14, 2026SEC Form D 0001741718-26-000003
Axena HealthRaised $15.05M (Form D filed Apr 14, 2026).
Evidence (1 event)
  • Apr 14, 2026 · SEC Form D 0001988865-26-000003
    Name of Issuer: Axena Health, Inc.; CIK: 1988865; Address: Auburndale, MA; Submission type: D; Filing date: 2026-04-14; Industry Group: Other Health Care; Date of First Sale: 2025-12-19; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (Convertibles); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 15046942; Federal exemptions: 06b
Apr 14, 2026SEC Form D 0001988865-26-000003
Rakuten MedicalRaised $8.97M (Form D filed Oct 6, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Oct 6, 2026 · SEC Form D 0001595215-26-000002
    Name of Issuer: Rakuten Medical, Inc.; CIK: 1595215; Address: San Diego, CA; Submission type: D; Filing date: 2026-10-06; Industry Group: Biotechnology; Date of First Sale: 2026-08-16; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 8974943; Total Amount Sold: 8974943; Federal exemptions: 06b
  • Apr 13, 2026 · SEC Form D 0001595215-26-000001
    Name of Issuer: Rakuten Medical, Inc.; CIK: 1595215; Address: San Diego, CA; Submission type: D; Filing date: 2026-04-13; Industry Group: Biotechnology; Date of First Sale: 2025-07-11; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 116672752; Total Amount Sold: 111522289; Federal exemptions: 06b
Oct 6, 2026SEC Form D 0001595215-26-000002
TAS MedicalRaised $3.89M (Form D filed Apr 10, 2026).
Evidence (1 event)
  • Apr 10, 2026 · SEC Form D 0001437749-26-012054
    Name of Issuer: TAS Medical, Inc.; CIK: 1739794; Address: Windermere, FL; Submission type: D; Filing date: 2026-04-10; Industry Group: Other Technology; Date of First Sale: 2026-03-27; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 6511056; Total Amount Sold: 3888800; Federal exemptions: 06b
Apr 10, 2026SEC Form D 0001437749-26-012054
Inso Biosciences Inc.Raised $750K in debt securities (Form D filed Apr 10, 2026).
Evidence (1 event)
  • Apr 10, 2026 · SEC Form D 0001906426-26-000003
    Name of Issuer: Inso Biosciences Inc.; CIK: 1906426; Address: Ithaca, NY; Submission type: D; Filing date: 2026-04-10; Industry Group: Biotechnology; Date of First Sale: 2026-03-03; Types of Securities Offered: Debt, Option/warrant, Security to be acquired, Other (Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be acquired upon such conversion.); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 750000; Federal exemptions: 06b
Apr 10, 2026SEC Form D 0001906426-26-000003
Marrow Access TechnologiesRaised $100K (Form D filed Apr 9, 2026).
Evidence (1 event)
  • Apr 9, 2026 · SEC Form D 0001758381-26-000002
    Name of Issuer: Marrow Access Technologies, Inc.; CIK: 1758381; Address: Eden Prairie, MN; Submission type: D; Filing date: 2026-04-09; Industry Group: Other Health Care; Date of First Sale: 2026-03-04; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 300000; Total Amount Sold: 100000; Federal exemptions: 06b
Apr 9, 2026SEC Form D 0001758381-26-000002
Virchow MedicalRaised $4.12M (Form D filed Apr 9, 2026).
Evidence (1 event)
  • Apr 9, 2026 · SEC Form D 0002128134-26-000001
    Name of Issuer: Virchow Medical, Inc.; CIK: 2128134; Address: San Diego, CA; Submission type: D; Filing date: 2026-04-09; Industry Group: Other Health Care; Date of First Sale: 2026-03-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 4120829; Total Amount Sold: 4120829; Federal exemptions: 06b
Apr 9, 2026SEC Form D 0002128134-26-000001
EnteroBiotixRaised $5.34M (Form D filed Apr 9, 2026).
Evidence (1 event)
  • Apr 9, 2026 · SEC Form D 0001104659-26-041397
    Name of Issuer: EnteroBiotix LTD; CIK: 1946072; Address: Glasgow, United Kingdom; Submission type: D; Filing date: 2026-04-09; Industry Group: Biotechnology; Date of First Sale: 2026-03-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 5341593; Federal exemptions: 06b
Apr 9, 2026SEC Form D 0001104659-26-041397
NextStep Robotics Inc.Raised $1M (Form D filed Apr 9, 2026).
Evidence (1 event)
  • Apr 9, 2026 · SEC Form D 0001729819-26-000001
    Name of Issuer: NEXTSTEP ROBOTICS, INC.; CIK: 1729819; Address: Baltimore, MD; Submission type: D; Filing date: 2026-04-09; Industry Group: Other Technology; Date of First Sale: 2025-11-24; Types of Securities Offered: Option/warrant, Security to be acquired, Other (SIMPLE AGREEMENT FOR FUTURE EQUITY); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1000000; Federal exemptions: 06b
Apr 9, 2026SEC Form D 0001729819-26-000001
OTU MedicalForm D reports $175K sold since 2017 (filed Apr 9, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Apr 9, 2026 · SEC Form D 0002107797-26-000002
    Name of Issuer: OTU Medical Inc.; CIK: 2107797; Address: Union City, CA; Submission type: D; Filing date: 2026-04-09; Industry Group: Other Technology; Date of First Sale: 2017-06-15; Types of Securities Offered: Equity, Other (Simple Agreement for Future Equity (SAFE)); Business combination transaction: false; Total Offering Amount: 175000; Total Amount Sold: 175000; Federal exemptions: 06b
  • Apr 8, 2026 · SEC Form D 0002107797-26-000001
    Name of Issuer: OTU Medical Inc.; CIK: 2107797; Address: Union City, CA; Submission type: D; Filing date: 2026-04-08; Industry Group: Other Technology; Date of First Sale: 2017-11-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1500000; Federal exemptions: 06b
Apr 9, 2026SEC Form D 0002107797-26-000002
OptimviaRaised $75K (Form D filed Apr 8, 2026).
Evidence (1 event)
  • Apr 8, 2026 · SEC Form D 0001140361-26-013767
    Name of Issuer: Optimvia, LLC; CIK: 1705874; Address: Cincinnati, OH; Submission type: D; Filing date: 2026-04-08; Industry Group: Other Health Care; Date of First Sale: 2026-03-26; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 75000; Federal exemptions: 06b
Apr 8, 2026SEC Form D 0001140361-26-013767
Myra EB SystemsRaised $10K in debt securities (Form D filed Apr 7, 2026).
Evidence (1 event)
  • Apr 7, 2026 · SEC Form D 0002125905-26-000001
    Name of Issuer: Myra EB Systems LLC; CIK: 2125905; Address: Boxborough, MA; Submission type: D; Filing date: 2026-04-07; Industry Group: Biotechnology; Date of First Sale: 2026-03-24; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 10000; Federal exemptions: 06b
Apr 7, 2026SEC Form D 0002125905-26-000001
Ancilia BiosciencesRaised $10.08M (Form D filed Apr 6, 2026).
Evidence (1 event)
  • Apr 6, 2026 · SEC Form D 0001975776-26-000006
    Name of Issuer: Ancilia Biosciences, Inc.; CIK: 1975776; Address: New York, NY; Submission type: D; Filing date: 2026-04-06; Industry Group: Other; Date of First Sale: 2026-02-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10076464; Total Amount Sold: 10076464; Federal exemptions: 06b
Apr 6, 2026SEC Form D 0001975776-26-000006
ElidahForm D reports $2.02M sold since 2023 (filed Apr 6, 2026).
Evidence (1 event)
  • Apr 6, 2026 · SEC Form D 0002113916-26-000001
    Name of Issuer: Elidah, Inc.; CIK: 2113916; Address: Newtown, CT; Submission type: D; Filing date: 2026-04-06; Industry Group: Manufacturing; Date of First Sale: 2023-06-02; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 2018000; Federal exemptions: 06b
Apr 6, 2026SEC Form D 0002113916-26-000001
LifewardRaised $11.16M (Form D filed Jul 8, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Jul 8, 2026 · SEC Form D 0001607962-26-000004
    Name of Issuer: Lifeward Ltd.; CIK: 1607962; Address: Hudson, MA; Submission type: D; Filing date: 2026-07-08; Industry Group: Biotechnology; Date of First Sale: 2026-07-06; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 11160000; Federal exemptions: 06b
  • Apr 2, 2026 · SEC Form D 0001607962-26-000003
    Name of Issuer: Lifeward Ltd.; CIK: 1607962; Address: Hudson, MA; Submission type: D; Filing date: 2026-04-02; Industry Group: Biotechnology; Date of First Sale: 2026-03-25; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 20000000; Federal exemptions: 06b
Jul 8, 2026SEC Form D 0001607962-26-000004
Vetmab Biosciences, Inc.Raised $11.44M (Form D filed Sep 29, 2026).
Evidence (1 event)
  • Sep 29, 2026 · SEC Form D 0001932050-26-000002
    Name of Issuer: Vetmab Biosciences, Inc.; CIK: 1932050; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-29; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11944990; Total Amount Sold: 11439990; Federal exemptions: 06b
Sep 29, 2026SEC Form D 0001932050-26-000002
GT BiopharmaRaised $7.75M (Form D filed Sep 29, 2026).
Evidence (1 event)
  • Sep 29, 2026 · SEC Form D 0000109657-26-000001
    Name of Issuer: GT Biopharma, Inc.; CIK: 109657; Address: San Francisco, CA; Submission type: D; Filing date: 2026-09-29; Industry Group: Biotechnology; Date of First Sale: 2026-09-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 38958054; Total Amount Sold: 7750000; Federal exemptions: 06b
Sep 29, 2026SEC Form D 0000109657-26-000001
Sialia Therapeutics, Inc.Raised $1.5M (Form D filed Sep 29, 2026).
Evidence (1 event)
  • Sep 29, 2026 · SEC Form D 0002156754-26-000001
    Name of Issuer: Sialia Therapeutics, Inc.; CIK: 2156754; Address: Irvine, CA; Submission type: D; Filing date: 2026-09-29; Industry Group: Biotechnology; Date of First Sale: 2026-09-02; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1500000; Federal exemptions: 06b
Sep 29, 2026SEC Form D 0002156754-26-000001
Laurentide Therapeutics Inc.Raised $100K (Form D filed Sep 28, 2026).
Evidence (1 event)
  • Sep 28, 2026 · SEC Form D 0002157396-26-000001
    Name of Issuer: Laurentide Therapeutics Inc.; CIK: 2157396; Address: Atlanta, GA; Submission type: D; Filing date: 2026-09-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-08-20; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 100000; Total Amount Sold: 99999; Federal exemptions: 06b
Sep 28, 2026SEC Form D 0002157396-26-000001
Pace Pharmaceuticals, Inc.Raised $50K (Form D filed Sep 28, 2026).
Evidence (1 event)
  • Sep 28, 2026 · SEC Form D 0002157304-26-000001
    Name of Issuer: Pace Pharmaceuticals, Inc.; CIK: 2157304; Address: Cupertino, CA; Submission type: D; Filing date: 2026-09-28; Industry Group: Biotechnology; Date of First Sale: 2026-09-18; Types of Securities Offered: Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 50000; Federal exemptions: 06c
Sep 28, 2026SEC Form D 0002157304-26-000001
Dignify TherapeuticsRaised $800K in debt securities (Form D filed Sep 25, 2026).
Evidence (1 event)
  • Sep 25, 2026 · SEC Form D 0001622906-26-000003
    Name of Issuer: Dignify Therapeutics, LLC; CIK: 1622906; Address: Research Triangle Park, NC; Submission type: D; Filing date: 2026-09-25; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-15; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 800000; Federal exemptions: 06b
Sep 25, 2026SEC Form D 0001622906-26-000003
Navigator MedicinesRaised $10M (Form D filed Sep 25, 2026).
Evidence (1 event)
  • Sep 25, 2026 · SEC Form D 0002035715-26-000005
    Name of Issuer: Navigator Medicines, Inc.; CIK: 2035715; Address: San Mateo, CA; Submission type: D; Filing date: 2026-09-25; Industry Group: Biotechnology; Date of First Sale: 2026-09-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 40000000; Total Amount Sold: 10000000; Federal exemptions: 06b
Sep 25, 2026SEC Form D 0002035715-26-000005
Aponia LaboratoriesFiled a Form D, amount not stated (filed Sep 24, 2026).
Evidence (1 event)
  • Sep 24, 2026 · SEC Form D 0001497705-26-000003
    Name of Issuer: Aponia Laboratories Inc; CIK: 1497705; Address: Portsmouth, NH; Submission type: D; Filing date: 2026-09-24; Industry Group: Other; Date of First Sale: Yet to Occur; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 0; Federal exemptions: 06b
Sep 24, 2026SEC Form D 0001497705-26-000003
Acuitive TechnologiesRaised $1.88M (Form D filed Sep 24, 2026).
Evidence (1 event)
  • Sep 24, 2026 · SEC Form D 0001864239-26-000004
    Name of Issuer: Acuitive Technologies, Inc.; CIK: 1864239; Address: Allendale, NJ; Submission type: D; Filing date: 2026-09-24; Industry Group: Other Health Care; Date of First Sale: 2026-08-14; Types of Securities Offered: Other (Simple Agreements for Future Equity (SAFEs)); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1875000; Federal exemptions: 06b
Sep 24, 2026SEC Form D 0001864239-26-000004
Caspian Therapeutics, Inc.Raised $50M (Form D filed Sep 23, 2026).
Evidence (1 event)
  • Sep 23, 2026 · SEC Form D 0001231919-26-001219
    Name of Issuer: Caspian Therapeutics, Inc.; CIK: 2156247; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-23; Industry Group: Biotechnology; Date of First Sale: 2026-09-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 50000000; Total Amount Sold: 50000000; Federal exemptions: 06b
Sep 23, 2026SEC Form D 0001231919-26-001219
Avery TherapeuticsRaised $8.47M (Form D filed Sep 21, 2026).
Evidence (1 event)
  • Sep 21, 2026 · SEC Form D 0001708135-26-000003
    Name of Issuer: Avery Therapeutics, Inc.; CIK: 1708135; Address: Tucson, AZ; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-08-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15400000; Total Amount Sold: 8468859; Federal exemptions: 06b
Sep 21, 2026SEC Form D 0001708135-26-000003
3HelixRaised $7.84M (Form D filed Sep 21, 2026).
Evidence (1 event)
  • Sep 21, 2026 · SEC Form D 0002001622-26-000003
    Name of Issuer: 3Helix, Inc.; CIK: 2001622; Address: Salt Lake City, UT; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-08-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 7835028; Federal exemptions: 06b
Sep 21, 2026SEC Form D 0002001622-26-000003
Aqur BiosciencesRaised $1.5M (Form D filed Sep 18, 2026).
Evidence (1 event)
  • Sep 18, 2026 · SEC Form D 0001640334-26-001574
    Name of Issuer: Aqur Biosciences, Inc.; CIK: 2094075; Address: Westlake Village, CA; Submission type: D; Filing date: 2026-09-18; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-03; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1500000; Federal exemptions: 06b
Sep 18, 2026SEC Form D 0001640334-26-001574
EncisionRaised $80K (Form D filed Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · SEC Form D 0001553350-26-000126
    Name of Issuer: ENCISION INC; CIK: 930775; Address: Boulder, CO; Submission type: D; Filing date: 2026-09-17; Industry Group: Other Health Care; Date of First Sale: 2026-09-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 80000; Total Amount Sold: 80000; Federal exemptions: 06b
Sep 17, 2026SEC Form D 0001553350-26-000126
SurgiBoxRaised $486K (Form D filed Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · SEC Form D 0001930227-26-000005
    Name of Issuer: SurgiBox Inc.; CIK: 1930227; Address: Cambridge, MA; Submission type: D; Filing date: 2026-09-17; Industry Group: Biotechnology; Date of First Sale: 2026-03-19; Types of Securities Offered: Security to be acquired, Other (Simple Agreement for Future Equity); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 486000; Federal exemptions: 06b
Sep 17, 2026SEC Form D 0001930227-26-000005
Theia Imaging LLCRaised $160K (Form D filed Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · SEC Form D 0002155415-26-000001
    Name of Issuer: Theia Imaging LLC; CIK: 2155415; Address: Durham, NC; Submission type: D; Filing date: 2026-09-17; Industry Group: Other Health Care; Date of First Sale: 2026-09-09; Types of Securities Offered: Other (SAFE (Simple Agreement for Future Equity)); Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 160000; Federal exemptions: 06b
Sep 17, 2026SEC Form D 0002155415-26-000001
Oncobiomix Inc.Raised $100K (Form D filed Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · SEC Form D 0001998501-26-000001
    Name of Issuer: Oncobiomix Inc.; CIK: 1998501; Address: San Antonio, TX; Submission type: D; Filing date: 2026-09-16; Industry Group: Other Health Care; Date of First Sale: 2026-09-14; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 100000; Federal exemptions: 06b
Sep 16, 2026SEC Form D 0001998501-26-000001
ROSE DiagnosticsRaised $2.21M (Form D filed Sep 15, 2026).
Evidence (1 event)
  • Sep 15, 2026 · SEC Form D 0002027716-26-000001
    Name of Issuer: ROSE DIAGNOSTICS INC.; CIK: 2027716; Address: Carlsbad, CA; Submission type: D; Filing date: 2026-09-15; Industry Group: Other Health Care; Date of First Sale: 2026-07-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 2208750; Federal exemptions: 06b
Sep 15, 2026SEC Form D 0002027716-26-000001
Hexamer TherapeuticsRaised $500K (Form D filed Sep 15, 2026).
Evidence (1 event)
  • Sep 15, 2026 · SEC Form D 0001797915-26-000002
    Name of Issuer: Hexamer Therapeutics, Inc; CIK: 1797915; Address: Pullman, WA; Submission type: D; Filing date: 2026-09-15; Industry Group: Biotechnology; Date of First Sale: 2026-07-07; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 500000; Federal exemptions: 06b
Sep 15, 2026SEC Form D 0001797915-26-000002
Moonwalk BiosciencesRaised $60M (Form D filed Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · SEC Form D 0002004362-26-000003
    Name of Issuer: Moonwalk Biosciences, Inc.; CIK: 2004362; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-09-14; Industry Group: Biotechnology; Date of First Sale: 2026-08-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 70249973; Total Amount Sold: 59999998; Federal exemptions: 06b
Sep 14, 2026SEC Form D 0002004362-26-000003
Retham Technologies LLCRaised $1.06M (Form D filed Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · SEC Form D 0002144681-26-000001
    Name of Issuer: Retham Technologies, Inc.; CIK: 2144681; Address: Wauwatosa, WI; Submission type: D; Filing date: 2026-09-11; Industry Group: Other; Date of First Sale: 2026-08-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1500000; Total Amount Sold: 1060000; Federal exemptions: 06b
Sep 11, 2026SEC Form D 0002144681-26-000001
Tempo Therapeutics IncRaised $14M in debt securities (Form D filed Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · SEC Form D 0001813688-26-000003
    Name of Issuer: Tempo Therapeutics, Inc.; CIK: 1813688; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-11; Industry Group: Biotechnology; Date of First Sale: 2026-08-27; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 14500000; Total Amount Sold: 14000000; Federal exemptions: 06b
Sep 11, 2026SEC Form D 0001813688-26-000003
AlzheonRaised $78.8M (Form D filed Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · SEC Form D 0001582636-26-000002
    Name of Issuer: ALZHEON, INC.; CIK: 1582636; Address: Framingham, MA; Submission type: D; Filing date: 2026-09-10; Industry Group: Biotechnology; Date of First Sale: 2026-08-26; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 499999999; Total Amount Sold: 78797184; Federal exemptions: 06b
Sep 10, 2026SEC Form D 0001582636-26-000002
seqWell, Inc.Raised $960K (Form D filed Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · SEC Form D 0001679720-26-000001
    Name of Issuer: seqWell Inc.; CIK: 1679720; Address: Beverly, MA; Submission type: D; Filing date: 2026-09-10; Industry Group: Other Technology; Date of First Sale: 2026-09-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 960110; Federal exemptions: 06b
Sep 10, 2026SEC Form D 0001679720-26-000001
CoologicsRaised $1M (Form D filed Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · SEC Form D 0002150705-26-000001
    Name of Issuer: Coologics, Inc.; CIK: 2150705; Address: Grove City, OH; Submission type: D; Filing date: 2026-09-10; Industry Group: Other; Date of First Sale: 2026-09-01; Types of Securities Offered: Other (Simple Agreement for Future Equity (SAFE)); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1000000; Federal exemptions: 06b
Sep 10, 2026SEC Form D 0002150705-26-000001
Airway TherapeuticsRaised $43.5M (Form D filed Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · SEC Form D 0000914062-26-000054
    Name of Issuer: Airway Therapeutics, Inc.; CIK: 1733867; Address: Marietta, GA; Submission type: D; Filing date: 2026-09-09; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 50584517; Total Amount Sold: 43496282; Federal exemptions: 06b
Sep 9, 2026SEC Form D 0000914062-26-000054
Cloverleaf Bio, Inc.Raised $14.8M (Form D filed Sep 9, 2026); 3 roles open.
Evidence (1 event)
  • Sep 9, 2026 · SEC Form D 0002153574-26-000001
    Name of Issuer: Cloverleaf Bio, Inc.; CIK: 2153574; Address: New Haven, CT; Submission type: D; Filing date: 2026-09-09; Industry Group: Biotechnology; Date of First Sale: 2026-08-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 29599977; Total Amount Sold: 14799988; Federal exemptions: 06b
Sep 9, 2026SEC Form D 0002153574-26-000001
Malcova Inc.Raised $1.21M (Form D filed Sep 8, 2026).
Evidence (1 event)
  • Sep 8, 2026 · SEC Form D 0002152940-26-000001
    Name of Issuer: Malcova, Inc; CIK: 2152940; Address: Newark, CA; Submission type: D; Filing date: 2026-09-08; Industry Group: Other Technology; Date of First Sale: 2026-08-24; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1214000; Federal exemptions: 06b
Sep 8, 2026SEC Form D 0002152940-26-000001
Jupiter NeurosciencesRaised $775K (Form D filed Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · SEC Form D 0001493152-26-041606
    Name of Issuer: JUPITER NEUROSCIENCES, INC.; CIK: 1679628; Address: Palm Beach Gardens, FL; Submission type: D; Filing date: 2026-09-04; Industry Group: Other Health Care; Date of First Sale: 2026-08-20; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 774787; Total Amount Sold: 774787; Federal exemptions: 06b
Sep 4, 2026SEC Form D 0001493152-26-041606
Superluminal MedicinesRaised $65.48M (Form D filed Sep 3, 2026).
Evidence (1 event)
  • Sep 3, 2026 · SEC Form D 0001989478-26-000001
    Name of Issuer: Superluminal Medicines, Inc.; CIK: 1989478; Address: Boston, MA; Submission type: D; Filing date: 2026-09-03; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 65480796; Total Amount Sold: 65480796; Federal exemptions: 06b
Sep 3, 2026SEC Form D 0001989478-26-000001
OrthobondRaised $8.35M in debt securities (Form D filed Sep 1, 2026).
Evidence (1 event)
  • Sep 1, 2026 · SEC Form D 0001329147-26-000003
    Name of Issuer: Orthobond Corp; CIK: 1329147; Address: Monmouth Junction, NJ; Submission type: D; Filing date: 2026-09-01; Industry Group: Other Technology; Date of First Sale: 2026-08-24; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 8346000; Federal exemptions: 06b
Sep 1, 2026SEC Form D 0001329147-26-000003
Halia TherapeuticsRaised $3.49M (Form D filed Aug 31, 2026).
Evidence (1 event)
  • Aug 31, 2026 · SEC Form D 0001829255-26-000001
    Name of Issuer: Halia Therapeutics, Inc.; CIK: 1829255; Address: Lehi, UT; Submission type: D; Filing date: 2026-08-31; Industry Group: Biotechnology; Date of First Sale: 2026-08-17; Types of Securities Offered: Equity, Option/warrant, Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 3486474; Federal exemptions: 06b
Aug 31, 2026SEC Form D 0001829255-26-000001
DalCor PharmaceuticalsRaised $6.96M (Form D filed Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · SEC Form D 0001231919-26-001113
    Name of Issuer: DalCor Pharmaceuticals US, LLC; CIK: 1673368; Address: Sarasota, FL; Submission type: D; Filing date: 2026-08-28; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 6958236; Total Amount Sold: 6958236; Federal exemptions: 06b
Aug 28, 2026SEC Form D 0001231919-26-001113
Noveome BiotherapeuticsRaised $6.75M in debt securities (Form D filed Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · SEC Form D 0001478304-26-000003
    Name of Issuer: Noveome Biotherapeutics, Inc.; CIK: 1478304; Address: Pittsburgh, PA; Submission type: D; Filing date: 2026-08-27; Industry Group: Biotechnology; Date of First Sale: 2026-08-12; Types of Securities Offered: Debt, Other (Convertible promissory notes); Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 6750503; Federal exemptions: 06b
Aug 27, 2026SEC Form D 0001478304-26-000003
BiolibertyRaised $2.95M (Form D filed Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · SEC Form D 0002151818-26-000001
    Name of Issuer: Bioliberty Ltd; CIK: 2151818; Address: Edinburgh, United Kingdom; Submission type: D; Filing date: 2026-08-27; Industry Group: Other Technology; Date of First Sale: 2026-07-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2947097; Total Amount Sold: 2947097; Federal exemptions: 06b
Aug 27, 2026SEC Form D 0002151818-26-000001
FluidForm Inc.Raised $1.7M (Form D filed Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · SEC Form D 0001123292-26-001178
    Name of Issuer: FluidForm Bio, Inc.; CIK: 2062460; Address: Waltham, MA; Submission type: D; Filing date: 2026-08-27; Industry Group: Biotechnology; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1703371; Federal exemptions: 06b
Aug 27, 2026SEC Form D 0001123292-26-001178
ProEncia BiotechnologyForm D reports $1.51M sold since 2024 (filed Aug 26, 2026).
Evidence (1 event)
  • Aug 26, 2026 · SEC Form D 0002103044-26-000001
    Name of Issuer: ProEncia Biotechnology Inc.; CIK: 2103044; Address: Woodbury, MN; Submission type: D; Filing date: 2026-08-26; Industry Group: Biotechnology; Date of First Sale: 2024-10-04; Types of Securities Offered: Equity, Debt; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 1510000; Federal exemptions: 06b
Aug 26, 2026SEC Form D 0002103044-26-000001
Turn TherapeuticsRaised $1.65M (Form D filed Aug 26, 2026).
Evidence (1 event)
  • Aug 26, 2026 · SEC Form D 0002023016-26-000001
    Name of Issuer: Turn Therapeutics Inc.; CIK: 2023016; Address: Westlake Village, CA; Submission type: D; Filing date: 2026-08-26; Industry Group: Biotechnology; Date of First Sale: 2026-08-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1650000; Federal exemptions: 06b
Aug 26, 2026SEC Form D 0002023016-26-000001
Aptevo TherapeuticsRaised $3.47M (Form D filed Aug 26, 2026).
Evidence (1 event)
  • Aug 26, 2026 · SEC Form D 0001193125-26-368286
    Name of Issuer: Aptevo Therapeutics Inc.; CIK: 1671584; Address: Seattle, WA; Submission type: D; Filing date: 2026-08-26; Industry Group: Pharmaceuticals; Date of First Sale: 2026-08-12; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 3472683; Total Amount Sold: 3472683; Federal exemptions: 06c
Aug 26, 2026SEC Form D 0001193125-26-368286
MalarVxRaised $125K (Form D filed Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · SEC Form D 0001559688-26-000003
    Name of Issuer: MalarVx, Inc.; CIK: 1559688; Address: Seattle, WA; Submission type: D; Filing date: 2026-08-25; Industry Group: Biotechnology; Date of First Sale: 2026-08-08; Types of Securities Offered: Other (Promissory Note convertible into equity.); Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 125000; Federal exemptions: 06b
Aug 25, 2026SEC Form D 0001559688-26-000003
Gradient Health, Inc.Raised $2.13M (Form D filed Oct 7, 2026); +1 other Form D filing in the last 12 months.
Evidence (2 events)
  • Oct 7, 2026 · SEC Form D 0001914365-26-000003
    Name of Issuer: Gradient Health, Inc.; CIK: 1914365; Address: Durham, NC; Submission type: D; Filing date: 2026-10-07; Industry Group: Other Health Care; Date of First Sale: 2026-10-06; Types of Securities Offered: Equity, Other (Shares of Issuer preferred stock and the issuer capital stock into which such preferred stock may convert.); Business combination transaction: false; Total Offering Amount: 2132720; Total Amount Sold: 2132720; Federal exemptions: 06b
  • Aug 25, 2026 · SEC Form D 0001914365-26-000002
    Name of Issuer: Gradient Health, Inc.; CIK: 1914365; Address: Durham, NC; Submission type: D; Filing date: 2026-08-25; Industry Group: Other Health Care; Date of First Sale: 2026-08-13; Types of Securities Offered: Equity, Other (The equity sold is shares of Issuer preferred stock and the Issuer capital stock into which such preferred stock may convert.); Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b
Oct 7, 2026SEC Form D 0001914365-26-000003
Unravel BiosciencesRaised $4.1M in debt securities (Form D filed Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · SEC Form D 0001876967-26-000002
    Name of Issuer: Unravel Biosciences, Inc.; CIK: 1876967; Address: Medford, MA; Submission type: D; Filing date: 2026-08-24; Industry Group: Biotechnology; Date of First Sale: 2026-08-07; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 4500000; Total Amount Sold: 4100000; Federal exemptions: 06b
Aug 24, 2026SEC Form D 0001876967-26-000002
CardiosenseRaised $26.14M (Form D filed Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · SEC Form D 0001957335-26-000003
    Name of Issuer: Cardiosense, Inc.; CIK: 1957335; Address: Chicago, IL; Submission type: D; Filing date: 2026-08-24; Industry Group: Other Health Care; Date of First Sale: 2026-08-07; Types of Securities Offered: Equity, Security to be acquired, Other (Convertible Promissory Notes have converted into equity in connection with this transaction); Business combination transaction: false; Total Offering Amount: 42012230; Total Amount Sold: 26137050; Federal exemptions: 06b
Aug 24, 2026SEC Form D 0001957335-26-000003
Aer TherapeuticsRaised $3M in debt securities (Form D filed Aug 19, 2026).
Evidence (1 event)
  • Aug 19, 2026 · SEC Form D 0001959576-26-000001
    Name of Issuer: Aer Therapeutics, Inc.; CIK: 1959576; Address: Research Triangle Park, NC; Submission type: D; Filing date: 2026-08-19; Industry Group: Biotechnology; Date of First Sale: 2026-08-07; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 3000000; Federal exemptions: 06b
Aug 19, 2026SEC Form D 0001959576-26-000001
MaxQ MedicalRaised $31.53M (Form D filed Aug 19, 2026).
Evidence (1 event)
  • Aug 19, 2026 · SEC Form D 0002027191-26-000003
    Name of Issuer: MaxQ Medical Inc.; CIK: 2027191; Address: Sunnyvale, CA; Submission type: D; Filing date: 2026-08-19; Industry Group: Manufacturing; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 31529997; Total Amount Sold: 31529997; Federal exemptions: 06b, 4a5
Aug 19, 2026SEC Form D 0002027191-26-000003
FareonRaised $7M (Form D filed Aug 19, 2026; amended Oct 7, 2026).
Evidence (1 event)
  • Aug 19, 2026 · SEC Form D 0001963942-26-000003
    Name of Issuer: Fareon, Inc.; CIK: 1963942; Address: San Francisco, CA; Submission type: D; Filing date: 2026-08-19; Industry Group: Other Technology; Date of First Sale: 2026-08-11; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 11400000; Total Amount Sold: 2000000; Federal exemptions: 06b || Name of Issuer: Fareon, Inc.; CIK: 1963942; Address: San Francisco, CA; Submission type: D/A; Filing date: 2026-10-07; Industry Group: Other Technology; Date of First Sale: 2026-08-11; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 7000000; Federal exemptions: 06b
Aug 19, 2026SEC Form D 0001963942-26-000003
Limber Prosthetics & Orthotics Inc.Raised $135K (Form D filed Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · SEC Form D 0000892251-26-000115
    Name of Issuer: Limber Prosthetics, Inc.; CIK: 2072119; Address: San Diego, CA; Submission type: D; Filing date: 2026-08-18; Industry Group: Other Health Care; Date of First Sale: 2026-08-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1875000; Total Amount Sold: 135343; Federal exemptions: 06b
Aug 18, 2026SEC Form D 0000892251-26-000115
GeorgiamuneRaised $92.69M (Form D filed Aug 17, 2026).
Evidence (1 event)
  • Aug 17, 2026 · SEC Form D 0000905148-26-003774
    Name of Issuer: Georgiamune, Inc.; CIK: 2148230; Address: Gaithersburg, MD; Submission type: D; Filing date: 2026-08-17; Industry Group: Biotechnology; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity, Other (Series B Preferred Stock); Business combination transaction: false; Total Offering Amount: 131852011; Total Amount Sold: 92692709; Federal exemptions: 06b
Aug 17, 2026SEC Form D 0000905148-26-003774
MBQ PharmaRaised $991K (Form D filed Aug 14, 2026); +4 other Form D filings in the last 12 months.
Evidence (5 events)
  • Aug 14, 2026 · SEC Form D 0002148840-26-000005
    Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 991038; Federal exemptions: 06b
  • Aug 14, 2026 · SEC Form D 0002148840-26-000004
    Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2023-08-24; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 500000; Federal exemptions: 06b
  • Aug 14, 2026 · SEC Form D 0002148840-26-000003
    Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2022-03-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 325000; Total Amount Sold: 325000; Federal exemptions: 06b
  • Aug 14, 2026 · SEC Form D 0002148840-26-000002
    Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2021-02-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 882000; Total Amount Sold: 882000; Federal exemptions: 06b
  • Aug 14, 2026 · SEC Form D 0002148840-26-000001
    Name of Issuer: MBQ PHARMA INC.; CIK: 2148840; Address: San Juan, PR; Submission type: D; Filing date: 2026-08-14; Industry Group: Pharmaceuticals; Date of First Sale: 2018-06-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 1530000; Federal exemptions: 06b
Aug 14, 2026SEC Form D 0002148840-26-000005
Teal Health, Inc.Raised $21.26M (Form D filed Aug 13, 2026); since then posted 4 roles.
Evidence (1 event)
  • Aug 13, 2026 · SEC Form D 0001231919-26-000877
    Name of Issuer: Teal Health, Inc.; CIK: 2046595; Address: San Francisco, CA; Submission type: D; Filing date: 2026-08-13; Industry Group: Other; Date of First Sale: 2026-08-05; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 22999984; Total Amount Sold: 21264213; Federal exemptions: 06b
Aug 13, 2026SEC Form D 0001231919-26-000877
Auron TherapeuticsRaised $7.12M in debt securities (Form D filed Aug 13, 2026).
Evidence (1 event)
  • Aug 13, 2026 · SEC Form D 0001746139-26-000002
    Name of Issuer: Auron Therapeutics, Inc.; CIK: 1746139; Address: Wellesley, MA; Submission type: D; Filing date: 2026-08-13; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 7118141; Federal exemptions: 06b
Aug 13, 2026SEC Form D 0001746139-26-000002
Trace BiosciencesRaised $8.33M (Form D filed Aug 12, 2026).
Evidence (1 event)
  • Aug 12, 2026 · SEC Form D 0002147501-26-000002
    Name of Issuer: Trace Biosciences Inc.; CIK: 2147501; Address: Beaverton, OR; Submission type: D; Filing date: 2026-08-12; Industry Group: Biotechnology; Date of First Sale: 2026-07-28; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 16234498; Total Amount Sold: 8334499; Federal exemptions: 06b
Aug 12, 2026SEC Form D 0002147501-26-000002
Merlin Biotech Inc.Raised $50K in debt securities (Form D filed Aug 11, 2026).
Evidence (1 event)
  • Aug 11, 2026 · SEC Form D 0002149714-26-000001
    Name of Issuer: Merlin Biotech, Inc.; CIK: 2149714; Address: Doylestown, PA; Submission type: D; Filing date: 2026-08-11; Industry Group: Biotechnology; Date of First Sale: 2026-06-30; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 50000; Total Amount Sold: 50000; Federal exemptions: 06b
Aug 11, 2026SEC Form D 0002149714-26-000001
Prana Therapies, Inc.Raised $40.23M (Form D filed Aug 10, 2026).
Evidence (1 event)
  • Aug 10, 2026 · SEC Form D 0001231919-26-000849
    Name of Issuer: Prana Therapies, Inc.; CIK: 2029240; Address: Encinitas, CA; Submission type: D; Filing date: 2026-08-10; Industry Group: Biotechnology; Date of First Sale: 2025-11-25; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 40226932; Total Amount Sold: 40226932; Federal exemptions: 06b
Aug 10, 2026SEC Form D 0001231919-26-000849
PleoPharmaRaised $5.5M in debt securities (Form D filed Aug 10, 2026).
Evidence (1 event)
  • Aug 10, 2026 · SEC Form D 0001801323-26-000001
    Name of Issuer: PLEOPHARMA, INC.; CIK: 1801323; Address: Phoenixville, PA; Submission type: D; Filing date: 2026-08-10; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-28; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 5500000; Federal exemptions: 06b
Aug 10, 2026SEC Form D 0001801323-26-000001
Pelva Health CorporationRaised $30K (Form D filed Aug 7, 2026).
Evidence (1 event)
  • Aug 7, 2026 · SEC Form D 0002008160-26-000004
    Name of Issuer: Pelva Health Corp; CIK: 2008160; Address: Edina, MN; Submission type: D; Filing date: 2026-08-07; Industry Group: Other Health Care; Date of First Sale: 2026-07-09; Types of Securities Offered: Other (SAFE instrument); Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 30000; Federal exemptions: 06b
Aug 7, 2026SEC Form D 0002008160-26-000004
Cerium PharmaceuticalsRaised $750K (Form D filed Aug 6, 2026).
Evidence (1 event)
  • Aug 6, 2026 · SEC Form D 0001677995-26-000003
    Name of Issuer: Cerium Pharmaceuticals, Inc.; CIK: 1677995; Address: Gaithersburg, MD; Submission type: D; Filing date: 2026-08-06; Industry Group: Pharmaceuticals; Date of First Sale: 2026-05-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2544000; Total Amount Sold: 750000; Federal exemptions: 06b
Aug 6, 2026SEC Form D 0001677995-26-000003
Integrated BiosciencesRaised $68.37M (Form D filed Aug 5, 2026); since then posted 5 roles.
Evidence (1 event)
  • Aug 5, 2026 · SEC Form D 0002148371-26-000001
    Name of Issuer: Integrated Biosciences, Inc.; CIK: 2148371; Address: Redwood City, CA; Submission type: D; Filing date: 2026-08-05; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 100000000; Total Amount Sold: 68374977; Federal exemptions: 06b
Aug 5, 2026SEC Form D 0002148371-26-000001
Jasper Therapeutics, Inc.Raised $132M (Form D filed Aug 5, 2026).
Evidence (1 event)
  • Aug 5, 2026 · SEC Form D 0001213900-26-085315
    Name of Issuer: Jasper Therapeutics, Inc.; CIK: 1788028; Address: Redwood City, CA; Submission type: D; Filing date: 2026-08-05; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 131999611; Total Amount Sold: 131999611; Federal exemptions: 06b
Aug 5, 2026SEC Form D 0001213900-26-085315
TheradaptiveRaised $36.16M (Form D filed Aug 4, 2026).
Evidence (1 event)
  • Aug 4, 2026 · SEC Form D 0002148461-26-000001
    Name of Issuer: Theradaptive, Inc.; CIK: 2148461; Address: Frederick, MD; Submission type: D; Filing date: 2026-08-04; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 77925166; Total Amount Sold: 36156177; Federal exemptions: 06b
Aug 4, 2026SEC Form D 0002148461-26-000001
oRF BiologicsRaised $1.73M (Form D filed Jul 31, 2026).
Evidence (1 event)
  • Jul 31, 2026 · SEC Form D 0002048350-26-000004
    Name of Issuer: ORF Biologics, Inc.; CIK: 2048350; Address: Tiffin, IA; Submission type: D; Filing date: 2026-07-31; Industry Group: Biotechnology; Date of First Sale: 2026-07-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2500000; Total Amount Sold: 1734220; Federal exemptions: 06b
Jul 31, 2026SEC Form D 0002048350-26-000004
Shape Memory MedicalRaised $6.91M in debt securities (Form D filed Jul 16, 2026; amended Jul 31, 2026).
Evidence (1 event)
  • Jul 16, 2026 · SEC Form D 0001630786-26-000002
    Name of Issuer: Shape Memory Medical Inc.; CIK: 1630786; Address: San Jose, CA; Submission type: D; Filing date: 2026-07-16; Industry Group: Other Health Care; Date of First Sale: 2026-07-02; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 6724900; Federal exemptions: 06b || Name of Issuer: Shape Memory Medical Inc.; CIK: 1630786; Address: San Jose, CA; Submission type: D/A; Filing date: 2026-07-31; Industry Group: Other Health Care; Date of First Sale: 2026-07-02; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 6912400; Federal exemptions: 06b
Jul 16, 2026SEC Form D 0001630786-26-000002
Ratio TherapeuticsRaised $70M (Form D filed Jul 31, 2026); 7 roles open.
Evidence (1 event)
  • Jul 31, 2026 · SEC Form D 0002004792-26-000001
    Name of Issuer: Ratio Therapeutics, Inc.; CIK: 2004792; Address: Boston, MA; Submission type: D; Filing date: 2026-07-31; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-16; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 69999974; Total Amount Sold: 69999974; Federal exemptions: 06b
Jul 31, 2026SEC Form D 0002004792-26-000001
NextPoint TherapeuticsRaised $33.73M (Form D filed Jul 30, 2026).
Evidence (1 event)
  • Jul 30, 2026 · SEC Form D 0001959209-26-000002
    Name of Issuer: NextPoint Therapeutics, Inc.; CIK: 1959209; Address: Cambridge, MA; Submission type: D; Filing date: 2026-07-30; Industry Group: Biotechnology; Date of First Sale: 2026-07-22; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 48729165; Total Amount Sold: 33728772; Federal exemptions: 06b
Jul 30, 2026SEC Form D 0001959209-26-000002
GenomenonRaised $6.03M (Form D filed Jul 30, 2026); 3 roles open.
Evidence (1 event)
  • Jul 30, 2026 · SEC Form D 0001650557-26-000004
    Name of Issuer: Genomenon, Inc.; CIK: 1650557; Address: Ann Arbor, MI; Submission type: D; Filing date: 2026-07-30; Industry Group: Biotechnology; Date of First Sale: 2026-07-15; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 6025002; Federal exemptions: 06b
Jul 30, 2026SEC Form D 0001650557-26-000004
MagnendoRaised $18M (Form D filed Jul 29, 2026).
Evidence (1 event)
  • Jul 29, 2026 · SEC Form D 0002026763-26-000003
    Name of Issuer: Magnendo Corp.; CIK: 2026763; Address: Newton, MA; Submission type: D; Filing date: 2026-07-29; Industry Group: Biotechnology; Date of First Sale: 2026-07-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 18000000; Total Amount Sold: 18000000; Federal exemptions: 06b
Jul 29, 2026SEC Form D 0002026763-26-000003
SonavexRaised $3.1M (Form D filed Jul 28, 2026).
Evidence (1 event)
  • Jul 28, 2026 · SEC Form D 0001645892-26-000003
    Name of Issuer: Sonavex, Inc.; CIK: 1645892; Address: city not listed;DONNELL STREET, BALTIMORE, MARYLAND; Submission type: D; Filing date: 2026-07-28; Industry Group: Biotechnology; Date of First Sale: 2026-07-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 3102995; Federal exemptions: 06b
Jul 28, 2026SEC Form D 0001645892-26-000003
Accipiter BiosciencesRaised $10.49M (Form D filed Jul 28, 2026).
Evidence (1 event)
  • Jul 28, 2026 · SEC Form D 0001973963-26-000002
    Name of Issuer: Accipiter Biosciences Inc.; CIK: 1973963; Address: Seattle, WA; Submission type: D; Filing date: 2026-07-28; Industry Group: Biotechnology; Date of First Sale: 2026-07-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10492778; Total Amount Sold: 10492778; Federal exemptions: 06b
Jul 28, 2026SEC Form D 0001973963-26-000002
TECLensRaised $5.23M in debt securities (Form D filed Jul 24, 2026).
Evidence (1 event)
  • Jul 24, 2026 · SEC Form D 0001708436-26-000003
    Name of Issuer: TECLens, Inc.; CIK: 1708436; Address: Stamford, CT; Submission type: D; Filing date: 2026-07-24; Industry Group: Other Health Care; Date of First Sale: 2026-07-09; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 10230000; Total Amount Sold: 5230000; Federal exemptions: 06b
Jul 24, 2026SEC Form D 0001708436-26-000003
Cooler Heads Care Inc.Raised $3.27M (Form D filed Jul 23, 2026).
Evidence (1 event)
  • Jul 23, 2026 · SEC Form D 0001972845-26-000001
    Name of Issuer: COOLER HEADS CARE, INC.; CIK: 1972845; Address: San Diego, CA; Submission type: D; Filing date: 2026-07-23; Industry Group: Other Health Care; Date of First Sale: 2026-07-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 5999928; Total Amount Sold: 3267467; Federal exemptions: 06b
Jul 23, 2026SEC Form D 0001972845-26-000001
CSA MedicalRaised $2.91M (Form D filed Jul 23, 2026).
Evidence (1 event)
  • Jul 23, 2026 · SEC Form D 0001403000-26-000004
    Name of Issuer: CSA Medical, Inc.; CIK: 1403000; Address: Lexington, MA; Submission type: D; Filing date: 2026-07-23; Industry Group: Other; Date of First Sale: 2026-06-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11217710; Total Amount Sold: 2908295; Federal exemptions: 06b
Jul 23, 2026SEC Form D 0001403000-26-000004
GT Medical TechnologiesRaised $50.06M (Form D filed Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · SEC Form D 0001723008-26-000002
    Name of Issuer: GT MEDICAL TECHNOLOGIES, INC.; CIK: 1723008; Address: Tempe, AZ; Submission type: D; Filing date: 2026-07-22; Industry Group: Other Health Care; Date of First Sale: 2026-05-08; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 100056698; Total Amount Sold: 50056676; Federal exemptions: 06b
Jul 22, 2026SEC Form D 0001723008-26-000002
Holobiome, Inc.Raised $10M (Form D filed Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · SEC Form D 0001104659-26-085757
    Name of Issuer: Holobiome, Inc.; CIK: 1763027; Address: Boston, MA; Submission type: D; Filing date: 2026-07-22; Industry Group: Biotechnology; Date of First Sale: 2025-12-24; Types of Securities Offered: Other (Simple Agreement for Future Equity (SAFES)); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 10000000; Federal exemptions: 06b
Jul 22, 2026SEC Form D 0001104659-26-085757
TYBR HealthRaised $14.35M (Form D filed Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · SEC Form D 0001835188-26-000001
    Name of Issuer: TYBR Health, Inc.; CIK: 1835188; Address: Houston, TX; Submission type: D; Filing date: 2026-07-22; Industry Group: Biotechnology; Date of First Sale: 2026-07-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 14354342; Federal exemptions: 06b
Jul 22, 2026SEC Form D 0001835188-26-000001
ALZpath, Inc.Raised $8.41M (Form D filed Jul 21, 2026).
Evidence (1 event)
  • Jul 21, 2026 · SEC Form D 0002145244-26-000001
    Name of Issuer: ALZpath, Inc.; CIK: 2145244; Address: Carlsbad, CA; Submission type: D; Filing date: 2026-07-21; Industry Group: Biotechnology; Date of First Sale: 2026-07-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10411219; Total Amount Sold: 8411219; Federal exemptions: 06b
Jul 21, 2026SEC Form D 0002145244-26-000001
InterAct TherapeuticsRaised $250K in debt securities (Form D filed Jul 21, 2026).
Evidence (1 event)
  • Jul 21, 2026 · SEC Form D 0002107143-26-000001
    Name of Issuer: InterAct Therapeutics, Inc.; CIK: 2107143; Address: Dallas, TX; Submission type: D; Filing date: 2026-07-21; Industry Group: Other Health Care; Date of First Sale: 2026-07-20; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 250000; Federal exemptions: 06b
Jul 21, 2026SEC Form D 0002107143-26-000001
410 MedicalRaised $10.32M (Form D filed Jul 15, 2026).
Evidence (1 event)
  • Jul 15, 2026 · SEC Form D 0001630050-26-000002
    Name of Issuer: 410 Medical, Inc.; CIK: 1630050; Address: Durham, NC; Submission type: D; Filing date: 2026-07-15; Industry Group: Other Health Care; Date of First Sale: 2026-06-30; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 10323798; Federal exemptions: 06b
Jul 15, 2026SEC Form D 0001630050-26-000002
Cellular LogisticsRaised $50K in debt securities (Form D filed Jul 15, 2026).
Evidence (1 event)
  • Jul 15, 2026 · SEC Form D 0001688621-26-000005
    Name of Issuer: Cellular Logistics, Inc.; CIK: 1688621; Address: Madison, WI; Submission type: D; Filing date: 2026-07-15; Industry Group: Biotechnology; Date of First Sale: 2026-06-25; Types of Securities Offered: Debt, Other (convertible promissory note); Business combination transaction: false; Total Offering Amount: 100000; Total Amount Sold: 50000; Federal exemptions: 06b
Jul 15, 2026SEC Form D 0001688621-26-000005
ImmunoVecRaised $12.71M (Form D filed Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · SEC Form D 0001231919-26-000761
    Name of Issuer: ImmunoVec, Inc.; CIK: 1914272; Address: Los Angeles, CA; Submission type: D; Filing date: 2026-07-14; Industry Group: Other Technology; Date of First Sale: 2026-06-29; Types of Securities Offered: Equity, Security to be acquired, Other (Preferred Stock and Common Stock issuable upon conversion thereof. Total Offering Amount and Total Amount Sold include conversion of the previously issued convertible securities.); Business combination transaction: false; Total Offering Amount: 14999944; Total Amount Sold: 12705822; Federal exemptions: 06b
Jul 14, 2026SEC Form D 0001231919-26-000761
Silo PharmaRaised $4M (Form D filed Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · SEC Form D 0001213900-26-077974
    Name of Issuer: Silo Pharma, Inc.; CIK: 1514183; Address: Sarasota, FL; Submission type: D; Filing date: 2026-07-14; Industry Group: Pharmaceuticals; Date of First Sale: 2026-07-09; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 4000015; Total Amount Sold: 4000015; Federal exemptions: 06b
Jul 14, 2026SEC Form D 0001213900-26-077974
InnSight TechnologyRaised $1.35M (Form D filed Jul 13, 2026).
Evidence (1 event)
  • Jul 13, 2026 · SEC Form D 0001956287-26-000005
    Name of Issuer: InnSight Technology, Inc.; CIK: 1956287; Address: Pittsburgh, PA; Submission type: D; Filing date: 2026-07-13; Industry Group: Other Health Care; Date of First Sale: 2026-06-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1350000; Federal exemptions: 06b
Jul 13, 2026SEC Form D 0001956287-26-000005
PluristyxRaised $9.76M (Form D filed Jul 13, 2026).
Evidence (1 event)
  • Jul 13, 2026 · SEC Form D 0001991664-26-000003
    Name of Issuer: Pluristyx Inc.; CIK: 1991664; Address: Seattle, WA; Submission type: D; Filing date: 2026-07-13; Industry Group: Biotechnology; Date of First Sale: 2026-07-01; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 14757793; Total Amount Sold: 9757789; Federal exemptions: 06b
Jul 13, 2026SEC Form D 0001991664-26-000003
Vantis VascularRaised $18.64M (Form D filed Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · SEC Form D 0002080612-26-000043
    Name of Issuer: Vantis Vascular, Inc.; CIK: 1761882; Address: San Jose, CA; Submission type: D; Filing date: 2026-07-10; Industry Group: Other; Date of First Sale: 2026-06-26; Types of Securities Offered: Equity, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 21500000; Total Amount Sold: 18639500; Federal exemptions: 06b
Jul 10, 2026SEC Form D 0002080612-26-000043
Akadeum Life SciencesRaised $2.13M (Form D filed Jul 9, 2026).
Evidence (1 event)
  • Jul 9, 2026 · SEC Form D 0001622872-26-000001
    Name of Issuer: AKADEUM LIFE SCIENCES, INC.; CIK: 1622872; Address: Ann Arbor, MI; Submission type: D; Filing date: 2026-07-09; Industry Group: Biotechnology; Date of First Sale: 2026-06-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3427230; Total Amount Sold: 2130557; Federal exemptions: 06b
Jul 9, 2026SEC Form D 0001622872-26-000001
CeleCor TherapeuticsRaised $11.86M (Form D filed Jul 9, 2026).
Evidence (1 event)
  • Jul 9, 2026 · SEC Form D 0001705381-26-000006
    Name of Issuer: CeleCor Therapeutics, Inc.; CIK: 1705381; Address: Del Mar, CA; Submission type: D; Filing date: 2026-07-09; Industry Group: Pharmaceuticals; Date of First Sale: 2026-06-09; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 11856325; Federal exemptions: 06b
Jul 9, 2026SEC Form D 0001705381-26-000006
AmlogenyxRaised $10M (Form D filed Jul 9, 2026).
Evidence (1 event)
  • Jul 9, 2026 · SEC Form D 0001231919-26-000740
    Name of Issuer: Amlogenyx Inc.; CIK: 2031988; Address: Novato, CA; Submission type: D; Filing date: 2026-07-09; Industry Group: Biotechnology; Date of First Sale: 2026-07-01; Types of Securities Offered: Other (Convertible Promissory Notes and equity securities issuable upon conversion thereof); Business combination transaction: false; Total Offering Amount: 20000000; Total Amount Sold: 10000000; Federal exemptions: 06b
Jul 9, 2026SEC Form D 0001231919-26-000740
Micropure Genomics Inc.Raised $675K (Form D filed Jul 8, 2026).
Evidence (1 event)
  • Jul 8, 2026 · SEC Form D 0002143996-26-000001
    Name of Issuer: MicroPure Genomics, Inc.; CIK: 2143996; Address: San Diego, CA; Submission type: D; Filing date: 2026-07-08; Industry Group: Biotechnology; Date of First Sale: 2026-04-20; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 675000; Federal exemptions: 06b
Jul 8, 2026SEC Form D 0002143996-26-000001
Medicenna Therapeutics, Inc.Raised $253K (Form D filed Jul 6, 2026).
Evidence (1 event)
  • Jul 6, 2026 · SEC Form D 0001807983-26-000003
    Name of Issuer: Medicenna Therapeutics Corp.; CIK: 1807983; Address: Ontario, Canada; Submission type: D; Filing date: 2026-07-06; Industry Group: Biotechnology; Date of First Sale: 2026-05-28; Types of Securities Offered: Equity, Option/warrant, Security to be acquired, Other (Each Unit is comprised of 1 common share and 1/2 of 1 common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional Share at an exercise price of CDN$0.65 per Share for a period of 3 years following May 28, 2026.); Business combination transaction: false; Total Offering Amount: 2343400; Total Amount Sold: 253458; Federal exemptions: 06b
Jul 6, 2026SEC Form D 0001807983-26-000003
Cognos TherapeuticsRaised $250K in debt securities (Form D filed Jul 2, 2026).
Evidence (1 event)
  • Jul 2, 2026 · SEC Form D 0001651490-26-000003
    Name of Issuer: Cognos Therapeutics Inc; CIK: 1651490; Address: Inglewood, CA; Submission type: D; Filing date: 2026-07-02; Industry Group: Biotechnology; Date of First Sale: 2026-05-21; Types of Securities Offered: Debt, Security to be acquired; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 250000; Federal exemptions: 06b
Jul 2, 2026SEC Form D 0001651490-26-000003
CYduct DiagnosticsRaised $1.96M (Form D filed Jul 2, 2026).
Evidence (1 event)
  • Jul 2, 2026 · SEC Form D 0001493152-26-031760
    Name of Issuer: CYduct Diagnostics, Inc.; CIK: 1388994; Address: Westport, CT; Submission type: D; Filing date: 2026-07-02; Industry Group: Biotechnology; Date of First Sale: 2026-06-15; Types of Securities Offered: Equity, Other (Common Stock); Business combination transaction: false; Total Offering Amount: 1961000; Total Amount Sold: 1961000; Federal exemptions: 06b
Jul 2, 2026SEC Form D 0001493152-26-031760
Pneuma RespiratoryRaised $3.57M (Form D filed Jul 1, 2026).
Evidence (1 event)
  • Jul 1, 2026 · SEC Form D 0000935836-26-000338
    Name of Issuer: Pneuma Respiratory, Inc.; CIK: 1701794; Address: Boone, NC; Submission type: D; Filing date: 2026-07-01; Industry Group: Pharmaceuticals; Date of First Sale: 2026-06-18; Types of Securities Offered: Equity, Option/warrant, Other (Common Stock and Warrants to Purchase Common Stock); Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 3570115; Federal exemptions: 06b
Jul 1, 2026SEC Form D 0000935836-26-000338
Altay Therapeutics, Inc.Raised $15.74M (Form D filed Oct 2, 2026).
Evidence (1 event)
  • Oct 2, 2026 · SEC Form D 0002157551-26-000001
    Name of Issuer: Altay Therapeutics, Inc.; CIK: 2157551; Address: San Carlos, CA; Submission type: D; Filing date: 2026-10-02; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 45067885; Total Amount Sold: 15738155; Federal exemptions: 06b
Oct 2, 2026SEC Form D 0002157551-26-000001
Anvion Bio, Inc.Raised $100K (Form D filed Oct 7, 2026).
Evidence (1 event)
  • Oct 7, 2026 · SEC Form D 0001493152-26-046112
    Name of Issuer: Anvion Bio, Inc.; CIK: 2158000; Address: San Diego, CA; Submission type: D; Filing date: 2026-10-07; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-22; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 100000; Federal exemptions: 06b
Oct 7, 2026SEC Form D 0001493152-26-046112
CAD Therapeutics, Inc.Raised $4M (Form D filed Oct 2, 2026).
Evidence (1 event)
  • Oct 2, 2026 · SEC Form D 0002157566-26-000001
    Name of Issuer: CAD Therapeutics, Inc.; CIK: 2157566; Address: New York, NY; Submission type: D; Filing date: 2026-10-02; Industry Group: Biotechnology; Date of First Sale: 2026-09-17; Types of Securities Offered: Equity, Other (SERIES A COMMON STOCK); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4000000; Federal exemptions: 06b
Oct 2, 2026SEC Form D 0002157566-26-000001
Click Therapeutics, Inc.Raised $50M (Form D filed Oct 1, 2026).
Evidence (1 event)
  • Oct 1, 2026 · SEC Form D 0001623326-26-000001
    Name of Issuer: Click Therapeutics, Inc.; CIK: 1623326; Address: New York, NY; Submission type: D; Filing date: 2026-10-01; Industry Group: Other Health Care; Date of First Sale: 2026-04-07; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 49999999; Total Amount Sold: 49999999; Federal exemptions: 06b
Oct 1, 2026SEC Form D 0001623326-26-000001
CoeurativeRaised $100K (Form D filed Oct 13, 2026).
Evidence (1 event)
  • Oct 13, 2026 · SEC Form D 0001577355-26-000003
    Name of Issuer: Coeurative, Inc.; CIK: 1577355; Address: Roanoke, VA; Submission type: D; Filing date: 2026-10-13; Industry Group: Other Health Care; Date of First Sale: 2026-09-27; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 100000; Federal exemptions: 06b
Oct 13, 2026SEC Form D 0001577355-26-000003
EpiVario Inc.Raised $185K in debt securities (Form D filed Oct 13, 2026).
Evidence (1 event)
  • Oct 13, 2026 · SEC Form D 0001753351-26-000001
    Name of Issuer: EpiVario Inc.; CIK: 1753351; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: 2026-09-25; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 500000; Total Amount Sold: 185000; Federal exemptions: 06b
Oct 13, 2026SEC Form D 0001753351-26-000001
J3 BioscienceRaised $50K in debt securities (Form D filed Oct 16, 2026).
Evidence (1 event)
  • Oct 16, 2026 · SEC Form D 0001408012-26-000003
    Name of Issuer: J3 BIOSCIENCE, INC.; CIK: 1408012; Address: Salt Lake City, UT; Submission type: D; Filing date: 2026-10-16; Industry Group: Other Health Care; Date of First Sale: 2026-09-30; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 50000; Total Amount Sold: 50000; Federal exemptions: 06b
Oct 16, 2026SEC Form D 0001408012-26-000003
Lucier Pharmaceuticals Inc.Filed a Form D for an offering of up to $2M, no sales reported yet (filed Oct 13, 2026).
Evidence (1 event)
  • Oct 13, 2026 · SEC Form D 0002158290-26-000003
    Name of Issuer: LUCIER PHARMACEUTICALS INC; CIK: 2158290; Address: Bryan, TX; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: Yet to Occur; Types of Securities Offered: Other (SAFE (Simple Agreement for Future Equity), which does not grant immediate equity or voting rights.); Business combination transaction: false; Total Offering Amount: 2000000; Total Amount Sold: 0; Federal exemptions: 06b
Oct 13, 2026SEC Form D 0002158290-26-000003
Myris TherapeuticsRaised $500K (Form D filed Oct 14, 2026).
Evidence (1 event)
  • Oct 14, 2026 · SEC Form D 0001924725-26-000004
    Name of Issuer: Myris Therapeutics, Inc.; CIK: 1924725; Address: Sharpsburg, PA; Submission type: D; Filing date: 2026-10-14; Industry Group: Biotechnology; Date of First Sale: 2026-09-01; Types of Securities Offered: Other (Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 4500000; Total Amount Sold: 500000; Federal exemptions: 06b
Oct 14, 2026SEC Form D 0001924725-26-000004
OncoNano MedicineRaised $10.05M (Form D filed Oct 8, 2026).
Evidence (1 event)
  • Oct 8, 2026 · SEC Form D 0001735726-26-000001
    Name of Issuer: OncoNano Medicine, Inc.; CIK: 1735726; Address: Dallas, TX; Submission type: D; Filing date: 2026-10-08; Industry Group: Biotechnology; Date of First Sale: 2026-09-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 15000000; Total Amount Sold: 10051615; Federal exemptions: 06b
Oct 8, 2026SEC Form D 0001735726-26-000001
PreciseDxRaised $3.7M (Form D filed Oct 7, 2026).
Evidence (1 event)
  • Oct 7, 2026 · SEC Form D 0002013833-26-000007
    Name of Issuer: PreciseDx, Inc.; CIK: 2013833; Address: New York, NY; Submission type: D; Filing date: 2026-10-07; Industry Group: Other Health Care; Date of First Sale: 2026-09-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 3699998; Total Amount Sold: 3699998; Federal exemptions: 06b
Oct 7, 2026SEC Form D 0002013833-26-000007
Renovare Therapeutics, Inc.Raised $100K (Form D filed Oct 2, 2026).
Evidence (1 event)
  • Oct 2, 2026 · SEC Form D 0002158361-26-000001
    Name of Issuer: Renovare Therapeutics, Inc.; CIK: 2158361; Address: Boulder, CO; Submission type: D; Filing date: 2026-10-02; Industry Group: Biotechnology; Date of First Sale: 2026-09-14; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 100000; Federal exemptions: 06b
Oct 2, 2026SEC Form D 0002158361-26-000001
SeaStar MedicalRaised $3.3M (Form D filed Oct 8, 2026).
Evidence (1 event)
  • Oct 8, 2026 · SEC Form D 0001831868-26-000002
    Name of Issuer: SeaStar Medical Holding Corp; CIK: 1831868; Address: Denver, CO; Submission type: D; Filing date: 2026-10-08; Industry Group: Other Health Care; Date of First Sale: 2026-10-05; Types of Securities Offered: Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3301572; Total Amount Sold: 3301572; Federal exemptions: 06b
Oct 8, 2026SEC Form D 0001831868-26-000002
Thetis Pharmaceuticals LLCRaised $560K in debt securities (Form D filed Oct 13, 2026).
Evidence (1 event)
  • Oct 13, 2026 · SEC Form D 0001528491-26-000003
    Name of Issuer: Thetis Pharmaceuticals LLC; CIK: 1528491; Address: Deep River, CT; Submission type: D; Filing date: 2026-10-13; Industry Group: Pharmaceuticals; Date of First Sale: 2026-08-13; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 1000000; Total Amount Sold: 560300; Federal exemptions: 06b
Oct 13, 2026SEC Form D 0001528491-26-000003
Virtual IncisionRaised $35.14M (Form D filed Oct 5, 2026).
Evidence (1 event)
  • Oct 5, 2026 · SEC Form D 0001380771-26-000002
    Name of Issuer: Virtual Incision Corp; CIK: 1380771; Address: Lincoln, NE; Submission type: D; Filing date: 2026-10-05; Industry Group: Biotechnology; Date of First Sale: 2026-09-18; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 80140041; Total Amount Sold: 35140060; Federal exemptions: 06b
Oct 5, 2026SEC Form D 0001380771-26-000002

NIH award: 569 companies

CompanySignalEvent dateSource
CerovationsNIH awarded $1.5M (SBIR Phase II 5U44NS121557-02, continuation, notice Sep 18, 2026).
Evidence (1 event)
  • Sep 18, 2026 · NIH RePORTER 5U44NS121557-02
    Organization: CEROVATIONS, LLC; City/State: Woodbury, MN; Project number: 5U44NS121557-02; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 1499369; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Pilot Clinical Study to Assess Safety and Efficacy of External Ventricular Drainage with Cerebrospinal Fluid Water Removal Osmotherapy for Traumatic Brain Injury-Induced Cerebral Edema; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 5U44NS121557-02
Autonomous TherapeuticsNIH awarded $977K (SBIR Phase II 5R44AI186871-02, continuation, notice Aug 14, 2026); 2 NIH awards totaling $2.49M in the last 12 months.
Evidence (2 events)
  • Aug 14, 2026 · NIH RePORTER 5R44AI186871-02
    Organization: AUTONOMOUS THERAPEUTICS, INC.; City/State: SILVER SPRING, MD; Project number: 5R44AI186871-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 976628; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy; Organization type: Domestic For-Profits
  • Dec 10, 2025 · NIH RePORTER 5R01AI180651-03
    Organization: AUTONOMOUS THERAPEUTICS, INC.; City/State: SILVER SPRING, MD; Project number: 5R01AI180651-03; Activity code: R01; Fiscal year: 2026; Award notice date: 2025-12-10; FY total cost (award amount): 1510374; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Targeting Feedback Circuitry for Antiviral Therapy; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R44AI186871-02
Transtimulation Research, IncNIH awarded $991K (NIH grant 4UH3NS125182-03, extension, notice Apr 9, 2026).
Evidence (1 event)
  • Apr 9, 2026 · NIH RePORTER 4UH3NS125182-03
    Organization: TRANSTIMULATION RESEARCH, INC.; City/State: OKLAHOMA CITY, OK; Project number: 4UH3NS125182-03; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-04-09; FY total cost (award amount): 990897; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: AccelBand, a leg-worn transcutaneous neuromodulation device for treating neurogenic bowel dysfunction in individuals with spinal cord injury; Organization type: Domestic For-Profits
Apr 9, 2026NIH RePORTER 4UH3NS125182-03
The Tiny Cargo CompanyNIH awarded $1.02M (SBIR Phase II 5R44CA272078-03, continuation, notice Sep 8, 2026); 2 NIH awards totaling $2.01M in the last 12 months.
Evidence (2 events)
  • Sep 8, 2026 · NIH RePORTER 5R44CA272078-03
    Organization: TINY CARGO COMPANY, THE; City/State: ROANOKE, VA; Project number: 5R44CA272078-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 1022907; Administering IC: National Cancer Institute; Project title: XoLacta: An Adjuvant Therapy for treatment of Radiation Side effects during HER2-Positive Breast Cancer Treatment; Organization type: Domestic For-Profits
  • Jun 23, 2026 · NIH RePORTER 1U44TR004958-01A1
    Organization: TINY CARGO COMPANY, THE; City/State: ROANOKE, VA; Project number: 1U44TR004958-01A1; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 985974; Administering IC: National Center for Advancing Translational Sciences; Project title: Industrial production of milk extracellular vesicles for dual-use as a systemic radiotherapeutic medical countermeasure and cancer adjuvant therapy; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 5R44CA272078-03
Molecular Targeting Technologies, Inc.NIH awarded $638K (NIH grant 1R01CA299133-01, new, notice Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · NIH RePORTER 1R01CA299133-01
    Organization: MOLECULAR TARGETING TECHNOLOGIES, INC.; City/State: WEST CHESTER, PA; Project number: 1R01CA299133-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 637529; Administering IC: National Cancer Institute; Project title: Targeted radionuclide therapy for non-small cell lung cancer with Lu-177 EBRGD; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 1R01CA299133-01
Luna Labs USA LLCNIH awarded $871K (SBIR Phase II 5R44MH133249-04, continuation, notice Jul 16, 2026).
Evidence (1 event)
  • Jul 16, 2026 · NIH RePORTER 5R44MH133249-04
    Organization: LUNA LABS USA, LLC; City/State: CHARLOTTESVILLE, VA; Project number: 5R44MH133249-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 870685; Administering IC: National Institute of Mental Health; Project title: Carbon Nanotube Enabled Delivery of mRNA for an HIV Vaccine Candidate; Organization type: Domestic For-Profits
Jul 16, 2026NIH RePORTER 5R44MH133249-04
Trellis BioscienceNIH awarded $999K (SBIR Phase II 4U44AI183920-02, extension, notice Aug 12, 2026); 2 NIH awards totaling $2M in the last 12 months.
Evidence (2 events)
  • Aug 12, 2026 · NIH RePORTER 4U44AI183920-02
    Organization: TRELLIS BIOSCIENCE, INC.; City/State: Redwood City, CA; Project number: 4U44AI183920-02; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 998879; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bacterial Pneumonia Therapeutic Antibody Safety Trial; Organization type: Domestic For-Profits
  • Jul 29, 2026 · NIH RePORTER 1SB1AI191674-01
    Organization: TRELLIS BIOSCIENCE, INC.; City/State: Redwood City, CA; Project number: 1SB1AI191674-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 999759; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Human Antibody for Acute Infection Treatment of RSV; Organization type: Domestic For-Profits
Aug 12, 2026NIH RePORTER 4U44AI183920-02
VirticiNIH awarded $306K (SBIR Phase I 1R43DE036133-01, new, notice Sep 14, 2026); 6 NIH awards totaling $2.43M in the last 12 months.
Evidence (6 events)
  • Sep 14, 2026 · NIH RePORTER 1R43DE036133-01
    Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R43DE036133-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 306464; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Sublingual Vaccine for Preventing andTreating Periodontitis; Organization type: Domestic For-Profits
  • Sep 2, 2026 · NIH RePORTER 1R43AI188659-01A1
    Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R43AI188659-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 306500; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Novel Preventative and Treatment for Klebsiella Pneumoniae Infection; Organization type: Domestic For-Profits
  • Aug 26, 2026 · NIH RePORTER 1R44AR087173-01
    Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R44AR087173-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 306341; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A Bioengineered Probiotic for Resetting Immune Function in Rheumatoid Arthritis; Organization type: Domestic For-Profits
  • Aug 13, 2026 · NIH RePORTER 1R44AI188778-01A1
    Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R44AI188778-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 300222; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Novel Immune-modulating Probiotic for Treating Rheumatoid Arthritis; Organization type: Domestic For-Profits
  • Jul 21, 2026 · NIH RePORTER 5R43DE034614-02
    Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 5R43DE034614-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 308096; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Anti-infective Therapy for Treating Periodontitis; Organization type: Domestic For-Profits
  • Jun 1, 2026 · NIH RePORTER 5R44HL164202-05
    Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 5R44HL164202-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 903600; Administering IC: National Heart Lung and Blood Institute; Project title: A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 1R43DE036133-01
Sciogen LLCNIH awarded $314K (SBIR Phase I 1R43AI191860-01, new, notice Aug 21, 2026).
Evidence (1 event)
  • Aug 21, 2026 · NIH RePORTER 1R43AI191860-01
    Organization: SCIOGEN, LLC; City/State: San Jose, CA; Project number: 1R43AI191860-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel respiratory syncytial virus therapeutics targeting G-receptor binding; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 1R43AI191860-01
Oak Therapeutics Inc.NIH awarded $899K (SBIR Phase II 2R44AI170237-02A1, competing renewal, notice Aug 5, 2026); 2 NIH awards totaling $1.71M in the last 12 months.
Evidence (2 events)
  • Aug 5, 2026 · NIH RePORTER 2R44AI170237-02A1
    Organization: OAK THERAPEUTICS, INC.; City/State: Lawrence, KS; Project number: 2R44AI170237-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 899010; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel antiretroviral therapy delivery platform for infants and young children: oral dispensable strips (ODS); Organization type: Domestic For-Profits
  • Jul 28, 2026 · NIH RePORTER 5R44AI179391-03
    Organization: OAK THERAPEUTICS, INC.; City/State: Lawrence, KS; Project number: 5R44AI179391-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 814340; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis; Organization type: Domestic For-Profits
Aug 5, 2026NIH RePORTER 2R44AI170237-02A1
3D Molecular Designs, LLCNIH awarded $1M (SBIR Phase II 2R44GM154526-02, competing renewal, notice Aug 12, 2026); 2 NIH awards totaling $1.27M in the last 12 months.
Evidence (2 events)
  • Aug 12, 2026 · NIH RePORTER 2R44GM154526-02
    Organization: 3D MOLECULAR DESIGNS; City/State: MILWAUKEE, WI; Project number: 2R44GM154526-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 1004963; Administering IC: National Institute of General Medical Sciences; Project title: Harnessing Machine Learning & Object Detection for Automated Evaluation of Student-folded Protein Models; Organization type: Domestic For-Profits
  • Jun 30, 2026 · NIH RePORTER 5R25GM146236-06
    Organization: 3D MOLECULAR DESIGNS; City/State: MILWAUKEE, WI; Project number: 5R25GM146236-06; Activity code: R25; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 270000; Administering IC: National Institute of General Medical Sciences; Project title: Exploring the Molecular Biology of infectious Diseases; Organization type: Domestic For-Profits
Aug 12, 2026NIH RePORTER 2R44GM154526-02
iFIT ProstheticsNIH awarded $307K (STTR Phase I 1R41HD118857-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R41HD118857-01
    Organization: IFIT PROSTHETICS, LLC; City/State: PEWAUKEE, WI; Project number: 1R41HD118857-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 306870; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: ADVANCED CLOSURE SYSTEM FOR ADJUSTABLE , SUBISCHIAL TRANSFEMORAL SOCKETS; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R41HD118857-01
Anvil Diagnostics Inc.NIH awarded $296K (SBIR Phase I 1R43CK000714-01A1, new, notice Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · NIH RePORTER 1R43CK000714-01A1
    Organization: ANVIL DIAGNOSTICS INC.; City/State: CAMBRIDGE, MA; Project number: 1R43CK000714-01A1; Activity code: R43; Fiscal year: 2025; Award notice date: 2026-08-24; FY total cost (award amount): 296185; Administering IC: National Center for Emerging and Zoonotic Infectious Diseases; Project title: Rapid and Highly Multiplexed Pathogen Detection for Sepsis Patients with Compressed Sensing and Digital PCR; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 1R43CK000714-01A1
Microsensor Labs, LLCNIH awarded $307K (SBIR Phase I 1R43CK000713-01A1, new, notice Aug 15, 2026).
Evidence (1 event)
  • Aug 15, 2026 · NIH RePORTER 1R43CK000713-01A1
    Organization: MICROSENSOR LABS, LLC; City/State: CHICAGO, IL; Project number: 1R43CK000713-01A1; Activity code: R43; Fiscal year: 2025; Award notice date: 2026-08-15; FY total cost (award amount): 306872; Administering IC: National Center for Emerging and Zoonotic Infectious Diseases; Project title: A High-throughput Automated Platform for Rapid Isolation and Testing of Salmonella; Organization type: Domestic For-Profits
Aug 15, 2026NIH RePORTER 1R43CK000713-01A1
Applied Biotechnology Institute, Inc.NIH awarded $288K (SBIR Phase I 1R43DK148203-01, new, notice Sep 17, 2026); 2 NIH awards totaling $588K in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R43DK148203-01
    Organization: APPLIED BIOTECHNOLOGY INSTITUTE; City/State: SAN LUIS OBISPO, CA; Project number: 1R43DK148203-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 288221; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Production in maize of low-cost heat stable forms of GLP-1 and GIP receptor agonists for treatment of diabetes and obesity; Organization type: Domestic For-Profits
  • Aug 14, 2026 · NIH RePORTER 1R43AI186801-01A1
    Organization: APPLIED BIOTECHNOLOGY INSTITUTE; City/State: SAN LUIS OBISPO, CA; Project number: 1R43AI186801-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 299936; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Production of low-cost heat stable forms of adalimumab in maize for treatment of inflammatory bowel disease.; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43DK148203-01
Peak Diagnostic PartnersNIH awarded $1M (SBIR Phase II 1R44AI186802-01A1, new, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 1R44AI186802-01A1
    Organization: PEAK DIAGNOSTIC PARTNERS LLC; City/State: Aurora, CO; Project number: 1R44AI186802-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multidimensional analysis of biologic treatment failure in uncontrolled asthma; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 1R44AI186802-01A1
Partillion BioscienceNIH awarded $979K (SBIR Phase II 1R44GM165220-01, new, notice Sep 1, 2026); 3 NIH awards totaling $2.29M in the last 12 months.
Evidence (3 events)
  • Sep 1, 2026 · NIH RePORTER 1R44GM165220-01
    Organization: PARTILLION BIOSCIENCE CORPORATION; City/State: LOS ANGELES, CA; Project number: 1R44GM165220-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 979071; Administering IC: National Institute of General Medical Sciences; Project title: Nanovial Kits for Large-Scale Cell-Cell Interaction Sequencing; Organization type: Domestic For-Profits
  • Jul 16, 2026 · NIH RePORTER 1R43AI186929-01A1
    Organization: PARTILLION BIOSCIENCE CORPORATION; City/State: LOS ANGELES, CA; Project number: 1R43AI186929-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 306865; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multiplexed analysis of antibody secreting cells for enhanced function first antibody discovery; Organization type: Domestic For-Profits
  • Jun 9, 2026 · NIH RePORTER 5R44AI193415-02
    Organization: PARTILLION BIOSCIENCE CORPORATION; City/State: LOS ANGELES, CA; Project number: 5R44AI193415-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Scaling function-first antibody discovery leveraging memory B cells; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R44GM165220-01
Atticus PharmaNIH awarded $1.01M (SBIR Phase II 1R44AR087266-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $1.97M in the last 12 months.
Evidence (2 events)
  • Sep 19, 2026 · NIH RePORTER 1R44AR087266-01A1
    Organization: ATTICUS PHARMA INC; City/State: GREENVILLE, SC; Project number: 1R44AR087266-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 1007121; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus; Organization type: Domestic For-Profits
  • Aug 13, 2026 · NIH RePORTER 2R44DK129147-02
    Organization: ATTICUS PHARMA INC; City/State: GREENVILLE, SC; Project number: 2R44DK129147-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 965708; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Phase II: Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction; Organization type: Domestic For-Profits
Sep 19, 2026NIH RePORTER 1R44AR087266-01A1
Armor MedicalNIH awarded $1.22M (SBIR Phase II 2R44DP006818-03, competing renewal, notice Aug 15, 2026).
Evidence (1 event)
  • Aug 15, 2026 · NIH RePORTER 2R44DP006818-03
    Organization: ARMOR MEDICAL INC.; City/State: SAINT LOUIS, MO; Project number: 2R44DP006818-03; Activity code: R44; Fiscal year: 2025; Award notice date: 2026-08-15; FY total cost (award amount): 1223371; Administering IC: National Center for Chronic Disease Prev and Health Promo; Project title: Early Alerts, Safer Births: A Wearable Device for Real-time Maternal Hemorrhage Monitoring; Organization type: Domestic For-Profits
Aug 15, 2026NIH RePORTER 2R44DP006818-03
ResVita BioNIH awarded $1M (SBIR Phase II 2R44AI179327-02A1, competing renewal, notice Jul 30, 2026).
Evidence (1 event)
  • Jul 30, 2026 · NIH RePORTER 2R44AI179327-02A1
    Organization: RESVITA BIO, INC.; City/State: Berkeley, CA; Project number: 2R44AI179327-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 999988; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Skin probiotics to treat atopic dermatitis; Organization type: Domestic For-Profits
Jul 30, 2026NIH RePORTER 2R44AI179327-02A1
FzataNIH awarded $2.06M (NIH grant 4UH3NS135350-02, extension, notice Sep 19, 2026); 3 NIH awards totaling $2.74M in the last 12 months.
Evidence (3 events)
  • Sep 19, 2026 · NIH RePORTER 4UH3NS135350-02
    Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 4UH3NS135350-02; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 2058422; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome; Organization type: Domestic For-Profits
  • Sep 17, 2026 · NIH RePORTER 1R44DK146567-01
    Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 1R44DK146567-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 372153; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Gut-Targeted IL-10 Delivery via Engineered Saccharomyces boulardii to Prevent Immune Checkpoint Inhibitor Colitis; Organization type: Domestic For-Profits
  • Sep 11, 2026 · NIH RePORTER 1R44AI197301-01
    Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 1R44AI197301-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 313095; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Dual-Action Oral Immunotherapy for Clostridioides difficile Prevention; Organization type: Domestic For-Profits
Sep 19, 2026NIH RePORTER 4UH3NS135350-02
Exai Bio Inc.NIH awarded $719K (SBIR Phase II 5R44CA291369-02, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44CA291369-02
    Organization: EXAI BIO, INC.; City/State: PALO ALTO, CA; Project number: 5R44CA291369-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 718994; Administering IC: National Cancer Institute; Project title: Orphan Non-coding RNA-based Test for Detecting Minimal Residual Disease in Resectable Non-small Cell Lung Cancer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44CA291369-02
ProkaryoticsNIH awarded $977K (SBIR Phase II 5R44AI165008-03, continuation, notice Jun 3, 2026); 3 NIH awards totaling $1.86M in the last 12 months.
Evidence (3 events)
  • Jun 3, 2026 · NIH RePORTER 5R44AI165008-03
    Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R44AI165008-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 977454; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics; Organization type: Domestic For-Profits
  • Feb 17, 2026 · NIH RePORTER 5R21AI185171-02
    Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R21AI185171-02; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-02-17; FY total cost (award amount): 204000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Structure-based design of antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, Mcd4; Organization type: Domestic For-Profits
  • Feb 2, 2026 · NIH RePORTER 5R01AI165740-04
    Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R01AI165740-04; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-02; FY total cost (award amount): 679600; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis; Organization type: Domestic For-Profits
Jun 3, 2026NIH RePORTER 5R44AI165008-03
Versatope TherapeuticsNIH awarded $1M (SBIR Phase II 5R44AI181242-03, continuation, notice Jun 11, 2026).
Evidence (1 event)
  • Jun 11, 2026 · NIH RePORTER 5R44AI181242-03
    Organization: VERSATOPE THERAPEUTICS, INC.; City/State: Lowell, MA; Project number: 5R44AI181242-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 999925; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine; Organization type: Domestic For-Profits
Jun 11, 2026NIH RePORTER 5R44AI181242-03
Molecular Theranostics, LLCNIH awarded $528K (NIH grant 1R01CA297667-01A1, new, notice Aug 20, 2026).
Evidence (1 event)
  • Aug 20, 2026 · NIH RePORTER 1R01CA297667-01A1
    Organization: MOLECULAR THERANOSTICS, LLC; City/State: BEACHWOOD, OH; Project number: 1R01CA297667-01A1; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 528259; Administering IC: National Cancer Institute; Project title: Development of next-generation targeted MRI contrast agents; Organization type: Domestic For-Profits
Aug 20, 2026NIH RePORTER 1R01CA297667-01A1
Virogenomics Biodevelopment, Inc.NIH awarded $400K (STTR Phase I 1R41DA064189-01, new, notice May 27, 2026); 2 NIH awards totaling $3.7M in the last 12 months.
Evidence (2 events)
  • May 27, 2026 · NIH RePORTER 1R41DA064189-01
    Organization: VIROGENOMICS BIODEVELOPMENT, INC.; City/State: Tigard, OR; Project number: 1R41DA064189-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-27; FY total cost (award amount): 399889; Administering IC: National Institute on Drug Abuse; Project title: Treatment of CNS damage from non-disordered drug use with DRhQ, a novel regulator of CD74 signaling; Organization type: Domestic For-Profits
  • Apr 24, 2026 · NIH RePORTER 5UG3DA061709-02
    Organization: VIROGENOMICS BIODEVELOPMENT, INC.; City/State: Tigard, OR; Project number: 5UG3DA061709-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-04-24; FY total cost (award amount): 3300978; Administering IC: National Institute on Drug Abuse; Project title: IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder; Organization type: Domestic For-Profits
May 27, 2026NIH RePORTER 1R41DA064189-01
Lifegene- Biomarks, Inc.NIH awarded $900K (SBIR Phase II 5R44CA281719-03, continuation, notice Jul 7, 2026); 2 NIH awards totaling $1.27M in the last 12 months.
Evidence (2 events)
  • Jul 7, 2026 · NIH RePORTER 5R44CA281719-03
    Organization: LIFEGENE-BIOMARKS, INC.; City/State: SAN JUAN, PR; Project number: 5R44CA281719-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 900350; Administering IC: National Cancer Institute; Project title: Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings; Organization type: Domestic For-Profits
  • May 13, 2026 · NIH RePORTER 5R42MD018231-03
    Organization: LIFEGENE-BIOMARKS, INC.; City/State: SAN JUAN, PR; Project number: 5R42MD018231-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 366433; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas; Organization type: Domestic For-Profits
Jul 7, 2026NIH RePORTER 5R44CA281719-03
Modulo BioNIH awarded $848K (SBIR Phase II 1R44NS143633-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $2.33M in the last 12 months.
Evidence (2 events)
  • Sep 19, 2026 · NIH RePORTER 1R44NS143633-01A1
    Organization: MODULO BIO, INC.; City/State: San Diego, CA; Project number: 1R44NS143633-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 847695; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: The Therapeutic Development of a Clinical NR1H3 Antisense Oligonucleotide to Reprogram Microglia into a Neuroprotective State in ALS and FTD; Organization type: Domestic For-Profits
  • Feb 25, 2026 · NIH RePORTER 1R61MH143793-01
    Organization: MODULO BIO, INC.; City/State: San Diego, CA; Project number: 1R61MH143793-01; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-02-25; FY total cost (award amount): 1479470; Administering IC: National Institute of Mental Health; Project title: Developing an AI-Guided Triculture Platform to Model NeuroHIV specific Microglial States Under ART Suppression with CellPaint/Morphological and Transcriptomic Readouts; Organization type: Domestic For-Profits
Sep 19, 2026NIH RePORTER 1R44NS143633-01A1
Rhaeos, Inc.NIH awarded $420K (NIH grant 5UH3NS130338-04, continuation, notice Aug 21, 2026); 3 NIH awards totaling $1.49M in the last 12 months.
Evidence (3 events)
  • Aug 21, 2026 · NIH RePORTER 5UH3NS130338-04
    Organization: RHAEOS, INC.; City/State: EVANSTON, IL; Project number: 5UH3NS130338-04; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 419724; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of wireless, wearable flow sensors for continuous, long-term tracking of cerebrospinal fluid dynamics in patients with hydrocephalus; Organization type: Domestic For-Profits
  • Jun 19, 2026 · NIH RePORTER 5R44NS121555-05
    Organization: RHAEOS, INC.; City/State: EVANSTON, IL; Project number: 5R44NS121555-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 965691; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Enhancing Healthcare Delivery and Patient Outcomes: Noninvasive Wireless Sensors to Improve Ventricular Shunt Monitoring, Reduce Imaging, and Alleviate the Burden on Providers, Patients, and Families; Organization type: Domestic For-Profits
  • May 26, 2026 · NIH RePORTER 3UH3NS130338-03S1
    Organization: RHAEOS, INC.; City/State: EVANSTON, IL; Project number: 3UH3NS130338-03S1; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 99586; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of wireless, wearable flow sensors for continuous, long-term tracking of cerebrospinal fluid dynamics in patients with hydrocephalus; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 5UH3NS130338-04
Sanguina, LLCNIH awarded $962K (SBIR Phase II 5R44HL139250-06, continuation, notice Jul 6, 2026).
Evidence (1 event)
  • Jul 6, 2026 · NIH RePORTER 5R44HL139250-06
    Organization: SANGUINA, LLC; City/State: ATLANTA, GA; Project number: 5R44HL139250-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 962375; Administering IC: National Heart Lung and Blood Institute; Project title: Translation of a personalized, non-invasive smartphone app for hemoglobin monitoring for chronic anemia patients; Organization type: Domestic For-Profits
Jul 6, 2026NIH RePORTER 5R44HL139250-06
SynviviaNIH awarded $856K (SBIR Phase II 5R44GM158472-02, continuation, notice May 7, 2026).
Evidence (1 event)
  • May 7, 2026 · NIH RePORTER 5R44GM158472-02
    Organization: SYNVIVIA, INC.; City/State: Emeryville, CA; Project number: 5R44GM158472-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 856268; Administering IC: National Institute of General Medical Sciences; Project title: Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes; Organization type: Domestic For-Profits
May 7, 2026NIH RePORTER 5R44GM158472-02
Precision Biotools Inc.NIH awarded $1.22M (SBIR Phase II 5R44GM149009-04, continuation, notice Jun 30, 2026).
Evidence (1 event)
  • Jun 30, 2026 · NIH RePORTER 5R44GM149009-04
    Organization: PRECISION BIOTOOLS INC; City/State: BRANFORD, CT; Project number: 5R44GM149009-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1221747; Administering IC: National Institute of General Medical Sciences; Project title: A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D; Organization type: Domestic For-Profits
Jun 30, 2026NIH RePORTER 5R44GM149009-04
Starlight CardiovascularNIH awarded $500K (SBIR commercialization 1SB1HL184388-01, new, notice Aug 10, 2026); 3 NIH awards totaling $2.67M in the last 12 months.
Evidence (3 events)
  • Aug 10, 2026 · NIH RePORTER 1SB1HL184388-01
    Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 1SB1HL184388-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 499952; Administering IC: National Heart Lung and Blood Institute; Project title: Commercialization Readiness of a Pulmonary Flow Restrictor for Hypoplastic Left Heart Syndrome; Organization type: Domestic For-Profits
  • Aug 3, 2026 · NIH RePORTER 2R44HL162218-04
    Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 2R44HL162218-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1166665; Administering IC: National Heart Lung and Blood Institute; Project title: DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME; Organization type: Domestic For-Profits
  • May 13, 2026 · NIH RePORTER 5R44HL158304-05
    Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 5R44HL158304-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 999876; Administering IC: National Heart Lung and Blood Institute; Project title: DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 1SB1HL184388-01
HelixBindNIH awarded $1M (SBIR Phase II 2R44AI157322-04A1, competing renewal, notice Aug 6, 2026); 5 NIH awards totaling $5.04M in the last 12 months.
Evidence (5 events)
  • Aug 6, 2026 · NIH RePORTER 2R44AI157322-04A1
    Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 2R44AI157322-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Direct-from-specimen characterization of bloodstream infections; Organization type: Domestic For-Profits
  • Jul 16, 2026 · NIH RePORTER 1R44AI197309-01
    Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 1R44AI197309-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 1029859; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Automated system for the direct from blood characterization of bloodstream infections; Organization type: Domestic For-Profits
  • Jun 30, 2026 · NIH RePORTER 5R44AI186712-03
    Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 5R44AI186712-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1019702; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: An automated culture-free system for the identification of bloodstream infections direct from blood; Organization type: Domestic For-Profits
  • Jun 19, 2026 · NIH RePORTER 5R44AI136064-07
    Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 5R44AI136064-07; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 986903; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Direct-from-specimen identification of pathogens common in endocarditis; Organization type: Domestic For-Profits
  • May 27, 2026 · NIH RePORTER 5SB1AI183963-03
    Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 5SB1AI183963-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-27; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections.; Organization type: Domestic For-Profits
Aug 6, 2026NIH RePORTER 2R44AI157322-04A1
Loki TherapeuticsNIH awarded $727K (STTR Phase II 4R42CA287679-02, extension, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 4R42CA287679-02
    Organization: LOKI THERAPEUTICS, INC; City/State: Sa, CA; Project number: 4R42CA287679-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 726592; Administering IC: National Cancer Institute; Project title: Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 4R42CA287679-02
Viewpoint Molecular Targeting, Inc.NIH awarded $1.01M (STTR Phase II 4R42CA287696-02, extension, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 4R42CA287696-02
    Organization: VIEWPOINT MOLECULAR TARGETING, INC.; City/State: Coralville, IA; Project number: 4R42CA287696-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1006109; Administering IC: National Cancer Institute; Project title: Antibody-based prertargeted alpha particle therapy for ovarian cancer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 4R42CA287696-02
PhageProNIH awarded $1M (SBIR Phase II 5R44AI188855-02, continuation, notice Jun 9, 2026).
Evidence (1 event)
  • Jun 9, 2026 · NIH RePORTER 5R44AI188855-02
    Organization: PHAGEPRO, INC.; City/State: Mansfield, MA; Project number: 5R44AI188855-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail; Organization type: Domestic For-Profits
Jun 9, 2026NIH RePORTER 5R44AI188855-02
Microbiotix, Inc.NIH awarded $299K (STTR Phase I 5R41AI195240-02, continuation, notice Aug 25, 2026); 4 NIH awards totaling $2.23M in the last 12 months.
Evidence (4 events)
  • Aug 25, 2026 · NIH RePORTER 5R41AI195240-02
    Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R41AI195240-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 299381; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections; Organization type: Domestic For-Profits
  • Aug 3, 2026 · NIH RePORTER 5R43AI188690-02
    Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R43AI188690-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 289318; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of well tolerated novel Inhibitors of drug resistant CMV; Organization type: Domestic For-Profits
  • May 19, 2026 · NIH RePORTER 5R42AI165102-04
    Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R42AI165102-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 969050; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral; Organization type: Domestic For-Profits
  • Jan 29, 2026 · NIH RePORTER 5R33EY036947-02
    Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R33EY036947-02; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-01-29; FY total cost (award amount): 669859; Administering IC: National Eye Institute; Project title: Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R41AI195240-02
Scanogen Inc.NIH awarded $972K (SBIR commercialization 5SB1AI192001-02, continuation, notice Sep 18, 2026); 3 NIH awards totaling $2.77M in the last 12 months.
Evidence (3 events)
  • Sep 18, 2026 · NIH RePORTER 5SB1AI192001-02
    Organization: SCANOGEN, INC.; City/State: Baltimore, MD; Project number: 5SB1AI192001-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 972243; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bloodstream infection detection directly on whole blood; Organization type: Domestic For-Profits
  • Jun 30, 2026 · NIH RePORTER 5R44AI124871-07
    Organization: SCANOGEN, INC.; City/State: Baltimore, MD; Project number: 5R44AI124871-07; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bloodstream infection detection directly on whole blood; Organization type: Domestic For-Profits
  • Dec 23, 2025 · NIH RePORTER 5R01AI175063-04
    Organization: SCANOGEN, INC.; City/State: Baltimore, MD; Project number: 5R01AI175063-04; Activity code: R01; Fiscal year: 2026; Award notice date: 2025-12-23; FY total cost (award amount): 796572; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Rapid ID and AST Directly from Whole Blood Using Single Molecule Detection; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 5SB1AI192001-02
Vast TherapeuticsNIH awarded $1M (SBIR Phase II 1R44AI191890-01A1, new, notice Sep 14, 2026); 3 NIH awards totaling $2.94M in the last 12 months.
Evidence (3 events)
  • Sep 14, 2026 · NIH RePORTER 1R44AI191890-01A1
    Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 1R44AI191890-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Inhaled Nitric-Oxide Releasing Prodrug to Treat Drug Resistant Klebsiella pneumoniae Infections; Organization type: Domestic For-Profits
  • Aug 14, 2026 · NIH RePORTER 5R44AI186617-02
    Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 5R44AI186617-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 950129; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections; Organization type: Domestic For-Profits
  • May 26, 2026 · NIH RePORTER 5R44AI184225-02
    Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 5R44AI184225-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 988594; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 1R44AI191890-01A1
Biological MimeticsNIH awarded $278K (SBIR Phase I 5R43AI189041-02, continuation, notice May 27, 2026).
Evidence (1 event)
  • May 27, 2026 · NIH RePORTER 5R43AI189041-02
    Organization: BIOLOGICAL MIMETICS, INC.; City/State: FREDERICK, MD; Project number: 5R43AI189041-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-27; FY total cost (award amount): 277962; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Subunit Vaccine Against Acinetobacter Baumannii; Organization type: Domestic For-Profits
May 27, 2026NIH RePORTER 5R43AI189041-02
Celdara MedicalNIH awarded $356K (SBIR Phase I 1R43DK143897-01A1, new, notice Aug 28, 2026); 6 NIH awards totaling $2.5M in the last 12 months.
Evidence (6 events)
  • Aug 28, 2026 · NIH RePORTER 1R43DK143897-01A1
    Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43DK143897-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 356328; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a Novel, Allogeneic Cell Therapy for Difficult to Treat IBD; Organization type: Domestic For-Profits
  • Aug 24, 2026 · NIH RePORTER 1R43AI197698-01
    Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43AI197698-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 320863; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Precision CAR-NK therapy for VK4-1 autoreactive B cells in autoimmune diseases: advancing treatment with preserved immune function.; Organization type: Domestic For-Profits
  • Aug 21, 2026 · NIH RePORTER 1R43AI192073-01A1
    Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43AI192073-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 320863; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of an immunotherapeutic agent for treatment of osteomyelitis; Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5R25AG078135-05
    Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 5R25AG078135-05; Activity code: R25; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 162000; Administering IC: National Institute on Aging; Project title: Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF); Organization type: Domestic For-Profits
  • Jun 16, 2026 · NIH RePORTER 1R43TR006062-01A1
    Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43TR006062-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 310564; Administering IC: National Center for Advancing Translational Sciences; Project title: Engineered Tregs as a therapy to Gaucher syndrome; Organization type: Domestic For-Profits
  • May 26, 2026 · NIH RePORTER 5R44CA298512-02
    Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 5R44CA298512-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1024401; Administering IC: National Cancer Institute; Project title: Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 1R43DK143897-01A1
Dayi Therapeutics, Inc.NIH awarded $845K (STTR Phase II 5R42HD111138-03, continuation, notice May 11, 2026).
Evidence (1 event)
  • May 11, 2026 · NIH RePORTER 5R42HD111138-03
    Organization: DAYI THERAPEUTICS, INC.; City/State: New York, NY; Project number: 5R42HD111138-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 845187; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Developing RNA therapeutics for rare neurodevelopmental disorders; Organization type: Domestic For-Profits
May 11, 2026NIH RePORTER 5R42HD111138-03
Doty Scientific, Inc.NIH awarded $994K (SBIR Phase II 2R44GM156167-02, competing renewal, notice Sep 7, 2026); 2 NIH awards totaling $1.94M in the last 12 months.
Evidence (2 events)
  • Sep 7, 2026 · NIH RePORTER 2R44GM156167-02
    Organization: DOTY SCIENTIFIC, INC.; City/State: COLUMBIA, SC; Project number: 2R44GM156167-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 994403; Administering IC: National Institute of General Medical Sciences; Project title: Low-loss Bidirectional THz Couplers to Enable Affordable MAS-DNP-NMR; Organization type: Domestic For-Profits
  • May 11, 2026 · NIH RePORTER 5R44GM148111-03
    Organization: DOTY SCIENTIFIC, INC.; City/State: COLUMBIA, SC; Project number: 5R44GM148111-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 946077; Administering IC: National Institute of General Medical Sciences; Project title: Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials; Organization type: Domestic For-Profits
Sep 7, 2026NIH RePORTER 2R44GM156167-02
Sonoran BiosciencesNIH awarded $1.01M (SBIR Phase II 5R44GM145020-03, continuation, notice Jul 9, 2026).
Evidence (1 event)
  • Jul 9, 2026 · NIH RePORTER 5R44GM145020-03
    Organization: SONORAN BIOSCIENCES, INC.; City/State: TEMPE, AZ; Project number: 5R44GM145020-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-09; FY total cost (award amount): 1009908; Administering IC: National Institute of General Medical Sciences; Project title: Extended-release injectable gel for multi-day treatment of postoperative pain; Organization type: Domestic For-Profits
Jul 9, 2026NIH RePORTER 5R44GM145020-03
Heligenics, Inc.NIH awarded $801K (SBIR Phase II 5R44AI188872-02, continuation, notice Jun 11, 2026).
Evidence (1 event)
  • Jun 11, 2026 · NIH RePORTER 5R44AI188872-02
    Organization: HELIGENICS INC; City/State: HENDERSON, NV; Project number: 5R44AI188872-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 801133; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: High Content Screening for Bifunctional Chimera Biologics; Organization type: Domestic For-Profits
Jun 11, 2026NIH RePORTER 5R44AI188872-02
Ligo AnalyticsNIH awarded $763K (SBIR Phase II 5R44GM148105-03, continuation, notice May 7, 2026).
Evidence (1 event)
  • May 7, 2026 · NIH RePORTER 5R44GM148105-03
    Organization: LIGO ANALYTICS, INC.; City/State: DALLAS, TX; Project number: 5R44GM148105-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 762936; Administering IC: National Institute of General Medical Sciences; Project title: Dynamical Diffraction Analysis for 3D Electron Crystallography; Organization type: Domestic For-Profits
May 7, 2026NIH RePORTER 5R44GM148105-03
Actuated MedicalNIH awarded $1.04M (SBIR Phase II 2R44NS155776-04, competing renewal, notice Sep 17, 2026); 2 NIH awards totaling $1.7M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 2R44NS155776-04
    Organization: ACTUATED MEDICAL, INC.; City/State: BELLEFONTE, PA; Project number: 2R44NS155776-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1040504; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Vibration-integrated Lancing System to Reduce Stress, Pain Response, Heel Damage and Developmental Harm from Recurring Heel Sticks in Neonates; Organization type: Domestic For-Profits
  • May 18, 2026 · NIH RePORTER 5R44AA030512-04
    Organization: ACTUATED MEDICAL, INC.; City/State: BELLEFONTE, PA; Project number: 5R44AA030512-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 660862; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS Therapy in Alcohol Addiction Treatment; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44NS155776-04
Merlin Biotech Inc.NIH awarded $400K (SBIR Phase I 1R43DE035421-01, new, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 1R43DE035421-01
    Organization: MERLIN BIOTECH INC; City/State: DOYLESTOWN, PA; Project number: 1R43DE035421-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 400000; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Investigating Enhanced Activity of MER-101 in HPV+ Head and Neck Cancer; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 1R43DE035421-01
En Solucion IncNIH awarded $1.02M (SBIR Phase II 2R44FD008038-02, competing renewal, notice Sep 28, 2026).
Evidence (1 event)
  • Sep 28, 2026 · NIH RePORTER 2R44FD008038-02
    Organization: EN SOLUCION, INC.; City/State: WILMINGTON, DE; Project number: 2R44FD008038-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-28; FY total cost (award amount): 1022906; Administering IC: Food and Drug Administration; Project title: Innovative Continuous Sanitization of Fresh Produce Harvesting Equipment; Organization type: Domestic For-Profits
Sep 28, 2026NIH RePORTER 2R44FD008038-02
Capienda Biotech, LLCNIH awarded $1.4M (SBIR Phase II 2R44TR005335-02A1, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44TR005335-02A1
    Organization: CAPIENDA BIOTECH, LLC; City/State: San Diego, CA; Project number: 2R44TR005335-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1401698; Administering IC: National Center for Advancing Translational Sciences; Project title: High-throughput kinetic system for small-molecule drug discovery; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44TR005335-02A1
Exavir TherapeuticsNIH awarded $998K (SBIR Phase II 1R44AI195119-01, new, notice Aug 4, 2026).
Evidence (1 event)
  • Aug 4, 2026 · NIH RePORTER 1R44AI195119-01
    Organization: EXAVIR THERAPEUTICS INC.; City/State: San Francisco, CA; Project number: 1R44AI195119-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 998034; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infection; Organization type: Domestic For-Profits
Aug 4, 2026NIH RePORTER 1R44AI195119-01
PraeventixNIH awarded $355K (SBIR Phase I 1R43DA064569-01, new, notice May 19, 2026).
Evidence (1 event)
  • May 19, 2026 · NIH RePORTER 1R43DA064569-01
    Organization: PRAEVENTIX, LLC; City/State: EXTON, PA; Project number: 1R43DA064569-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 355190; Administering IC: National Institute on Drug Abuse; Project title: In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder; Organization type: Domestic For-Profits
May 19, 2026NIH RePORTER 1R43DA064569-01
Astrocyte Pharmaceuticals Inc.NIH awarded $1.5M (SBIR Phase II 5R44NS137896-02, continuation, notice Aug 24, 2026); 2 NIH awards totaling $1.9M in the last 12 months.
Evidence (2 events)
  • Aug 24, 2026 · NIH RePORTER 5R44NS137896-02
    Organization: ASTROCYTE PHARMACEUTICALS, INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS137896-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1499802; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI); Organization type: Domestic For-Profits
  • Jul 7, 2026 · NIH RePORTER 1R41DA064479-01
    Organization: ASTROCYTE PHARMACEUTICALS, INC.; City/State: CAMBRIDGE, MA; Project number: 1R41DA064479-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 399680; Administering IC: National Institute on Drug Abuse; Project title: Preclinical efficacy of AST-004 as a treatment for substance use disorder; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 5R44NS137896-02
Sanaria Inc.NIH awarded $1M (SBIR commercialization 1SB1AI195021-01, new, notice Sep 18, 2026); 2 NIH awards totaling $2M in the last 12 months.
Evidence (2 events)
  • Sep 18, 2026 · NIH RePORTER 1SB1AI195021-01
    Organization: SANARIA, INC.; City/State: ROCKVILLE, MD; Project number: 1SB1AI195021-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: New cryovials with integral septum for cryopreservation of PfSPZ vaccine and PfSPZ challenge products.; Organization type: Domestic For-Profits
  • Sep 17, 2026 · NIH RePORTER 5U44AI124867-08
    Organization: SANARIA, INC.; City/State: ROCKVILLE, MD; Project number: 5U44AI124867-08; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 1SB1AI195021-01
JAN Biotech, Inc.NIH awarded $999K (SBIR Phase II 5R44AI155075-05, continuation, notice Aug 4, 2026); 2 NIH awards totaling $1.3M in the last 12 months.
Evidence (2 events)
  • Aug 4, 2026 · NIH RePORTER 5R44AI155075-05
    Organization: JAN BIOTECH, INC.; City/State: ITHACA, NY; Project number: 5R44AI155075-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 998781; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Sequence-based RNA Fluorescence Assay to Measure Latent HIV Reservoirs; Organization type: Domestic For-Profits
  • Jul 31, 2026 · NIH RePORTER 1R44AI195231-01
    Organization: JAN BIOTECH, INC.; City/State: ITHACA, NY; Project number: 1R44AI195231-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Clinical Assay to Accurately Profile and Monitor the HIV-1 Reservoir in Chronic-treated Individuals to Guide Treatment Decisions; Organization type: Domestic For-Profits
Aug 4, 2026NIH RePORTER 5R44AI155075-05
Collaborations PharmaceuticalsNIH awarded $307K (SBIR Phase I 1R43AI191982-01A1, new, notice Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · NIH RePORTER 1R43AI191982-01A1
    Organization: COLLABORATIONS PHARMACEUTICALS, INC.; City/State: FUQUAY VARINA, NC; Project number: 1R43AI191982-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 306870; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Long-term formulation for combination antiviral treatment of HIV; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 1R43AI191982-01A1
Vincere BiosciencesNIH awarded $1.3M (SBIR Phase II 1R44DK143820-01A1, new, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 1R44DK143820-01A1
    Organization: VINCERE BIOSCIENCES, INC.; City/State: Cambridge, MA; Project number: 1R44DK143820-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1297479; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: IND-enabling studies of a USP30 inhibitor for acute kidney injury; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 1R44DK143820-01A1
Kephera DiagnosticsNIH awarded $1.01M (SBIR Phase II 5R44HL180181-02, continuation, notice Sep 4, 2026); 2 NIH awards totaling $1.31M in the last 12 months.
Evidence (2 events)
  • Sep 4, 2026 · NIH RePORTER 5R44HL180181-02
    Organization: KEPHERA DIAGNOSTICS, LLC; City/State: Framingham, MA; Project number: 5R44HL180181-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1008567; Administering IC: National Heart Lung and Blood Institute; Project title: Peptide-based ELISA for laboratory diagnosis of sarcoidosis; Organization type: Domestic For-Profits
  • Aug 24, 2026 · NIH RePORTER 1R43AI186917-01A1
    Organization: KEPHERA DIAGNOSTICS, LLC; City/State: Framingham, MA; Project number: 1R43AI186917-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 303250; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Rapid Diagnostic Immunoassay for Strongyloidiasis; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R44HL180181-02
Vivid BioInnovations, PBCNIH awarded $506K (SBIR Phase II 1R44AG102286-01, new, notice Sep 8, 2026); 7 NIH awards totaling $3.76M in the last 12 months.
Evidence (7 events)
  • Sep 8, 2026 · NIH RePORTER 1R44AG102286-01
    Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44AG102286-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 506495; Administering IC: National Institute on Aging; Project title: AstroTarget™ Astro-Enrichment Kit: A Microfluidic-Free Platform for High-Throughput Rare-Astrocyte Isolation and Multi-Omic Profiling from Frozen Alzheimer’s Brain; Organization type: Domestic For-Profits
  • Aug 27, 2026 · NIH RePORTER 4R44AG091101-02
    Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 4R44AG091101-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1012648; Administering IC: National Institute on Aging; Project title: FIND-seq: A Novel Cell Sorting Technology to Enable Investigation of Rare Cells in Primary Human Tissues; Organization type: Domestic For-Profits
  • Aug 20, 2026 · NIH RePORTER 4R44GM161309-02
    Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 4R44GM161309-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 1027505; Administering IC: National Institute of General Medical Sciences; Project title: A Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution With micro-Mass Spectrometry; Organization type: Domestic For-Profits
  • Aug 19, 2026 · NIH RePORTER 1R44AI195215-01
    Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44AI195215-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 307074; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: HIVE-seq: A Novel Omics Technology to Profile Thousands of Single HIV-Positive Cells; Organization type: Domestic For-Profits
  • Aug 19, 2026 · NIH RePORTER 1R44AI197850-01
    Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44AI197850-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 299991; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Spatially Resolved Single-Cell DNA Sequencing: A General Spatial Genomics Platform with Application to HIV Reservoir Mapping; Organization type: Domestic For-Profits
  • Aug 7, 2026 · NIH RePORTER 1R44CA310740-01
    Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44CA310740-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 306872; Administering IC: National Cancer Institute; Project title: Ultrahigh-Throughput Cell Interaction Screening to Advance CAR-T Therapeutic Development; Organization type: Domestic For-Profits
  • Aug 4, 2026 · NIH RePORTER 1R44GM163514-01
    Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44GM163514-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 300001; Administering IC: National Institute of General Medical Sciences; Project title: Integrated High-Throughput Microfluidic-Mass Spectrometry for Enhanced Biomedical Data Generation and AI Model Training; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 1R44AG102286-01
EicOsisNIH awarded $2.38M (NIH grant 5UH3DA048767-05, continuation, notice Jan 29, 2026).
Evidence (1 event)
  • Jan 29, 2026 · NIH RePORTER 5UH3DA048767-05
    Organization: EICOSIS, LLC; City/State: Davis, CA; Project number: 5UH3DA048767-05; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-01-29; FY total cost (award amount): 2377268; Administering IC: National Institute on Drug Abuse; Project title: Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics; Organization type: Domestic For-Profits
Jan 29, 2026NIH RePORTER 5UH3DA048767-05
Linnaeus TherapeuticsNIH awarded $1M (SBIR Phase II 5R44CA297994-02, continuation, notice May 19, 2026).
Evidence (1 event)
  • May 19, 2026 · NIH RePORTER 5R44CA297994-02
    Organization: LINNAEUS THERAPEUTICS INC; City/State: HADDONFIELD, NJ; Project number: 5R44CA297994-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 999960; Administering IC: National Cancer Institute; Project title: Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy; Organization type: Domestic For-Profits
May 19, 2026NIH RePORTER 5R44CA297994-02
Vantis VascularNIH awarded $496K (SBIR commercialization 1SB1HL184525-01, new, notice Sep 1, 2026); 2 NIH awards totaling $1.49M in the last 12 months.
Evidence (2 events)
  • Sep 1, 2026 · NIH RePORTER 1SB1HL184525-01
    Organization: VANTIS VASCULAR INC; City/State: KALAMAZOO, MI; Project number: 1SB1HL184525-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 496437; Administering IC: National Heart Lung and Blood Institute; Project title: Commercial Readiness of a Catheter for Complex Percutaneous Coronary Intervention; Organization type: Domestic For-Profits
  • Aug 25, 2026 · NIH RePORTER 5R44HL152835-06
    Organization: VANTIS VASCULAR INC; City/State: KALAMAZOO, MI; Project number: 5R44HL152835-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 997212; Administering IC: National Heart Lung and Blood Institute; Project title: Catheter for Complex Percutaneous Coronary Intervention; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1SB1HL184525-01
Redbud LabsNIH awarded $307K (SBIR Phase I 1R43JG000001-01A1, new, notice Aug 18, 2026); 2 NIH awards totaling $1.26M in the last 12 months.
Evidence (2 events)
  • Aug 18, 2026 · NIH RePORTER 1R43JG000001-01A1
    Organization: REDBUD LABS, INC.; City/State: Durham, NC; Project number: 1R43JG000001-01A1; Activity code: R43; Fiscal year: 2025; Award notice date: 2026-08-18; FY total cost (award amount): 306872; Administering IC: None; Project title: Development of an automated, compact sample-to-sequencer ready system for extensively/multi drug-resistant TB detection; Organization type: Domestic For-Profits
  • Jul 22, 2026 · NIH RePORTER 1SB1AI191998-01A1
    Organization: REDBUD LABS, INC.; City/State: Durham, NC; Project number: 1SB1AI191998-01A1; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 956224; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Redbud NA1 transfer to manufacturing; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 1R43JG000001-01A1
ReacX PharmaceuticalsNIH awarded $3.45M (NIH grant 5UH3DA047707-04, continuation, notice Mar 4, 2026).
Evidence (1 event)
  • Mar 4, 2026 · NIH RePORTER 5UH3DA047707-04
    Organization: REACX PHARMACEUTICALS, INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 5UH3DA047707-04; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-03-04; FY total cost (award amount): 3450000; Administering IC: National Institute on Drug Abuse; Project title: Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder; Organization type: Domestic For-Profits
Mar 4, 2026NIH RePORTER 5UH3DA047707-04
Rational Vaccines Inc.NIH awarded $999K (SBIR Phase II 5R44AI170133-03, continuation, notice May 13, 2026).
Evidence (1 event)
  • May 13, 2026 · NIH RePORTER 5R44AI170133-03
    Organization: RATIONAL VACCINES, INC.; City/State: WOBURN, MA; Project number: 5R44AI170133-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 999160; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections; Organization type: Domestic For-Profits
May 13, 2026NIH RePORTER 5R44AI170133-03
Quiver Bioscience Inc.NIH awarded $886K (SBIR Phase II 5R44NS141534-02, continuation, notice May 5, 2026); 2 NIH awards totaling $2.88M in the last 12 months.
Evidence (2 events)
  • May 5, 2026 · NIH RePORTER 5R44NS141534-02
    Organization: QUIVER BIOSCIENCE INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS141534-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-05; FY total cost (award amount): 886042; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity; Organization type: Domestic For-Profits
  • Apr 28, 2026 · NIH RePORTER 1UG3NS146009-01
    Organization: QUIVER BIOSCIENCE INC.; City/State: CAMBRIDGE, MA; Project number: 1UG3NS146009-01; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-04-28; FY total cost (award amount): 1993248; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Nav channel targeting antisense oligonucleotides as chronic pain therapeutics using an integrated platform based on machine learning and optical electrophysiology; Organization type: Domestic For-Profits
May 5, 2026NIH RePORTER 5R44NS141534-02
Cellergy PharmaNIH awarded $294K (STTR Phase I 5R41AI188995-02, continuation, notice May 28, 2026).
Evidence (1 event)
  • May 28, 2026 · NIH RePORTER 5R41AI188995-02
    Organization: CELLERGY PHARMA; City/State: Wilmington, DE; Project number: 5R41AI188995-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-28; FY total cost (award amount): 294407; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bispecific antibody targeting IgE-producing B cells for treating allergic diseases; Organization type: Domestic For-Profits
May 28, 2026NIH RePORTER 5R41AI188995-02
Halcyon Biomedical Inc.NIH awarded $352K (NIH grant 1R33HL183009-01, new, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 1R33HL183009-01
    Organization: HALCYON BIOMEDICAL, INC.; City/State: FRIENDSWOOD, TX; Project number: 1R33HL183009-01; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 351949; Administering IC: National Heart Lung and Blood Institute; Project title: Development and validation of a cell separation platform technology; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 1R33HL183009-01
MDC Studio INCNIH awarded $310K (NIH grant 1R61HL183026-01, new, notice Sep 1, 2026).
Evidence (1 event)
  • Sep 1, 2026 · NIH RePORTER 1R61HL183026-01
    Organization: MDC STUDIO, INC.; City/State: BALTIMORE, MD; Project number: 1R61HL183026-01; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 309813; Administering IC: National Heart Lung and Blood Institute; Project title: Automated vascular access device development; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R61HL183026-01
Greenstone Biosciences, Inc.NIH awarded $626K (NIH grant 1R61HL179715-01A1, new, notice Aug 3, 2026).
Evidence (1 event)
  • Aug 3, 2026 · NIH RePORTER 1R61HL179715-01A1
    Organization: GREENSTONE BIOSCIENCES, INC.; City/State: PALO ALTO, CA; Project number: 1R61HL179715-01A1; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 625968; Administering IC: National Heart Lung and Blood Institute; Project title: Small Molecule Drug Discovery for Cardiac Fibrosis using AI/ML and iPSC-Derived Organoids; Organization type: Domestic For-Profits
Aug 3, 2026NIH RePORTER 1R61HL179715-01A1
PsychoGenicsNIH awarded $924K (SBIR Phase II 4R44MH138151-03, extension, notice Aug 18, 2026); 2 NIH awards totaling $1.32M in the last 12 months.
Evidence (2 events)
  • Aug 18, 2026 · NIH RePORTER 4R44MH138151-03
    Organization: PSYCHOGENICS, INC.; City/State: Paramus, NJ; Project number: 4R44MH138151-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 924001; Administering IC: National Institute of Mental Health; Project title: EEG Signature Analysis for Drug Repurposing for Rare Diseases; Organization type: Domestic For-Profits
  • Jun 9, 2026 · NIH RePORTER 1R43DA061847-01A1
    Organization: PSYCHOGENICS, INC.; City/State: Paramus, NJ; Project number: 1R43DA061847-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 398947; Administering IC: National Institute on Drug Abuse; Project title: TAAR1 Agonists for the Treatment of Stimulant Use Disorder; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 4R44MH138151-03
Arisan Therapeutics, Inc.NIH awarded $1M (SBIR commercialization 5SB1AI112097-10, continuation, notice May 22, 2026).
Evidence (1 event)
  • May 22, 2026 · NIH RePORTER 5SB1AI112097-10
    Organization: ARISAN THERAPEUTICS, INC.; City/State: Carlsbad, CA; Project number: 5SB1AI112097-10; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product; Organization type: Domestic For-Profits
May 22, 2026NIH RePORTER 5SB1AI112097-10
General Biophysics LLCNIH awarded $479K (SBIR Phase I 1R43HL184078-01, new, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 1R43HL184078-01
    Organization: GENERAL BIOPHYSICS, LLC; City/State: WAYLAND, MA; Project number: 1R43HL184078-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 479185; Administering IC: National Heart Lung and Blood Institute; Project title: Xenon Gas Preservation of Refrigerated Platelets; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 1R43HL184078-01
AbVaccNIH awarded $642K (NIH grant 5R01AI193221-02, continuation, notice Sep 17, 2026); 3 NIH awards totaling $2.34M in the last 12 months.
Evidence (3 events)
  • Sep 17, 2026 · NIH RePORTER 5R01AI193221-02
    Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R01AI193221-02; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 642054; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia; Organization type: Domestic For-Profits
  • May 19, 2026 · NIH RePORTER 5R44AI179371-03
    Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R44AI179371-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease; Organization type: Domestic For-Profits
  • Feb 19, 2026 · NIH RePORTER 5R01AI111205-10
    Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R01AI111205-10; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-19; FY total cost (award amount): 697200; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R01AI193221-02
Boston Immune Technologies and TherapeuticsNIH awarded $990K (SBIR Phase II 5R44AI179385-03, continuation, notice Jun 1, 2026).
Evidence (1 event)
  • Jun 1, 2026 · NIH RePORTER 5R44AI179385-03
    Organization: BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC.; City/State: WINCHESTER, MA; Project number: 5R44AI179385-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 990243; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.; Organization type: Domestic For-Profits
Jun 1, 2026NIH RePORTER 5R44AI179385-03
SKM Instruments, LLCNIH awarded $314K (SBIR Phase I 1R43DA064718-01, new, notice Jun 19, 2026).
Evidence (1 event)
  • Jun 19, 2026 · NIH RePORTER 1R43DA064718-01
    Organization: SKM INSTRUMENTS, LLC; City/State: LARAMIE, WY; Project number: 1R43DA064718-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 314317; Administering IC: National Institute on Drug Abuse; Project title: Low-Cost, User-Friendly SERS Technology for Rapid Detection of Emerging Drug Threats; Organization type: Domestic For-Profits
Jun 19, 2026NIH RePORTER 1R43DA064718-01
Alleviant Medical, Inc.NIH awarded $996K (SBIR Phase II 5R44HL142440-06, continuation, notice May 13, 2026).
Evidence (1 event)
  • May 13, 2026 · NIH RePORTER 5R44HL142440-06
    Organization: ALLEVIANT MEDICAL, INC.; City/State: Austin, TX; Project number: 5R44HL142440-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 996173; Administering IC: National Heart Lung and Blood Institute; Project title: Transcatheter Device for Congestive Heart Failure Treatment Through Left Atrial Decompression; Organization type: Domestic For-Profits
May 13, 2026NIH RePORTER 5R44HL142440-06
Artery Therapeutics, Inc.NIH awarded $2.27M (SBIR Phase II 1R44AG099463-01, new, notice Sep 17, 2026); 2 NIH awards totaling $4.91M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R44AG099463-01
    Organization: ARTERY THERAPEUTICS, INC.; City/State: SAN RAMON, CA; Project number: 1R44AG099463-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2267403; Administering IC: National Institute on Aging; Project title: Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PK; Organization type: Domestic For-Profits
  • Mar 3, 2026 · NIH RePORTER 1UG3AG098023-01
    Organization: ARTERY THERAPEUTICS, INC.; City/State: SAN RAMON, CA; Project number: 1UG3AG098023-01; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-03-03; FY total cost (award amount): 2644490; Administering IC: National Institute on Aging; Project title: CS6253 Sequential Subcutaneous Pharmacokinetic Study followed by Phase 2A Placebo-Controlled Trial with Three Fixed Doses in APOE4 MCI and AD Patients to assess Safety, PK, and Biomarker Effects; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG099463-01
NeuroNexus TechnologiesNIH awarded $450K (SBIR Phase I 5R43MH139259-02, continuation, notice May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · NIH RePORTER 5R43MH139259-02
    Organization: NEURONEXUS TECHNOLOGIES; City/State: Ann Arbor, MI; Project number: 5R43MH139259-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 449677; Administering IC: National Institute of Mental Health; Project title: Advanced culture and recording system for long-term electrophysiological profiling in human brain organoids; Organization type: Domestic For-Profits
May 12, 2026NIH RePORTER 5R43MH139259-02
BiomeSenseNIH awarded $677K (SBIR Phase II 5R44TR003744-03, continuation, notice Jun 16, 2026).
Evidence (1 event)
  • Jun 16, 2026 · NIH RePORTER 5R44TR003744-03
    Organization: BIOMESENSE, INC.; City/State: CHICAGO, IL; Project number: 5R44TR003744-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 676980; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome; Organization type: Domestic For-Profits
Jun 16, 2026NIH RePORTER 5R44TR003744-03
LinshomNIH awarded $184K (SBIR commercialization 5SB1HL182474-02, continuation, notice Sep 16, 2026); 2 NIH awards totaling $1.32M in the last 12 months.
Evidence (2 events)
  • Sep 16, 2026 · NIH RePORTER 5SB1HL182474-02
    Organization: LINSHOM MEDICAL INC; City/State: ELLICOTT CITY, MD; Project number: 5SB1HL182474-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 184164; Administering IC: National Heart Lung and Blood Institute; Project title: Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline with the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS); Organization type: Domestic For-Profits
  • Sep 4, 2026 · NIH RePORTER 2R44HL164222-04
    Organization: LINSHOM MEDICAL INC; City/State: ELLICOTT CITY, MD; Project number: 2R44HL164222-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1133058; Administering IC: National Heart Lung and Blood Institute; Project title: Development and Multi-Site Clinical Evaluation of the Linshom CPRM System - A Wearable, AI Enabled, Wireless Alarm Activated Detection System for Early Intervention of Emerging Respiratory Decline; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 5SB1HL182474-02
Phenomix SciencesNIH awarded $348K (SBIR Phase II 5R44DK138619-03, continuation, notice May 7, 2026).
Evidence (1 event)
  • May 7, 2026 · NIH RePORTER 5R44DK138619-03
    Organization: PHENOMIX SCIENCES, LLC; City/State: Menlo Park, CA; Project number: 5R44DK138619-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 348022; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A NOVEL PRECISION MEDICINE APPROACH FOR OBESITY: A RANDOMIZED, MULTI-CENTER TRIAL; Organization type: Domestic For-Profits
May 7, 2026NIH RePORTER 5R44DK138619-03
LASE InnovationNIH awarded $900K (SBIR Phase II 5R44HG013591-03, continuation, notice Jul 7, 2026).
Evidence (1 event)
  • Jul 7, 2026 · NIH RePORTER 5R44HG013591-03
    Organization: LASE INNOVATION INC.; City/State: Waltham, MA; Project number: 5R44HG013591-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 900298; Administering IC: National Human Genome Research Institute; Project title: DNA-optical barcoding technology for spatiotemporal single-cell analysis; Organization type: Domestic For-Profits
Jul 7, 2026NIH RePORTER 5R44HG013591-03
Fox Chase Chemical Diversity Center Inc.NIH awarded $965K (STTR Phase II 5R42AI162385-05, continuation, notice Jun 30, 2026); 2 NIH awards totaling $2.04M in the last 12 months.
Evidence (2 events)
  • Jun 30, 2026 · NIH RePORTER 5R42AI162385-05
    Organization: FOX CHASE CHEMICAL DIVERSITY CENTER, INC; City/State: DOYLESTOWN, PA; Project number: 5R42AI162385-05; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 964562; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum; Organization type: Domestic For-Profits
  • Feb 17, 2026 · NIH RePORTER 1R01AG098139-01
    Organization: FOX CHASE CHEMICAL DIVERSITY CENTER, INC; City/State: DOYLESTOWN, PA; Project number: 1R01AG098139-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-17; FY total cost (award amount): 1074362; Administering IC: National Institute on Aging; Project title: AI-driven discovery of in vivo chemical probes for understudied targets for the treatment of Alzheimer's disease and related disorders (ADRD); Organization type: Domestic For-Profits
Jun 30, 2026NIH RePORTER 5R42AI162385-05
Cantata BioNIH awarded $407K (SBIR Phase I 1R43HG014887-01, new, notice Sep 7, 2026).
Evidence (1 event)
  • Sep 7, 2026 · NIH RePORTER 1R43HG014887-01
    Organization: CANTATA BIO LLC; City/State: Worcester, MA; Project number: 1R43HG014887-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 406703; Administering IC: National Human Genome Research Institute; Project title: Pangenome-based Inference of Phased, Inherited Genome from Patient-Derived Sequencing Data; Organization type: Domestic For-Profits
Sep 7, 2026NIH RePORTER 1R43HG014887-01
InstanosisNIH awarded $1.41M (SBIR Phase II 5R44DA061963-02, continuation, notice May 22, 2026); 3 NIH awards totaling $3.58M in the last 12 months.
Evidence (3 events)
  • May 22, 2026 · NIH RePORTER 5R44DA061963-02
    Organization: INSTANOSIS, INC.; City/State: MILFORD, DE; Project number: 5R44DA061963-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1414924; Administering IC: National Institute on Drug Abuse; Project title: A Rapid, Sensitive and Instrument-free Oral Fluid Fentanyl Test; Organization type: Domestic For-Profits
  • May 18, 2026 · NIH RePORTER 5U44DA060264-03
    Organization: INSTANOSIS, INC.; City/State: MILFORD, DE; Project number: 5U44DA060264-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 760678; Administering IC: National Institute on Drug Abuse; Project title: Addressing Emerging Drug Threats with InstaStrip Rapid Tests; Organization type: Domestic For-Profits
  • May 12, 2026 · NIH RePORTER 5R44DA060647-03
    Organization: INSTANOSIS, INC.; City/State: MILFORD, DE; Project number: 5R44DA060647-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1399878; Administering IC: National Institute on Drug Abuse; Project title: Rapid, Instrument-free and High Sensitivity Over-the-counter Urine Fentanyl Testing; Organization type: Domestic For-Profits
May 22, 2026NIH RePORTER 5R44DA061963-02
Lebrun Labs LLCNIH awarded $96K (SBIR commercialization 1SB1ES038803-01, new, notice Jun 23, 2026); 2 NIH awards totaling $1.18M in the last 12 months.
Evidence (2 events)
  • Jun 23, 2026 · NIH RePORTER 1SB1ES038803-01
    Organization: LEBRUN LABS, LLC; City/State: ANAHEIM, CA; Project number: 1SB1ES038803-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 95664; Administering IC: National Institute of Environmental Health Sciences; Project title: IVD EIT: A Nonanimal Alternative Method for the Detection of Ocular Irritants; Organization type: Domestic For-Profits
  • May 18, 2026 · NIH RePORTER 5R44ES036065-03
    Organization: LEBRUN LABS, LLC; City/State: ANAHEIM, CA; Project number: 5R44ES036065-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 1088111; Administering IC: National Institute of Environmental Health Sciences; Project title: An In Chemico Test to Identify Dermal Corrosives; Organization type: Domestic For-Profits
Jun 23, 2026NIH RePORTER 1SB1ES038803-01
Mercator MedSystems, Inc.NIH awarded $1M (SBIR Phase II 5R44HL102998-06, continuation, notice May 11, 2026).
Evidence (1 event)
  • May 11, 2026 · NIH RePORTER 5R44HL102998-06
    Organization: MERCATOR MEDSYSTEMS, INC.; City/State: San Leandro, CA; Project number: 5R44HL102998-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 1000000; Administering IC: National Heart Lung and Blood Institute; Project title: Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease; Organization type: Domestic For-Profits
May 11, 2026NIH RePORTER 5R44HL102998-06
Dignify TherapeuticsNIH awarded $95K (SBIR Phase II 3U44NS129628-04S1, supplement, notice Sep 3, 2026); 2 NIH awards totaling $294K in the last 12 months.
Evidence (2 events)
  • Sep 3, 2026 · NIH RePORTER 3U44NS129628-04S1
    Organization: DIGNIFY THERAPEUTICS, LLC; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 3U44NS129628-04S1; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 94793; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding; Organization type: Domestic For-Profits
  • May 5, 2026 · NIH RePORTER 5U44NS129628-04
    Organization: DIGNIFY THERAPEUTICS, LLC; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 5U44NS129628-04; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-05-05; FY total cost (award amount): 199520; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 3U44NS129628-04S1
Trace-Ability Inc.NIH awarded $1M (SBIR Phase II 5R44AI162202-04, continuation, notice May 22, 2026).
Evidence (1 event)
  • May 22, 2026 · NIH RePORTER 5R44AI162202-04
    Organization: TRACE-ABILITY, INC.; City/State: VAN NUYS, CA; Project number: 5R44AI162202-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.; Organization type: Domestic For-Profits
May 22, 2026NIH RePORTER 5R44AI162202-04
PAI Life Sciences Inc.NIH awarded $391K (SBIR Phase I 1R43CA298357-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $1.11M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R43CA298357-01A1
    Organization: PAI LIFE SCIENCES, INC.; City/State: SEATTLE, WA; Project number: 1R43CA298357-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 391300; Administering IC: National Cancer Institute; Project title: LiT4Q TLR4 Agonist Formulation for Mucosal Melanoma; Organization type: Domestic For-Profits
  • May 19, 2026 · NIH RePORTER 5R44AI140708-07
    Organization: PAI LIFE SCIENCES, INC.; City/State: SEATTLE, WA; Project number: 5R44AI140708-07; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 713883; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Vaccine for Lymphatic Filariasis, LFGuard™; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43CA298357-01A1
Proneurogen, IncNIH awarded $500K (SBIR Phase I 1R43AG099316-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43AG099316-01
    Organization: PRONEUROGEN, INC.; City/State: TUCSON, AZ; Project number: 1R43AG099316-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 499802; Administering IC: National Institute on Aging; Project title: Scale-up GMP Manufacturing of Extended-Release PNA5 for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Dementia; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG099316-01
PEER Technologies PLLCNIH awarded $1.26M (SBIR Phase II 5R44AR085500-02, continuation, notice Jun 1, 2026).
Evidence (1 event)
  • Jun 1, 2026 · NIH RePORTER 5R44AR085500-02
    Organization: PEER TECHNOLOGIES, PLLC; City/State: Washington, DC; Project number: 5R44AR085500-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 1256846; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Smart Cavity Creator Drill for Lumbar Interbody Fusion: Direct to Phase II; Organization type: Domestic For-Profits
Jun 1, 2026NIH RePORTER 5R44AR085500-02
Taxis Pharmaceuticals IncNIH awarded $876K (SBIR Phase II 5R44AI174351-03, continuation, notice Sep 11, 2026); 3 NIH awards totaling $2.17M in the last 12 months.
Evidence (3 events)
  • Sep 11, 2026 · NIH RePORTER 5R44AI174351-03
    Organization: TAXIS PHARMACEUTICALS, INC.; City/State: MONMOUTH JUNCTION, NJ; Project number: 5R44AI174351-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 875798; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa; Organization type: Domestic For-Profits
  • Aug 12, 2026 · NIH RePORTER 1R43AI197297-01
    Organization: TAXIS PHARMACEUTICALS, INC.; City/State: MONMOUTH JUNCTION, NJ; Project number: 1R43AI197297-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 294729; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Lead identification of oral FtsZ inhibitors for the treatment of Clostridioides difficile infections(CDI); Organization type: Domestic For-Profits
  • May 26, 2026 · NIH RePORTER 5R44AI191886-02
    Organization: TAXIS PHARMACEUTICALS, INC.; City/State: MONMOUTH JUNCTION, NJ; Project number: 5R44AI191886-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 5R44AI174351-03
Rise TherapeuticsNIH awarded $740K (SBIR Phase II 1R44CA306440-01A1, new, notice Sep 16, 2026); 5 NIH awards totaling $4.11M in the last 12 months.
Evidence (5 events)
  • Sep 16, 2026 · NIH RePORTER 1R44CA306440-01A1
    Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 1R44CA306440-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 740140; Administering IC: National Cancer Institute; Project title: Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors; Organization type: Domestic For-Profits
  • Sep 3, 2026 · NIH RePORTER 1R44DK146369-01
    Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 1R44DK146369-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1042478; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease; Organization type: Domestic For-Profits
  • Sep 1, 2026 · NIH RePORTER 4UH3DE034134-02
    Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 4UH3DE034134-02; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 549833; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome; Organization type: Domestic For-Profits
  • Jul 28, 2026 · NIH RePORTER 5R44AG084484-04
    Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 5R44AG084484-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 967715; Administering IC: National Institute on Aging; Project title: A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis; Organization type: Domestic For-Profits
  • Jul 16, 2026 · NIH RePORTER 5SB1DK141356-03
    Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 5SB1DK141356-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 811362; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R44CA306440-01A1
AyuVis Research, Inc.NIH awarded $360K (SBIR Phase II 5R44HD112276-03, continuation, notice May 25, 2026).
Evidence (1 event)
  • May 25, 2026 · NIH RePORTER 5R44HD112276-03
    Organization: AYUVIS RESEARCH, INC.; City/State: FORT WORTH, TX; Project number: 5R44HD112276-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 359812; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates; Organization type: Domestic For-Profits
May 25, 2026NIH RePORTER 5R44HD112276-03
Kuria Therapeutics, Inc.NIH awarded $307K (SBIR Phase I 1R43EY038532-01, new, notice Sep 2, 2026).
Evidence (1 event)
  • Sep 2, 2026 · NIH RePORTER 1R43EY038532-01
    Organization: KURIA THERAPEUTICS, INC; City/State: LITTLE ROCK, AR; Project number: 1R43EY038532-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 306805; Administering IC: National Eye Institute; Project title: Testing of SCO-116, an NRF2 activator for Fuchs' Dystrophy, in cultured human corneas; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 1R43EY038532-01
Cellectgen, Inc.NIH awarded $936K (SBIR Phase II 2R44DE032549-02A1, competing renewal, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 2R44DE032549-02A1
    Organization: CELLECTGEN, INC.; City/State: PASADENA, CA; Project number: 2R44DE032549-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 935551; Administering IC: National Institute of Dental and Craniofacial Research; Project title: DEVELOPMENT OF A SALIVARY ASSAY FOR MEASURING PERIODONTAL DISEASE ACTIVITY; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 2R44DE032549-02A1
Young Therapeutics, LLCNIH awarded $1.49M (SBIR Phase II 5R44HL160338-03, continuation, notice Jun 30, 2026).
Evidence (1 event)
  • Jun 30, 2026 · NIH RePORTER 5R44HL160338-03
    Organization: YOUNG THERAPEUTICS, LLC; City/State: PHILADELPHIA, PA; Project number: 5R44HL160338-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1488899; Administering IC: National Heart Lung and Blood Institute; Project title: Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.; Organization type: Domestic For-Profits
Jun 30, 2026NIH RePORTER 5R44HL160338-03
Analytical Diagnostic Solutions Inc.NIH awarded $312K (SBIR Phase I 1R43DK143768-01A1, new, notice Sep 10, 2026); 3 NIH awards totaling $1.72M in the last 12 months.
Evidence (3 events)
  • Sep 10, 2026 · NIH RePORTER 1R43DK143768-01A1
    Organization: ANALYTICAL DIAGNOSTIC SOLUTIONS, INC.; City/State: MOUNT LAUREL, NJ; Project number: 1R43DK143768-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 312453; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Point of Care-Device for the Determination of Blood Tyrosine (TYR) the "TYR Now"; Organization type: Domestic For-Profits
  • Sep 2, 2026 · NIH RePORTER 5R44HD114325-03
    Organization: ANALYTICAL DIAGNOSTIC SOLUTIONS, INC.; City/State: MOUNT LAUREL, NJ; Project number: 5R44HD114325-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 1095992; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: A point of care-device for the determination of creatinine phosphokinase (CPK), theCPK Now; Organization type: Domestic For-Profits
  • Aug 5, 2026 · NIH RePORTER 1R43DK146426-01
    Organization: ANALYTICAL DIAGNOSTIC SOLUTIONS, INC.; City/State: MOUNT LAUREL, NJ; Project number: 1R43DK146426-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 311172; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Point of Care Device for Patients with Oxalurias, the Oxalate Now; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 1R43DK143768-01A1
Amplo BiotechnologyNIH awarded $1.36M (STTR Phase II 5R42NS127713-04, continuation, notice May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · NIH RePORTER 5R42NS127713-04
    Organization: AMPLO BIOTECHNOLOGY, INC.; City/State: TOWSON, MD; Project number: 5R42NS127713-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1357367; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Targeted ColQ gene therapy for Congenital Myasthenic Syndromes; Organization type: Domestic For-Profits
May 12, 2026NIH RePORTER 5R42NS127713-04
Nabgen Inc.NIH awarded $1.01M (STTR Phase II 5R42TR004338-03, continuation, notice Aug 25, 2026); 2 NIH awards totaling $1.33M in the last 12 months.
Evidence (2 events)
  • Aug 25, 2026 · NIH RePORTER 5R42TR004338-03
    Organization: NABGEN, INC.; City/State: DURHAM, NC; Project number: 5R42TR004338-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 1014676; Administering IC: National Center for Advancing Translational Sciences; Project title: Novel strategy to block AAV neutralizing antibody activity; Organization type: Domestic For-Profits
  • Jul 8, 2026 · NIH RePORTER 1R41TR006064-01
    Organization: NABGEN, INC.; City/State: DURHAM, NC; Project number: 1R41TR006064-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 312461; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a universal approach to block inhibitors for protein replacement therapy; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R42TR004338-03
Bmseed LLCNIH awarded $701K (SBIR Phase II 2R44NS124469-02, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44NS124469-02
    Organization: BMSEED, LLC; City/State: TEMPE, AZ; Project number: 2R44NS124469-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 700518; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: The first adaptable 3D-formfitting microelectrode array for organoid-based models of neurological and neurodegenerative diseases; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44NS124469-02
Scientific Horizons Consulting LLCNIH awarded $399K (SBIR Phase I 1R43DA065300-01, new, notice Jun 23, 2026).
Evidence (1 event)
  • Jun 23, 2026 · NIH RePORTER 1R43DA065300-01
    Organization: SCIENTIFIC HORIZONS CONSULTING LLC; City/State: Irvine, CA; Project number: 1R43DA065300-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 399250; Administering IC: National Institute on Drug Abuse; Project title: Water Inhalable Nicotine (WIN) as An Innovative Orally Inhaled Nicotine Replacement Therapy (NRT) for Smoking Cessation; Organization type: Domestic For-Profits
Jun 23, 2026NIH RePORTER 1R43DA065300-01
Cell Reprogramming & Therapeutics LLCNIH awarded $422K (SBIR Phase I 1R43GM165021-01, new, notice Aug 18, 2026); 2 NIH awards totaling $845K in the last 12 months.
Evidence (2 events)
  • Aug 18, 2026 · NIH RePORTER 1R43GM165021-01
    Organization: CELL REPROGRAMMING AND THERAPEUTICS, LLC; City/State: GREENFIELD, WI; Project number: 1R43GM165021-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 422285; Administering IC: National Institute of General Medical Sciences; Project title: Novel Cell Culture Supplement from Adipocyte-Origin Megakaryocytes and Platelets; Organization type: Domestic For-Profits
  • Aug 14, 2026 · NIH RePORTER 1R43GM161870-01A1
    Organization: CELL REPROGRAMMING AND THERAPEUTICS, LLC; City/State: GREENFIELD, WI; Project number: 1R43GM161870-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 422285; Administering IC: National Institute of General Medical Sciences; Project title: Development of a Novel, Safe, Easily Standardized, and Cost-Effective Cell Growth Supplement for Diverse Cell Culture Applications; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 1R43GM165021-01
Cell Preservation Services Inc.NIH awarded $314K (SBIR Phase I 1R43CA310739-01, new, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 1R43CA310739-01
    Organization: CELL PRESERVATION SERVICES, INC.; City/State: OWEGO, NY; Project number: 1R43CA310739-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 314400; Administering IC: National Cancer Institute; Project title: Improving Human Hematopoietic Progenitor Cell Cryopreservation using Anti-aging, Nature-inspired and Stress Modulation Formulations; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R43CA310739-01
Keylicon BiosciencesNIH awarded $400K (SBIR Phase I 1R43EB038819-01A1, new, notice Sep 7, 2026); 4 NIH awards totaling $1.43M in the last 12 months.
Evidence (4 events)
  • Sep 7, 2026 · NIH RePORTER 1R43EB038819-01A1
    Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43EB038819-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 400000; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: Improving the Stability of saRNA LNP Formulations To Overcome Cold Chain Challenges; Organization type: Domestic For-Profits
  • Aug 21, 2026 · NIH RePORTER 1R43DK146746-01
    Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43DK146746-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 400000; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Extended In Situ Production of Glucocerebrosidase (GCase) for the Treatment of Gaucher Disease; Organization type: Domestic For-Profits
  • Jul 29, 2026 · NIH RePORTER 1R43AI197306-01
    Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43AI197306-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Low Dose Multivalent Influenza Vaccine via Modified Self-Amplifying RNA; Organization type: Domestic For-Profits
  • Jul 20, 2026 · NIH RePORTER 1R43AI197345-01
    Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43AI197345-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multivalent Vaccine Against Lyme Disease via Modified Self-Amplifying RNA; Organization type: Domestic For-Profits
Sep 7, 2026NIH RePORTER 1R43EB038819-01A1
OCULOGENEXNIH awarded $1.09M (SBIR Phase II 1R44EY038510-01, new, notice Aug 4, 2026).
Evidence (1 event)
  • Aug 4, 2026 · NIH RePORTER 1R44EY038510-01
    Organization: OCULOGENEX; City/State: Dallas, TX; Project number: 1R44EY038510-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 1092536; Administering IC: National Eye Institute; Project title: Developing a gene therapy-based solution for early intervention in age related macular degeneration (AMD) to prevent disease progression; Organization type: Domestic For-Profits
Aug 4, 2026NIH RePORTER 1R44EY038510-01
Astero EradoNIH awarded $306K (SBIR Phase I 1R43AI197270-01, new, notice Aug 11, 2026); 2 NIH awards totaling $1.33M in the last 12 months.
Evidence (2 events)
  • Aug 11, 2026 · NIH RePORTER 1R43AI197270-01
    Organization: ASTERO ERADO INC; City/State: COLLEGE STATION, TX; Project number: 1R43AI197270-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 306449; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Severe Autoantibody-Mediated Autoimmune Disease: A New Treatment Approach; Organization type: Domestic For-Profits
  • May 19, 2026 · NIH RePORTER 5R44AI174502-03
    Organization: ASTERO ERADO INC; City/State: COLLEGE STATION, TX; Project number: 5R44AI174502-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1018916; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel approaches for the treatment of autoimmune disease; Organization type: Domestic For-Profits
Aug 11, 2026NIH RePORTER 1R43AI197270-01
37degreesNIH awarded $360K (STTR Phase I 1R41GM165131-01, new, notice Aug 6, 2026); 2 NIH awards totaling $817K in the last 12 months.
Evidence (2 events)
  • Aug 6, 2026 · NIH RePORTER 1R41GM165131-01
    Organization: 37DEGREES, INC.; City/State: GENEVA, IL; Project number: 1R41GM165131-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 360247; Administering IC: National Institute of General Medical Sciences; Project title: PamON: 3D imaging of live and incubated engineered tissue with photoacoustic microscopy; Organization type: Domestic For-Profits
  • Aug 3, 2026 · NIH RePORTER 1R43MH139167-01A1
    Organization: 37DEGREES, INC.; City/State: GENEVA, IL; Project number: 1R43MH139167-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 456902; Administering IC: National Institute of Mental Health; Project title: InVitreON: A compact and integrated platform for long-term neuronal culture incubation, recording and closed-loop stimulation; Organization type: Domestic For-Profits
Aug 6, 2026NIH RePORTER 1R41GM165131-01
BiaCure TherapiesNIH awarded $1M (SBIR Phase II 5R44AI188772-02, continuation, notice May 22, 2026).
Evidence (1 event)
  • May 22, 2026 · NIH RePORTER 5R44AI188772-02
    Organization: BIACURE THERAPIES, INC.; City/State: Waukesha, WI; Project number: 5R44AI188772-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Using Targeted, Controlled High Frequency Energy for Treatment of Onychomycosis; Organization type: Domestic For-Profits
May 22, 2026NIH RePORTER 5R44AI188772-02
Fibroplate Inc.NIH awarded $1.16M (SBIR Phase II 1R44AG099306-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44AG099306-01
    Organization: FIBROPLATE, INC.; City/State: LAS VEGAS, NV; Project number: 1R44AG099306-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1162390; Administering IC: National Institute on Aging; Project title: Fibrinogen-coated albumin spheres to accelerate bone healing in older adults; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG099306-01
EydisBioNIH awarded $406K (SBIR Phase I 1R43CA310084-01, new, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 1R43CA310084-01
    Organization: EYDIS BIO, INC.; City/State: DURHAM, NC; Project number: 1R43CA310084-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 406496; Administering IC: National Cancer Institute; Project title: Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R43CA310084-01
ImagenomixNIH awarded $158K (SBIR Phase I 1R43CA309961-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43CA309961-01
    Organization: IMAGENOMIX CORP.; City/State: BROOKLYN, NY; Project number: 1R43CA309961-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 157826; Administering IC: National Cancer Institute; Project title: Analytical Variables and Clinical Utility of AKT1 Mutation Prediction in Breast Cancer Using Deep Learning on Histopathology Images; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43CA309961-01
Mitotherapeutix, LLCNIH awarded $996K (SBIR Phase II 2R44DK129102-04A1, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44DK129102-04A1
    Organization: MITOTHERAPEUTIX, LLC; City/State: CHESHIRE, CT; Project number: 2R44DK129102-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 996169; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: cGMP Production, IND-enabling studies, and Phase I Clinical Studies to Test a Novel siRNA drug product for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH); Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44DK129102-04A1
Photothermal Spectroscopy CorpNIH awarded $307K (SBIR Phase I 1R43GM165235-01, new, notice Aug 27, 2026); 2 NIH awards totaling $1.33M in the last 12 months.
Evidence (2 events)
  • Aug 27, 2026 · NIH RePORTER 1R43GM165235-01
    Organization: PHOTOTHERMAL SPECTROSCOPY CORP.; City/State: SANTA BARBARA, CA; Project number: 1R43GM165235-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 306802; Administering IC: National Institute of General Medical Sciences; Project title: High-Speed, High-Content, Label-Free Live-Cell Chemical Imaging in Multiwell Plates Using Photothermal Stimulated Raman Scattering (PT-SRS) Microscopy; Organization type: Domestic For-Profits
  • Aug 13, 2026 · NIH RePORTER 1R44ES035665-01A1
    Organization: PHOTOTHERMAL SPECTROSCOPY CORP.; City/State: SANTA BARBARA, CA; Project number: 1R44ES035665-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1022908; Administering IC: National Institute of Environmental Health Sciences; Project title: High-Speed Automated Analysis of Sub-20 µm Microplastics by Photothermal Infrared Spectroscopy; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 1R43GM165235-01
SynCardia SystemsNIH awarded $606K (SBIR Phase I 1R43HL184460-01, new, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 1R43HL184460-01
    Organization: SYNCARDIA SYSTEMS, LLC; City/State: Tucson, AZ; Project number: 1R43HL184460-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 606498; Administering IC: National Heart Lung and Blood Institute; Project title: A wearable, mechanically actuated total artificial heart (Emperor) enabling destination therapy for severe biventricular heart failure patients; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 1R43HL184460-01
Double Helix Optics, Inc.NIH awarded $976K (SBIR Phase II 5R44GM151926-03, continuation, notice May 11, 2026).
Evidence (1 event)
  • May 11, 2026 · NIH RePORTER 5R44GM151926-03
    Organization: DOUBLE HELIX OPTICS INC.; City/State: BOULDER, CO; Project number: 5R44GM151926-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 976236; Administering IC: National Institute of General Medical Sciences; Project title: High-resolution extended-depth phase-engineered objectives to accelerate spatial 'omics R&D through computational optics; Organization type: Domestic For-Profits
May 11, 2026NIH RePORTER 5R44GM151926-03
Kovina TherapeuticsNIH awarded $1.14M (SBIR Phase II 1R44CA302154-01A1, new, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 1R44CA302154-01A1
    Organization: KOVINA THERAPEUTICS INC.; City/State: INDIANAPOLIS, IN; Project number: 1R44CA302154-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 1143891; Administering IC: National Cancer Institute; Project title: Novel Therapeutics to Treat HPV-Associated Cancers; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 1R44CA302154-01A1
Emmune Inc.NIH awarded $300K (SBIR Phase II 1R44HL184837-01A1, new, notice Aug 24, 2026); 2 NIH awards totaling $599K in the last 12 months.
Evidence (2 events)
  • Aug 24, 2026 · NIH RePORTER 1R44HL184837-01A1
    Organization: EMMUNE, INC; City/State: Juno Beach, FL; Project number: 1R44HL184837-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 299664; Administering IC: National Heart Lung and Blood Institute; Project title: Non-viral gene therapy to treat and prevent atherosclerosis; Organization type: Domestic For-Profits
  • Jul 24, 2026 · NIH RePORTER 1R44AI197364-01
    Organization: EMMUNE, INC; City/State: Juno Beach, FL; Project number: 1R44AI197364-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-24; FY total cost (award amount): 299352; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PK, tolerability, and toxicology studies for eCD4-Ig as a long-acting recombinant protein therapeutic; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 1R44HL184837-01A1
InBios InternationalNIH awarded $314K (STTR Phase I 1R41AI197509-01, new, notice Sep 8, 2026); 2 NIH awards totaling $1.29M in the last 12 months; 5 roles open.
Evidence (2 events)
  • Sep 8, 2026 · NIH RePORTER 1R41AI197509-01
    Organization: INBIOS INTERNATIONAL, INC.; City/State: Seattle, WA; Project number: 1R41AI197509-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a sensitive Point-of-Care immunoassay for tick- borne spotted fever group rickettsioses; Organization type: Domestic For-Profits
  • Jun 11, 2026 · NIH RePORTER 5R44AI184032-03
    Organization: INBIOS INTERNATIONAL, INC.; City/State: Seattle, WA; Project number: 5R44AI184032-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 974356; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Next-gen Chagas DetectTM Plus Rapid test for sensitive and specific diagnosis of Chagas disease; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 1R41AI197509-01
Epicypher, Inc.NIH awarded $1.26M (SBIR Phase II 5R44GM154510-02, continuation, notice Aug 21, 2026); 5 NIH awards totaling $5.62M in the last 12 months.
Evidence (5 events)
  • Aug 21, 2026 · NIH RePORTER 5R44GM154510-02
    Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 5R44GM154510-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1264176; Administering IC: National Institute of General Medical Sciences; Project title: Asymmetric nucleosome substrates to advance the study of the histone code; Organization type: Domestic For-Profits
  • Aug 21, 2026 · NIH RePORTER 1R44AI197362-01
    Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 1R44AI197362-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 999268; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Scalable, single-molecule and single-cell chromatin accessibility profiling in primary immune cells; Organization type: Domestic For-Profits
  • Aug 18, 2026 · NIH RePORTER 1R44TR006068-01A1
    Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 1R44TR006068-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1062099; Administering IC: National Center for Advancing Translational Sciences; Project title: Genomic profiling of drug-chromatin interactions for accelerated drug development research; Organization type: Domestic For-Profits
  • Jun 26, 2026 · NIH RePORTER 5R44CA284973-03
    Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 5R44CA284973-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 1047610; Administering IC: National Cancer Institute; Project title: Epigenomic analysis of cell-free nucleosomes for cancer research; Organization type: Domestic For-Profits
  • Jun 3, 2026 · NIH RePORTER 5R44AG091990-02
    Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 5R44AG091990-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1249682; Administering IC: National Institute on Aging; Project title: Development of novel epigenetic biomarkers and detection reagents for aging; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 5R44GM154510-02
MabSwitchNIH awarded $400K (SBIR Phase I 1R43CA310118-01, new, notice Sep 17, 2026); 2 NIH awards totaling $800K in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R43CA310118-01
    Organization: MABSWITCH, INC.; City/State: VAN NUYS, CA; Project number: 1R43CA310118-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399998; Administering IC: National Cancer Institute; Project title: Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors; Organization type: Domestic For-Profits
  • Sep 10, 2026 · NIH RePORTER 1R43CA314526-01
    Organization: MABSWITCH, INC.; City/State: VAN NUYS, CA; Project number: 1R43CA314526-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 399992; Administering IC: National Cancer Institute; Project title: Affinity-tunable Antibody Drug Conjugate (ADC) against High-Grade Serous Ovarian Cancer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43CA310118-01
SUS Clinicals Inc.NIH awarded $400K (STTR Phase II 1R42CA302217-01A1, new, notice Aug 10, 2026).
Evidence (1 event)
  • Aug 10, 2026 · NIH RePORTER 1R42CA302217-01A1
    Organization: SUS CLINICALS, INC.; City/State: CINCINNATI, OH; Project number: 1R42CA302217-01A1; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 400001; Administering IC: National Cancer Institute; Project title: Development and Validation of Orthotopic Oncopig Glioma Models for Preclinical Locoregional Therapeutic Evaluation; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 1R42CA302217-01A1
Kinvard BioNIH awarded $314K (SBIR Phase I 1R43AI197431-01, new, notice Aug 3, 2026).
Evidence (1 event)
  • Aug 3, 2026 · NIH RePORTER 1R43AI197431-01
    Organization: KINVARD BIO, INC.; City/State: FLOURTOWN, PA; Project number: 1R43AI197431-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of oxepanoprolinamide antibiotics for the treatment of complicated urinary tract infections.; Organization type: Domestic For-Profits
Aug 3, 2026NIH RePORTER 1R43AI197431-01
Haima TherapeuticsNIH awarded $500K (SBIR commercialization 1SB1HL184353-01, new, notice Sep 17, 2026); 3 NIH awards totaling $1.53M in the last 12 months.
Evidence (3 events)
  • Sep 17, 2026 · NIH RePORTER 1SB1HL184353-01
    Organization: HAIMA THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 1SB1HL184353-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 499999; Administering IC: National Heart Lung and Blood Institute; Project title: Commercialization Strategy for an Intravenous Hemostatic Nanotechnology for Bleeding Management; Organization type: Domestic For-Profits
  • Aug 14, 2026 · NIH RePORTER 3R44HL180258-02S1
    Organization: HAIMA THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 3R44HL180258-02S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 50000; Administering IC: National Heart Lung and Blood Institute; Project title: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents; Organization type: Domestic For-Profits
  • Aug 4, 2026 · NIH RePORTER 5R44HL180258-02
    Organization: HAIMA THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 5R44HL180258-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 978218; Administering IC: National Heart Lung and Blood Institute; Project title: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1SB1HL184353-01
Envisagenics Inc.NIH awarded $890K (SBIR Phase II 1R44CA310213-01, new, notice Jul 21, 2026).
Evidence (1 event)
  • Jul 21, 2026 · NIH RePORTER 1R44CA310213-01
    Organization: ENVISAGENICS, INC.; City/State: Long Island City, NY; Project number: 1R44CA310213-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 889653; Administering IC: National Cancer Institute; Project title: SpliceDisco: A Machine Learning Tool for the Identification of Alternative Splicing Events Directly Regulated by Pathological Splicing Factors in Cancer; Organization type: Domestic For-Profits
Jul 21, 2026NIH RePORTER 1R44CA310213-01
Alveolus BioNIH awarded $273K (SBIR Phase I 1R43AI191900-01A1, new, notice Sep 11, 2026); 2 NIH awards totaling $575K in the last 12 months.
Evidence (2 events)
  • Sep 11, 2026 · NIH RePORTER 1R43AI191900-01A1
    Organization: ALVEOLUS BIO, INC.; City/State: BIRMINGHAM, AL; Project number: 1R43AI191900-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 273123; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: An Inhaled Live Biotherapeutic for Influenza Viral Infection; Organization type: Domestic For-Profits
  • Aug 18, 2026 · NIH RePORTER 1R43AI197548-01
    Organization: ALVEOLUS BIO, INC.; City/State: BIRMINGHAM, AL; Project number: 1R43AI197548-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 301768; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Leveraging Live Biotherapeutics for the Treatment of Chronic Rhinosinusitis; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 1R43AI191900-01A1
Opsin Biotherapeutics Inc.NIH awarded $1.11M (SBIR Phase II 2R44NS132623-02, competing renewal, notice Sep 21, 2026).
Evidence (1 event)
  • Sep 21, 2026 · NIH RePORTER 2R44NS132623-02
    Organization: OPSIN BIOTHERAPEUTICS INC.; City/State: BEDFORD, TX; Project number: 2R44NS132623-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-21; FY total cost (award amount): 1113701; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Optogenetic Neuromodulation for Chronic Pain; Organization type: Domestic For-Profits
Sep 21, 2026NIH RePORTER 2R44NS132623-02
Physical SciencesNIH awarded $312K (SBIR Phase I 1R43GM164214-01, new, notice Aug 10, 2026); 2 NIH awards totaling $1.36M in the last 12 months.
Evidence (2 events)
  • Aug 10, 2026 · NIH RePORTER 1R43GM164214-01
    Organization: PHYSICAL SCIENCES, INC; City/State: ANDOVER, MA; Project number: 1R43GM164214-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 311847; Administering IC: National Institute of General Medical Sciences; Project title: Fluorescence-based Lyobead Assay for Rapid Phage Detection in Bioreactor Systems; Organization type: Domestic For-Profits
  • Aug 4, 2026 · NIH RePORTER 2R44GM150354-02A1
    Organization: PHYSICAL SCIENCES, INC; City/State: ANDOVER, MA; Project number: 2R44GM150354-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 1049845; Administering IC: National Institute of General Medical Sciences; Project title: Metabolic Cytometry for In-line Process Analysis; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 1R43GM164214-01
Parabon NanolabsNIH awarded $295K (SBIR Phase I 1R43AI192177-01A1, new, notice Jun 16, 2026).
Evidence (1 event)
  • Jun 16, 2026 · NIH RePORTER 1R43AI192177-01A1
    Organization: PARABON NANOLABS, INC.; City/State: RESTON, VA; Project number: 1R43AI192177-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 295294; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: MetaDx: Rapid Diagnosis of Fungal, Bacterial, and Viral Infections Using Whole Metagenomic Sequencing; Organization type: Domestic For-Profits
Jun 16, 2026NIH RePORTER 1R43AI192177-01A1
TEGA TherapeuticsNIH awarded $498K (SBIR Phase I 1R43HL184653-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43HL184653-01
    Organization: TEGA THERAPEUTICS, INC.; City/State: LA JOLLA, CA; Project number: 1R43HL184653-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 498086; Administering IC: National Heart Lung and Blood Institute; Project title: Activities and Biophysical Properties of Heparins, Engineered to Reduce HIT; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43HL184653-01
NytricxNIH awarded $314K (SBIR Phase I 1R43HL184590-01, new, notice Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · NIH RePORTER 1R43HL184590-01
    Organization: NYTRICX INC.; City/State: ATHENS, GA; Project number: 1R43HL184590-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 314337; Administering IC: National Heart Lung and Blood Institute; Project title: Engineering Nitric Oxide Releasing Intravascular Catheters with Solid Slippery Surfaces to Combat Infection and Thrombosis; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 1R43HL184590-01
Luna Bioscience, Inc.NIH awarded $300K (STTR Phase I 5R41AI188742-02, continuation, notice Sep 2, 2026); 2 NIH awards totaling $601K in the last 12 months.
Evidence (2 events)
  • Sep 2, 2026 · NIH RePORTER 5R41AI188742-02
    Organization: LUNA BIOSCIENCE, INC.; City/State: WESTPORT, CT; Project number: 5R41AI188742-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 300435; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Antibody Detection for Diagnosis of Acute Leptospirosis; Organization type: Domestic For-Profits
  • Jul 14, 2026 · NIH RePORTER 1R41AI197598-01
    Organization: LUNA BIOSCIENCE, INC.; City/State: WESTPORT, CT; Project number: 1R41AI197598-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 300239; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Surrogate Biomarkers for Supporting Clinical Trials of Human Leptospirosis Vaccines; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 5R41AI188742-02
CellFENIH awarded $1.05M (SBIR Phase II 1R44CA310250-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44CA310250-01
    Organization: CELLFE INC.; City/State: ATLANTA, GA; Project number: 1R44CA310250-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1052108; Administering IC: National Cancer Institute; Project title: High throughput, high efficiency, rapid mechanical transfection for CAR T-cell therapeutics; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44CA310250-01
Panorama Research IncorporatedNIH awarded $387K (SBIR Phase I 1R43CA310345-01, new, notice Sep 18, 2026).
Evidence (1 event)
  • Sep 18, 2026 · NIH RePORTER 1R43CA310345-01
    Organization: PANORAMA RESEARCH, INC.; City/State: SUNNYVALE, CA; Project number: 1R43CA310345-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 387240; Administering IC: National Cancer Institute; Project title: Novel macrophage repolarization therapy for colorectal cancer; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 1R43CA310345-01
Arkayli BiopharmaNIH awarded $1M (SBIR Phase II 1R44HL184627-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44HL184627-01
    Organization: ARKAYLI BIOPHARMA, INC.; City/State: Tracys Landing, MD; Project number: 1R44HL184627-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 999904; Administering IC: National Heart Lung and Blood Institute; Project title: Clinical Development of ARK001 Formulation as a Targeted Therapeutic for InfantileHemangioma; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44HL184627-01
Potomac Affinity Protein LLCNIH awarded $378K (SBIR Phase I 1R43GM159468-01A1, new, notice Jun 23, 2026); 2 NIH awards totaling $1.49M in the last 12 months.
Evidence (2 events)
  • Jun 23, 2026 · NIH RePORTER 1R43GM159468-01A1
    Organization: POTOMAC AFFINITY PROTEINS, LLC; City/State: NORTH POTOMAC, MD; Project number: 1R43GM159468-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 377602; Administering IC: National Institute of General Medical Sciences; Project title: Self-amplifying protease chain reactions for simple, sensitive, and quantitative detection; Organization type: Domestic For-Profits
  • Jun 9, 2026 · NIH RePORTER 2R44GM140633-02A1
    Organization: POTOMAC AFFINITY PROTEINS, LLC; City/State: NORTH POTOMAC, MD; Project number: 2R44GM140633-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1109087; Administering IC: National Institute of General Medical Sciences; Project title: Selection system for identifying protein-specific folding tags that enable purification of native cytokines from E. coli; Organization type: Domestic For-Profits
Jun 23, 2026NIH RePORTER 1R43GM159468-01A1
Athna Biotech Inc.NIH awarded $937K (STTR Phase II 2R42CA262399-02, competing renewal, notice Sep 10, 2026); 2 NIH awards totaling $2.04M in the last 12 months.
Evidence (2 events)
  • Sep 10, 2026 · NIH RePORTER 2R42CA262399-02
    Organization: ATHNA BIOTECH, INC.; City/State: Athens, GA; Project number: 2R42CA262399-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 937492; Administering IC: National Cancer Institute; Project title: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 5R42CA257584-03
    Organization: ATHNA BIOTECH, INC.; City/State: Athens, GA; Project number: 5R42CA257584-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1098560; Administering IC: National Cancer Institute; Project title: Development of a radiation-activatable nanoparticle for lung cancer therapy; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 2R42CA262399-02
CMTX Biotech Inc.NIH awarded $296K (STTR Phase I 1R41AI197642-01, new, notice Sep 1, 2026); 3 NIH awards totaling $1.01M in the last 12 months.
Evidence (3 events)
  • Sep 1, 2026 · NIH RePORTER 1R41AI197642-01
    Organization: CMTX BIOTECH, INC.; City/State: KINGS PARK, NY; Project number: 1R41AI197642-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 296470; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Drug Repurposing for the Treatment of Staphylococcus aureus Bacteremia; Organization type: Domestic For-Profits
  • Aug 28, 2026 · NIH RePORTER 1R41HL184801-01A1
    Organization: CMTX BIOTECH, INC.; City/State: KINGS PARK, NY; Project number: 1R41HL184801-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 367988; Administering IC: National Heart Lung and Blood Institute; Project title: A Lung-Specific, Sulfonium Lipid Nanoparticle (sLNP) Formulation of Incyclinide for the Treatment of ALI/ARDS; Organization type: Domestic For-Profits
  • Jun 23, 2026 · NIH RePORTER 1R41DK143771-01A1
    Organization: CMTX BIOTECH, INC.; City/State: KINGS PARK, NY; Project number: 1R41DK143771-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 349687; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel Small Molecule for the Prevention of Hemorrhagic Cystitis; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R41AI197642-01
Claria Medical, Inc.NIH awarded $1.68M (SBIR Phase II 1R44HD121300-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.78M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R44HD121300-01
    Organization: CLARIA MEDICAL, INC.; City/State: Mountain View, CA; Project number: 1R44HD121300-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1675722; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: A Multicenter Randomized Controlled Trial of a Safer and Faster Contained Tissue Extraction System for Laparoscopic Hysterectomy; Organization type: Domestic For-Profits
  • Sep 2, 2026 · NIH RePORTER 5R44HD105575-04
    Organization: CLARIA MEDICAL, INC.; City/State: Mountain View, CA; Project number: 5R44HD105575-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 107203; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: A Safe, Fast, and Cost-Effective System for Tissue Removal in Laparoscopic Hysterectomy and Other Minimally Invasive Surgery; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44HD121300-01
Foli BioNIH awarded $400K (SBIR Phase I 1R43HG014430-01A1, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43HG014430-01A1
    Organization: FOLI BIO INC.; City/State: NEW YORK, NY; Project number: 1R43HG014430-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399875; Administering IC: National Human Genome Research Institute; Project title: Development of fecal exfoliome sequencing as a multi-omics approach for gut health management; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43HG014430-01A1
Tango BiosciencesNIH awarded $1.15M (SBIR Phase II 2R44GM146514-02, competing renewal, notice Sep 1, 2026); 2 NIH awards totaling $1.48M in the last 12 months.
Evidence (2 events)
  • Sep 1, 2026 · NIH RePORTER 2R44GM146514-02
    Organization: TANGO BIOSCIENCES, INC.; City/State: CHICAGO, IL; Project number: 2R44GM146514-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1150462; Administering IC: National Institute of General Medical Sciences; Project title: Generating phosphobodies to activated protein kinases; Organization type: Domestic For-Profits
  • Aug 24, 2026 · NIH RePORTER 1R43GM165191-01
    Organization: TANGO BIOSCIENCES, INC.; City/State: CHICAGO, IL; Project number: 1R43GM165191-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 332917; Administering IC: National Institute of General Medical Sciences; Project title: Peptide Glues; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 2R44GM146514-02
Medosome BiotecNIH awarded $356K (SBIR Phase I 1R43DK146558-01, new, notice Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · NIH RePORTER 1R43DK146558-01
    Organization: MEDOSOME BIOTEC, LLC; City/State: Alachua, FL; Project number: 1R43DK146558-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 356251; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Developing GLP-1 Producing Genetically Engineered Probiotics for Treatment of Metabolic Diseases; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 1R43DK146558-01
Allied Innovative SystemsNIH awarded $371K (SBIR Phase I 1R43HL184623-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43HL184623-01
    Organization: ALLIED INNOVATIVE SYSTEMS, LLC; City/State: Chatham, NJ; Project number: 1R43HL184623-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 371226; Administering IC: National Heart Lung and Blood Institute; Project title: A new method for the determination of alloantibody titer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43HL184623-01
Retham Technologies LLCNIH awarded $1.69M (SBIR Phase II 5R44HL147734-05, continuation, notice Jun 16, 2026).
Evidence (1 event)
  • Jun 16, 2026 · NIH RePORTER 5R44HL147734-05
    Organization: RETHAM TECHNOLOGIES, INC.; City/State: Wauwatosa, WI; Project number: 5R44HL147734-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 1693897; Administering IC: National Heart Lung and Blood Institute; Project title: An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia; Organization type: Domestic For-Profits
Jun 16, 2026NIH RePORTER 5R44HL147734-05
AnnoviantNIH awarded $895K (SBIR Phase II 5R44HL147771-06, continuation, notice May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · NIH RePORTER 5R44HL147771-06
    Organization: ANNOVIANT, INC; City/State: ALPHARETTA, GA; Project number: 5R44HL147771-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 895062; Administering IC: National Heart Lung and Blood Institute; Project title: Pulmonary Valved Graft with Regeneration Potential for Pediatric Patients; Organization type: Domestic For-Profits
May 12, 2026NIH RePORTER 5R44HL147771-06
SignaBlok, Inc.NIH awarded $353K (SBIR Phase I 1R43DK148026-01, new, notice Sep 4, 2026); 2 NIH awards totaling $1.18M in the last 12 months.
Evidence (2 events)
  • Sep 4, 2026 · NIH RePORTER 1R43DK148026-01
    Organization: SIGNABLOK, INC.; City/State: WORCESTER, MA; Project number: 1R43DK148026-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 353264; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: New TREM-1 therapy for inflammatory bowel disease; Organization type: Domestic For-Profits
  • May 13, 2026 · NIH RePORTER 5R44EY034015-03
    Organization: SIGNABLOK, INC.; City/State: WORCESTER, MA; Project number: 5R44EY034015-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 830491; Administering IC: National Eye Institute; Project title: First-in-class TREM-1 inhibitors for neovascular retinal diseases; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 1R43DK148026-01
PASCALL Systems, IncorporatedNIH awarded $1.07M (SBIR Phase II 5R44AG090247-03, continuation, notice Jul 10, 2026); 6 NIH awards totaling $7M in the last 12 months.
Evidence (6 events)
  • Jul 10, 2026 · NIH RePORTER 5R44AG090247-03
    Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R44AG090247-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1069722; Administering IC: National Institute on Aging; Project title: Developing an Elderly Patient-Specific, Accurate, Intuitive and Highly Interpretable System for Unconsciousness Management in General Anesthesia Using PASCALL FDA-Cleared Intraoperative EEG Monitor; Organization type: Domestic For-Profits
  • Jul 1, 2026 · NIH RePORTER 1SB1NS147475-01
    Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 1SB1NS147475-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 199806; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Embedded Entrepreneur to Commercialize Active Stimulation/Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care; Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5R42AG084399-03
    Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R42AG084399-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 999317; Administering IC: National Institute on Aging; Project title: Developing a novel system combining cognitive assessment with PASCALL FDA-cleared intraoperative anesthesia EEG brain monitor to prevent postoperative neurocognitive disorders in aging patients; Organization type: Domestic For-Profits
  • Jun 3, 2026 · NIH RePORTER 5SB1AG097192-02
    Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5SB1AG097192-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1998482; Administering IC: National Institute on Aging; Project title: Commercialization Readiness of an Intraoperative EEG-Guided Precision Anesthesia Management System to Prevent Postoperative Delirium in Elderly and Patients at Risk for Alzheimer's & Related Dementia; Organization type: Domestic For-Profits
  • Jun 3, 2026 · NIH RePORTER 5R44AG066325-05
    Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R44AG066325-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1499986; Administering IC: National Institute on Aging; Project title: Developing an Intraoperative EEG-Guided Precision Anesthesia Management System to Prevent Postoperative Delirium in Elderly and Patients at Risk for Alzheimer's & Related Dementias; Organization type: Domestic For-Profits
  • Jun 3, 2026 · NIH RePORTER 5R44AG087872-03
    Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R44AG087872-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1236964; Administering IC: National Institute on Aging; Project title: Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 5R44AG090247-03
Via Therapeutics, LLCNIH awarded $277K (SBIR Phase I 1R43EY038569-01, new, notice Sep 18, 2026); 5 NIH awards totaling $2.54M in the last 12 months.
Evidence (5 events)
  • Sep 18, 2026 · NIH RePORTER 1R43EY038569-01
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R43EY038569-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 277143; Administering IC: National Eye Institute; Project title: Novel Ocular Aerosol Drug Delivery Device for the Treatment Optimization of Glaucoma.; Organization type: Domestic For-Profits
  • Sep 17, 2026 · NIH RePORTER 2R44CA257783-02A1
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 2R44CA257783-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 660779; Administering IC: National Cancer Institute; Project title: Development of dermal targeting formulations for squamous cell carcinoma; Organization type: Domestic For-Profits
  • Sep 9, 2026 · NIH RePORTER 1R43AI197715-01
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R43AI197715-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 313674; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Macrophage Targeting Inhaled Tigecycline Dry Powder Formulation for Treating Non-Tuberculous Mycobacterial (NTM) Infections; Organization type: Domestic For-Profits
  • Aug 28, 2026 · NIH RePORTER 1R41HL186958-01
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R41HL186958-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 315082; Administering IC: National Heart Lung and Blood Institute; Project title: Dry powders of whole blood prepared by thin-film freeze-drying; Organization type: Domestic For-Profits
  • Jul 10, 2026 · NIH RePORTER 5R44AI174337-03
    Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 5R44AI174337-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 971316; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 1R43EY038569-01
Riptide BioscienceNIH awarded $1M (SBIR Phase II 1R44AI197713-01, new, notice Aug 1, 2026).
Evidence (1 event)
  • Aug 1, 2026 · NIH RePORTER 1R44AI197713-01
    Organization: RIPTIDE BIOSCIENCE, INC.; City/State: VALLEJO, CA; Project number: 1R44AI197713-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-01; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Designed Host Defense Peptide to Prevent Burn Infections; Organization type: Domestic For-Profits
Aug 1, 2026NIH RePORTER 1R44AI197713-01
Xleratehealth, LLCNIH awarded $1.25M (SBIR Phase II 2R44GM148083-04, competing renewal, notice Jun 19, 2026).
Evidence (1 event)
  • Jun 19, 2026 · NIH RePORTER 2R44GM148083-04
    Organization: XLERATEHEALTH, LLC; City/State: LOUISVILLE, KY; Project number: 2R44GM148083-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1250177; Administering IC: National Institute of General Medical Sciences; Project title: XLerator Network - From Lab to Market: Scaling Academic Innovation for Commercial Success; Organization type: Domestic For-Profits
Jun 19, 2026NIH RePORTER 2R44GM148083-04
Inherent BiosciencesNIH awarded $1.17M (SBIR Phase II 1R44HD121294-01, new, notice Aug 21, 2026).
Evidence (1 event)
  • Aug 21, 2026 · NIH RePORTER 1R44HD121294-01
    Organization: INHERENT BIOSCIENCES, INC.; City/State: Salt Lake City, UT; Project number: 1R44HD121294-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1167156; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Epigenetic Diagnostic for Severe Spermatogenic Failure and Associated Malignancy Risks; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 1R44HD121294-01
Phoenix NestNIH awarded $1.49M (SBIR Phase II 1R44NS147802-01, new, notice Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · NIH RePORTER 1R44NS147802-01
    Organization: PHOENIX NEST, INC.; City/State: BROOKLYN, NY; Project number: 1R44NS147802-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 1492329; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Manufacturing and Analytical Development for JLK-247 Gene Therapy; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 1R44NS147802-01
Ividence Inc.NIH awarded $315K (SBIR Phase I 1R43MH143510-01, new, notice Aug 7, 2026).
Evidence (1 event)
  • Aug 7, 2026 · NIH RePORTER 1R43MH143510-01
    Organization: IVIDENCE INC; City/State: HOCKESSIN, DE; Project number: 1R43MH143510-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 315276; Administering IC: National Institute of Mental Health; Project title: Repurposing Glucagon-Like Peptide-1 Receptor Agonists for Mental Health Outcomes via Federated Causal Inference; Organization type: Domestic For-Profits
Aug 7, 2026NIH RePORTER 1R43MH143510-01
Amelia Technologies LLCNIH awarded $1.04M (SBIR Phase II 1R44ES038434-01, new, notice Jun 23, 2026).
Evidence (1 event)
  • Jun 23, 2026 · NIH RePORTER 1R44ES038434-01
    Organization: AMELIA TECHNOLOGIES, LLC; City/State: WASHINGTON, DC; Project number: 1R44ES038434-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 1037876; Administering IC: National Institute of Environmental Health Sciences; Project title: EcoWell: Smart Incubation Technology for Next-Generation Environmental Science Labs; Organization type: Domestic For-Profits
Jun 23, 2026NIH RePORTER 1R44ES038434-01
Nephropathology Associates, PLCNIH awarded $267K (SBIR Phase I 1R43AI197708-01, new, notice Aug 12, 2026).
Evidence (1 event)
  • Aug 12, 2026 · NIH RePORTER 1R43AI197708-01
    Organization: NEPHROPATHOLOGY ASSOCIATES; City/State: LITTLE ROCK, AR; Project number: 1R43AI197708-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 266613; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Precision Diagnostics in T-cell Mediated Rejection: Predicting Treatment Resistance at Time of Diagnosis; Organization type: Domestic For-Profits
Aug 12, 2026NIH RePORTER 1R43AI197708-01
Vasoptic MedicalNIH awarded $948K (SBIR Phase II 1R44AG099581-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.95M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R44AG099581-01
    Organization: VASOPTIC MEDICAL, INC.; City/State: BALTIMORE, MD; Project number: 1R44AG099581-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 947679; Administering IC: National Institute on Aging; Project title: Noninvasive assessment of neurovascular coupling for early diagnosis of cognitive impairment; Organization type: Domestic For-Profits
  • Aug 19, 2026 · NIH RePORTER 2R44EY032847-02A1
    Organization: VASOPTIC MEDICAL, INC.; City/State: BALTIMORE, MD; Project number: 2R44EY032847-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 999883; Administering IC: National Eye Institute; Project title: Imaging of episcleral venous blood flow for assessment of micro-invasive glaucoma surgery; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG099581-01
North Shore Therapeutics, Inc.NIH awarded $450K (STTR Phase I 1R41MH140642-01A1, new, notice Aug 26, 2026).
Evidence (1 event)
  • Aug 26, 2026 · NIH RePORTER 1R41MH140642-01A1
    Organization: NORTH SHORE THERAPEUTICS, INC.; City/State: Rochester, MN; Project number: 1R41MH140642-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 450020; Administering IC: National Institute of Mental Health; Project title: NST-SPARK: Developing an Augmented Reality (AR) Digital Health Intervention for Negative Symptoms in Schizophrenia; Organization type: Domestic For-Profits
Aug 26, 2026NIH RePORTER 1R41MH140642-01A1
MucommuneNIH awarded $1.16M (SBIR Phase II 1R44HD121291-01, new, notice Sep 17, 2026); 14 NIH awards totaling $11.08M in the last 12 months.
Evidence (14 events)
  • Sep 17, 2026 · NIH RePORTER 1R44HD121291-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1R44HD121291-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1163587; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: IND-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ring; Organization type: Domestic For-Profits
  • Sep 11, 2026 · NIH RePORTER 1R44AI197810-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1R44AI197810-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 1006467; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: SBIR: In vivo engineering of dual CD19/CD138 CAR-T cells for treatment of Systemic Lupus Erythematosus; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1860006; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Preclinical and clinical development of on-demand and sustained non-hormonal contraceptives based on highly multivalent contraceptive antibody; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1441607; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Clinical development of MM011, an instantly dissolving vaginal tablet releasing HCMA for on-demand non-hormonal contraception; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 208837; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Establishing a rhesus macaque post-coital test model to predict clinical efficacy of HCMA contraceptives; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 95436; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Biospecimen Core supporting the preclinical and clinical development of highly multivalent contraceptive antibody (HMCA); Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 82731; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: HMCA-CDRC: Administrative Core; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 31395; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Clinical development of MM012, a vaginal ring releasing HCMA for month-long non-hormonal contraception; Organization type: Domestic For-Profits
  • Sep 4, 2026 · NIH RePORTER 5R44HD118898-02
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44HD118898-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1168977; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception; Organization type: Domestic For-Profits
  • Aug 26, 2026 · NIH RePORTER 5R44CA306674-02
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44CA306674-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 1025819; Administering IC: National Cancer Institute; Project title: SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy; Organization type: Domestic For-Profits
  • Aug 13, 2026 · NIH RePORTER 5R44CA310402-02
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44CA310402-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1146083; Administering IC: National Cancer Institute; Project title: SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma; Organization type: Domestic For-Profits
  • Aug 5, 2026 · NIH RePORTER 5R43AI189008-02
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R43AI189008-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 309210; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis; Organization type: Domestic For-Profits
  • May 26, 2026 · NIH RePORTER 5R44AI192170-02
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44AI192170-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 992780; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis; Organization type: Domestic For-Profits
  • Mar 4, 2026 · NIH RePORTER 4R33HD117428-02
    Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 4R33HD117428-02; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-03-04; FY total cost (award amount): 550000; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44HD121291-01
TrAMPoline PharmaNIH awarded $398K (SBIR Phase I 1R43CA310292-01, new, notice Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · NIH RePORTER 1R43CA310292-01
    Organization: TRAMPOLINE PHARMA, INC.; City/State: AURORA, CO; Project number: 1R43CA310292-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 398039; Administering IC: National Cancer Institute; Project title: Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 1R43CA310292-01
Iaso TherapeuticsNIH awarded $300K (SBIR Phase I 1R43AI197624-01, new, notice Jul 1, 2026).
Evidence (1 event)
  • Jul 1, 2026 · NIH RePORTER 1R43AI197624-01
    Organization: IASO THERAPEUTICS, INC.; City/State: EAST LANSING, MI; Project number: 1R43AI197624-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 299999; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Next generation multi-antigen Staphylococcus aureus vaccine enabled by proprietary mutant bacteriophage Qbeta; Organization type: Domestic For-Profits
Jul 1, 2026NIH RePORTER 1R43AI197624-01
Merakris TherapeuticsNIH awarded $1.11M (SBIR Phase II 1R44DK146625-01, new, notice Jul 17, 2026).
Evidence (1 event)
  • Jul 17, 2026 · NIH RePORTER 1R44DK146625-01
    Organization: MERAKRIS THERAPEUTICS INC; City/State: HILLSBOROUGH, NC; Project number: 1R44DK146625-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1109504; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Evaluation of Efficacy and Safety of MTX-001 in Diabetic Foot Ulcers; Organization type: Domestic For-Profits
Jul 17, 2026NIH RePORTER 1R44DK146625-01
Ramona Optics Inc.NIH awarded $745K (SBIR Phase II 2R44MH133521-03, competing renewal, notice Sep 4, 2026); 2 NIH awards totaling $1.75M in the last 12 months.
Evidence (2 events)
  • Sep 4, 2026 · NIH RePORTER 2R44MH133521-03
    Organization: RAMONA OPTICS, INC.; City/State: DURHAM, NC; Project number: 2R44MH133521-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 745337; Administering IC: National Institute of Mental Health; Project title: A parallelized imaging platform for accurate and efficient long-term assessment of brain organoid development; Organization type: Domestic For-Profits
  • Jul 14, 2026 · NIH RePORTER 5R44CA285197-03
    Organization: RAMONA OPTICS, INC.; City/State: DURHAM, NC; Project number: 5R44CA285197-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 1000000; Administering IC: National Cancer Institute; Project title: A parallelized computational microscope platform for high-throughput live imaging of patient-derived organoids; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 2R44MH133521-03
Triangle BiotechnologyNIH awarded $1M (SBIR commercialization 1SB1AI197360-01, new, notice Jul 20, 2026).
Evidence (1 event)
  • Jul 20, 2026 · NIH RePORTER 1SB1AI197360-01
    Organization: TRIANGLE BIOTECHNOLOGY, INC.; City/State: Chapel Hill, NC; Project number: 1SB1AI197360-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Commercializing nanodroplet technology to improve diagnostic sensitivity for difficult-to-lyse microbial samples; Organization type: Domestic For-Profits
Jul 20, 2026NIH RePORTER 1SB1AI197360-01
Neurexis Therapeutics, Inc.NIH awarded $485K (SBIR Phase I 1R43AG094353-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $723K in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R43AG094353-01A1
    Organization: NEUREXIS THERAPEUTICS, INC.; City/State: AURORA, CO; Project number: 1R43AG094353-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 484929; Administering IC: National Institute on Aging; Project title: Restoring AD-related neuronal dysfunction with a neuroprotective peptide; Organization type: Domestic For-Profits
  • Aug 27, 2026 · NIH RePORTER 5R44NS120427-04
    Organization: NEUREXIS THERAPEUTICS, INC.; City/State: AURORA, CO; Project number: 5R44NS120427-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 238126; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: IND-enabling studies for a potent and efficient neuroprotective drug; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG094353-01A1
PrenosisNIH awarded $1.22M (SBIR Phase II 1R44HL180159-01A1, new, notice Aug 21, 2026).
Evidence (1 event)
  • Aug 21, 2026 · NIH RePORTER 1R44HL180159-01A1
    Organization: PRENOSIS, INC.; City/State: CHAMPAIGN, IL; Project number: 1R44HL180159-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1218102; Administering IC: National Heart Lung and Blood Institute; Project title: Derivation and Validation of the Heart Failure CardioScore: an AI Diagnostic for HeartFailure using Novel Biomarkers and Clinical Data; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 1R44HL180159-01A1
Giner Inc.NIH awarded $591K (SBIR Phase I 1R43HL184803-01, new, notice Sep 1, 2026); 2 NIH awards totaling $1.6M in the last 12 months.
Evidence (2 events)
  • Sep 1, 2026 · NIH RePORTER 1R43HL184803-01
    Organization: GINER, INC.; City/State: NEWTON, MA; Project number: 1R43HL184803-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 591499; Administering IC: National Heart Lung and Blood Institute; Project title: Asthma Management by Monitoring Nitric Oxide (NO) Levels in Exhaled Breath; Organization type: Domestic For-Profits
  • Aug 31, 2026 · NIH RePORTER 5R44ES033890-03
    Organization: GINER, INC.; City/State: NEWTON, MA; Project number: 5R44ES033890-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1003898; Administering IC: National Institute of Environmental Health Sciences; Project title: Low-Cost Amperometric Ozone Monitor for Communities Affected by Wildfires; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R43HL184803-01
Limax BiosciencesNIH awarded $1.05M (SBIR Phase II 1R44HL184761-01, new, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 1R44HL184761-01
    Organization: LIMAX BIOSCIENCES INC; City/State: SOMERVILLE, MA; Project number: 1R44HL184761-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1047908; Administering IC: National Heart Lung and Blood Institute; Project title: Advanced Hemostatic Adhesive Hydrogel System for Postpartum Hemorrhage Control; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 1R44HL184761-01
Innovative Design Labs Inc.NIH awarded $1.05M (SBIR Phase II 5R44GM161237-02, continuation, notice Aug 31, 2026); 6 NIH awards totaling $5.9M in the last 12 months.
Evidence (6 events)
  • Aug 31, 2026 · NIH RePORTER 5R44GM161237-02
    Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44GM161237-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1047458; Administering IC: National Institute of General Medical Sciences; Project title: PhysioSim: Innovative Physiology Simulation Education Kits for Pre-College Students and Teachers; Organization type: Domestic For-Profits
  • Aug 21, 2026 · NIH RePORTER 1R44HL186085-01
    Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 1R44HL186085-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1020633; Administering IC: National Heart Lung and Blood Institute; Project title: Improving the Training of CPR and AED Interventions to Real World Characteristics; Organization type: Domestic For-Profits
  • Aug 18, 2026 · NIH RePORTER 1R43AI197687-01
    Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 1R43AI197687-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 313110; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Automated Skill Assessment of Sterile Procedures; Organization type: Domestic For-Profits
  • Jul 10, 2026 · NIH RePORTER 5R44AG060779-05
    Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44AG060779-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1508825; Administering IC: National Institute on Aging; Project title: Non-Contact Point of Care Device for Sleep Studies; Organization type: Domestic For-Profits
  • Jul 10, 2026 · NIH RePORTER 5R44AG063679-04
    Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44AG063679-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 962408; Administering IC: National Institute on Aging; Project title: A Gait and Path Tortuosity System for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD); Organization type: Domestic For-Profits
  • Jun 12, 2026 · NIH RePORTER 5R44MD020606-02
    Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44MD020606-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-12; FY total cost (award amount): 1048499; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Addressing Challenges in Peripheral Intravenous Catheter Education; Organization type: Domestic For-Profits
Aug 31, 2026NIH RePORTER 5R44GM161237-02
Stem PharmNIH awarded $971K (SBIR Phase II 2R44AG082625-02, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44AG082625-02
    Organization: STEM PHARM, INC.; City/State: MADISON, WI; Project number: 2R44AG082625-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 971368; Administering IC: National Institute on Aging; Project title: Alzheimer's Disease Drug Discovery Using a Human Organoid Model of Neuroinflammation; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44AG082625-02
Abterra BiosciencesNIH awarded $307K (SBIR Phase I 1R43AI197772-01, new, notice Aug 17, 2026).
Evidence (1 event)
  • Aug 17, 2026 · NIH RePORTER 1R43AI197772-01
    Organization: ABTERRA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R43AI197772-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 306555; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A platform for serum antibody repertoire analysis for autoimmune disease diagnosis; Organization type: Domestic For-Profits
Aug 17, 2026NIH RePORTER 1R43AI197772-01
ProteovistaNIH awarded $286K (SBIR Phase I 1R43GM165210-01, new, notice Sep 16, 2026); 2 NIH awards totaling $592K in the last 12 months.
Evidence (2 events)
  • Sep 16, 2026 · NIH RePORTER 1R43GM165210-01
    Organization: PROTEOVISTA, LLC; City/State: MADISON, WI; Project number: 1R43GM165210-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 286118; Administering IC: National Institute of General Medical Sciences; Project title: Development of the High-Density SNAP-Dimer Microarray for Functional Analysis of Dimeric Protein Complexes; Organization type: Domestic For-Profits
  • Jun 5, 2026 · NIH RePORTER 1R43GM163471-01
    Organization: PROTEOVISTA, LLC; City/State: MADISON, WI; Project number: 1R43GM163471-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-05; FY total cost (award amount): 306151; Administering IC: National Institute of General Medical Sciences; Project title: Development of ClusterBuild to Synthesize Biosynthetic Gene Clusters; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R43GM165210-01
Creosalus Inc.NIH awarded $314K (STTR Phase I 1R41EB038861-01, new, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 1R41EB038861-01
    Organization: CREOSALUS, INC.; City/State: LOUISVILLE, KY; Project number: 1R41EB038861-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 314359; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: Point of Care Differential Scanning Calorimetry; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 1R41EB038861-01
HesperosNIH awarded $1M (SBIR Phase II 1R44AI197758-01, new, notice Aug 28, 2026); 3 NIH awards totaling $3.22M in the last 12 months.
Evidence (3 events)
  • Aug 28, 2026 · NIH RePORTER 1R44AI197758-01
    Organization: HESPEROS, INC; City/State: ORLANDO, FL; Project number: 1R44AI197758-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Expanded implementation of a human-based Malaria-on-a-Chip phenotypic disease model for the evaluation of therapeutic efficacy and off-target toxicity; Organization type: Domestic For-Profits
  • Jul 21, 2026 · NIH RePORTER 2R44TR004811-03
    Organization: HESPEROS, INC; City/State: ORLANDO, FL; Project number: 2R44TR004811-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 720882; Administering IC: National Center for Advancing Translational Sciences; Project title: Human Neuromuscular Junction Platform to Evaluate Botulinum Toxin Potency; Organization type: Domestic For-Profits
  • May 12, 2026 · NIH RePORTER 5R44AG071386-04
    Organization: HESPEROS, INC; City/State: ORLANDO, FL; Project number: 5R44AG071386-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1499996; Administering IC: National Institute on Aging; Project title: Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 1R44AI197758-01
Javelin Biotech Inc.NIH awarded $350K (SBIR Phase I 1R43TR005374-01A1, new, notice Jun 16, 2026).
Evidence (1 event)
  • Jun 16, 2026 · NIH RePORTER 1R43TR005374-01A1
    Organization: JAVELIN BIOTECH; City/State: Billerica, MA; Project number: 1R43TR005374-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 349677; Administering IC: National Center for Advancing Translational Sciences; Project title: Investigating the Impact of Metabolic Disease States on the Pharmacodynamics and Toxicity of FDA-Approved Antisense Oligonucleotides Using an Integrated Liver-Kidney Model; Organization type: Domestic For-Profits
Jun 16, 2026NIH RePORTER 1R43TR005374-01A1
Amissa Inc.NIH awarded $313K (SBIR Phase I 1R43AG099614-01, new, notice Sep 17, 2026); 2 NIH awards totaling $817K in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R43AG099614-01
    Organization: AMISSA, INC.; City/State: Charlotte, NC; Project number: 1R43AG099614-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 313211; Administering IC: National Institute on Aging; Project title: SMART-HRT: Smartwatch-Based Monitoring and Real-Time Tracking for Optimizing Hormone Replacement Therapy Efficacy in Menopause.; Organization type: Domestic For-Profits
  • Aug 19, 2026 · NIH RePORTER 1R43MD021449-01
    Organization: AMISSA, INC.; City/State: Charlotte, NC; Project number: 1R43MD021449-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 504222; Administering IC: National Institute on Minority Health and Health Disparities; Project title: HERMOSA: Understanding the Perimenopausal Health Experience of Latina Women Using Digital Biomarkers from Apple Watch.; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG099614-01
Xyone TherapeuticsNIH awarded $396K (SBIR Phase I 1R43AG099628-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43AG099628-01
    Organization: XYONE THERAPEUTICS INC.; City/State: WESTON, MA; Project number: 1R43AG099628-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 396322; Administering IC: National Institute on Aging; Project title: Development and Performance Evaluation of a TruE2 Diagnostic Algorithm for Free Estradiol; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG099628-01
Trace BiosciencesNIH awarded $449K (SBIR Phase II 1R44NS147800-01, new, notice Sep 3, 2026).
Evidence (1 event)
  • Sep 3, 2026 · NIH RePORTER 1R44NS147800-01
    Organization: TRACE BIOSCIENCES INC; City/State: Beaverton, OR; Project number: 1R44NS147800-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 448711; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Molecular Imaging of Peripheral and Central Nervous System Myelin; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 1R44NS147800-01
Aldatu BiosciencesNIH awarded $997K (SBIR Phase II 2R44AI172551-04, competing renewal, notice Sep 2, 2026); 2 NIH awards totaling $1.96M in the last 12 months.
Evidence (2 events)
  • Sep 2, 2026 · NIH RePORTER 2R44AI172551-04
    Organization: ALDATU BIOSCIENCES, INC.; City/State: Watertown, MA; Project number: 2R44AI172551-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 996962; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.; Organization type: Domestic For-Profits
  • Jul 30, 2026 · NIH RePORTER 5R44AI157650-05
    Organization: ALDATU BIOSCIENCES, INC.; City/State: Watertown, MA; Project number: 5R44AI157650-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 960045; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 2R44AI172551-04
Sinopia BiosciencesNIH awarded $1.48M (SBIR Phase II 2R44GM154585-02, competing renewal, notice Sep 10, 2026); 3 NIH awards totaling $4.59M in the last 12 months.
Evidence (3 events)
  • Sep 10, 2026 · NIH RePORTER 2R44GM154585-02
    Organization: SINOPIA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 2R44GM154585-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1477110; Administering IC: National Institute of General Medical Sciences; Project title: Development and Validation of Data Standards and Computational Methods for Large Scale Metabolomics Data Analysis for Data Driven Drug Discovery; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 2R44NS124398-04A1
    Organization: SINOPIA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 2R44NS124398-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 3000000; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical development of a novel therapeutic for Parkinson's disease; Organization type: Domestic For-Profits
  • Aug 10, 2026 · NIH RePORTER 5R43CA295316-02
    Organization: SINOPIA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 5R43CA295316-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 114274; Administering IC: National Cancer Institute; Project title: Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancer; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 2R44GM154585-02
Cellchorus Inc.NIH awarded $999K (SBIR commercialization 1SB1GM163323-01, new, notice Sep 14, 2026); 3 NIH awards totaling $3.05M in the last 12 months.
Evidence (3 events)
  • Sep 14, 2026 · NIH RePORTER 1SB1GM163323-01
    Organization: CELLCHORUS INC.; City/State: Houston, TX; Project number: 1SB1GM163323-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 998873; Administering IC: National Institute of General Medical Sciences; Project title: Dynamic single-cell analysis instrument commercial readiness (CRP); Organization type: Domestic For-Profits
  • Jul 21, 2026 · NIH RePORTER 5R42TR005299-03
    Organization: CELLCHORUS INC.; City/State: Houston, TX; Project number: 5R42TR005299-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 1021147; Administering IC: National Center for Advancing Translational Sciences; Project title: LF-TIMING: Large-scale label-free profiling of cell-cell interactions; Organization type: Domestic For-Profits
  • Jun 8, 2026 · NIH RePORTER 5R44TR005137-03
    Organization: CELLCHORUS INC.; City/State: Houston, TX; Project number: 5R44TR005137-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-08; FY total cost (award amount): 1034752; Administering IC: National Center for Advancing Translational Sciences; Project title: Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 1SB1GM163323-01
Infixion Bioscience Inc.NIH awarded $479K (SBIR Phase I 1R43NS147645-01, new, notice Aug 26, 2026).
Evidence (1 event)
  • Aug 26, 2026 · NIH RePORTER 1R43NS147645-01
    Organization: INFIXION BIOSCIENCE, INC.; City/State: ESCONDIDO, CA; Project number: 1R43NS147645-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 478799; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Selection of a Lead Candidate for the Development of an ASO Therapeutic for NF1 Cognitive and Social Deficits; Organization type: Domestic For-Profits
Aug 26, 2026NIH RePORTER 1R43NS147645-01
PopCheck TechnologiesNIH awarded $391K (SBIR Phase I 1R43HL184749-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43HL184749-01
    Organization: POPCHECK TECHNOLOGIES INC; City/State: MEMPHIS, TN; Project number: 1R43HL184749-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 390966; Administering IC: National Heart Lung and Blood Institute; Project title: A Non-invasive Wearable Device for Monitoring and Predicting the Development of Venous Clots; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43HL184749-01
Integrated Medical SensorsNIH awarded $923K (SBIR Phase II 1R44DK146647-01, new, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 1R44DK146647-01
    Organization: INTEGRATED MEDICAL SENSORS; City/State: IRVINE, CA; Project number: 1R44DK146647-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 922875; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Miniaturized and Flexible Continuous Glucose Monitoring Platform using Scalable Semiconductor Manufacturing; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 1R44DK146647-01
Monod BioNIH awarded $377K (SBIR Phase II 1R44GM161195-01A1, new, notice Aug 3, 2026); 2 NIH awards totaling $708K in the last 12 months.
Evidence (2 events)
  • Aug 3, 2026 · NIH RePORTER 1R44GM161195-01A1
    Organization: MONOD BIO, INC.; City/State: SEATTLE, WA; Project number: 1R44GM161195-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 377260; Administering IC: National Institute of General Medical Sciences; Project title: Design of rapid and quantitative biosensors with computational protein design; Organization type: Domestic For-Profits
  • Jul 23, 2026 · NIH RePORTER 1R43GM163512-01
    Organization: MONOD BIO, INC.; City/State: SEATTLE, WA; Project number: 1R43GM163512-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 330955; Administering IC: National Institute of General Medical Sciences; Project title: Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents; Organization type: Domestic For-Profits
Aug 3, 2026NIH RePORTER 1R44GM161195-01A1
Unandup, LLCNIH awarded $406K (SBIR Phase I 1R43CA310649-01, new, notice Sep 1, 2026); 2 NIH awards totaling $695K in the last 12 months.
Evidence (2 events)
  • Sep 1, 2026 · NIH RePORTER 1R43CA310649-01
    Organization: UNANDUP, LLC; City/State: SAINT LOUIS, MO; Project number: 1R43CA310649-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 405753; Administering IC: National Cancer Institute; Project title: Improved Magnetomotive Embolization for Hepatocellular Carcinoma; Organization type: Domestic For-Profits
  • May 12, 2026 · NIH RePORTER 5R43HL178364-02
    Organization: UNANDUP, LLC; City/State: SAINT LOUIS, MO; Project number: 5R43HL178364-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 289177; Administering IC: National Heart Lung and Blood Institute; Project title: Magnetic Rotational Platform for Coronary Lesions; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R43CA310649-01
Primrose BioNIH awarded $952K (SBIR Phase II 1R44TR006096-01, new, notice Jul 8, 2026).
Evidence (1 event)
  • Jul 8, 2026 · NIH RePORTER 1R44TR006096-01
    Organization: PRIMROSE BIO, INC.; City/State: SAN DIEGO, CA; Project number: 1R44TR006096-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 951630; Administering IC: National Center for Advancing Translational Sciences; Project title: Enhanced nucleic acid therapeutics: synthetic sequence elements for boosting protein expression in genetic medicines; Organization type: Domestic For-Profits
Jul 8, 2026NIH RePORTER 1R44TR006096-01
Makani ScienceNIH awarded $363K (NIH grant 5R61HL177500-02, continuation, notice May 7, 2026).
Evidence (1 event)
  • May 7, 2026 · NIH RePORTER 5R61HL177500-02
    Organization: MAKANI SCIENCE, INC.; City/State: IRVINE, CA; Project number: 5R61HL177500-02; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 362934; Administering IC: National Heart Lung and Blood Institute; Project title: Continuous Respiratory Monitoring Platform for Classifying Apnea of Prematurity; Organization type: Domestic For-Profits
May 7, 2026NIH RePORTER 5R61HL177500-02
Accelevir Diagnostics LLCNIH awarded $532K (NIH grant 3R24AI143502-07S1, supplement, notice Sep 17, 2026); 2 NIH awards totaling $1.3M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 3R24AI143502-07S1
    Organization: ACCELEVIR DIAGNOSTICS, LLC; City/State: BALTIMORE, MD; Project number: 3R24AI143502-07S1; Activity code: R24; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 531874; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirs; Organization type: Domestic For-Profits
  • May 14, 2026 · NIH RePORTER 5R24AI143502-07
    Organization: ACCELEVIR DIAGNOSTICS, LLC; City/State: BALTIMORE, MD; Project number: 5R24AI143502-07; Activity code: R24; Fiscal year: 2026; Award notice date: 2026-05-14; FY total cost (award amount): 764899; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirs; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 3R24AI143502-07S1
Link Biosystems Inc.NIH awarded $781K (SBIR Phase II 5R44CA281356-03, continuation, notice Jul 7, 2026).
Evidence (1 event)
  • Jul 7, 2026 · NIH RePORTER 5R44CA281356-03
    Organization: LINK BIOSYSTEMS INC.; City/State: IRVINGTON, NY; Project number: 5R44CA281356-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 780952; Administering IC: National Cancer Institute; Project title: CELL EXPANSION BIOREACTORS FOR ASSAY-READY IMMUNOCOMPETENT PATIENT MODELS; Organization type: Domestic For-Profits
Jul 7, 2026NIH RePORTER 5R44CA281356-03
Endomet Biosciences, Inc.NIH awarded $2.05M (SBIR commercialization 5SB1HD118921-02, continuation, notice May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · NIH RePORTER 5SB1HD118921-02
    Organization: ENDOMET BIOSCIENCES, INC; City/State: Irvine, CA; Project number: 5SB1HD118921-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 2045762; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Novel, Non-hormonal Therapeutic for Endometriosis; Organization type: Domestic For-Profits
May 12, 2026NIH RePORTER 5SB1HD118921-02
Biosensing Instrument Inc.NIH awarded $921K (STTR Phase II 5R42GM154550-03, continuation, notice Jul 22, 2026); 2 NIH awards totaling $1.73M in the last 12 months.
Evidence (2 events)
  • Jul 22, 2026 · NIH RePORTER 5R42GM154550-03
    Organization: BIOSENSING INSTRUMENT, INC.; City/State: TEMPE, AZ; Project number: 5R42GM154550-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 920788; Administering IC: National Institute of General Medical Sciences; Project title: Plasmonic Scattering Microscopy for high-throughput in-situ quantification of molecular binding kinetics on single cells; Organization type: Domestic For-Profits
  • Jul 20, 2026 · NIH RePORTER 4R42GM157918-02
    Organization: BIOSENSING INSTRUMENT, INC.; City/State: TEMPE, AZ; Project number: 4R42GM157918-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 807496; Administering IC: National Institute of General Medical Sciences; Project title: Spotting-free Nano-Oscillator Array for Quantification of Virion Displayed Membrane Protein Binding Kinetics; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 5R42GM154550-03
IRIS Media IncNIH awarded $789K (SBIR Phase II 5R44HD111084-03, continuation, notice May 25, 2026).
Evidence (1 event)
  • May 25, 2026 · NIH RePORTER 5R44HD111084-03
    Organization: IRIS MEDIA, INC.; City/State: EUGENE, OR; Project number: 5R44HD111084-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 789175; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Promoting Parallel Parenting: Putting Children First during High-Conflict Divorce and Separation (PCF); Organization type: Domestic For-Profits
May 25, 2026NIH RePORTER 5R44HD111084-03
Allander BiotechnologiesNIH awarded $1.21M (SBIR Phase II 1R44DE034643-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $2.28M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R44DE034643-01A1
    Organization: ALLANDER BIOTECHNOLOGIES, INC.; City/State: AURORA, CO; Project number: 1R44DE034643-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1210798; Administering IC: National Institute of Dental and Craniofacial Research; Project title: cGMP manufacturing the clinical batch of oral gel drug for treating oral mucositis in cancer patients; Organization type: Domestic For-Profits
  • Sep 14, 2026 · NIH RePORTER 5R44CA310522-02
    Organization: ALLANDER BIOTECHNOLOGIES, INC.; City/State: AURORA, CO; Project number: 5R44CA310522-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1066148; Administering IC: National Cancer Institute; Project title: First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44DE034643-01A1
Nextgenjane Inc.NIH awarded $714K (SBIR Phase II 5R44HD118899-02, continuation, notice May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · NIH RePORTER 5R44HD118899-02
    Organization: NEXTGENJANE, INC.; City/State: Oakland, CA; Project number: 5R44HD118899-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 714095; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Performance evaluation of a non-invasive menstrual test for endometriosis in infertility patients; Organization type: Domestic For-Profits
May 12, 2026NIH RePORTER 5R44HD118899-02
SensydiaNIH awarded $816K (STTR Phase II 5R42HL167342-03, continuation, notice May 13, 2026).
Evidence (1 event)
  • May 13, 2026 · NIH RePORTER 5R42HL167342-03
    Organization: SENSYDIA CORPORATION; City/State: LOS ANGELES, CA; Project number: 5R42HL167342-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 816106; Administering IC: National Heart Lung and Blood Institute; Project title: A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension; Organization type: Domestic For-Profits
May 13, 2026NIH RePORTER 5R42HL167342-03
Covira SurgicalNIH awarded $1M (STTR Phase II 5R42AI174369-03, continuation, notice May 26, 2026).
Evidence (1 event)
  • May 26, 2026 · NIH RePORTER 5R42AI174369-03
    Organization: COVIRA SURGICAL; City/State: NORTH CHICAGO, IL; Project number: 5R42AI174369-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection; Organization type: Domestic For-Profits
May 26, 2026NIH RePORTER 5R42AI174369-03
Akyso TherapeuticsNIH awarded $2.93M (NIH grant 5UG3DA062511-02, continuation, notice Aug 4, 2026); 2 NIH awards totaling $5.65M in the last 12 months.
Evidence (2 events)
  • Aug 4, 2026 · NIH RePORTER 5UG3DA062511-02
    Organization: AKYSO THERAPEUTICS, LLC; City/State: SALISBURY, MD; Project number: 5UG3DA062511-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 2932500; Administering IC: National Institute on Drug Abuse; Project title: Development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for opioid use disorder; Organization type: Domestic For-Profits
  • Jun 11, 2026 · NIH RePORTER 5UH3DA048338-05
    Organization: AKYSO THERAPEUTICS, LLC; City/State: SALISBURY, MD; Project number: 5UH3DA048338-05; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 2715203; Administering IC: National Institute on Drug Abuse; Project title: A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder; Organization type: Domestic For-Profits
Aug 4, 2026NIH RePORTER 5UG3DA062511-02
ProThera BiologicsNIH awarded $954K (SBIR Phase II 5R44AI141283-06, continuation, notice May 13, 2026).
Evidence (1 event)
  • May 13, 2026 · NIH RePORTER 5R44AI141283-06
    Organization: PROTHERA BIOLOGICS, LLC; City/State: PROVIDENCE, RI; Project number: 5R44AI141283-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 954189; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis; Organization type: Domestic For-Profits
May 13, 2026NIH RePORTER 5R44AI141283-06
Nanoscope TechnologiesNIH awarded $786K (NIH grant 5U01EY035026-03, continuation, notice May 13, 2026).
Evidence (1 event)
  • May 13, 2026 · NIH RePORTER 5U01EY035026-03
    Organization: NANOSCOPE TECHNOLOGIES, LLC; City/State: ARLINGTON, TX; Project number: 5U01EY035026-03; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 785718; Administering IC: National Eye Institute; Project title: Sonogenetic Restoration of Vision for Retinitis Pigmentosa; Organization type: Domestic For-Profits
May 13, 2026NIH RePORTER 5U01EY035026-03
Progentec DiagnosticsNIH awarded $895K (SBIR commercialization 5SB1AI184309-03, continuation, notice Jun 12, 2026).
Evidence (1 event)
  • Jun 12, 2026 · NIH RePORTER 5SB1AI184309-03
    Organization: PROGENTEC DIAGNOSTICS, INC.; City/State: Oklahoma City, OK; Project number: 5SB1AI184309-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-12; FY total cost (award amount): 895140; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Commercialization Readiness of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE); Organization type: Domestic For-Profits
Jun 12, 2026NIH RePORTER 5SB1AI184309-03
GMJ Technologies, Inc.NIH awarded $902K (SBIR Phase II 5R44GM156142-03, continuation, notice May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · NIH RePORTER 5R44GM156142-03
    Organization: GMJ TECHNOLOGIES, INC.; City/State: EVERETT, WA; Project number: 5R44GM156142-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 902099; Administering IC: National Institute of General Medical Sciences; Project title: High-Resolution Native Capillary Zone Electrophoresis with Inline UV and Native Mass Spectrometry for Characterizing Charge Variants in Biologics; Organization type: Domestic For-Profits
May 12, 2026NIH RePORTER 5R44GM156142-03
Thymmune TherapeuticsNIH awarded $1M (SBIR Phase II 5R44AI170266-05, continuation, notice Jun 5, 2026).
Evidence (1 event)
  • Jun 5, 2026 · NIH RePORTER 5R44AI170266-05
    Organization: THYMMUNE THERAPEUTICS, INC; City/State: CAMBRIDGE, MA; Project number: 5R44AI170266-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-05; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a stem-cell derived thymic cell therapy to treat patients with athymia; Organization type: Domestic For-Profits
Jun 5, 2026NIH RePORTER 5R44AI170266-05
Axonova MedicalNIH awarded $903K (SBIR Phase II 5R44NS125892-04, continuation, notice Jun 11, 2026).
Evidence (1 event)
  • Jun 11, 2026 · NIH RePORTER 5R44NS125892-04
    Organization: AXONOVA MEDICAL, LLC; City/State: PHILADELPHIA, PA; Project number: 5R44NS125892-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 902542; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons; Organization type: Domestic For-Profits
Jun 11, 2026NIH RePORTER 5R44NS125892-04
Moonlight Therapeutics, Inc.NIH awarded $1M (SBIR Phase II 5U44AI165328-03, continuation, notice Jun 8, 2026); 2 NIH awards totaling $2M in the last 12 months.
Evidence (2 events)
  • Jun 8, 2026 · NIH RePORTER 5U44AI165328-03
    Organization: MOONLIGHT THERAPEUTICS, INC.; City/State: Marietta, GA; Project number: 5U44AI165328-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-06-08; FY total cost (award amount): 999927; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy; Organization type: Domestic For-Profits
  • May 28, 2026 · NIH RePORTER 5SB1AI184000-03
    Organization: MOONLIGHT THERAPEUTICS, INC.; City/State: Marietta, GA; Project number: 5SB1AI184000-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-28; FY total cost (award amount): 999380; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Scale-up manufacturing of microneedle stamp for peanut allergen immunotherapy; Organization type: Domestic For-Profits
Jun 8, 2026NIH RePORTER 5U44AI165328-03
Jacaranda Biosciences, Inc.NIH awarded $1.44M (SBIR Phase II 5R44DC020069-03, continuation, notice Jul 16, 2026).
Evidence (1 event)
  • Jul 16, 2026 · NIH RePORTER 5R44DC020069-03
    Organization: JACARANDA BIOSCIENCES, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44DC020069-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 1436795; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: eiF2B Activators to Treat Noise-Induced Hearing Loss; Organization type: Domestic For-Profits
Jul 16, 2026NIH RePORTER 5R44DC020069-03
3DT Holdings, LLCNIH awarded $1.05M (SBIR Phase II 5R44HL169034-03, continuation, notice Jun 9, 2026).
Evidence (1 event)
  • Jun 9, 2026 · NIH RePORTER 5R44HL169034-03
    Organization: 3DT HOLDINGS, LLC; City/State: SAN DIEGO, CA; Project number: 5R44HL169034-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1050048; Administering IC: National Heart Lung and Blood Institute; Project title: Software-guided Operative Planning of MitraClip Placement; Organization type: Domestic For-Profits
Jun 9, 2026NIH RePORTER 5R44HL169034-03
Insilica LLCNIH awarded $1.01M (SBIR Phase II 5R44ES035359-03, continuation, notice May 11, 2026).
Evidence (1 event)
  • May 11, 2026 · NIH RePORTER 5R44ES035359-03
    Organization: INSILICA, LLC; City/State: Bethesda, MD; Project number: 5R44ES035359-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 1005398; Administering IC: National Institute of Environmental Health Sciences; Project title: srvc-EHSR: Sysrev Version Control - Environmental and Health Related Systematic Reviews; Organization type: Domestic For-Profits
May 11, 2026NIH RePORTER 5R44ES035359-03
Microsurgical Innovations IncNIH awarded $1.01M (STTR Phase II 5R42NS112066-03, continuation, notice May 19, 2026).
Evidence (1 event)
  • May 19, 2026 · NIH RePORTER 5R42NS112066-03
    Organization: MICROSURGICAL INNOVATIONS, INC.; City/State: SALT LAKE CITY, UT; Project number: 5R42NS112066-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1005546; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries; Organization type: Domestic For-Profits
May 19, 2026NIH RePORTER 5R42NS112066-03
MicroCures Inc.NIH awarded $236K (STTR Phase I 5R41NS137941-02, continuation, notice May 18, 2026).
Evidence (1 event)
  • May 18, 2026 · NIH RePORTER 5R41NS137941-02
    Organization: MICROCURES, INC.; City/State: SANTA CRUZ, CA; Project number: 5R41NS137941-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 235898; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2.; Organization type: Domestic For-Profits
May 18, 2026NIH RePORTER 5R41NS137941-02
Hepatx CorporationNIH awarded $149K (SBIR Phase I 5R43DK139879-02, continuation, notice Jun 23, 2026).
Evidence (1 event)
  • Jun 23, 2026 · NIH RePORTER 5R43DK139879-02
    Organization: HEPATX CORPORATION; City/State: PALO ALTO, CA; Project number: 5R43DK139879-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 149068; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a proteomic assay for monitoring transplanted cells and tissues; Organization type: Domestic For-Profits
Jun 23, 2026NIH RePORTER 5R43DK139879-02
Belay Diagnostics, LLCNIH awarded $919K (STTR Phase II 5R42NS135834-03, continuation, notice Jul 15, 2026); 1 role open.
Evidence (1 event)
  • Jul 15, 2026 · NIH RePORTER 5R42NS135834-03
    Organization: BELAY DIAGNOSTICS, LLC; City/State: Chicago, IL; Project number: 5R42NS135834-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-15; FY total cost (award amount): 919093; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Multi-omic CSF Assay for the Diagnosis of Brain Cancers; Organization type: Domestic For-Profits
Jul 15, 2026NIH RePORTER 5R42NS135834-03
POP Biotechnologies Inc.NIH awarded $310K (STTR Phase I 1R41HL184798-01A1, new, notice Jul 31, 2026); 3 NIH awards totaling $2.08M in the last 12 months.
Evidence (3 events)
  • Jul 31, 2026 · NIH RePORTER 1R41HL184798-01A1
    Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 1R41HL184798-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 309794; Administering IC: National Heart Lung and Blood Institute; Project title: Liposome-displayed ApoB fragment for active immunotherapy against atherosclerosis; Organization type: Domestic For-Profits
  • Jun 26, 2026 · NIH RePORTER 5R44AI181479-03
    Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 5R44AI181479-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 948983; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment; Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5R42AG082620-04
    Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 5R42AG082620-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 822289; Administering IC: National Institute on Aging; Project title: Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes; Organization type: Domestic For-Profits
Jul 31, 2026NIH RePORTER 1R41HL184798-01A1
Noctrix Health, Inc.NIH awarded $1.32M (SBIR Phase II 5R44NS117294-05, continuation, notice May 19, 2026); since then posted 11 roles.
Evidence (1 event)
  • May 19, 2026 · NIH RePORTER 5R44NS117294-05
    Organization: NOCTRIX HEALTH, INC; City/State: Pleasanton, CA; Project number: 5R44NS117294-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1324304; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome; Organization type: Domestic For-Profits
May 19, 2026NIH RePORTER 5R44NS117294-05
Turing MedicalNIH awarded $1.25M (SBIR Phase II 4R44AG097349-02, extension, notice Aug 27, 2026); 2 NIH awards totaling $2.59M in the last 12 months.
Evidence (2 events)
  • Aug 27, 2026 · NIH RePORTER 4R44AG097349-02
    Organization: TURING MEDICAL TECHNOLOGIES INC; City/State: SAINT LOUIS, MO; Project number: 4R44AG097349-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1245404; Administering IC: National Institute on Aging; Project title: Real-time head motion monitoring for all clinical MR sequences using Universal FIRMM; Organization type: Domestic For-Profits
  • Jun 9, 2026 · NIH RePORTER 5SB1MH135555-03
    Organization: TURING MEDICAL TECHNOLOGIES INC; City/State: SAINT LOUIS, MO; Project number: 5SB1MH135555-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1346397; Administering IC: National Institute of Mental Health; Project title: Commercialization readiness of motion-robust brain MRI for pediatric healthcare; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 4R44AG097349-02
Spike Neuro LLCNIH awarded $1.69M (SBIR Phase II 1R44NS145912-01A1, new, notice Sep 18, 2026); 2 NIH awards totaling $1.87M in the last 12 months.
Evidence (2 events)
  • Sep 18, 2026 · NIH RePORTER 1R44NS145912-01A1
    Organization: SPIKE NEURO LLC; City/State: ANN ARBOR, MI; Project number: 1R44NS145912-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 1693866; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Advancing High-Density Carbon Fiber Electrode Arrays for Commercial Neurotechnology Applications; Organization type: Domestic For-Profits
  • Aug 18, 2026 · NIH RePORTER 5R41MH141906-02
    Organization: SPIKE NEURO LLC; City/State: ANN ARBOR, MI; Project number: 5R41MH141906-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 173801; Administering IC: National Institute of Mental Health; Project title: The development of a flexible carbon fiber penetrating nerve cuff and cortical array for neural recording, stimulation, and neurochemical detection; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 1R44NS145912-01A1
MyoGene BioNIH awarded $498K (SBIR commercialization 5SB1AR084953-02, continuation, notice Jul 9, 2026); 2 NIH awards totaling $1.48M in the last 12 months.
Evidence (2 events)
  • Jul 9, 2026 · NIH RePORTER 5SB1AR084953-02
    Organization: MYOGENE BIO, LLC; City/State: San Diego, CA; Project number: 5SB1AR084953-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-09; FY total cost (award amount): 498365; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy; Organization type: Domestic For-Profits
  • May 13, 2026 · NIH RePORTER 5R44NS141438-05
    Organization: MYOGENE BIO, LLC; City/State: San Diego, CA; Project number: 5R44NS141438-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 978397; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy; Organization type: Domestic For-Profits
Jul 9, 2026NIH RePORTER 5SB1AR084953-02
Sur180 Therapeutics, Inc.NIH awarded $1.14M (SBIR Phase II 5R44HD109055-03, continuation, notice Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · NIH RePORTER 5R44HD109055-03
    Organization: SUR180 THERAPEUTICS, LLC; City/State: MCALLEN, TX; Project number: 5R44HD109055-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1140501; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Phase II- Repurposing CRH antagonists for the treatment of endometriosis; Organization type: Domestic For-Profits
Jun 3, 2026NIH RePORTER 5R44HD109055-03
RareCyteNIH awarded $658K (SBIR Phase II 5R44CA298064-02, continuation, notice Jul 17, 2026).
Evidence (1 event)
  • Jul 17, 2026 · NIH RePORTER 5R44CA298064-02
    Organization: RARECYTE, INC.; City/State: SEATTLE, WA; Project number: 5R44CA298064-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 658336; Administering IC: National Cancer Institute; Project title: Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis; Organization type: Domestic For-Profits
Jul 17, 2026NIH RePORTER 5R44CA298064-02
Allvivo VascularNIH awarded $1M (SBIR Phase II 5R44AI136195-06, continuation, notice Jul 16, 2026).
Evidence (1 event)
  • Jul 16, 2026 · NIH RePORTER 5R44AI136195-06
    Organization: ALLVIVO VASCULAR, INC.; City/State: LAKE FOREST, CA; Project number: 5R44AI136195-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 999999; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Antimicrobial Treatment to Combat Wound Biofilm; Organization type: Domestic For-Profits
Jul 16, 2026NIH RePORTER 5R44AI136195-06
Stress Therapeutics, Inc.NIH awarded $995K (SBIR Phase I 5U43AA032129-02, continuation, notice May 18, 2026).
Evidence (1 event)
  • May 18, 2026 · NIH RePORTER 5U43AA032129-02
    Organization: STRESS THERAPEUTICS, INC.; City/State: SAN DIEGO, CA; Project number: 5U43AA032129-02; Activity code: U43; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 995447; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Investigational New Drug (IND)-enabling Study for a New Therapeutic for Alcohol Use Disorder (AUD); Organization type: Domestic For-Profits
May 18, 2026NIH RePORTER 5U43AA032129-02
Synapticure Inc.NIH awarded $1.25M (SBIR Phase II 5R44NS143521-02, continuation, notice May 26, 2026).
Evidence (1 event)
  • May 26, 2026 · NIH RePORTER 5R44NS143521-02
    Organization: SYNAPTICURE, INC.; City/State: KENILWORTH, IL; Project number: 5R44NS143521-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1246192; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development; Organization type: Domestic For-Profits
May 26, 2026NIH RePORTER 5R44NS143521-02
MiNK TherapeuticsNIH awarded $307K (STTR Phase I 5R41AI192061-02, continuation, notice May 22, 2026).
Evidence (1 event)
  • May 22, 2026 · NIH RePORTER 5R41AI192061-02
    Organization: MINK THERAPEUTICS INC; City/State: NEW YORK, NY; Project number: 5R41AI192061-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 306500; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications; Organization type: Domestic For-Profits
May 22, 2026NIH RePORTER 5R41AI192061-02
Northstar Genomics, LLCNIH awarded $98K (STTR Phase I 5R41AR086049-02, continuation, notice Aug 17, 2026); 2 NIH awards totaling $368K in the last 12 months.
Evidence (2 events)
  • Aug 17, 2026 · NIH RePORTER 5R41AR086049-02
    Organization: NORTHSTAR GENOMICS, LLC; City/State: EAGAN, MN; Project number: 5R41AR086049-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 98483; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Novel approaches to humanized skeletal muscle in pig; Organization type: Domestic For-Profits
  • Jun 16, 2026 · NIH RePORTER 5R41HL174447-02
    Organization: NORTHSTAR GENOMICS, LLC; City/State: EAGAN, MN; Project number: 5R41HL174447-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 269750; Administering IC: National Heart Lung and Blood Institute; Project title: Bioengineering strategies for exogenic organ production; Organization type: Domestic For-Profits
Aug 17, 2026NIH RePORTER 5R41AR086049-02
Syntis Bio Inc.NIH awarded $917K (SBIR Phase II 5R44DK141341-03, continuation, notice Aug 10, 2026); 2 NIH awards totaling $2.11M in the last 12 months.
Evidence (2 events)
  • Aug 10, 2026 · NIH RePORTER 5R44DK141341-03
    Organization: SYNTIS BIO INC; City/State: Boston, MA; Project number: 5R44DK141341-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 916664; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of an Oral Pill to Mimic the Effects of Gastric Bypass Surgery; Organization type: Domestic For-Profits
  • May 26, 2026 · NIH RePORTER 5R44DK138869-03
    Organization: SYNTIS BIO INC; City/State: Boston, MA; Project number: 5R44DK138869-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1190375; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Polymer Epithelial Lining for the Oral Delivery of Macromolecules; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 5R44DK141341-03
TissueVisionNIH awarded $1.44M (SBIR Phase II 5R44MH129132-04, continuation, notice Jul 20, 2026).
Evidence (1 event)
  • Jul 20, 2026 · NIH RePORTER 5R44MH129132-04
    Organization: TISSUEVISION, INC.; City/State: Newton, MA; Project number: 5R44MH129132-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 1438419; Administering IC: National Institute of Mental Health; Project title: The Development of Tabletop Brain-Mapping Platform; Organization type: Domestic For-Profits
Jul 20, 2026NIH RePORTER 5R44MH129132-04
DoseOptics LLCNIH awarded $999K (SBIR Phase II 5R44CA232879-06, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44CA232879-06
    Organization: DOSEOPTICS, LLC; City/State: LEBANON, NH; Project number: 5R44CA232879-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 998974; Administering IC: National Cancer Institute; Project title: DoseRT™ : A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44CA232879-06
Spatial Genomics, Inc.NIH awarded $1.24M (SBIR Phase II 5R44MH140731-02, continuation, notice May 22, 2026).
Evidence (1 event)
  • May 22, 2026 · NIH RePORTER 5R44MH140731-02
    Organization: SPATIAL GENOMICS, INC.; City/State: Pasadena, CA; Project number: 5R44MH140731-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1244076; Administering IC: National Institute of Mental Health; Project title: Next generation spatial genomics tools for the human brain; Organization type: Domestic For-Profits
May 22, 2026NIH RePORTER 5R44MH140731-02
CG ScientificNIH awarded $765K (SBIR Phase II 5R44GM139391-03, continuation, notice Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · NIH RePORTER 5R44GM139391-03
    Organization: CG SCIENTIFIC, INC.; City/State: WORCESTER, MA; Project number: 5R44GM139391-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 765267; Administering IC: National Institute of General Medical Sciences; Project title: Low-Cost Platform Technology for Rapid Isolation of Peripheral Blood Mononuclear Cells; Organization type: Domestic For-Profits
Jun 3, 2026NIH RePORTER 5R44GM139391-03
SimplusDx, Inc.NIH awarded $532K (NIH grant 1R01CA310960-01, new, notice Jun 18, 2026).
Evidence (1 event)
  • Jun 18, 2026 · NIH RePORTER 1R01CA310960-01
    Organization: SIMPLUSDX, INC.; City/State: DURHAM, NC; Project number: 1R01CA310960-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-06-18; FY total cost (award amount): 532105; Administering IC: National Cancer Institute; Project title: Development and validation of a point-of-need screening test for hepatocellular carcinoma; Organization type: Domestic For-Profits
Jun 18, 2026NIH RePORTER 1R01CA310960-01
Electronic Biosciences, Inc.NIH awarded $466K (NIH grant 1R21GM165253-01, new, notice Sep 14, 2026); 3 NIH awards totaling $1.36M in the last 12 months.
Evidence (3 events)
  • Sep 14, 2026 · NIH RePORTER 1R21GM165253-01
    Organization: ELECTRONIC BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R21GM165253-01; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 466291; Administering IC: National Institute of General Medical Sciences; Project title: Enabling Protein Sequencing Through Friction-Mediated Nanopore Transport; Organization type: Domestic For-Profits
  • Sep 10, 2026 · NIH RePORTER 1R21HD121871-01
    Organization: ELECTRONIC BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R21HD121871-01; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 472706; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: High-Fidelity Nanopore Sequencing of CGG Repeats and Methylation in the FMR1 Gene; Organization type: Domestic For-Profits
  • Jun 9, 2026 · NIH RePORTER 1R21CA304932-01A1
    Organization: ELECTRONIC BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R21CA304932-01A1; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 418854; Administering IC: National Cancer Institute; Project title: Next-Generation Oncoproteomic Sequencing and Precision Profiling; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 1R21GM165253-01
Velorum TherapeuticsNIH awarded $1.26M (SBIR Phase II 5R44CA291444-02, continuation, notice Aug 6, 2026).
Evidence (1 event)
  • Aug 6, 2026 · NIH RePORTER 5R44CA291444-02
    Organization: VELORUM THERAPEUTICS INC.; City/State: PLANO, TX; Project number: 5R44CA291444-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1258345; Administering IC: National Cancer Institute; Project title: VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other solid tumors; Organization type: Domestic For-Profits
Aug 6, 2026NIH RePORTER 5R44CA291444-02
Cortechs Labs, Inc.NIH awarded $933K (SBIR Phase II 5R44AG079694-03, continuation, notice May 7, 2026).
Evidence (1 event)
  • May 7, 2026 · NIH RePORTER 5R44AG079694-03
    Organization: CORTECHS LABS, INC.; City/State: San Diego, CA; Project number: 5R44AG079694-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 932694; Administering IC: National Institute on Aging; Project title: Quantification of ARIA During the Treatment of Alzheimer's Patients; Organization type: Domestic For-Profits
May 7, 2026NIH RePORTER 5R44AG079694-03
Conifer Point Pharmaceuticals LLCNIH awarded $1M (SBIR Phase II 5R44GM109549-05, continuation, notice Jun 23, 2026).
Evidence (1 event)
  • Jun 23, 2026 · NIH RePORTER 5R44GM109549-05
    Organization: CONIFER POINT PHARMACEUTICALS, LLC; City/State: DOYLESTOWN, PA; Project number: 5R44GM109549-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 1000000; Administering IC: National Institute of General Medical Sciences; Project title: An Open Web Service For Fragment-based Design of Small Molecule Inhibitors; Organization type: Domestic For-Profits
Jun 23, 2026NIH RePORTER 5R44GM109549-05
Kathera Bioscience Inc.NIH awarded $995K (SBIR Phase II 5R44AI181163-03, continuation, notice May 25, 2026).
Evidence (1 event)
  • May 25, 2026 · NIH RePORTER 5R44AI181163-03
    Organization: KATHERA BIOSCIENCE INC.; City/State: UNION, NJ; Project number: 5R44AI181163-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 995100; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens; Organization type: Domestic For-Profits
May 25, 2026NIH RePORTER 5R44AI181163-03
Salimetrics, LLCNIH awarded $214K (SBIR Phase I 1R43MD021487-01, new, notice Aug 10, 2026).
Evidence (1 event)
  • Aug 10, 2026 · NIH RePORTER 1R43MD021487-01
    Organization: SALIMETRICS, LLC; City/State: STATE COLLEGE, PA; Project number: 1R43MD021487-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 213640; Administering IC: National Institute on Minority Health and Health Disparities; Project title: An At Home Dried Saliva Spot (DSS) Test to Determine Insulin Resistance: A Scalable Tool for Early Detection in Underserved Communities; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 1R43MD021487-01
Media REZ LLCNIH awarded $696K (SBIR Phase II 5R44CA254637-03, continuation, notice Jun 9, 2026).
Evidence (1 event)
  • Jun 9, 2026 · NIH RePORTER 5R44CA254637-03
    Organization: MEDIA REZ, LLC; City/State: WASHINGTON, DC; Project number: 5R44CA254637-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 696092; Administering IC: National Cancer Institute; Project title: Intervention for Chronic Insufficient Sleep in Young Adult Cancer Patients and Survivors; Organization type: Domestic For-Profits
Jun 9, 2026NIH RePORTER 5R44CA254637-03
Altis Biosystems, Inc.NIH awarded $1M (SBIR Phase II 5R44DK130708-03, continuation, notice May 19, 2026).
Evidence (1 event)
  • May 19, 2026 · NIH RePORTER 5R44DK130708-03
    Organization: ALTIS BIOSYSTEMS, INC.; City/State: Durham, NC; Project number: 5R44DK130708-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1001183; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Mucus and ALI Models of the Human Intestine; Organization type: Domestic For-Profits
May 19, 2026NIH RePORTER 5R44DK130708-03
Kinea Bio, Inc.NIH awarded $1.02M (SBIR Phase II 4R44AR084978-02, extension, notice Sep 23, 2026); 3 NIH awards totaling $2.42M in the last 12 months.
Evidence (3 events)
  • Sep 23, 2026 · NIH RePORTER 4R44AR084978-02
    Organization: KINEA BIO, INC.; City/State: Mukilteo, WA; Project number: 4R44AR084978-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-23; FY total cost (award amount): 1021458; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Scalable Non-viral Gene Delivery for Neuromuscular Diseases; Organization type: Domestic For-Profits
  • Aug 28, 2026 · NIH RePORTER 1R44HL182563-01A1
    Organization: KINEA BIO, INC.; City/State: Mukilteo, WA; Project number: 1R44HL182563-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 599669; Administering IC: National Heart Lung and Blood Institute; Project title: Split-Intein Protein Ligation: Enabling AAV Delivery of Large Genes for Clinical Translation in Genetic Cardiac Diseases; Organization type: Domestic For-Profits
  • Jun 16, 2026 · NIH RePORTER 5R44AR083801-03
    Organization: KINEA BIO, INC.; City/State: Mukilteo, WA; Project number: 5R44AR083801-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 796218; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Development of novel genetic medicine approaches to treat orphan diseases; Organization type: Domestic For-Profits
Sep 23, 2026NIH RePORTER 4R44AR084978-02
InnoTech Precision Medicine, IncNIH awarded $365K (SBIR Phase I 1R43DE035900-01, new, notice Sep 4, 2026); 2 NIH awards totaling $1.43M in the last 12 months.
Evidence (2 events)
  • Sep 4, 2026 · NIH RePORTER 1R43DE035900-01
    Organization: INNOTECH PRECISION MEDICINE, INC; City/State: BOSTON, MA; Project number: 1R43DE035900-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 365004; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Integrated Multiomics Diagnostics at the Point of Care for Healthy Living; Organization type: Domestic For-Profits
  • Aug 20, 2026 · NIH RePORTER 5R44DE033312-03
    Organization: INNOTECH PRECISION MEDICINE, INC; City/State: BOSTON, MA; Project number: 5R44DE033312-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 1069047; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Point of Care Detection of HPV and P16 in Saliva; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 1R43DE035900-01
Ensysce BiosciencesNIH awarded $5.28M (NIH grant 5U01DA059791-03, continuation, notice Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · NIH RePORTER 5U01DA059791-03
    Organization: ENSYSCE BIOSCIENCES, INC.; City/State: LA JOLLA, CA; Project number: 5U01DA059791-03; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 5279389; Administering IC: National Institute on Drug Abuse; Project title: PF614-MPAR: clinical development of opioid with oral overdose protection; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 5U01DA059791-03
Plakous TherapeuticsNIH awarded $827K (SBIR Phase II 5R44HD100243-06, continuation, notice Jun 9, 2026).
Evidence (1 event)
  • Jun 9, 2026 · NIH RePORTER 5R44HD100243-06
    Organization: PLAKOUS THERAPEUTICS, INC.; City/State: PFAFFTOWN, NC; Project number: 5R44HD100243-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 826522; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: IND Enabling Studies and Manufacturing Scale Up of Human Placental Extract to Prevent Surgical Necrotizing Enterocolitis; Organization type: Domestic For-Profits
Jun 9, 2026NIH RePORTER 5R44HD100243-06
Xylyx BioNIH awarded $957K (SBIR Phase II 5R44DK139877-03, continuation, notice Sep 10, 2026); 3 NIH awards totaling $3.44M in the last 12 months.
Evidence (3 events)
  • Sep 10, 2026 · NIH RePORTER 5R44DK139877-03
    Organization: XYLYX BIO, INC.; City/State: BROOKLYN, NY; Project number: 5R44DK139877-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 956566; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development; Organization type: Domestic For-Profits
  • Aug 7, 2026 · NIH RePORTER 5R44HL182545-02
    Organization: XYLYX BIO, INC.; City/State: BROOKLYN, NY; Project number: 5R44HL182545-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1483340; Administering IC: National Heart Lung and Blood Institute; Project title: Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation; Organization type: Domestic For-Profits
  • Jul 23, 2026 · NIH RePORTER 5R44CA287881-03
    Organization: XYLYX BIO, INC.; City/State: BROOKLYN, NY; Project number: 5R44CA287881-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 1003395; Administering IC: National Cancer Institute; Project title: Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 5R44DK139877-03
Biolinq Inc.NIH awarded $862K (SBIR Phase II 5R44DK129875-05, continuation, notice Jun 11, 2026).
Evidence (1 event)
  • Jun 11, 2026 · NIH RePORTER 5R44DK129875-05
    Organization: BIOLINQ INCORPORATED; City/State: San Diego, CA; Project number: 5R44DK129875-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 861567; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes; Organization type: Domestic For-Profits
Jun 11, 2026NIH RePORTER 5R44DK129875-05
Aquinnah PharmaceuticalsNIH awarded $1.5M (SBIR Phase II 5R44NS141531-02, continuation, notice Sep 2, 2026); 2 NIH awards totaling $2.5M in the last 12 months.
Evidence (2 events)
  • Sep 2, 2026 · NIH RePORTER 5R44NS141531-02
    Organization: AQUINNAH PHARMACEUTICALS, INC.; City/State: NEWTON, MA; Project number: 5R44NS141531-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 1499529; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of a novel oral brain penetrant therapeutic for ALS disease; Organization type: Domestic For-Profits
  • Aug 26, 2026 · NIH RePORTER 5R44AG060843-06
    Organization: AQUINNAH PHARMACEUTICALS, INC.; City/State: NEWTON, MA; Project number: 5R44AG060843-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 997942; Administering IC: National Institute on Aging; Project title: Development of a novel Alzheimer's disease therapeutic targeting tau; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 5R44NS141531-02
Gel4MedNIH awarded $1M (SBIR Phase II 5R44AI143079-03, continuation, notice Jun 25, 2026).
Evidence (1 event)
  • Jun 25, 2026 · NIH RePORTER 5R44AI143079-03
    Organization: GEL4MED, INC.; City/State: BRIGHTON, MA; Project number: 5R44AI143079-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds; Organization type: Domestic For-Profits
Jun 25, 2026NIH RePORTER 5R44AI143079-03
3D BioAnalytiX, Inc.NIH awarded $421K (NIH grant 1R33HL185603-01, new, notice Jun 25, 2026).
Evidence (1 event)
  • Jun 25, 2026 · NIH RePORTER 1R33HL185603-01
    Organization: 3D BIOANALYTIX, INC.; City/State: SAN DIEGO, CA; Project number: 1R33HL185603-01; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 421400; Administering IC: National Heart Lung and Blood Institute; Project title: A Transformative Structural Proteomics Platform for Early Detection of Misfolding-Driven Cardiovascular Diseases; Organization type: Domestic For-Profits
Jun 25, 2026NIH RePORTER 1R33HL185603-01
Chemia Biosciences, Inc.NIH awarded $958K (SBIR Phase II 2R44GM154504-02, competing renewal, notice Aug 7, 2026); 2 NIH awards totaling $1.73M in the last 12 months.
Evidence (2 events)
  • Aug 7, 2026 · NIH RePORTER 2R44GM154504-02
    Organization: CHEMIA BIOSCIENCES, INC.; City/State: PITTSBURGH, PA; Project number: 2R44GM154504-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 958339; Administering IC: National Institute of General Medical Sciences; Project title: Discovering novel natural products from fungal species; Organization type: Domestic For-Profits
  • Jun 26, 2026 · NIH RePORTER 5R44GM159545-02
    Organization: CHEMIA BIOSCIENCES, INC.; City/State: PITTSBURGH, PA; Project number: 5R44GM159545-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 767806; Administering IC: National Institute of General Medical Sciences; Project title: A novel platform for nonribosomal peptide discovery; Organization type: Domestic For-Profits
Aug 7, 2026NIH RePORTER 2R44GM154504-02
Advertent Biotherapeutics, Inc.NIH awarded $750K (SBIR Phase II 5R44AR081168-03, continuation, notice Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · NIH RePORTER 5R44AR081168-03
    Organization: ADVERTENT BIOTHERAPEUTICS, INC.; City/State: EAST LANSING, MI; Project number: 5R44AR081168-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 750221; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A novel agent for preventing fatty degeneration of muscles in LGMD2B; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 5R44AR081168-03
Privo TechnologiesNIH awarded $1.17M (SBIR Phase II 5R44CA281020-09, continuation, notice Jun 18, 2026).
Evidence (1 event)
  • Jun 18, 2026 · NIH RePORTER 5R44CA281020-09
    Organization: PRIVO TECHNOLOGIES, LLC; City/State: PEABODY, MA; Project number: 5R44CA281020-09; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-18; FY total cost (award amount): 1170285; Administering IC: National Cancer Institute; Project title: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer); Organization type: Domestic For-Profits
Jun 18, 2026NIH RePORTER 5R44CA281020-09
Innovative Biotherapies, Inc.NIH awarded $797K (SBIR Phase II 5R44HL170779-03, continuation, notice Jun 9, 2026).
Evidence (1 event)
  • Jun 9, 2026 · NIH RePORTER 5R44HL170779-03
    Organization: INNOVATIVE BIOTHERAPIES, INC.; City/State: ANN ARBOR, MI; Project number: 5R44HL170779-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 797411; Administering IC: National Heart Lung and Blood Institute; Project title: Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients; Organization type: Domestic For-Profits
Jun 9, 2026NIH RePORTER 5R44HL170779-03
Sparian Biosciences, IncNIH awarded $3.08M (NIH grant 5UG3DA064392-02, continuation, notice Jun 16, 2026).
Evidence (1 event)
  • Jun 16, 2026 · NIH RePORTER 5UG3DA064392-02
    Organization: SPARIAN BIOSCIENCES, INC.; City/State: NEW YORK CITY, NY; Project number: 5UG3DA064392-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 3084524; Administering IC: National Institute on Drug Abuse; Project title: Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain; Organization type: Domestic For-Profits
Jun 16, 2026NIH RePORTER 5UG3DA064392-02
WAViNIH awarded $1.21M (SBIR Phase II 4R44DA058431-02, extension, notice Sep 3, 2026).
Evidence (1 event)
  • Sep 3, 2026 · NIH RePORTER 4R44DA058431-02
    Organization: WAVI COMPANY; City/State: Englewood, CO; Project number: 4R44DA058431-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1208000; Administering IC: National Institute on Drug Abuse; Project title: Development of an AI-empowered device that utilizes multimodal data-visualization to aid in the diagnosis, and treatment, of OUD; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 4R44DA058431-02
Cerulean ScientificNIH awarded $1.07M (SBIR Phase II 5R44HL172473-03, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44HL172473-03
    Organization: CERULEAN SCIENTIFIC INC.; City/State: LANCASTER, PA; Project number: 5R44HL172473-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1072347; Administering IC: National Heart Lung and Blood Institute; Project title: Slippery, Omniphobic Coating to Prevent Thrombosis and Biofilm Formation on Peripheral Vascular Grafts; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44HL172473-03
Evrys BioNIH awarded $962K (SBIR Phase II 5R44AI157725-04, continuation, notice Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · NIH RePORTER 5R44AI157725-04
    Organization: EVRYS BIO, INC.; City/State: DOYLESTOWN, PA; Project number: 5R44AI157725-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 961797; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 5R44AI157725-04
Voxel Healthcare LLCNIH awarded $665K (SBIR Phase II 5R44CA281709-03, continuation, notice Jul 7, 2026).
Evidence (1 event)
  • Jul 7, 2026 · NIH RePORTER 5R44CA281709-03
    Organization: VOXEL HEALTHCARE, LLC; City/State: Pasadena, CA; Project number: 5R44CA281709-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 665400; Administering IC: National Cancer Institute; Project title: Long term radiation treatment planning in brain tumors in the pediatric population; Organization type: Domestic For-Profits
Jul 7, 2026NIH RePORTER 5R44CA281709-03
Pinnacle Technology, Inc.NIH awarded $984K (SBIR Phase II 5R44MH134669-03, continuation, notice Aug 13, 2026).
Evidence (1 event)
  • Aug 13, 2026 · NIH RePORTER 5R44MH134669-03
    Organization: PINNACLE TECHNOLOGY, INC; City/State: LAWRENCE, KS; Project number: 5R44MH134669-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 984425; Administering IC: National Institute of Mental Health; Project title: Functionalized Multi-Modal Tetrode Arrays for Real-Time, Site-Specific Neurochemical Monitoring; Organization type: Domestic For-Profits
Aug 13, 2026NIH RePORTER 5R44MH134669-03
Salus Discovery LLCNIH awarded $1M (SBIR Phase II 5R44AI184104-03, continuation, notice Aug 26, 2026); 2 NIH awards totaling $1.91M in the last 12 months.
Evidence (2 events)
  • Aug 26, 2026 · NIH RePORTER 5R44AI184104-03
    Organization: SALUS DISCOVERY, LLC; City/State: Madison, WI; Project number: 5R44AI184104-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 999991; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings; Organization type: Domestic For-Profits
  • Jul 1, 2026 · NIH RePORTER 5R44AI179588-03
    Organization: SALUS DISCOVERY, LLC; City/State: Madison, WI; Project number: 5R44AI179588-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 913705; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology; Organization type: Domestic For-Profits
Aug 26, 2026NIH RePORTER 5R44AI184104-03
The DNA Medicine Institute, Inc.NIH awarded $50K (SBIR Phase II 3R44HL151147-05S1, supplement, notice Jul 16, 2026); 2 NIH awards totaling $1.05M in the last 12 months.
Evidence (2 events)
  • Jul 16, 2026 · NIH RePORTER 3R44HL151147-05S1
    Organization: DNA MEDICINE INSTITUTE; City/State: Cambridge, MA; Project number: 3R44HL151147-05S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 50000; Administering IC: National Heart Lung and Blood Institute; Project title: TABA Supplement for Hemophilia Point-of-Care Device; Organization type: Domestic For-Profits
  • Jul 6, 2026 · NIH RePORTER 5R44HL151147-05
    Organization: DNA MEDICINE INSTITUTE; City/State: Cambridge, MA; Project number: 5R44HL151147-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 1000000; Administering IC: National Heart Lung and Blood Institute; Project title: Hemophilia Point-of-Care Monitoring Device and App; Organization type: Domestic For-Profits
Jul 16, 2026NIH RePORTER 3R44HL151147-05S1
ODMR Technologies, IncNIH awarded $984K (STTR Phase II 5R42GM145129-03, continuation, notice Jul 1, 2026).
Evidence (1 event)
  • Jul 1, 2026 · NIH RePORTER 5R42GM145129-03
    Organization: ODMR TECHNOLOGIES, INC.; City/State: EL CERRITO, CA; Project number: 5R42GM145129-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 984215; Administering IC: National Institute of General Medical Sciences; Project title: Diamond NMR spectrometer for microfluidic metabolite profiling; Organization type: Domestic For-Profits
Jul 1, 2026NIH RePORTER 5R42GM145129-03
Autonomous Healthcare Inc.NIH awarded $306K (SBIR Phase I 1R43HL187059-01, new, notice Aug 18, 2026); 2 NIH awards totaling $1.19M in the last 12 months.
Evidence (2 events)
  • Aug 18, 2026 · NIH RePORTER 1R43HL187059-01
    Organization: AUTONOMOUS HEALTHCARE, INC.; City/State: SANTA CLARA, CA; Project number: 1R43HL187059-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 305999; Administering IC: National Heart Lung and Blood Institute; Project title: A Feasibility Study for a Clinical Decision Support System to Assist with Vasopressor Titration; Organization type: Domestic For-Profits
  • Jul 20, 2026 · NIH RePORTER 5R44DA058470-03
    Organization: AUTONOMOUS HEALTHCARE, INC.; City/State: SANTA CLARA, CA; Project number: 5R44DA058470-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 886573; Administering IC: National Institute on Drug Abuse; Project title: Noncontact Monitoring for the Detection of Opioid-Induced Respiratory Depression; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 1R43HL187059-01
NeuroGTNIH awarded $1.48M (SBIR Phase II 5R44NS143501-02, continuation, notice Sep 14, 2026); 3 NIH awards totaling $3.17M in the last 12 months.
Evidence (3 events)
  • Sep 14, 2026 · NIH RePORTER 5R44NS143501-02
    Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R44NS143501-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1484525; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I; Organization type: Domestic For-Profits
  • Sep 14, 2026 · NIH RePORTER 5R44NS135667-03
    Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R44NS135667-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1341983; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of gene therapy product for treating MPS IIIB; Organization type: Domestic For-Profits
  • May 12, 2026 · NIH RePORTER 5R41NS143578-02
    Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R41NS143578-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 342740; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 5R44NS143501-02
Syracuse Biolabs, Inc.NIH awarded $534K (STTR Phase II 5R42GM140530-03, continuation, notice Jun 30, 2026).
Evidence (1 event)
  • Jun 30, 2026 · NIH RePORTER 5R42GM140530-03
    Organization: SYRACUSE BIOLABS, INC.; City/State: CAMILLUS, NY; Project number: 5R42GM140530-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 534278; Administering IC: National Institute of General Medical Sciences; Project title: Commercialization of a phylogenetic cell separation method for downstream purification of nucleic acids; Organization type: Domestic For-Profits
Jun 30, 2026NIH RePORTER 5R42GM140530-03
Vivreon BiosciencesNIH awarded $1.95M (SBIR commercialization 5SB1AG087756-02, continuation, notice May 12, 2026).
Evidence (1 event)
  • May 12, 2026 · NIH RePORTER 5SB1AG087756-02
    Organization: VIVREON BIOSCIENCES, LLC; City/State: San Diego, CA; Project number: 5SB1AG087756-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1948898; Administering IC: National Institute on Aging; Project title: Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease; Organization type: Domestic For-Profits
May 12, 2026NIH RePORTER 5SB1AG087756-02
Rivanna MedicalNIH awarded $1.1M (SBIR Phase II 5R44CA302033-02, continuation, notice Jul 14, 2026); 1 role open.
Evidence (1 event)
  • Jul 14, 2026 · NIH RePORTER 5R44CA302033-02
    Organization: RIVANNA MEDICAL, INC.; City/State: CHARLOTTESVILLE, VA; Project number: 5R44CA302033-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 1104515; Administering IC: National Cancer Institute; Project title: Reduced Traumatic Lumbar Puncture Rates in Pediatric Oncology Patients Through Development of an AI-Assisted, Ultrasound-Based Interventional Guidance Platform; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 5R44CA302033-02
March BiosciencesNIH awarded $399K (SBIR Phase II 1R44CA314963-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.52M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R44CA314963-01
    Organization: MARCH BIOSCIENCES INC; City/State: HOUSTON, TX; Project number: 1R44CA314963-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399003; Administering IC: National Cancer Institute; Project title: Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy; Organization type: Domestic For-Profits
  • Aug 31, 2026 · NIH RePORTER 5R44CA302357-02
    Organization: MARCH BIOSCIENCES INC; City/State: HOUSTON, TX; Project number: 5R44CA302357-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1124607; Administering IC: National Cancer Institute; Project title: A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44CA314963-01
SurgiVanceNIH awarded $1.27M (SBIR Phase II 5R44CA302122-02, continuation, notice Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · NIH RePORTER 5R44CA302122-02
    Organization: SURGIVANCE, INC.; City/State: Portland, OR; Project number: 5R44CA302122-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1271776; Administering IC: National Cancer Institute; Project title: Rapid 3D POC digital cancer pathology by unique confocal microscopy instrumentation and downstream AI: a simple, efficient, robust direct-to-digital approach to meet market demand; Organization type: Domestic For-Profits
Jun 3, 2026NIH RePORTER 5R44CA302122-02
NE Scientific INCNIH awarded $689K (SBIR Phase II 5R44CA287803-03, continuation, notice May 14, 2026).
Evidence (1 event)
  • May 14, 2026 · NIH RePORTER 5R44CA287803-03
    Organization: NE SCIENTIFIC, INC.; City/State: BURLINGTON, MA; Project number: 5R44CA287803-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-14; FY total cost (award amount): 689478; Administering IC: National Cancer Institute; Project title: Computer Guided Microwave Liver Ablation; Organization type: Domestic For-Profits
May 14, 2026NIH RePORTER 5R44CA287803-03
Kinetic River Corp.NIH awarded $1M (SBIR commercialization 5SB1GM157775-02, continuation, notice May 7, 2026).
Evidence (1 event)
  • May 7, 2026 · NIH RePORTER 5SB1GM157775-02
    Organization: KINETIC RIVER CORPORATION; City/State: MOUNTAIN VIEW, CA; Project number: 5SB1GM157775-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 999993; Administering IC: National Institute of General Medical Sciences; Project title: Compensation-Free Flow Cytometer with Expanded Reagent Choices and Reduced Manufacturing Costs; Organization type: Domestic For-Profits
May 7, 2026NIH RePORTER 5SB1GM157775-02
Outlier Technology, LLCNIH awarded $1.15M (SBIR Phase II 5R44AG081111-03, continuation, notice Jul 28, 2026).
Evidence (1 event)
  • Jul 28, 2026 · NIH RePORTER 5R44AG081111-03
    Organization: OUTLIER TECHNOLOGY, LLC; City/State: GAINESVILLE, FL; Project number: 5R44AG081111-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 1152435; Administering IC: National Institute on Aging; Project title: NeuroSync: a data-driven, music-based augmented reality neurorehabilitation platform of games & puzzles to stimulate neuroplasticity and prolong functional independence in Alzheimer's Disease patients; Organization type: Domestic For-Profits
Jul 28, 2026NIH RePORTER 5R44AG081111-03
NovoPedicsNIH awarded $1.02M (SBIR Phase II 5R44AR081745-03, continuation, notice Jun 11, 2026).
Evidence (1 event)
  • Jun 11, 2026 · NIH RePORTER 5R44AR081745-03
    Organization: NOVOPEDICS, INC.; City/State: Princeton, NJ; Project number: 5R44AR081745-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 1016692; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Efficacy of MeniscoFix for Sub-Total Meniscal Replacement: A Comprehensive Approach in Cadaver Knees and an Ovine Surgical Model; Organization type: Domestic For-Profits
Jun 11, 2026NIH RePORTER 5R44AR081745-03
Marker Therapeutics, Inc.NIH awarded $645K (NIH grant 1R01FD008756-01, new, notice Sep 24, 2026); 2 NIH awards totaling $1.31M in the last 12 months.
Evidence (2 events)
  • Sep 24, 2026 · NIH RePORTER 1R01FD008756-01
    Organization: MARKER THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 1R01FD008756-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-24; FY total cost (award amount): 645493; Administering IC: Food and Drug Administration; Project title: Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients; Organization type: Domestic For-Profits
  • Jul 20, 2026 · NIH RePORTER 5R44CA291521-03
    Organization: MARKER THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 5R44CA291521-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 665000; Administering IC: National Cancer Institute; Project title: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma; Organization type: Domestic For-Profits
Sep 24, 2026NIH RePORTER 1R01FD008756-01
Genetivision CorporationNIH awarded $984K (SBIR Phase II 5R44GM161181-02, continuation, notice Jun 26, 2026).
Evidence (1 event)
  • Jun 26, 2026 · NIH RePORTER 5R44GM161181-02
    Organization: GENETIVISION CORPORATION; City/State: Stafford, TX; Project number: 5R44GM161181-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 984472; Administering IC: National Institute of General Medical Sciences; Project title: A Precisely Controllable Loss-of-Function Mutation Collection in Drosophila; Organization type: Domestic For-Profits
Jun 26, 2026NIH RePORTER 5R44GM161181-02
VeriSIM Life, Inc.NIH awarded $513K (STTR Phase II 5R42DA056084-03, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5R42DA056084-03
    Organization: VERISIM LIFE, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R42DA056084-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 512644; Administering IC: National Institute on Drug Abuse; Project title: Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and accelerated development; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R42DA056084-03
Doxy.me Inc.NIH awarded $704K (SBIR Phase II 5R44MH129065-04, continuation, notice Aug 13, 2026); 3 roles open.
Evidence (1 event)
  • Aug 13, 2026 · NIH RePORTER 5R44MH129065-04
    Organization: DOXY.ME, LLC; City/State: Charleston, SC; Project number: 5R44MH129065-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 704454; Administering IC: National Institute of Mental Health; Project title: Doxy.me VR: A scalable virtual reality app to facilitate evidence-based immersive telemental health; Organization type: Domestic For-Profits
Aug 13, 2026NIH RePORTER 5R44MH129065-04
AronoraNIH awarded $1.07M (SBIR Phase II 5R44HL170881-03, continuation, notice Jun 1, 2026).
Evidence (1 event)
  • Jun 1, 2026 · NIH RePORTER 5R44HL170881-03
    Organization: ARONORA, INC.; City/State: Portland, OR; Project number: 5R44HL170881-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 1069527; Administering IC: National Heart Lung and Blood Institute; Project title: Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis; Organization type: Domestic For-Profits
Jun 1, 2026NIH RePORTER 5R44HL170881-03
Ortholevo, Inc.NIH awarded $490K (SBIR commercialization 5SB1AR084380-03, continuation, notice Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · NIH RePORTER 5SB1AR084380-03
    Organization: ORTHOLEVO, INC.; City/State: Lynnfield, MA; Project number: 5SB1AR084380-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 490333; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 5SB1AR084380-03
BriteseedNIH awarded $1M (SBIR Phase II 5R44EB036417-03, continuation, notice Jul 6, 2026).
Evidence (1 event)
  • Jul 6, 2026 · NIH RePORTER 5R44EB036417-03
    Organization: BRITESEED, LLC; City/State: CHICAGO, IL; Project number: 5R44EB036417-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 1000469; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: Development of a Multispectral Kerrison Rongeur for Dura and Nerve Root Detection; Organization type: Domestic For-Profits
Jul 6, 2026NIH RePORTER 5R44EB036417-03
AbbraTech Inc.NIH awarded $301K (SBIR Phase II 5R44GM156476-03, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5R44GM156476-03
    Organization: ABBRATECH, INC.; City/State: Branford, CT; Project number: 5R44GM156476-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 301174; Administering IC: National Institute of General Medical Sciences; Project title: DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R44GM156476-03
Fimbrion TherapeuticsNIH awarded $300K (SBIR Phase I 5R43AI192175-02, continuation, notice Sep 3, 2026); 3 NIH awards totaling $900K in the last 12 months.
Evidence (3 events)
  • Sep 3, 2026 · NIH RePORTER 5R43AI192175-02
    Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI192175-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis; Organization type: Domestic For-Profits
  • Aug 6, 2026 · NIH RePORTER 5R43AI192169-02
    Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI192169-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections; Organization type: Domestic For-Profits
  • Jul 29, 2026 · NIH RePORTER 5R43AI188991-02
    Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI188991-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 300001; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 5R43AI192175-02
Emmyon, Inc.NIH awarded $1.02M (SBIR Phase II 5R44DK142200-02, continuation, notice Jul 23, 2026).
Evidence (1 event)
  • Jul 23, 2026 · NIH RePORTER 5R44DK142200-02
    Organization: EMMYON, INC.; City/State: Rochester, MN; Project number: 5R44DK142200-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 1021719; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of novel therapeutics for obesity and type 2 diabetes; Organization type: Domestic For-Profits
Jul 23, 2026NIH RePORTER 5R44DK142200-02
BrightSpecNIH awarded $819K (SBIR Phase II 5R44GM157779-02, continuation, notice Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · NIH RePORTER 5R44GM157779-02
    Organization: BRIGHTSPEC, INC.; City/State: CHARLOTTESVILLE, VA; Project number: 5R44GM157779-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 819002; Administering IC: National Institute of General Medical Sciences; Project title: MR^3: Development of a Molecular Rotational Resonance Ratiometer; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 5R44GM157779-02
Litron LaboratoriesNIH awarded $645K (SBIR Phase II 5R44ES036902-03, continuation, notice Aug 14, 2026); 2 NIH awards totaling $1.49M in the last 12 months.
Evidence (2 events)
  • Aug 14, 2026 · NIH RePORTER 5R44ES036902-03
    Organization: LITRON LABORATORIES, LTD.; City/State: ROCHESTER, NY; Project number: 5R44ES036902-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 645357; Administering IC: National Institute of Environmental Health Sciences; Project title: Development of a Comprehensive Hen's Egg Model for Genotoxicity Testing; Organization type: Domestic For-Profits
  • Aug 10, 2026 · NIH RePORTER 5R44ES035550-03
    Organization: LITRON LABORATORIES, LTD.; City/State: ROCHESTER, NY; Project number: 5R44ES035550-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 843789; Administering IC: National Institute of Environmental Health Sciences; Project title: Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R44ES036902-03
DemeRxNIH awarded $796K (SBIR Phase I 5R43AA032127-02, continuation, notice Jul 23, 2026).
Evidence (1 event)
  • Jul 23, 2026 · NIH RePORTER 5R43AA032127-02
    Organization: DEMERX, INC.; City/State: MIAMI, FL; Project number: 5R43AA032127-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 796298; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Investigational New Drug Development of Noribogaine for Alcohol Use Disorder; Organization type: Domestic For-Profits
Jul 23, 2026NIH RePORTER 5R43AA032127-02
Solaris Vaccines, Inc.NIH awarded $274K (STTR Phase I 5R41AI186746-02, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5R41AI186746-02
    Organization: SOLARIS VACCINES, INC.; City/State: FORT COLLINS, CO; Project number: 5R41AI186746-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 274002; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A whole-cell inactivated vaccine for improved protection against tuberculosis; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R41AI186746-02
Pearl Diagnostics, Inc.NIH awarded $977K (SBIR commercialization 5SB1AI186689-02, continuation, notice Jun 30, 2026).
Evidence (1 event)
  • Jun 30, 2026 · NIH RePORTER 5SB1AI186689-02
    Organization: PEARL DIAGNOSTICS, INC.; City/State: BALTIMORE, MD; Project number: 5SB1AI186689-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 977071; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Point of Care Urine Test to Aid Diagnosis of Aspergillosis; Organization type: Domestic For-Profits
Jun 30, 2026NIH RePORTER 5SB1AI186689-02
Ometa Labs LLCNIH awarded $702K (SBIR Phase II 5R44GM162107-02, continuation, notice Jul 11, 2026).
Evidence (1 event)
  • Jul 11, 2026 · NIH RePORTER 5R44GM162107-02
    Organization: OMETA LABS LLC; City/State: CARLSBAD, CA; Project number: 5R44GM162107-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-11; FY total cost (award amount): 702348; Administering IC: National Institute of General Medical Sciences; Project title: Bioinformatics platform for large scale untargeted metabolomics analysis; Organization type: Domestic For-Profits
Jul 11, 2026NIH RePORTER 5R44GM162107-02
Ting TherapeuticsNIH awarded $524K (SBIR Phase II 5R44DC019065-05, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44DC019065-05
    Organization: TING THERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 5R44DC019065-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 524299; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: Therapeutics to prevent aminoglycoside-induced hearing loss; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44DC019065-05
Cognition TherapeuticsNIH awarded $16.49M (NIH grant 5R01AG065248-05, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5R01AG065248-05
    Organization: COGNITION THERAPEUTICS, INC.; City/State: PITTSBURGH, PA; Project number: 5R01AG065248-05; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 16494670; Administering IC: National Institute on Aging; Project title: Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R01AG065248-05
Owic Technologies Inc.NIH awarded $1.23M (SBIR Phase II 4R44GM161182-02, extension, notice Aug 21, 2026).
Evidence (1 event)
  • Aug 21, 2026 · NIH RePORTER 4R44GM161182-02
    Organization: OWIC TECHNOLOGIES INC; City/State: ITHACA, NY; Project number: 4R44GM161182-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1228929; Administering IC: National Institute of General Medical Sciences; Project title: High throughput electrosynthesis for enhanced drug discovery via light-powered smart microelectronics; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 4R44GM161182-02
NanoNewronNIH awarded $1.52M (STTR Phase II 5R42AG080864-03, continuation, notice Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · NIH RePORTER 5R42AG080864-03
    Organization: NANONEWRON LLC; City/State: Union, NJ; Project number: 5R42AG080864-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1519969; Administering IC: National Institute on Aging; Project title: Development of a therapeutic nanobody targeting brain TNFa for the treatment of Alzheimer Disease; Organization type: Domestic For-Profits
Jun 3, 2026NIH RePORTER 5R42AG080864-03
Topaz Biosciences, Inc.NIH awarded $576K (SBIR Phase II 5R44AR082722-03, continuation, notice Jul 17, 2026).
Evidence (1 event)
  • Jul 17, 2026 · NIH RePORTER 5R44AR082722-03
    Organization: TOPAZ BIOSCIENCES, INC.; City/State: EMERYVILLE, CA; Project number: 5R44AR082722-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 576499; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Development of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris; Organization type: Domestic For-Profits
Jul 17, 2026NIH RePORTER 5R44AR082722-03
Vasarya Therapeutics, Inc.NIH awarded $1.13M (SBIR Phase II 5R44HL170936-03, continuation, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 5R44HL170936-03
    Organization: VASARYA THERAPEUTICS, INC.; City/State: CAMDEN, DE; Project number: 5R44HL170936-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1126840; Administering IC: National Heart Lung and Blood Institute; Project title: Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R44HL170936-03
Molecular Intelligence LLCNIH awarded $88K (SBIR Phase I 5R43GM161135-02, continuation, notice Sep 8, 2026).
Evidence (1 event)
  • Sep 8, 2026 · NIH RePORTER 5R43GM161135-02
    Organization: MOLECULAR INTELLIGENCE LLC; City/State: WEST LAFAYETTE, IN; Project number: 5R43GM161135-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 87668; Administering IC: National Institute of General Medical Sciences; Project title: Modeling Receptor-ligand interactions for Drug Discoveryfrom Cryo-EM data using AI; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 5R43GM161135-02
Celestial Therapeutics Inc.NIH awarded $643K (SBIR Phase II 5R44AI177056-03, continuation, notice Jul 30, 2026).
Evidence (1 event)
  • Jul 30, 2026 · NIH RePORTER 5R44AI177056-03
    Organization: CELESTIAL THERAPEUTICS INC.; City/State: IRVINE, CA; Project number: 5R44AI177056-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 643140; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a dry powder inhalation product against Respiratory Syncytial Virus based on an endogenous anionic pulmonary surfactant lipid; Organization type: Domestic For-Profits
Jul 30, 2026NIH RePORTER 5R44AI177056-03
INSIGHTFILNIH awarded $598K (SBIR Phase II 5R44TR003071-04, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5R44TR003071-04
    Organization: INSIGHTFIL; City/State: BOSTON, MA; Project number: 5R44TR003071-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 598106; Administering IC: National Center for Advancing Translational Sciences; Project title: Personalized multi-medication packaging with integrated real-time instrumentation to improve adherence; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R44TR003071-04
Killer Snails LLCNIH awarded $1.3M (SBIR Phase II 4R44GM161184-02, extension, notice Jul 27, 2026).
Evidence (1 event)
  • Jul 27, 2026 · NIH RePORTER 4R44GM161184-02
    Organization: KILLER SNAILS LLC; City/State: BROOKLYN, NY; Project number: 4R44GM161184-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-27; FY total cost (award amount): 1299019; Administering IC: National Institute of General Medical Sciences; Project title: Flu Finders: Data Literacy through Wastewater Monitoring; Organization type: Domestic For-Profits
Jul 27, 2026NIH RePORTER 4R44GM161184-02
Plumeria Therapeutics, Inc.NIH awarded $1.5M (SBIR Phase II 5R44NS120617-03, continuation, notice May 26, 2026).
Evidence (1 event)
  • May 26, 2026 · NIH RePORTER 5R44NS120617-03
    Organization: PLUMERIA THERAPEUTICS, INC.; City/State: Plainsboro, NJ; Project number: 5R44NS120617-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1499999; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Laboratory Developed Test (LDT) to Support Clinical Evaluation of a Drug for Painful Diabetic Neuropathy; Organization type: Domestic For-Profits
May 26, 2026NIH RePORTER 5R44NS120617-03
Shift Pharmaceuticals Holdings, Inc.NIH awarded $37K (STTR Phase I 5R41EY036319-02, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R41EY036319-02
    Organization: SHIFT PHARMACEUTICALS HOLDINGS, INC.; City/State: COLUMBIA, MO; Project number: 5R41EY036319-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 37074; Administering IC: National Eye Institute; Project title: Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R41EY036319-02
Gateway Bio, Inc.NIH awarded $735K (SBIR Phase II 5R44TR003255-04, continuation, notice Jul 20, 2026).
Evidence (1 event)
  • Jul 20, 2026 · NIH RePORTER 5R44TR003255-04
    Organization: GATEWAY BIO, INC.; City/State: DURHAM, NC; Project number: 5R44TR003255-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 735254; Administering IC: National Center for Advancing Translational Sciences; Project title: Scale-up and Toxicity Studies of POEGMA-Uricase; Organization type: Domestic For-Profits
Jul 20, 2026NIH RePORTER 5R44TR003255-04
CYTORUMNIH awarded $843K (SBIR Phase II 5R44GM146557-03, continuation, notice Aug 31, 2026).
Evidence (1 event)
  • Aug 31, 2026 · NIH RePORTER 5R44GM146557-03
    Organization: CYTORUM, INC.; City/State: Santa Clara, CA; Project number: 5R44GM146557-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 843224; Administering IC: National Institute of General Medical Sciences; Project title: Xbeads: A Platform for Flow Cytometry Sample QC and Harmonization; Organization type: Domestic For-Profits
Aug 31, 2026NIH RePORTER 5R44GM146557-03
HDT Bio Corp.NIH awarded $1.06M (NIH grant 5R01AI180195-03, continuation, notice Jul 24, 2026).
Evidence (1 event)
  • Jul 24, 2026 · NIH RePORTER 5R01AI180195-03
    Organization: HDT BIO CORPORATION; City/State: SEATTLE, WA; Project number: 5R01AI180195-03; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-07-24; FY total cost (award amount): 1063126; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Immunological mechanism of muscle-localizing self-replicating RNA vaccines; Organization type: Domestic For-Profits
Jul 24, 2026NIH RePORTER 5R01AI180195-03
IN Vivo Analytics, Inc.NIH awarded $907K (SBIR Phase II 5R44MH140129-03, continuation, notice Aug 19, 2026).
Evidence (1 event)
  • Aug 19, 2026 · NIH RePORTER 5R44MH140129-03
    Organization: IN VIVO ANALYTICS, INC.; City/State: NEW YORK, NY; Project number: 5R44MH140129-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 907050; Administering IC: National Institute of Mental Health; Project title: A modular bioluminescence imaging platform using a novel multi-aperture method; Organization type: Domestic For-Profits
Aug 19, 2026NIH RePORTER 5R44MH140129-03
Epoulosis Therapeutics, Inc.NIH awarded $1.01M (SBIR Phase II 5R44DK141401-02, continuation, notice Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · NIH RePORTER 5R44DK141401-02
    Organization: EPOULOSIS THERAPEUTICS, INC.; City/State: NEWTON, MA; Project number: 5R44DK141401-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 1012588; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Metrifonate local application for DFU treatment; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 5R44DK141401-02
Onc.AI, Inc.NIH awarded $314K (SBIR Phase II 5R44CA302212-02, continuation, notice Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · NIH RePORTER 5R44CA302212-02
    Organization: ONC.AI, INC.; City/State: SAN CARLOS, CA; Project number: 5R44CA302212-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 313742; Administering IC: National Cancer Institute; Project title: Deep Learning Serial Radiomics for Improved Cancer Therapy Response Assessment.; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 5R44CA302212-02
Spikegadgets, Inc.NIH awarded $861K (SBIR Phase II 5R44MH142264-02, continuation, notice Jul 17, 2026).
Evidence (1 event)
  • Jul 17, 2026 · NIH RePORTER 5R44MH142264-02
    Organization: SPIKEGADGETS, LLC; City/State: San Francisco, CA; Project number: 5R44MH142264-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 860666; Administering IC: National Institute of Mental Health; Project title: A Commercial Platform for High-Volume Behavior and Electrophysiology Research; Organization type: Domestic For-Profits
Jul 17, 2026NIH RePORTER 5R44MH142264-02
Tymora Analytical Operations LLCNIH awarded $747K (SBIR Phase II 5R44AG063589-04, continuation, notice Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · NIH RePORTER 5R44AG063589-04
    Organization: TYMORA ANALYTICAL OPERATIONS, LLC; City/State: WEST LAFAYETTE, IN; Project number: 5R44AG063589-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 747422; Administering IC: National Institute on Aging; Project title: Validation and clinicaldevelopment of plasma EV protein biomarkers for minimally-invasive detection of Alzheimersdisease; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 5R44AG063589-04
Siolta Therapeutics, Inc.NIH awarded $935K (SBIR Phase II 5R44AI195248-02, continuation, notice Jul 14, 2026).
Evidence (1 event)
  • Jul 14, 2026 · NIH RePORTER 5R44AI195248-02
    Organization: SIOLTA THERAPEUTICS, INC.; City/State: SAN CARLOS, CA; Project number: 5R44AI195248-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 935435; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a multispecies live biotherapeutic product for the prevention of recurrent bacterial vaginosis; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 5R44AI195248-02
Zymo Research Corp.NIH awarded $908K (STTR Phase II 5R42NS098918-06, continuation, notice Aug 11, 2026).
Evidence (1 event)
  • Aug 11, 2026 · NIH RePORTER 5R42NS098918-06
    Organization: ZYMO RESEARCH CORPORATION; City/State: IRVINE, CA; Project number: 5R42NS098918-06; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 907735; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A Novel Xenon Delivery Platform for Cerebroprotection During Stroke; Organization type: Domestic For-Profits
Aug 11, 2026NIH RePORTER 5R42NS098918-06
Myosin Therapeutics Inc.NIH awarded $2.24M (SBIR Phase II 5R44CA278293-05, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44CA278293-05
    Organization: MYOSIN THERAPEUTICS INC.; City/State: JUPITER, FL; Project number: 5R44CA278293-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2241448; Administering IC: National Cancer Institute; Project title: Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44CA278293-05
WestatNIH awarded $3.52M (NIH grant 5U54DA046060-09, continuation, notice Sep 11, 2026); 20 NIH awards totaling $86.82M in the last 12 months.
Evidence (20 events)
  • Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 3517105; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science; Organization type: Domestic For-Profits
  • Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879278; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Leadership and Logistics Core; Organization type: Domestic For-Profits
  • Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879277; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Analysis and Rapid Response Core; Organization type: Domestic For-Profits
  • Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879275; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Career Enhancement Core; Organization type: Domestic For-Profits
  • Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879275; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Dissemination Core; Organization type: Domestic For-Profits
  • Sep 3, 2026 · NIH RePORTER 5U24MH139129-02
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U24MH139129-02; Activity code: U24; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1891124; Administering IC: National Institute of Mental Health; Project title: Early Psychosis Intervention Network (EPINET) Data Coordinating Center; Organization type: Domestic For-Profits
  • Aug 28, 2026 · NIH RePORTER 4OT2HL158287-02
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 4OT2HL158287-02; Activity code: OT2; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 41085453; Administering IC: National Heart Lung and Blood Institute; Project title: NHLBI Community Engagement Technical Assistance Center (CETAC); Organization type: Domestic For-Profits
  • Jul 20, 2026 · NIH RePORTER 3U54DA046060-08S1
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 3U54DA046060-08S1; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 127945; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science; Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 7732236; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 4439439; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Operations and Collaborations Center - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 463713; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: St. Jude Children's Research Hospital - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 447573; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Fenway Community Health Center, Inc., Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 408234; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Children's Hospital Los Angeles Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 349649; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: The Hektoen Institute of Medical Research Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 348214; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Children's National Hospital Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 329106; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: The Administrators of the Tulane Educational Fund dba TUHSC Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Tri; Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 321882; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Johns Hopkins University Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 320315; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Baylor College of Medicine Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 304111; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: University of South Florida Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits
  • Jan 30, 2026 · NIH RePORTER 3OT2HL158287-01SG
    Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 3OT2HL158287-01SG; Activity code: OT2; Fiscal year: 2026; Award notice date: 2026-01-30; FY total cost (award amount): 21218938; Administering IC: National Heart Lung and Blood Institute; Project title: NHLBI Community Engagement Technical Assistance Center (CETAC); Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 5U54DA046060-09
Attagene, Inc.NIH awarded $50K (SBIR Phase II 3R44ES038062-02S1, supplement, notice Aug 31, 2026); 2 NIH awards totaling $1.15M in the last 12 months.
Evidence (2 events)
  • Aug 31, 2026 · NIH RePORTER 3R44ES038062-02S1
    Organization: ATTAGENE, INC.; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 3R44ES038062-02S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 50000; Administering IC: National Institute of Environmental Health Sciences; Project title: A Two-Tier Effect-Based Water Bioactivity Surveillance System.; Organization type: Domestic For-Profits
  • Aug 19, 2026 · NIH RePORTER 5R44ES038062-02
    Organization: ATTAGENE, INC.; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 5R44ES038062-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 1095747; Administering IC: National Institute of Environmental Health Sciences; Project title: A Two-Tier Effect-Based Water Bioactivity Surveillance System.; Organization type: Domestic For-Profits
Aug 31, 2026NIH RePORTER 3R44ES038062-02S1
TretheraNIH awarded $897K (STTR Phase II 5R42DK138578-03, continuation, notice Sep 17, 2026); 3 NIH awards totaling $3.04M in the last 12 months.
Evidence (3 events)
  • Sep 17, 2026 · NIH RePORTER 5R42DK138578-03
    Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R42DK138578-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 897265; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease; Organization type: Domestic For-Profits
  • Aug 11, 2026 · NIH RePORTER 5R44AI188587-02
    Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R44AI188587-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 994978; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus; Organization type: Domestic For-Profits
  • Aug 5, 2026 · NIH RePORTER 5R44CA302066-02
    Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R44CA302066-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 1150000; Administering IC: National Cancer Institute; Project title: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R42DK138578-03
Alcamena Stem Cell TherapeuticsNIH awarded $1.5M (SBIR Phase II 5R44NS145934-02, continuation, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 5R44NS145934-02
    Organization: ALCAMENA STEM CELL THERAPEUTICS, LLC; City/State: Baltimore, MD; Project number: 5R44NS145934-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1500000; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R44NS145934-02
Faknostics, LLCNIH awarded $663K (STTR Phase II 5R42HL162392-04, continuation, notice Sep 4, 2026); 2 NIH awards totaling $1.33M in the last 12 months.
Evidence (2 events)
  • Sep 4, 2026 · NIH RePORTER 5R42HL162392-04
    Organization: FAKNOSTICS, LLC; City/State: PHOENIX, AZ; Project number: 5R42HL162392-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 662561; Administering IC: National Heart Lung and Blood Institute; Project title: Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis; Organization type: Domestic For-Profits
  • Aug 3, 2026 · NIH RePORTER 5R42DK141379-03
    Organization: FAKNOSTICS, LLC; City/State: PHOENIX, AZ; Project number: 5R42DK141379-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 669464; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R42HL162392-04
IVOS Medical, Inc.NIH awarded $145K (SBIR Phase II 5R44HL164325-04, continuation, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 5R44HL164325-04
    Organization: IVOS MEDICAL, INC.; City/State: DANA POINT, CA; Project number: 5R44HL164325-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 144919; Administering IC: National Heart Lung and Blood Institute; Project title: IVOS Medical: Intubation, Optimized.; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 5R44HL164325-04
Arbor Medical Innovations LLCNIH awarded $1.33M (SBIR Phase II 5U44NS122002-05, continuation, notice Aug 21, 2026).
Evidence (1 event)
  • Aug 21, 2026 · NIH RePORTER 5U44NS122002-05
    Organization: ARBOR MEDICAL INNOVATIONS, LLC; City/State: YPSILANTI, MI; Project number: 5U44NS122002-05; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1327568; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Actigraphy Enhanced Clinical Chronic Lower Back Pain Management; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 5U44NS122002-05
ZetrOZ SystemsNIH awarded $2.15M (SBIR Phase II 5R44AG061985-08, continuation, notice Aug 17, 2026).
Evidence (1 event)
  • Aug 17, 2026 · NIH RePORTER 5R44AG061985-08
    Organization: ZETROZ SYSTEMS, LLC; City/State: TRUMBULL, CT; Project number: 5R44AG061985-08; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 2154078; Administering IC: National Institute on Aging; Project title: Daily & Localized NSAID Sonophoresis for Symptomatic Treatment of Knee Osteoarthritis; Organization type: Domestic For-Profits
Aug 17, 2026NIH RePORTER 5R44AG061985-08
PleoPharmaNIH awarded $2.2M (NIH grant 1U01DA066079-01, new, notice Aug 12, 2026).
Evidence (1 event)
  • Aug 12, 2026 · NIH RePORTER 1U01DA066079-01
    Organization: PLEOPHARMA, INC.; City/State: MALVERN, PA; Project number: 1U01DA066079-01; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 2199962; Administering IC: National Institute on Drug Abuse; Project title: Phase 3 Trial of PP-01 for Mitigation of Cannabis Withdrawal in CUD; Organization type: Domestic For-Profits
Aug 12, 2026NIH RePORTER 1U01DA066079-01
Newleos Therapeutics, Inc.NIH awarded $3.1M (NIH grant 1UG3DA066264-01, new, notice Sep 8, 2026).
Evidence (1 event)
  • Sep 8, 2026 · NIH RePORTER 1UG3DA066264-01
    Organization: NEWLEOS THERAPEUTICS, INC.; City/State: HOPKINTON, MA; Project number: 1UG3DA066264-01; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 3097247; Administering IC: National Institute on Drug Abuse; Project title: NTX-2001, a trace amine-associated receptor 1 (TAAR1) partial agonist, for the treatment of Cocaine Use Disorder; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 1UG3DA066264-01
TwoStep TherapeuticsNIH awarded $1.3M (SBIR Phase II 1R44CA306597-01A1, new, notice Sep 4, 2026); 1 role open.
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 1R44CA306597-01A1
    Organization: TWOSTEP THERAPEUTICS, INC.; City/State: SAN CARLOS, CA; Project number: 1R44CA306597-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1303289; Administering IC: National Cancer Institute; Project title: Developing a broadly applicable targeted peptide-drug conjugate for the treatment of solid tumors; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 1R44CA306597-01A1
Curza IncNIH awarded $1M (SBIR Phase II 5R44AI186898-03, continuation, notice Jun 26, 2026).
Evidence (1 event)
  • Jun 26, 2026 · NIH RePORTER 5R44AI186898-03
    Organization: CURZA INC; City/State: Salt Lake City, UT; Project number: 5R44AI186898-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: New oral antibiotics focused on treating MDR Gram-negative infections; Organization type: Domestic For-Profits
Jun 26, 2026NIH RePORTER 5R44AI186898-03
Clear Scientific, Inc.NIH awarded $3M (NIH grant 1U01DA066075-01, new, notice Jul 20, 2026).
Evidence (1 event)
  • Jul 20, 2026 · NIH RePORTER 1U01DA066075-01
    Organization: CLEAR SCIENTIFIC, LLC; City/State: CAMBRIDGE, MA; Project number: 1U01DA066075-01; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 3000030; Administering IC: National Institute on Drug Abuse; Project title: A Phase 2a clinical study to evaluate the safety and efficacy of CS-1103, a therapeutic agent to treat methamphetamine intoxication; Organization type: Domestic For-Profits
Jul 20, 2026NIH RePORTER 1U01DA066075-01
NewomicsNIH awarded $1M (SBIR Phase II 5R44GM161156-02, continuation, notice Aug 31, 2026).
Evidence (1 event)
  • Aug 31, 2026 · NIH RePORTER 5R44GM161156-02
    Organization: NEWOMICS, INC; City/State: Berkeley, CA; Project number: 5R44GM161156-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1000000; Administering IC: National Institute of General Medical Sciences; Project title: Multispray Technology for Studying Biomolecular Interactions; Organization type: Domestic For-Profits
Aug 31, 2026NIH RePORTER 5R44GM161156-02
atai Therapeutics, Inc.NIH awarded $2.73M (NIH grant 5UG3DA064403-02, continuation, notice Jul 6, 2026).
Evidence (1 event)
  • Jul 6, 2026 · NIH RePORTER 5UG3DA064403-02
    Organization: ATAI THERAPEUTICS, INC.; City/State: NEW YORK, NY; Project number: 5UG3DA064403-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 2733774; Administering IC: National Institute on Drug Abuse; Project title: Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics; Organization type: Domestic For-Profits
Jul 6, 2026NIH RePORTER 5UG3DA064403-02
Alida Biosciences Inc.NIH awarded $1.15M (SBIR Phase II 5R44GM159469-02, continuation, notice Jul 17, 2026).
Evidence (1 event)
  • Jul 17, 2026 · NIH RePORTER 5R44GM159469-02
    Organization: ALIDA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 5R44GM159469-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1146785; Administering IC: National Institute of General Medical Sciences; Project title: Pseudouridine detection with single-base resolution in a multiplexed epitranscriptomics assay; Organization type: Domestic For-Profits
Jul 17, 2026NIH RePORTER 5R44GM159469-02
Mirecule Inc.NIH awarded $609K (SBIR Phase II 5R44NS119147-05, continuation, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 5R44NS119147-05
    Organization: MIRECULE, INC.; City/State: Gaithersburg, MD; Project number: 5R44NS119147-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 608751; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R44NS119147-05
Stingray Therapeutics Inc.NIH awarded $1.46M (SBIR Phase II 5R44CA278144-04, continuation, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 5R44CA278144-04
    Organization: STINGRAY THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 5R44CA278144-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1460952; Administering IC: National Cancer Institute; Project title: A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 5R44CA278144-04
Tendel Therapies Inc.NIH awarded $1M (SBIR Phase II 5R44AI192249-02, continuation, notice Aug 4, 2026).
Evidence (1 event)
  • Aug 4, 2026 · NIH RePORTER 5R44AI192249-02
    Organization: TENDEL THERAPIES INC.; City/State: KENSINGTON, CA; Project number: 5R44AI192249-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 999990; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Optimizing SIV reservoir depletion by Tendel bsAb-98; Organization type: Domestic For-Profits
Aug 4, 2026NIH RePORTER 5R44AI192249-02
ArcascopeNIH awarded $598K (STTR Phase II 5R42HL163783-04, continuation, notice Sep 2, 2026).
Evidence (1 event)
  • Sep 2, 2026 · NIH RePORTER 5R42HL163783-04
    Organization: ARCASCOPE, INC; City/State: CHANTILLY, VA; Project number: 5R42HL163783-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 598418; Administering IC: National Heart Lung and Blood Institute; Project title: Real-world translation of a dynamic and personalized intervention for shift workers; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 5R42HL163783-04
Revel PharmaceuticalsNIH awarded $924K (SBIR Phase II 5R44AG084351-03, continuation, notice Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · NIH RePORTER 5R44AG084351-03
    Organization: REVEL PHARMACEUTICALS INC.; City/State: San Francisco, CA; Project number: 5R44AG084351-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 923550; Administering IC: National Institute on Aging; Project title: Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 5R44AG084351-03
Scarab Genomics LLCNIH awarded $852K (SBIR Phase II 5R44GM156147-03, continuation, notice Sep 4, 2026); 2 NIH awards totaling $1.77M in the last 12 months.
Evidence (2 events)
  • Sep 4, 2026 · NIH RePORTER 5R44GM156147-03
    Organization: SCARAB GENOMICS, LLC; City/State: MADISON, WI; Project number: 5R44GM156147-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 851745; Administering IC: National Institute of General Medical Sciences; Project title: An improved low-endotoxin Clean Genome E. coli strain for production of biological products; Organization type: Domestic For-Profits
  • Sep 2, 2026 · NIH RePORTER 5R44GM161364-02
    Organization: SCARAB GENOMICS, LLC; City/State: MADISON, WI; Project number: 5R44GM161364-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 917119; Administering IC: National Institute of General Medical Sciences; Project title: Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R44GM156147-03
Toi Labs, Inc.NIH awarded $1.09M (SBIR Phase II 5R44AG074812-03, continuation, notice Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · NIH RePORTER 5R44AG074812-03
    Organization: TOI LABS, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44AG074812-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1089746; Administering IC: National Institute on Aging; Project title: Use of a Novel Toilet Seat to Passively Collect Digital Biomarkers in Assisted Living Settings; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 5R44AG074812-03
Lighthouse PharmaceuticalsNIH awarded $12.59M (NIH grant 5R01AG088524-02, continuation, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 5R01AG088524-02
    Organization: LIGHTHOUSE PHARMACEUTICALS, INC.; City/State: Novato, CA; Project number: 5R01AG088524-02; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 12591952; Administering IC: National Institute on Aging; Project title: A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects with P. gingivalis-Positive Alzheimer's Disease; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 5R01AG088524-02
GentiBio, IncNIH awarded $1.06M (SBIR Phase II 1R44DK148134-01, new, notice Sep 17, 2026); 4 NIH awards totaling $3.6M in the last 12 months.
Evidence (4 events)
  • Sep 17, 2026 · NIH RePORTER 1R44DK148134-01
    Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R44DK148134-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1061227; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Disease; Organization type: Domestic For-Profits
  • Sep 7, 2026 · NIH RePORTER 1R43NS149828-01
    Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R43NS149828-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 320037; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Engineered Tissue Treg Therapy for the Treatment of ALS; Organization type: Domestic For-Profits
  • Aug 24, 2026 · NIH RePORTER 1R44DK148168-01
    Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R44DK148168-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1066332; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: GNTI-148: an allogeneic islet-specific engineered Treg for treating T1D; Organization type: Domestic For-Profits
  • Jul 8, 2026 · NIH RePORTER 5R44NS145848-02
    Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS145848-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 1150749; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44DK148134-01
Zymtronix Catalytic Systems, Inc.NIH awarded $202K (SBIR Phase II 5R44GM134847-04, continuation, notice Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · NIH RePORTER 5R44GM134847-04
    Organization: ZYMTRONIX CATALYTIC SYSTEMS, INC.; City/State: Durham, NC; Project number: 5R44GM134847-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 201770; Administering IC: National Institute of General Medical Sciences; Project title: Scaling-up flow processes for the chemoenzymatic synthesis of a sialylated glycan; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 5R44GM134847-04
Integral MolecularNIH awarded $879K (SBIR commercialization 5SB1GM156044-03, continuation, notice Sep 8, 2026); 3 NIH awards totaling $2.05M in the last 12 months; since then posted 2 roles.
Evidence (3 events)
  • Sep 8, 2026 · NIH RePORTER 5SB1GM156044-03
    Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5SB1GM156044-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 879255; Administering IC: National Institute of General Medical Sciences; Project title: Specificity Screening Drug Development Tool for Biotherapeutic Safety; Organization type: Domestic For-Profits
  • Jul 30, 2026 · NIH RePORTER 5R44GM150317-03
    Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5R44GM150317-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 631033; Administering IC: National Institute of General Medical Sciences; Project title: High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA; Organization type: Domestic For-Profits
  • Jun 19, 2026 · NIH RePORTER 5U24AI189369-02
    Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5U24AI189369-02; Activity code: U24; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 541852; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Generation of Pan-reactive Antibody and Cytokine Reagents for Immunologic Analysis of Bats; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 5SB1GM156044-03
Expanse Bio LLCNIH awarded $983K (SBIR Phase II 5R44AI186974-04, continuation, notice Jul 15, 2026).
Evidence (1 event)
  • Jul 15, 2026 · NIH RePORTER 5R44AI186974-04
    Organization: EXPANSE BIO LLC; City/State: NORTH CHARLESTON, SC; Project number: 5R44AI186974-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-15; FY total cost (award amount): 983076; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Neonatal and Young Pediatric Kidney Preservation through Nanowarming and Vitrification; Organization type: Domestic For-Profits
Jul 15, 2026NIH RePORTER 5R44AI186974-04
ImmunovaNIH awarded $460K (SBIR Phase I 1R43AG102094-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43AG102094-01
    Organization: IMMUNOVA, LLC; City/State: GAINESVILLE, FL; Project number: 1R43AG102094-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 459616; Administering IC: National Institute on Aging; Project title: Mitigating Age-Related Cognitive Decline through a First-in-Class Lipid Neurogenic Therapy; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG102094-01
Highland Instruments Inc.NIH awarded $1.5M (SBIR Phase II 2R44NS110237-04, competing renewal, notice Aug 6, 2026); 2 NIH awards totaling $3.41M in the last 12 months.
Evidence (2 events)
  • Aug 6, 2026 · NIH RePORTER 2R44NS110237-04
    Organization: HIGHLAND INSTRUMENTS, INC.; City/State: CAMBRIDGE, MA; Project number: 2R44NS110237-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1496687; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: ESStim for the Treatment of Postural Instability in Patients with Parkinson's Disease - Phase IIB; Organization type: Domestic For-Profits
  • Jun 3, 2026 · NIH RePORTER 5SB1AG091887-02
    Organization: HIGHLAND INSTRUMENTS, INC.; City/State: CAMBRIDGE, MA; Project number: 5SB1AG091887-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1916568; Administering IC: National Institute on Aging; Project title: CRP: Noninvasive brain stimulation for chronic pain treatment; Organization type: Domestic For-Profits
Aug 6, 2026NIH RePORTER 2R44NS110237-04
Corami BiotechNIH awarded $1.16M (STTR Phase II 5R42HL149495-03, continuation, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 5R42HL149495-03
    Organization: CORAMI BIOTECH INC.; City/State: MEMPHIS, TN; Project number: 5R42HL149495-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1164977; Administering IC: National Heart Lung and Blood Institute; Project title: Minimally Invasive Local Delivery of Cardiac Gene Therapy; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 5R42HL149495-03
Light Research Inc.NIH awarded $477K (SBIR Phase II 5R44DE033307-03, continuation, notice Aug 20, 2026).
Evidence (1 event)
  • Aug 20, 2026 · NIH RePORTER 5R44DE033307-03
    Organization: LIGHT RESEARCH, INC.; City/State: TUCSON, AZ; Project number: 5R44DE033307-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 477217; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Multimodal intraoral camera; Organization type: Domestic For-Profits
Aug 20, 2026NIH RePORTER 5R44DE033307-03
BEAM Diagnostics, Inc.NIH awarded $1.75M (SBIR commercialization 5SB1AA032146-02, continuation, notice Aug 13, 2026).
Evidence (1 event)
  • Aug 13, 2026 · NIH RePORTER 5SB1AA032146-02
    Organization: BEAM DIAGNOSTICS, INC.; City/State: Roanoke, VA; Project number: 5SB1AA032146-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1749353; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Achieving FDA Approval & Commercial Readiness for Beacon-AUD: A Digital Diagnostic Medical Device for Alcohol Use Disorder; Organization type: Domestic For-Profits
Aug 13, 2026NIH RePORTER 5SB1AA032146-02
Paratechs Corp.NIH awarded $535K (SBIR Phase II 5R44OD032088-03, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5R44OD032088-03
    Organization: PARATECHS CORP.; City/State: LEXINGTON, KY; Project number: 5R44OD032088-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 535088; Administering IC: NIH Office of the Director; Project title: A novel rat sperm cryopreservation and artificial insemination system; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R44OD032088-03
Harlingene Life Sciences LLCNIH awarded $1M (STTR Phase II 5R42AI177204-04, continuation, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 5R42AI177204-04
    Organization: HARLINGENE LIFE SCIENCES LLC; City/State: DOYLESTOWN, PA; Project number: 5R42AI177204-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 5R42AI177204-04
Tezcat BiosciencesNIH awarded $929K (SBIR Phase II 5R44CA265512-03, continuation, notice Aug 27, 2026); 2 NIH awards totaling $1.33M in the last 12 months.
Evidence (2 events)
  • Aug 27, 2026 · NIH RePORTER 5R44CA265512-03
    Organization: TEZCAT BIOSCIENCES, INC.; City/State: NEW HAVEN, CT; Project number: 5R44CA265512-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 928698; Administering IC: National Cancer Institute; Project title: A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.; Organization type: Domestic For-Profits
  • Aug 18, 2026 · NIH RePORTER 1R41CA306696-01A1
    Organization: TEZCAT BIOSCIENCES, INC.; City/State: NEW HAVEN, CT; Project number: 1R41CA306696-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 399855; Administering IC: National Cancer Institute; Project title: Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer.; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 5R44CA265512-03
EvoDenovo Inc.NIH awarded $687K (SBIR Phase II 5R44DA053844-04, continuation, notice Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · NIH RePORTER 5R44DA053844-04
    Organization: EVODENOVO, INC.; City/State: andover, MA; Project number: 5R44DA053844-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 687310; Administering IC: National Institute on Drug Abuse; Project title: Development of small molecule therapeutics for mitigating opioid withdrawal syndrome; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 5R44DA053844-04
Great Lakes NeuroTechnologies Inc.NIH awarded $949K (SBIR Phase II 2R44MD013767-04A1, competing renewal, notice Aug 25, 2026); 2 NIH awards totaling $1.88M in the last 12 months.
Evidence (2 events)
  • Aug 25, 2026 · NIH RePORTER 2R44MD013767-04A1
    Organization: GREAT LAKES NEUROTECHNOLOGIES; City/State: Independence, OH; Project number: 2R44MD013767-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 949447; Administering IC: National Institute on Minority Health and Health Disparities; Project title: DiSCERN: Advanced PD Therapy Candidacy and Evaluation System; Organization type: Domestic For-Profits
  • Jun 19, 2026 · NIH RePORTER 5R44NS143484-02
    Organization: GREAT LAKES NEUROTECHNOLOGIES; City/State: Independence, OH; Project number: 5R44NS143484-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 926671; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: DBS-Expert Pro: Automated Deep Brain Stimulation Programming Using Functional Mapping; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 2R44MD013767-04A1
Ship of Theseus LLCNIH awarded $50K (SBIR Phase II 3R44HL158313-03S1, supplement, notice Aug 13, 2026); 2 NIH awards totaling $375K in the last 12 months.
Evidence (2 events)
  • Aug 13, 2026 · NIH RePORTER 3R44HL158313-03S1
    Organization: SHIP OF THESEUS, LLC; City/State: Eagleville, PA; Project number: 3R44HL158313-03S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 50000; Administering IC: National Heart Lung and Blood Institute; Project title: Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant; Organization type: Domestic For-Profits
  • Jul 22, 2026 · NIH RePORTER 5R44HL158313-03
    Organization: SHIP OF THESEUS, LLC; City/State: Eagleville, PA; Project number: 5R44HL158313-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 324853; Administering IC: National Heart Lung and Blood Institute; Project title: Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant; Organization type: Domestic For-Profits
Aug 13, 2026NIH RePORTER 3R44HL158313-03S1
BriaCell TherapeuticsNIH awarded $948K (SBIR Phase II 5R44CA281555-03, continuation, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 5R44CA281555-03
    Organization: BRIACELL THERAPEUTICS CORP; City/State: PHILADELPHIA, PA; Project number: 5R44CA281555-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 947870; Administering IC: National Cancer Institute; Project title: An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 5R44CA281555-03
Optimeos Life Sciences, Inc.NIH awarded $300K (SBIR Phase I 5R43AI188970-02, continuation, notice Jul 23, 2026).
Evidence (1 event)
  • Jul 23, 2026 · NIH RePORTER 5R43AI188970-02
    Organization: OPTIMEOS LIFE SCIENCES, INC.; City/State: Princeton, NJ; Project number: 5R43AI188970-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: In vivo targeted delivery of nucleic acids to hematopoietic stem cells for treating primary immunodeficiencies; Organization type: Domestic For-Profits
Jul 23, 2026NIH RePORTER 5R43AI188970-02
Nurelm, Inc.NIH awarded $588K (SBIR Phase II 5R44MH138145-03, continuation, notice Jul 15, 2026).
Evidence (1 event)
  • Jul 15, 2026 · NIH RePORTER 5R44MH138145-03
    Organization: NURELM E-BUSINESS SOFTWARE; City/State: PITTSBURGH, PA; Project number: 5R44MH138145-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-15; FY total cost (award amount): 587897; Administering IC: National Institute of Mental Health; Project title: Using Machine Learning and Sensing to Contextualize Hyperactivity Measurement on Wearable Devices; Organization type: Domestic For-Profits
Jul 15, 2026NIH RePORTER 5R44MH138145-03
Circumvent PharmaceuticalsNIH awarded $1.22M (SBIR Phase II 5R44NS120360-04, continuation, notice Aug 3, 2026).
Evidence (1 event)
  • Aug 3, 2026 · NIH RePORTER 5R44NS120360-04
    Organization: CIRCUMVENT PHARMACEUTICALS, INC.; City/State: PORTLAND, CA; Project number: 5R44NS120360-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1219273; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a Therapeutic Agent for Treating CLN1 Batten Disease; Organization type: Domestic For-Profits
Aug 3, 2026NIH RePORTER 5R44NS120360-04
Attogene CorporationNIH awarded $421K (SBIR Phase II 2R44ES034301-02A1, competing renewal, notice Jul 28, 2026).
Evidence (1 event)
  • Jul 28, 2026 · NIH RePORTER 2R44ES034301-02A1
    Organization: ATTOGENE; City/State: AUSTIN, TX; Project number: 2R44ES034301-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 421018; Administering IC: National Institute of Environmental Health Sciences; Project title: Development of a portable, rapid, easy-to-use, quantitative dihydroanatoxin-a detection system; Organization type: Domestic For-Profits
Jul 28, 2026NIH RePORTER 2R44ES034301-02A1
RealSeq BiosciencesNIH awarded $383K (SBIR Phase I 1R43CA314894-01, new, notice Aug 20, 2026); 2 NIH awards totaling $1.4M in the last 12 months.
Evidence (2 events)
  • Aug 20, 2026 · NIH RePORTER 1R43CA314894-01
    Organization: REALSEQ BIOSCIENCES, INC.; City/State: SANTA CRUZ, CA; Project number: 1R43CA314894-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 382518; Administering IC: National Cancer Institute; Project title: Advanced approach for target small RNAs enrichment from biological samples and sequencing library preparation (TSR-Seq); Organization type: Domestic For-Profits
  • Aug 7, 2026 · NIH RePORTER 5R44HG013284-03
    Organization: REALSEQ BIOSCIENCES, INC.; City/State: SANTA CRUZ, CA; Project number: 5R44HG013284-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1020220; Administering IC: National Human Genome Research Institute; Project title: Preparation of sequencing libraries for multi-analyte analysis of RNAs; Organization type: Domestic For-Profits
Aug 20, 2026NIH RePORTER 1R43CA314894-01
Sylvatica Biotech Inc.NIH awarded $972K (SBIR Phase II 5R44DK136457-03, continuation, notice Aug 7, 2026).
Evidence (1 event)
  • Aug 7, 2026 · NIH RePORTER 5R44DK136457-03
    Organization: SYLVATICA BIOTECH, INC.; City/State: NORTH CHARLESTON, SC; Project number: 5R44DK136457-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 972116; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Enhanced supercooling for extending non-freezing preservation in preclinical porcine and human donor livers; Organization type: Domestic For-Profits
Aug 7, 2026NIH RePORTER 5R44DK136457-03
Evidation Health, Inc.NIH awarded $2.02M (SBIR Phase II 4R44DA062284-02, extension, notice Jun 23, 2026).
Evidence (1 event)
  • Jun 23, 2026 · NIH RePORTER 4R44DA062284-02
    Organization: EVIDATION HEALTH, INC.; City/State: MENLO PARK, CA; Project number: 4R44DA062284-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 2023761; Administering IC: National Institute on Drug Abuse; Project title: Research and Engagement on Substance use Harnessing Awareness and Personalized Education (RESHAPE); Organization type: Domestic For-Profits
Jun 23, 2026NIH RePORTER 4R44DA062284-02
Merlin TherapeuticsNIH awarded $1.5M (SBIR Phase II 5R44NS145814-02, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5R44NS145814-02
    Organization: MERLIN THERAPEUTICS INC; City/State: KING OF PRUSSIA, PA; Project number: 5R44NS145814-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 1500000; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannoma; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R44NS145814-02
CND Life SciencesNIH awarded $1.01M (SBIR Phase II 5R44NS143486-02, continuation, notice Sep 7, 2026).
Evidence (1 event)
  • Sep 7, 2026 · NIH RePORTER 5R44NS143486-02
    Organization: CND LIFE SCIENCES, INC.; City/State: Scottsdale, AZ; Project number: 5R44NS143486-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1012800; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Analysis of Cutaneous Phosphorylated alpha-Synuclein to Identify Patients at Risk of Progressing from Essential Tremor to Parkinson's Disease; Organization type: Domestic For-Profits
Sep 7, 2026NIH RePORTER 5R44NS143486-02
BacStitch DNANIH awarded $1.08M (SBIR Phase II 1R44HG014736-01A1, new, notice Sep 3, 2026).
Evidence (1 event)
  • Sep 3, 2026 · NIH RePORTER 1R44HG014736-01A1
    Organization: BACSTITCH DNA INC.; City/State: Los Altos, CA; Project number: 1R44HG014736-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1077022; Administering IC: National Human Genome Research Institute; Project title: Hierarchical in vivo assembly for rapid and high-throughput construction of long DNA sequences; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 1R44HG014736-01A1
MitoChem TherapeuticsNIH awarded $321K (SBIR Phase I 1R43EY037591-01A1, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43EY037591-01A1
    Organization: MITOCHEM THERAPEUTICS INC.; City/State: CHARLESTON, SC; Project number: 1R43EY037591-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 320790; Administering IC: National Eye Institute; Project title: Novel gene mutation agnostic small molecule to treat retinitis pigmentosa; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43EY037591-01A1
SFC FluidicsNIH awarded $250K (SBIR Phase I 1R43DK146368-01A1, new, notice Aug 31, 2026).
Evidence (1 event)
  • Aug 31, 2026 · NIH RePORTER 1R43DK146368-01A1
    Organization: SFC FLUIDICS, LLC; City/State: FAYETTEVILLE, AR; Project number: 1R43DK146368-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 250000; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a Phenolics Depletion Chip (PDC) for Use in Insulin Delivery Patch Pumps; Organization type: Domestic For-Profits
Aug 31, 2026NIH RePORTER 1R43DK146368-01A1
Simulations Plus Inc.NIH awarded $115K (NIH grant 5U01FD008388-03, continuation, notice Sep 8, 2026).
Evidence (1 event)
  • Sep 8, 2026 · NIH RePORTER 5U01FD008388-03
    Organization: SIMULATIONS PLUS, INC.; City/State: LANCASTER, CA; Project number: 5U01FD008388-03; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 114912; Administering IC: Food and Drug Administration; Project title: From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 5U01FD008388-03
Blotting InnovationsNIH awarded $1.03M (SBIR Phase II 5R44GM148112-03, continuation, notice Aug 7, 2026).
Evidence (1 event)
  • Aug 7, 2026 · NIH RePORTER 5R44GM148112-03
    Organization: BLOTTING INNOVATIONS, INC; City/State: CENTRAL, SC; Project number: 5R44GM148112-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1026555; Administering IC: National Institute of General Medical Sciences; Project title: High-Throughput Western Blotting; Organization type: Domestic For-Profits
Aug 7, 2026NIH RePORTER 5R44GM148112-03
NephroDi TherapeuticsNIH awarded $999K (SBIR Phase II 5R44DK127798-03, continuation, notice Jul 27, 2026).
Evidence (1 event)
  • Jul 27, 2026 · NIH RePORTER 5R44DK127798-03
    Organization: NEPHRODI THERAPEUTICS, INC.; City/State: Seattle, WA; Project number: 5R44DK127798-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-27; FY total cost (award amount): 998617; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patients; Organization type: Domestic For-Profits
Jul 27, 2026NIH RePORTER 5R44DK127798-03
MyolexNIH awarded $137K (SBIR Phase I 5R43CA306431-02, continuation, notice Sep 1, 2026).
Evidence (1 event)
  • Sep 1, 2026 · NIH RePORTER 5R43CA306431-02
    Organization: MYOLEX, INC.; City/State: Brookline, MA; Project number: 5R43CA306431-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 136944; Administering IC: National Cancer Institute; Project title: Electrical impedance myography (EIM) to detect and track cancer cachexia; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 5R43CA306431-02
iVeena Delivery Systems, Inc.NIH awarded $1.11M (SBIR Phase II 5R44EY034770-03, continuation, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 5R44EY034770-03
    Organization: IVEENA DELIVERY SYSTEMS, INC.; City/State: SALT LAKE CITY, UT; Project number: 5R44EY034770-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 1111998; Administering IC: National Eye Institute; Project title: Topical Eyedrops Increasing Lysyl Oxidase and Dopamine Activity to Control Myopia; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 5R44EY034770-03
Oncotherapy SolutionsNIH awarded $400K (SBIR Phase I 1R43CA306418-01A1, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43CA306418-01A1
    Organization: ONCOTHERAPY SOLUTIONS, LLC; City/State: Seattle, WA; Project number: 1R43CA306418-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer.; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43CA306418-01A1
Remedy Plan TherapeuticsNIH awarded $1.18M (SBIR Phase II 1R44CA314487-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44CA314487-01
    Organization: REMEDY PLAN; City/State: GAITHERSBURG, MD; Project number: 1R44CA314487-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1181436; Administering IC: National Cancer Institute; Project title: Preclinical validation of NAMPT and PARP inhibitor combinations for breast cancer to support clinical studies; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44CA314487-01
Enyx Therapeutics LLCNIH awarded $792K (STTR Phase II 5R42AA028465-03, continuation, notice Aug 13, 2026).
Evidence (1 event)
  • Aug 13, 2026 · NIH RePORTER 5R42AA028465-03
    Organization: ENYX THERAPEUTICS, LLC; City/State: NEW YORK, NY; Project number: 5R42AA028465-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 791929; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency in Post-menopausal East Asian Women; Organization type: Domestic For-Profits
Aug 13, 2026NIH RePORTER 5R42AA028465-03
IHP TherapeuticsNIH awarded $433K (NIH grant 5UH3NS134781-03, continuation, notice Sep 7, 2026).
Evidence (1 event)
  • Sep 7, 2026 · NIH RePORTER 5UH3NS134781-03
    Organization: IHP THERAPEUTICS, INC.; City/State: San Carlos, CA; Project number: 5UH3NS134781-03; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 433322; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease; Organization type: Domestic For-Profits
Sep 7, 2026NIH RePORTER 5UH3NS134781-03
SHY TherapeuticsNIH awarded $287K (SBIR Phase I 5R43AI186577-02, continuation, notice Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · NIH RePORTER 5R43AI186577-02
    Organization: SHY THERAPEUTICS, LLC; City/State: HARRISON, NY; Project number: 5R43AI186577-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 286724; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Novel Class of Antifungal Therapy; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 5R43AI186577-02
Palvella TherapeuticsNIH awarded $484K (NIH grant 5R01FD008196-03, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R01FD008196-03
    Organization: PALVELLA THERAPEUTICS, INC.; City/State: WAYNE, PA; Project number: 5R01FD008196-03; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 484481; Administering IC: Food and Drug Administration; Project title: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R01FD008196-03
AivoCodeNIH awarded $500K (SBIR Phase I 1R43AG099485-01A1, new, notice Sep 16, 2026); 2 NIH awards totaling $1.74M in the last 12 months.
Evidence (2 events)
  • Sep 16, 2026 · NIH RePORTER 1R43AG099485-01A1
    Organization: AIVOCODE, LLP; City/State: Encinitas, CA; Project number: 1R43AG099485-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 499880; Administering IC: National Institute on Aging; Project title: Early Detection of Alzheimer’s Disease Using a Novel ImmunoPET Conjugate; Organization type: Domestic For-Profits
  • Jun 3, 2026 · NIH RePORTER 5R44AG097127-02
    Organization: AIVOCODE, LLP; City/State: Encinitas, CA; Project number: 5R44AG097127-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1237522; Administering IC: National Institute on Aging; Project title: Single domain antibody development for improving vascular dysfunction in Alzheimer’s disease; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R43AG099485-01A1
Theia Imaging LLCNIH awarded $61K (SBIR Phase II 3R44EY033604-03S2, supplement, notice Sep 21, 2026); 2 NIH awards totaling $1.09M in the last 12 months.
Evidence (2 events)
  • Sep 21, 2026 · NIH RePORTER 3R44EY033604-03S2
    Organization: THEIA IMAGING LLC; City/State: CHAPEL HILL, NC; Project number: 3R44EY033604-03S2; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-21; FY total cost (award amount): 60860; Administering IC: National Eye Institute; Project title: A Widefield, Handheld OCT system for Patients who are Unable to Cooperate; Organization type: Domestic For-Profits
  • Jul 17, 2026 · NIH RePORTER 2R44EY034418-02A1
    Organization: THEIA IMAGING LLC; City/State: CHAPEL HILL, NC; Project number: 2R44EY034418-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1031041; Administering IC: National Eye Institute; Project title: Ultrahigh Speed, Widefield OCT Angiography System for Patients who are Unable to Cooperate; Organization type: Domestic For-Profits
Sep 21, 2026NIH RePORTER 3R44EY033604-03S2
Max Biopharma, Inc.NIH awarded $365K (SBIR Phase I 1R43HL184363-01A1, new, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 1R43HL184363-01A1
    Organization: MAX BIOPHARMA, INC.; City/State: LOS ANGELES, CA; Project number: 1R43HL184363-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 364853; Administering IC: National Heart Lung and Blood Institute; Project title: Examination of anti-fibrotic and immune modulatory effects of Oxy210 for targeting cystic fibrosis; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 1R43HL184363-01A1
YourChoice TherapeuticsNIH awarded $994K (SBIR Phase II 1R44HD120117-01A1, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44HD120117-01A1
    Organization: YOURCHOICE THERAPEUTICS, INC.; City/State: Berkeley, CA; Project number: 1R44HD120117-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 994056; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Tablet development and relative bioavailability study in men for ongoing clinical development of YCT-529 as an oral non-hormonal male contraceptive; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44HD120117-01A1
Allinaire TherapeuticsNIH awarded $1.5M (SBIR Phase II 1R44HL186831-01, new, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 1R44HL186831-01
    Organization: ALLINAIRE THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 1R44HL186831-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1498892; Administering IC: National Heart Lung and Blood Institute; Project title: An anti-EMAP II monoclonal antibody as a first-in-class treatment for Group III pulmonary hypertension patients with chronic obstructive pulmonary disease; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 1R44HL186831-01
Cessation TherapeuticsNIH awarded $2.09M (NIH grant 5U01DA063352-02, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5U01DA063352-02
    Organization: CESSATION THERAPEUTICS, LLC; City/State: SAN JOSE, CA; Project number: 5U01DA063352-02; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 2089891; Administering IC: National Institute on Drug Abuse; Project title: Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5U01DA063352-02
Panome BioNIH awarded $1.16M (SBIR Phase II 5R44CA295318-02, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5R44CA295318-02
    Organization: PANOME BIO INC; City/State: SAINT LOUIS, MO; Project number: 5R44CA295318-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 1164167; Administering IC: National Cancer Institute; Project title: Biomarker discovery in colon cancer through next-generation metabolomics; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R44CA295318-02
Ossium Health Inc.NIH awarded $580K (SBIR Phase II 5R44AI183961-03, continuation, notice Aug 11, 2026); since then posted 4 roles.
Evidence (1 event)
  • Aug 11, 2026 · NIH RePORTER 5R44AI183961-03
    Organization: OSSIUM HEALTH, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44AI183961-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 579970; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury; Organization type: Domestic For-Profits
Aug 11, 2026NIH RePORTER 5R44AI183961-03
Framergy Inc.NIH awarded $400K (SBIR Phase I 1R43CA314462-01, new, notice Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · NIH RePORTER 1R43CA314462-01
    Organization: FRAMERGY, INC.; City/State: Wilmington, DE; Project number: 1R43CA314462-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: A Novel Sunscreen Formulation, Broad Spectrum UV Protection for Cancer Prevention Featuring Photoreactivation to Repair Existing Sun Damage; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 1R43CA314462-01
OncoTAbNIH awarded $1.13M (SBIR Phase II 1R44CA306447-01A1, new, notice Jul 17, 2026).
Evidence (1 event)
  • Jul 17, 2026 · NIH RePORTER 1R44CA306447-01A1
    Organization: ONCOTAB, INC; City/State: CHARLOTTE, NC; Project number: 1R44CA306447-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1130587; Administering IC: National Cancer Institute; Project title: Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment; Organization type: Domestic For-Profits
Jul 17, 2026NIH RePORTER 1R44CA306447-01A1
Noveome BiotherapeuticsNIH awarded $265K (STTR Phase I 1R41AG099399-01A1, new, notice Sep 7, 2026).
Evidence (1 event)
  • Sep 7, 2026 · NIH RePORTER 1R41AG099399-01A1
    Organization: NOVEOME BIOTHERAPEUTICS, INC.; City/State: PITTSBURGH, PA; Project number: 1R41AG099399-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 265064; Administering IC: National Institute on Aging; Project title: Intranasal ST266 Treatment of the Intracerebroventricular Streptozotocin Rat Model of Cognitive Impairment; Organization type: Domestic For-Profits
Sep 7, 2026NIH RePORTER 1R41AG099399-01A1
Ef Therapeutics LLCNIH awarded $1.06M (SBIR Phase II 5R44CA298522-02, continuation, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 5R44CA298522-02
    Organization: EF THERAPEUTICS CORP.; City/State: TAMPA, FL; Project number: 5R44CA298522-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1060745; Administering IC: National Cancer Institute; Project title: IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 5R44CA298522-02
Immunoshield TherapeuticsNIH awarded $935K (SBIR Phase II 5R44DK136496-03, continuation, notice Jul 30, 2026).
Evidence (1 event)
  • Jul 30, 2026 · NIH RePORTER 5R44DK136496-03
    Organization: IMMUNOSHIELD THERAPEUTICS INC.; City/State: CHANDLER, AZ; Project number: 5R44DK136496-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 935197; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Hydrogel injection molded islet macroencapsulation devices to treat diabetes in a non-human primate model; Organization type: Domestic For-Profits
Jul 30, 2026NIH RePORTER 5R44DK136496-03
Kano TherapeuticsNIH awarded $984K (SBIR Phase II 4R44GM159495-02, extension, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 4R44GM159495-02
    Organization: KANO THERAPEUTICS INC; City/State: CAMBRIDGE, MA; Project number: 4R44GM159495-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 984281; Administering IC: National Institute of General Medical Sciences; Project title: Active non-viral nuclear delivery of DNA templates independent of mitosis; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 4R44GM159495-02
Opus Genetics IncNIH awarded $1M (SBIR Phase II 1R44EY038152-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $2.02M in the last 12 months.
Evidence (2 events)
  • Sep 19, 2026 · NIH RePORTER 1R44EY038152-01A1
    Organization: OPUS GENETICS INC.; City/State: RALEIGH, NC; Project number: 1R44EY038152-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 1004925; Administering IC: National Eye Institute; Project title: Development of OPGx-RDH12 as a gene therapy for RDH12 deficiency associated Leber congenital amaurosis (LCA); Organization type: Domestic For-Profits
  • Sep 17, 2026 · NIH RePORTER 1R44EY038149-01A1
    Organization: OPUS GENETICS INC.; City/State: RALEIGH, NC; Project number: 1R44EY038149-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1012469; Administering IC: National Eye Institute; Project title: Development of OPGx-NMNAT1 as a gene therapy for NMNAT1 associated LCA.; Organization type: Domestic For-Profits
Sep 19, 2026NIH RePORTER 1R44EY038152-01A1
Enzyme by DesignNIH awarded $400K (SBIR Phase I 1R43CA306391-01A1, new, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 1R43CA306391-01A1
    Organization: ENZYME BY DESIGN, INC.; City/State: CHICAGO, IL; Project number: 1R43CA306391-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R43CA306391-01A1
Apex Biomedical Company, LLCNIH awarded $504K (SBIR commercialization 1SB1AR087897-01, new, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 1SB1AR087897-01
    Organization: APEX BIOMEDICAL COMPANY, LLC; City/State: Wilsonville, OR; Project number: 1SB1AR087897-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 504235; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Improving Fracture Healing with Active Plating Technology; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 1SB1AR087897-01
X-ThermaNIH awarded $1.1M (SBIR Phase II 2R44DK136396-03, competing renewal, notice Jul 7, 2026).
Evidence (1 event)
  • Jul 7, 2026 · NIH RePORTER 2R44DK136396-03
    Organization: X-THERMA INC.; City/State: Hercules, CA; Project number: 2R44DK136396-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 1100001; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Phase IIB - Greatly Extended Subzero Ischemic Storage of Renal Allografts Using Novel Bio-inspired Next Generation Cryoprotectants; Organization type: Domestic For-Profits
Jul 7, 2026NIH RePORTER 2R44DK136396-03
Ridgeline TherapeuticsNIH awarded $2.12M (SBIR Phase II 1R44AG102216-01, new, notice Sep 17, 2026); 2 NIH awards totaling $3.02M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1R44AG102216-01
    Organization: RIDGELINE THERAPEUTICS, INC.; City/State: Houston, TX; Project number: 1R44AG102216-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2117233; Administering IC: National Institute on Aging; Project title: Cardiovascular Safety and Scalable Manufacturing for Investigational New Drug Filing of a Novel Oral Drug to Accelerate Musculoskeletal Recovery in Older Adults; Organization type: Domestic For-Profits
  • Jul 28, 2026 · NIH RePORTER 5R44AG092210-02
    Organization: RIDGELINE THERAPEUTICS, INC.; City/State: Houston, TX; Project number: 5R44AG092210-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 904811; Administering IC: National Institute on Aging; Project title: Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG102216-01
Sano Healthcare Consultants, LLCNIH awarded $1.06M (SBIR Phase II 2R44DA061387-02, competing renewal, notice Aug 5, 2026).
Evidence (1 event)
  • Aug 5, 2026 · NIH RePORTER 2R44DA061387-02
    Organization: SANO HEALTHCARE CONSULTANTS, LLC; City/State: Ontario, CA; Project number: 2R44DA061387-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 1055180; Administering IC: National Institute on Drug Abuse; Project title: Secure Remote Dispensing of Liquid Methadone with Home Monitoring: Environmental Interactive Devices Support Sustainable Economic and Expansive Clinical Treatment of Opioid Use Disorder Treatment; Organization type: Domestic For-Profits
Aug 5, 2026NIH RePORTER 2R44DA061387-02
Serinus BiosciencesNIH awarded $349K (SBIR Phase II 1R44GM165171-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44GM165171-01
    Organization: SERINUS BIOSCIENCES INC; City/State: NEW YORK, NY; Project number: 1R44GM165171-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 349090; Administering IC: National Institute of General Medical Sciences; Project title: A massively parallel cell-based platform for the rational discovery of molecular glues; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44GM165171-01
HydroGene TherapeuticsNIH awarded $1.03M (SBIR Phase II 1R44HL187020-01, new, notice Sep 16, 2026); 2 NIH awards totaling $2.12M in the last 12 months.
Evidence (2 events)
  • Sep 16, 2026 · NIH RePORTER 1R44HL187020-01
    Organization: HYDROGENE THERAPEUTICS INC; City/State: HOUSTON, TX; Project number: 1R44HL187020-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1027445; Administering IC: National Heart Lung and Blood Institute; Project title: Non-viral hydrodynamic gene therapy for life-long correction of hemophilia; Organization type: Domestic For-Profits
  • Sep 10, 2026 · NIH RePORTER 1R44DK148200-01
    Organization: HYDROGENE THERAPEUTICS INC; City/State: HOUSTON, TX; Project number: 1R44DK148200-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1097036; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Developing Hydrodynamic Injection through Biliary System for the Treatment of Wilson's Disease; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R44HL187020-01
Enigma BiomedicalNIH awarded $897K (SBIR Phase II 1R44AG102186-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44AG102186-01
    Organization: ENIGMA BIOMEDICAL USA, INC; City/State: KNOXVILLE, TN; Project number: 1R44AG102186-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 896719; Administering IC: National Institute on Aging; Project title: Clinical Evaluation of a Novel [18F] Positron Emission Tomography (PET) Tracer for Differential Diagnosis and Staging of 4R Tauopathies; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG102186-01
Paulex BioNIH awarded $350K (STTR Phase II 1R42DK148220-01, new, notice Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · NIH RePORTER 1R42DK148220-01
    Organization: PAULEX BIO INC.; City/State: LA JOLLA, CA; Project number: 1R42DK148220-01; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 350000; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Preclinical Development of Paulex-4 for Human Trials for Beta Cell Regeneration to treat Diabetes; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 1R42DK148220-01
Switch TherapeuticsNIH awarded $1.61M (SBIR Phase II 1R44AG102082-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44AG102082-01
    Organization: SWITCH THERAPEUTICS INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 1R44AG102082-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1609473; Administering IC: National Institute on Aging; Project title: Liver-Sparing APOE Inhibitor for the Treatment of Alzheimer's Disease in APOE4 Homozygotes; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG102082-01
Bessor PharmaNIH awarded $1.1M (SBIR Phase II 5R44DK111251-05, continuation, notice Jul 28, 2026).
Evidence (1 event)
  • Jul 28, 2026 · NIH RePORTER 5R44DK111251-05
    Organization: BESSOR PHARMA, LLC; City/State: FRAMINGHAM, MA; Project number: 5R44DK111251-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 1099995; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a novel renalase agonist for the treatment of acute pancreatitis; Organization type: Domestic For-Profits
Jul 28, 2026NIH RePORTER 5R44DK111251-05
Constantiam BiosciencesNIH awarded $1.25M (SBIR Phase II 2R44AG084431-02, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44AG084431-02
    Organization: CONSTANTIAM BIOSCIENCES INC.; City/State: KATY, TX; Project number: 2R44AG084431-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1252240; Administering IC: National Institute on Aging; Project title: Leveraging high-throughput functional data for assessment of Alzheimer's risk; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44AG084431-02
Persista BioNIH awarded $1.01M (SBIR Phase II 5R44DK142496-02, continuation, notice Jul 31, 2026).
Evidence (1 event)
  • Jul 31, 2026 · NIH RePORTER 5R44DK142496-02
    Organization: PERSISTA BIO INC; City/State: ITHACA, NY; Project number: 5R44DK142496-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 1006033; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Advanced Pre-Clinical Development of O2LineTM System for Type 1 Diabetes Cell Therapy; Organization type: Domestic For-Profits
Jul 31, 2026NIH RePORTER 5R44DK142496-02
Nanohmics Inc.NIH awarded $1.02M (SBIR Phase II 5R44CK000679-03, continuation, notice Aug 24, 2026); 2 NIH awards totaling $1.34M in the last 12 months.
Evidence (2 events)
  • Aug 24, 2026 · NIH RePORTER 5R44CK000679-03
    Organization: NANOHMICS, INC.; City/State: AUSTIN, TX; Project number: 5R44CK000679-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1022797; Administering IC: National Center for Emerging and Zoonotic Infectious Diseases; Project title: Lateral Flow-Electrochemiluminescent (LF-ECL) Test Strips and Portable Reader for Ultrasensitive Foodborne Pathogen Detection; Organization type: Domestic For-Profits
  • Jul 23, 2026 · NIH RePORTER 1R43ES038796-01
    Organization: NANOHMICS, INC.; City/State: AUSTIN, TX; Project number: 1R43ES038796-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 313365; Administering IC: National Institute of Environmental Health Sciences; Project title: Handheld Fluorescent Lysosomal Yeast (FLY) Biosensor for Toxic Metal Ions andOrganic Pollutants in Water; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 5R44CK000679-03
MindImmune TherapeuticsNIH awarded $496K (SBIR Phase I 1R43AG102103-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43AG102103-01
    Organization: MINDIMMUNE THERAPEUTICS, INC.; City/State: KINGSTON, RI; Project number: 1R43AG102103-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 496415; Administering IC: National Institute on Aging; Project title: Targeting CD11c immune cells to alleviate cerebral amyloid angiopathy and amyloid-related imaging abnormality in patients with Alzheimer's disease; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG102103-01
KaliVir ImmunotherapeuticsNIH awarded $307K (SBIR Phase II 1R44CA314562-01, new, notice Sep 3, 2026).
Evidence (1 event)
  • Sep 3, 2026 · NIH RePORTER 1R44CA314562-01
    Organization: KALIVIR IMMUNOTHERAPEUTICS, INC; City/State: PITTSBURGH, PA; Project number: 1R44CA314562-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 306756; Administering IC: National Cancer Institute; Project title: Translation of the novel oncolytic immunotherapy VET6-PDI; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 1R44CA314562-01
Perception Dynamics InstituteNIH awarded $1.01M (SBIR Phase II 2R44NS132718-03, competing renewal, notice Sep 7, 2026).
Evidence (1 event)
  • Sep 7, 2026 · NIH RePORTER 2R44NS132718-03
    Organization: PERCEPTION DYNAMICS INSTITUTE; City/State: Encinitas, CA; Project number: 2R44NS132718-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1005434; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Retraining neural pathways improves cognitive skills after a mild traumatic brain injury; Organization type: Domestic For-Profits
Sep 7, 2026NIH RePORTER 2R44NS132718-03
RyTek Medical Inc.NIH awarded $472K (STTR Phase I 1R41NS143559-01A1, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R41NS143559-01A1
    Organization: RYTEK MEDICAL, INC.; City/State: LEBANON, NH; Project number: 1R41NS143559-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 472228; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: PulmoZ: A wearable bioimpedance-sensing patch for remote pulmonary function assessment in ALS; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R41NS143559-01A1
Thetis Pharmaceuticals LLCNIH awarded $670K (SBIR commercialization 1SB1DK145287-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $941K in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1SB1DK145287-01A1
    Organization: THETIS PHARMACEUTICALS, LLC; City/State: DEEP RIVER, CT; Project number: 1SB1DK145287-01A1; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 669925; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of TP-317 for Ulcerative Colitis; Organization type: Domestic For-Profits
  • Jul 6, 2026 · NIH RePORTER 5R44CA278026-03
    Organization: THETIS PHARMACEUTICALS, LLC; City/State: DEEP RIVER, CT; Project number: 5R44CA278026-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 271378; Administering IC: National Cancer Institute; Project title: Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1SB1DK145287-01A1
Glyphic Biotechnologies, Inc.NIH awarded $1.6M (SBIR Phase II 2R44GM151897-02A1, competing renewal, notice Jul 24, 2026); 5 roles open.
Evidence (1 event)
  • Jul 24, 2026 · NIH RePORTER 2R44GM151897-02A1
    Organization: GLYPHIC BIOTECHNOLOGIES, INC.; City/State: MENLO PARK, CA; Project number: 2R44GM151897-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-24; FY total cost (award amount): 1599463; Administering IC: National Institute of General Medical Sciences; Project title: Single-molecule protein sequencing: resolving individual amino acids via commercially accessible nanopores; Organization type: Domestic For-Profits
Jul 24, 2026NIH RePORTER 2R44GM151897-02A1
Tempo Therapeutics IncNIH awarded $1.42M (SBIR Phase II 1R44CA314892-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44CA314892-01
    Organization: TEMPO THERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 1R44CA314892-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1423186; Administering IC: National Cancer Institute; Project title: MOSAIC II: A Randomized Clinical Study of the MAP Wound Matrix to Reduce Time to Graft-Readiness after Non-Melanoma Skin Cancer Resection; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44CA314892-01
Bridgesource Medical, Corp.NIH awarded $1.51M (SBIR commercialization 1SB1AG102150-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.83M in the last 12 months.
Evidence (2 events)
  • Sep 17, 2026 · NIH RePORTER 1SB1AG102150-01
    Organization: BRIDGESOURCE MEDICAL CORPORATION; City/State: AUSTIN, TX; Project number: 1SB1AG102150-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1511003; Administering IC: National Institute on Aging; Project title: Medical Device Identifier to Improve Emergency Triage; Organization type: Domestic For-Profits
  • Aug 24, 2026 · NIH RePORTER 1R43HL182792-01A1
    Organization: BRIDGESOURCE MEDICAL CORPORATION; City/State: AUSTIN, TX; Project number: 1R43HL182792-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 320727; Administering IC: National Heart Lung and Blood Institute; Project title: A Right Heart Catheter for Pressure-Volume Loop Risk Stratification for Percutaneous Valve Repair in Tricuspid Regurgitation; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1SB1AG102150-01
Andson BiotechNIH awarded $1.4M (SBIR Phase II 1R44GM165164-01, new, notice Sep 3, 2026).
Evidence (1 event)
  • Sep 3, 2026 · NIH RePORTER 1R44GM165164-01
    Organization: ANDSON BIOTECH INC.; City/State: ATLANTA, GA; Project number: 1R44GM165164-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1403671; Administering IC: National Institute of General Medical Sciences; Project title: Development of an Automated Sample Preparation Platform for High Throughput Mass Spectrometry Characterization of Biotherapeutics; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 1R44GM165164-01
XCellAssayNIH awarded $1.14M (SBIR Phase II 2R44ES036049-02, competing renewal, notice Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · NIH RePORTER 2R44ES036049-02
    Organization: XCELLASSAY, INC.; City/State: SAN FRANCISCO, CA; Project number: 2R44ES036049-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1135244; Administering IC: National Institute of Environmental Health Sciences; Project title: Multiplexed Nuclear Receptor BioAssay platform to inexpensively and broadly survey the nation's water supply for contamination by endocrine disrupting chemicals; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 2R44ES036049-02
CognixionNIH awarded $1.26M (SBIR Phase II 1R44DC023888-01A1, new, notice Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · NIH RePORTER 1R44DC023888-01A1
    Organization: COGNIXION CORPORATION; City/State: SANTA BARBARA, CA; Project number: 1R44DC023888-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 1258551; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: BCI and Hybrid BCI Wearable Agency Device for ALS.; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 1R44DC023888-01A1
Enfuego Therapeutics, Inc.NIH awarded $312K (SBIR Phase II 1R44CA314597-01, new, notice Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · NIH RePORTER 1R44CA314597-01
    Organization: ENFUEGO THERAPEUTICS INC.; City/State: PITTSBORO, NC; Project number: 1R44CA314597-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 311734; Administering IC: National Cancer Institute; Project title: Overcoming Adaptive KRAS Inhibitor Resistance with Ligand-Directed KRAS G12V-panTEAD Chimeras; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 1R44CA314597-01
N.P. Photonics, Inc.NIH awarded $307K (SBIR Phase I 1R43GM165163-01, new, notice Sep 1, 2026).
Evidence (1 event)
  • Sep 1, 2026 · NIH RePORTER 1R43GM165163-01
    Organization: NP PHOTONICS, INC.; City/State: TUCSON, AZ; Project number: 1R43GM165163-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 306873; Administering IC: National Institute of General Medical Sciences; Project title: Low-cost robust compact 900 nm femtosecond laser source for two-photon microscopy; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R43GM165163-01
Origin EndoscopyNIH awarded $1.21M (SBIR Phase II 1R44DK145328-01A1, new, notice Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · NIH RePORTER 1R44DK145328-01A1
    Organization: ORIGIN ENDOSCOPY INC.; City/State: BALTIMORE, MD; Project number: 1R44DK145328-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1212289; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of EpiMAX, a first-in-class injectable hemostatic agent for long-acting hemostasis of gastrointestinal bleeding; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 1R44DK145328-01A1
Dauntless Biotherapeutics, Inc.NIH awarded $400K (SBIR Phase I 1R43CA306683-01A1, new, notice Aug 11, 2026).
Evidence (1 event)
  • Aug 11, 2026 · NIH RePORTER 1R43CA306683-01A1
    Organization: DAUNTLESS BIOTHERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 1R43CA306683-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Overcoming Breast Cancer Resistance with a Dual-Function Antibody Therapeutic; Organization type: Domestic For-Profits
Aug 11, 2026NIH RePORTER 1R43CA306683-01A1
Equator TherapeuticsNIH awarded $423K (SBIR Phase I 1R43DK146576-01A1, new, notice Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · NIH RePORTER 1R43DK146576-01A1
    Organization: EQUATOR THERAPEUTICS, INC.; City/State: Saint Louis, MO; Project number: 1R43DK146576-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 422785; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Partial Agonism of Mitochondrial Thermogenesis for the Safe Stimulation of Energy Expenditure; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 1R43DK146576-01A1
JiLLiON Therapeutics Inc.NIH awarded $1.12M (SBIR Phase II 2R44AG085856-02, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44AG085856-02
    Organization: JILLION THERAPEUTICS INC.; City/State: BROOKLYN, NY; Project number: 2R44AG085856-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1118025; Administering IC: National Institute on Aging; Project title: Advancing DEL-derived Small Molecule Inhibitors of Pathological Tau Toward Preclinical Development for Alzheimer’s Disease and Tauopathies; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44AG085856-02
AiM Medical RoboticsNIH awarded $1.01M (SBIR Phase II 1R44CA314728-01, new, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 1R44CA314728-01
    Organization: AIM MEDICAL ROBOTICS INC; City/State: WORCESTER, MA; Project number: 1R44CA314728-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 1008660; Administering IC: National Cancer Institute; Project title: Intraoperative MRI-Guided Neurosurgery Robot for Enhancing Ablative Treatment of Brain Cancer; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 1R44CA314728-01
Cellular Vehicles Inc.NIH awarded $1.02M (SBIR Phase II 2R44TR005112-02, competing renewal, notice Jun 16, 2026).
Evidence (1 event)
  • Jun 16, 2026 · NIH RePORTER 2R44TR005112-02
    Organization: CELLULAR VEHICLES INC.; City/State: SAN MATEO, CA; Project number: 2R44TR005112-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 1022611; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a novel tool that standardizes and automates the formulation of cell-laden hydrogels; Organization type: Domestic For-Profits
Jun 16, 2026NIH RePORTER 2R44TR005112-02
Airway TherapeuticsNIH awarded $1.91M (SBIR Phase II 1R44HL186892-01, new, notice Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · NIH RePORTER 1R44HL186892-01
    Organization: AIRWAY THERAPEUTICS, INC.; City/State: Atlanta, GA; Project number: 1R44HL186892-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1906253; Administering IC: National Heart Lung and Blood Institute; Project title: A Randomized,Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing BPD in High-Risk Preterm Neonates Compared to Standard of Care.; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 1R44HL186892-01
Claret BioscienceNIH awarded $386K (SBIR Phase I 1R43CA314763-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43CA314763-01
    Organization: CLARET BIOSCIENCE, LLC; City/State: BIRMINGHAM, MI; Project number: 1R43CA314763-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 385919; Administering IC: National Cancer Institute; Project title: A cfDNA methylo-fragmentomic assay for prediction of risk-progression in Prostate Cancer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43CA314763-01
Expression Therapeutics, LLCNIH awarded $1.13M (SBIR Phase II 2R44CA281633-02A1, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44CA281633-02A1
    Organization: EXPRESSION THERAPEUTICS; City/State: TUCKER, GA; Project number: 2R44CA281633-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1131730; Administering IC: National Cancer Institute; Project title: ADEPT-STAR therapy for high risk neuroblastoma; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44CA281633-02A1
Intus BiosciencesNIH awarded $404K (SBIR Phase II 1R44CA314644-01, new, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 1R44CA314644-01
    Organization: INTUS BIOSCIENCES LLC; City/State: FARMINGTON, CT; Project number: 1R44CA314644-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 404338; Administering IC: National Cancer Institute; Project title: Non-Invasive, Bacterial-Based Early-Onset Colorectal Screen; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 1R44CA314644-01
NextStep Robotics Inc.NIH awarded $307K (STTR Phase I 1R41AG102361-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R41AG102361-01
    Organization: NEXTSTEP ROBOTICS, LLC; City/State: BALTIMORE, MD; Project number: 1R41AG102361-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 306884; Administering IC: National Institute on Aging; Project title: A Modular Overground Balance Walkway for Task-Specific Perturbation-based Fall Prevention Assessment and Training; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R41AG102361-01
AlphaRose TherapeuticsNIH awarded $313K (SBIR Phase II 1R44HD122555-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44HD122555-01
    Organization: ALPHAROSE THERAPEUTICS INC.; City/State: Leander, TX; Project number: 1R44HD122555-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 313208; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder.; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44HD122555-01
Migra-TherapeuticsNIH awarded $315K (SBIR Phase I 1R43CA310425-01A1, new, notice Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · NIH RePORTER 1R43CA310425-01A1
    Organization: MIGRA-THERAPEUTICS, LLC; City/State: Atlanta, GA; Project number: 1R43CA310425-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 314896; Administering IC: National Cancer Institute; Project title: Development of tumor targeting and stroma penetrating toxin for pancreatic cancer treatment; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 1R43CA310425-01A1
Tiba Biotech LLCNIH awarded $397K (SBIR Phase I 1R43HL184887-01A1, new, notice Aug 3, 2026).
Evidence (1 event)
  • Aug 3, 2026 · NIH RePORTER 1R43HL184887-01A1
    Organization: TIBA BIOTECH, LLC; City/State: CAMBRIDGE, MA; Project number: 1R43HL184887-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 396805; Administering IC: National Heart Lung and Blood Institute; Project title: Lung-targeting delivery of small interfering RNA for pulmonary therapeutics; Organization type: Domestic For-Profits
Aug 3, 2026NIH RePORTER 1R43HL184887-01A1
Cascade Biocatalysts Inc.NIH awarded $307K (SBIR Phase I 1R43TR006332-01, new, notice Aug 5, 2026).
Evidence (1 event)
  • Aug 5, 2026 · NIH RePORTER 1R43TR006332-01
    Organization: CASCADE BIOCATALYSTS INC.; City/State: DENVER, CO; Project number: 1R43TR006332-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 306871; Administering IC: National Center for Advancing Translational Sciences; Project title: Immobilized Cofactor Regeneration Systems to Accelerate Enzymatic API Manufacturing; Organization type: Domestic For-Profits
Aug 5, 2026NIH RePORTER 1R43TR006332-01
Midwest Bioprocessing CenterNIH awarded $314K (SBIR Phase I 1R43GM165183-01, new, notice Aug 24, 2026); 2 NIH awards totaling $628K in the last 12 months.
Evidence (2 events)
  • Aug 24, 2026 · NIH RePORTER 1R43GM165183-01
    Organization: MIDWEST BIOPROCESSING CENTER, INC.; City/State: Peoria, IL; Project number: 1R43GM165183-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 313770; Administering IC: National Institute of General Medical Sciences; Project title: Production of Pseudaminic Acids and Their CMP-activated Derivatives; Organization type: Domestic For-Profits
  • Aug 13, 2026 · NIH RePORTER 1R43GM165201-01
    Organization: MIDWEST BIOPROCESSING CENTER, INC.; City/State: Peoria, IL; Project number: 1R43GM165201-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 313957; Administering IC: National Institute of General Medical Sciences; Project title: Chemoenzymatic Production of Bioorthogonal Carbohydrates for Glycan Research Applications; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 1R43GM165183-01
ISA Associates, Inc.NIH awarded $305K (SBIR Phase I 1R43HL186938-01, new, notice Jul 31, 2026).
Evidence (1 event)
  • Jul 31, 2026 · NIH RePORTER 1R43HL186938-01
    Organization: ISA ASSOCIATES, INC.; City/State: Arlington, VA; Project number: 1R43HL186938-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 305471; Administering IC: National Heart Lung and Blood Institute; Project title: Reducing Hypertension Among Men in Manual and Trade Labor: A Mobile Stress Management and Medication Adherence Intervention; Organization type: Domestic For-Profits
Jul 31, 2026NIH RePORTER 1R43HL186938-01
Catena BiosciencesNIH awarded $1.07M (SBIR Phase II 1R44CA314761-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44CA314761-01
    Organization: CATENA BIOSCIENCES, INC.; City/State: EL CERRITO, CA; Project number: 1R44CA314761-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1072102; Administering IC: National Cancer Institute; Project title: Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancers; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44CA314761-01
Zaiput Flow Technologies LLCNIH awarded $306K (SBIR Phase I 1R43TR006372-01, new, notice Aug 10, 2026).
Evidence (1 event)
  • Aug 10, 2026 · NIH RePORTER 1R43TR006372-01
    Organization: ZAIPUT FLOW TECHNOLOGIES LLC; City/State: Waltham, MA; Project number: 1R43TR006372-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 306301; Administering IC: National Center for Advancing Translational Sciences; Project title: Continuous, Scalable, Safe Hydrogenation for Pharmaceutical Manufacturing; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 1R43TR006372-01
Intero Biosystems Inc.NIH awarded $350K (SBIR Phase I 1R43TR006331-01, new, notice Jul 14, 2026); 2 NIH awards totaling $1.4M in the last 12 months.
Evidence (2 events)
  • Jul 14, 2026 · NIH RePORTER 1R43TR006331-01
    Organization: INTERO BIOSYSTEMS INC.; City/State: Aurora, CO; Project number: 1R43TR006331-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 349824; Administering IC: National Center for Advancing Translational Sciences; Project title: A Novel Human Intestinal Organoid Platform with Peristaltic Function for Drug Discovery and Pre-Clinical Testing in GI Motility Disorders; Organization type: Domestic For-Profits
  • Jul 7, 2026 · NIH RePORTER 2R44TR005379-02
    Organization: INTERO BIOSYSTEMS INC.; City/State: Aurora, CO; Project number: 2R44TR005379-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 1046897; Administering IC: National Center for Advancing Translational Sciences; Project title: A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing; Organization type: Domestic For-Profits
Jul 14, 2026NIH RePORTER 1R43TR006331-01
Hummingbird Precision Machine Co.NIH awarded $313K (SBIR Phase I 1R43GM165185-01, new, notice Jul 8, 2026).
Evidence (1 event)
  • Jul 8, 2026 · NIH RePORTER 1R43GM165185-01
    Organization: HUMMINGBIRD PRECISION MACHINE COMPANY; City/State: LACEY, WA; Project number: 1R43GM165185-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 313383; Administering IC: National Institute of General Medical Sciences; Project title: Integrated Mixing and Inkjet Deposition for Time Resolved Cryo-EM Sample Preparation; Organization type: Domestic For-Profits
Jul 8, 2026NIH RePORTER 1R43GM165185-01
SonALAsense, Inc.NIH awarded $497K (SBIR Phase II 5R44CA275508-03, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44CA275508-03
    Organization: SONALASENSE INC; City/State: San Carlos, CA; Project number: 5R44CA275508-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 497384; Administering IC: National Cancer Institute; Project title: Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44CA275508-03
GSNO TherapeuticsNIH awarded $303K (SBIR Phase I 1R43EY039156-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43EY039156-01
    Organization: GSNO THERAPEUTICS, INC.; City/State: SHELTON, WA; Project number: 1R43EY039156-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 303035; Administering IC: National Eye Institute; Project title: Inhibition of Optic Nerve Degeneration; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43EY039156-01
Quantum Simulation Technologies Inc.NIH awarded $1.02M (SBIR Phase II 2R44GM152994-02, competing renewal, notice Sep 1, 2026).
Evidence (1 event)
  • Sep 1, 2026 · NIH RePORTER 2R44GM152994-02
    Organization: QUANTUM SIMULATION TECHNOLOGIES, INC.; City/State: Boston, MA; Project number: 2R44GM152994-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1022908; Administering IC: National Institute of General Medical Sciences; Project title: Binding free energy predictions for peptide drugs: A novel machine learning-based peptide simulation model for high-throughput computational lead optimization with quantum mechanical accuracy.; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 2R44GM152994-02
DUB Therapeutics Inc.NIH awarded $1.01M (SBIR Phase II 5R44EY038138-02, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44EY038138-02
    Organization: DUB THERAPEUTICS INC.; City/State: SYRACUSE, NY; Project number: 5R44EY038138-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1009284; Administering IC: National Eye Institute; Project title: A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomy; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44EY038138-02
Koronis Biomedical TechnologiesNIH awarded $1.1M (SBIR Phase II 5R44DK127631-05, continuation, notice Aug 11, 2026).
Evidence (1 event)
  • Aug 11, 2026 · NIH RePORTER 5R44DK127631-05
    Organization: KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT; City/State: Minneapolis, MN; Project number: 5R44DK127631-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 1099700; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Kidney Support in Pediatric Patients using an Ultrafiltration Device; Organization type: Domestic For-Profits
Aug 11, 2026NIH RePORTER 5R44DK127631-05
AgonOx, Inc.NIH awarded $978K (SBIR Phase II 1R44CA314796-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44CA314796-01
    Organization: AGONOX, INC.; City/State: PORTLAND, OR; Project number: 1R44CA314796-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 977639; Administering IC: National Cancer Institute; Project title: Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44CA314796-01
NeuroTherapiaNIH awarded $1.21M (SBIR Phase II 1R44AG102269-01, new, notice Sep 8, 2026).
Evidence (1 event)
  • Sep 8, 2026 · NIH RePORTER 1R44AG102269-01
    Organization: NEUROTHERAPIA, INC.; City/State: CLEVELAND, OH; Project number: 1R44AG102269-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 1213723; Administering IC: National Institute on Aging; Project title: Preclinical toxicology in animals to prove the safety of a novel Alzheimer's Disease treatment; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 1R44AG102269-01
Virtus Therapeutics CorporationNIH awarded $1M (SBIR Phase II 2R44NS127740-03A1, competing renewal, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 2R44NS127740-03A1
    Organization: VIRTUS THERAPEUTICS CORPORATION; City/State: Groton, CT; Project number: 2R44NS127740-03A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 999841; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: PanK Activators for the Treatment of Pantothenate Kinase-Associated Neurodegeneration; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 2R44NS127740-03A1
Ora Biomedical, Inc.NIH awarded $300K (SBIR Phase I 1R43AG102309-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43AG102309-01
    Organization: ORA BIOMEDICAL, INC.; City/State: TUKWILA, WA; Project number: 1R43AG102309-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 299783; Administering IC: National Institute on Aging; Project title: RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biology; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG102309-01
Goeppert LLCNIH awarded $350K (SBIR Phase I 1R43TR006093-01A1, new, notice Jun 26, 2026).
Evidence (1 event)
  • Jun 26, 2026 · NIH RePORTER 1R43TR006093-01A1
    Organization: GOEPPERT, LLC; City/State: PHILADELPHIA, PA; Project number: 1R43TR006093-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 350000; Administering IC: National Center for Advancing Translational Sciences; Project title: NANO-PAVE: A Nanopore-Based Method for AAV Capsid Quality Assessment; Organization type: Domestic For-Profits
Jun 26, 2026NIH RePORTER 1R43TR006093-01A1
AnelleONIH awarded $500K (SBIR commercialization 1SB1HD120142-01A1, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1SB1HD120142-01A1
    Organization: ANELLEO, INC.; City/State: CHAPEL HILL, NC; Project number: 1SB1HD120142-01A1; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 499604; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: CRP - Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1SB1HD120142-01A1
Cansera Inc.NIH awarded $291K (STTR Phase II 1R42CA314789-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R42CA314789-01
    Organization: CANSERA, INC.; City/State: LOS ANGELES, CA; Project number: 1R42CA314789-01; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 290828; Administering IC: National Cancer Institute; Project title: CellLogic: Deep Learning Identification and Characterization of Rare Events in Fluorescent Whole Slide Imaging; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R42CA314789-01
Lucier Pharmaceuticals Inc.NIH awarded $606K (STTR Phase I 1R41HL184579-01A1, new, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 1R41HL184579-01A1
    Organization: LUCIER PHARMACEUTICALS INC; City/State: CYPRESS, TX; Project number: 1R41HL184579-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 606311; Administering IC: National Heart Lung and Blood Institute; Project title: Diagnostic and Therapeutic Potential of LU-1001 for Coronary Microvascular Dysfunction; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 1R41HL184579-01A1
Nirrin Technologies Inc.NIH awarded $1.16M (SBIR Phase II 1R44GM165281-01, new, notice Aug 10, 2026).
Evidence (1 event)
  • Aug 10, 2026 · NIH RePORTER 1R44GM165281-01
    Organization: NIRRIN TECHNOLOGIES INC; City/State: BILLERICA, MA; Project number: 1R44GM165281-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 1156172; Administering IC: National Institute of General Medical Sciences; Project title: Integration of High-Precision Tunable Laser Spectroscopy (HPTLS) into Liquid Chromatography for Quantitative Bioformulation Analysis; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 1R44GM165281-01
Diorasis TherapeuticsNIH awarded $759K (SBIR Phase II 1R44EY039191-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44EY039191-01
    Organization: DIORASIS THERAPEUTICS CORPORATION; City/State: Watertown, MA; Project number: 1R44EY039191-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 758533; Administering IC: National Eye Institute; Project title: Gene therapy to normalize intraocular pressure for the treatment of juvenile open angle glaucoma; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44EY039191-01
Virtuoso SurgicalNIH awarded $1.09M (SBIR Phase II 1R44EB038843-01A1, new, notice Sep 1, 2026).
Evidence (1 event)
  • Sep 1, 2026 · NIH RePORTER 1R44EB038843-01A1
    Organization: VIRTUOSO SURGICAL, INC.; City/State: NASHVILLE, TN; Project number: 1R44EB038843-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1094485; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: A Robot to Enable Broad Deployment of the Least Invasive Uterine Fibroid Surgical Intervention; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R44EB038843-01A1
Arsenal Medical, Inc.NIH awarded $2.24M (SBIR commercialization 1SB1AG102149-01, new, notice Sep 18, 2026).
Evidence (1 event)
  • Sep 18, 2026 · NIH RePORTER 1SB1AG102149-01
    Organization: ARSENAL MEDICAL, INC.; City/State: Waltham, MA; Project number: 1SB1AG102149-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 2238626; Administering IC: National Institute on Aging; Project title: RADIANT: A Pivotal Clinical Study of a Next-Generation Embolic for Chronic Subdural Hematoma; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 1SB1AG102149-01
Levee MedicalNIH awarded $912K (SBIR Phase II 1R44CA314945-01, new, notice Jul 29, 2026).
Evidence (1 event)
  • Jul 29, 2026 · NIH RePORTER 1R44CA314945-01
    Organization: LEVEE MEDICAL INC; City/State: RALEIGH, NC; Project number: 1R44CA314945-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 912125; Administering IC: National Cancer Institute; Project title: Novel Scaffold for Mitigating Post-Prostatectomy Urinary Incontinence; Organization type: Domestic For-Profits
Jul 29, 2026NIH RePORTER 1R44CA314945-01
Junipero Therapeutics, Inc.NIH awarded $307K (STTR Phase I 1R41NS150094-01, new, notice Sep 8, 2026).
Evidence (1 event)
  • Sep 8, 2026 · NIH RePORTER 1R41NS150094-01
    Organization: JUNIPERO THERAPEUTICS, INC.; City/State: KANNAPOLIS, NC; Project number: 1R41NS150094-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 306872; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Epigenetic Silencing of VCP via an ASO-Conjugate Based Induced Proximity System for the Treatment of FTD-ALS in VCP Disease; Organization type: Domestic For-Profits
Sep 8, 2026NIH RePORTER 1R41NS150094-01
L2 DiagnosticsNIH awarded $323K (STTR Phase I 1R41AR087258-01A1, new, notice Sep 19, 2026); 4 NIH awards totaling $1.2M in the last 12 months.
Evidence (4 events)
  • Sep 19, 2026 · NIH RePORTER 1R41AR087258-01A1
    Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 1R41AR087258-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 323090; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (CLE); Organization type: Domestic For-Profits
  • Aug 28, 2026 · NIH RePORTER 5R41AI195230-02
    Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R41AI195230-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PfAg, a multivalent peptide vaccine against malaria; Organization type: Domestic For-Profits
  • Aug 19, 2026 · NIH RePORTER 5R43AI188960-02
    Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R43AI188960-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 274710; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Point of Care Test for Babesia microti; Organization type: Domestic For-Profits
  • Aug 14, 2026 · NIH RePORTER 5R41AI195232-02
    Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R41AI195232-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 300065; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A vaccine targeting mosquito metabolic pathways to eradicate malaria; Organization type: Domestic For-Profits
Sep 19, 2026NIH RePORTER 1R41AR087258-01A1
Signature DiagnosticsNIH awarded $307K (STTR Phase I 1R41HD122600-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R41HD122600-01
    Organization: SIGNATURE DIAGNOSTICS INC; City/State: PITTSBURGH, PA; Project number: 1R41HD122600-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 306510; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Development of a Stool-Based Screening Method for the Early Detection of Necrotizing Enterocolitis in Premature Neonates; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R41HD122600-01
Alphyn BiologicsNIH awarded $1.1M (SBIR Phase II 1R44AT013899-01, new, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 1R44AT013899-01
    Organization: ALPHYN BIOLOGICS, INC.; City/State: ANNAPOLIS, MD; Project number: 1R44AT013899-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1100000; Administering IC: National Center for Complementary and Integrative Health; Project title: AB-101: A Multi-Target Botanical Hydrogel for Combating Antimicrobial Resistance in Atopic Dermatitis; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 1R44AT013899-01
Acomhal ResearchNIH awarded $400K (STTR Phase I 1R41CA306619-01A1, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R41CA306619-01A1
    Organization: ACOMHAL RESEARCH, INC.; City/State: ROANOKE, VA; Project number: 1R41CA306619-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Alphavirus vector-mediated expression of a connexin43 mimetic peptide in glioblastoma therapy; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R41CA306619-01A1
MiTeGenNIH awarded $1M (SBIR Phase II 2R44GM156169-02, competing renewal, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 2R44GM156169-02
    Organization: MITEGEN, LLC; City/State: ITHACA, NY; Project number: 2R44GM156169-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 999741; Administering IC: National Institute of General Medical Sciences; Project title: Improving cryopreservation outcomes of small biological samples through ultra-fast convective cooling and warming; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 2R44GM156169-02
ProDa BioTech, LLCNIH awarded $1.14M (SBIR Phase II 1R44CA314813-01, new, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 1R44CA314813-01
    Organization: PRODA BIOTECH, LLC; City/State: MARIETTA, GA; Project number: 1R44CA314813-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1139113; Administering IC: National Cancer Institute; Project title: Development of a new combination therapy for pancreatic ductal adenocarcinoma treatment; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 1R44CA314813-01
Artificial Axon LabsNIH awarded $1.48M (SBIR Phase II 2R44NS135867-02, competing renewal, notice Aug 6, 2026).
Evidence (1 event)
  • Aug 6, 2026 · NIH RePORTER 2R44NS135867-02
    Organization: ARTIFICIAL AXON LABS INC.; City/State: TOPSFIELD, MA; Project number: 2R44NS135867-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1478216; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: In vitro myelination assay modeling the environment of MS lesions for predictive discovery of remyelinating therapies; Organization type: Domestic For-Profits
Aug 6, 2026NIH RePORTER 2R44NS135867-02
Rejuvenation Technologies Inc.NIH awarded $1.07M (SBIR Phase II 3R44TR005328-02S1, supplement, notice Aug 5, 2026); 2 NIH awards totaling $3.13M in the last 12 months.
Evidence (2 events)
  • Aug 5, 2026 · NIH RePORTER 3R44TR005328-02S1
    Organization: REJUVENATION TECHNOLOGIES, INC.; City/State: Mountain View, CA; Project number: 3R44TR005328-02S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 1065587; Administering IC: National Center for Advancing Translational Sciences; Project title: Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic; Organization type: Domestic For-Profits
  • Jul 1, 2026 · NIH RePORTER 1SB1AA033292-01
    Organization: REJUVENATION TECHNOLOGIES, INC.; City/State: Mountain View, CA; Project number: 1SB1AA033292-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 2063303; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Advancing a telomere extension biologic to treat alcohol-associated liver damage to IND; Organization type: Domestic For-Profits
Aug 5, 2026NIH RePORTER 3R44TR005328-02S1
Micro-LeadsNIH awarded $1.49M (SBIR Phase II 1R44DC023860-01, new, notice Jul 23, 2026).
Evidence (1 event)
  • Jul 23, 2026 · NIH RePORTER 1R44DC023860-01
    Organization: MICRO-LEADS, INC.; City/State: Somerville, MA; Project number: 1R44DC023860-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 1486972; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: Closed-Loop Stimulation to Restore Voice and Swallowing by Reanimating Paralyzed Vocal Folds; Organization type: Domestic For-Profits
Jul 23, 2026NIH RePORTER 1R44DC023860-01
Inomagen TherapeuticsNIH awarded $1.41M (SBIR Phase II 1R44HL187127-01, new, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 1R44HL187127-01
    Organization: INOMAGEN THERAPEUTICS, INC; City/State: CHICAGO, IL; Project number: 1R44HL187127-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1412149; Administering IC: National Heart Lung and Blood Institute; Project title: A New and Disruptive Gene Based Therapy for Atrial Fibrillation; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 1R44HL187127-01
eXoZymesNIH awarded $1.03M (SBIR Phase II 2R44GM159516-05A1, competing renewal, notice Jun 19, 2026).
Evidence (1 event)
  • Jun 19, 2026 · NIH RePORTER 2R44GM159516-05A1
    Organization: INVIZYNE TECHNOLOGIES, INC.; City/State: Monrovia, CA; Project number: 2R44GM159516-05A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1034289; Administering IC: National Institute of General Medical Sciences; Project title: SimplePath IIB: Pre-clinical development of Cannabinoid analogs; Organization type: Domestic For-Profits
Jun 19, 2026NIH RePORTER 2R44GM159516-05A1
OpenCell TechnologiesNIH awarded $287K (SBIR Phase I 1R43CA310210-01A1, new, notice Sep 15, 2026).
Evidence (1 event)
  • Sep 15, 2026 · NIH RePORTER 1R43CA310210-01A1
    Organization: OPENCELL TECHNOLOGIES, INC.; City/State: SAINT LOUIS, MO; Project number: 1R43CA310210-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-15; FY total cost (award amount): 287125; Administering IC: National Cancer Institute; Project title: Enhancing NK Cell Engineering Through Optimized SoftPoration(TM) for Cell-Based Therapeutics; Organization type: Domestic For-Profits
Sep 15, 2026NIH RePORTER 1R43CA310210-01A1
InSight Surgical Technologies LLCNIH awarded $982K (SBIR Phase II 1R44CA314780-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44CA314780-01
    Organization: INSIGHT SURGICAL TECHNOLOGIES INC.; City/State: Lebanon, NH; Project number: 1R44CA314780-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 982300; Administering IC: National Cancer Institute; Project title: Advanced Surgical Guidance with Image Updating; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44CA314780-01
Saros Therapeutics Inc.NIH awarded $1.16M (SBIR Phase II 1R44CA306545-01A1, new, notice Sep 1, 2026).
Evidence (1 event)
  • Sep 1, 2026 · NIH RePORTER 1R44CA306545-01A1
    Organization: SAROS THERAPEUTICS INC; City/State: CHICAGO, IL; Project number: 1R44CA306545-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1164203; Administering IC: National Cancer Institute; Project title: Demonstrating safety and combination therapy potential of a novel nanoparticle delivery system; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 1R44CA306545-01A1
Blacksmith MedicinesNIH awarded $400K (SBIR Phase I 1R43CA309911-01A1, new, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 1R43CA309911-01A1
    Organization: BLACKSMITH MEDICINES, INC.; City/State: SAN DIEGO, CA; Project number: 1R43CA309911-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 399915; Administering IC: National Cancer Institute; Project title: Combination of a novel selective FEN1 metallonuclease inhibitor with Olaparib for the treatment of PARP-resistant ovarian cancers; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 1R43CA309911-01A1
Assayquant Technologies, Inc.NIH awarded $1.31M (SBIR Phase II 1R44AG102290-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44AG102290-01
    Organization: ASSAYQUANT TECHNOLOGIES, INC.; City/State: MARLBOROUGH, MA; Project number: 1R44AG102290-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1312010; Administering IC: National Institute on Aging; Project title: Selective Sensor Peptides for High-throughput, Kinetic Biomarker Assays of Kinase Activity in Neurodegeneration and Related Disorders; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG102290-01
Auritec PharmaceuticalsNIH awarded $1.03M (SBIR Phase II 1R44AG102256-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R44AG102256-01
    Organization: AURITEC PHARMACEUTICALS, INC.; City/State: PASADENA, CA; Project number: 1R44AG102256-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1029519; Administering IC: National Institute on Aging; Project title: Long-acting Injectable Brexpiprazole for Agitation in Alzheimer's Dementia; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R44AG102256-01
Matregenix Inc.NIH awarded $314K (STTR Phase I 1R41HL184685-01A1, new, notice Aug 21, 2026); 2 NIH awards totaling $1.43M in the last 12 months.
Evidence (2 events)
  • Aug 21, 2026 · NIH RePORTER 1R41HL184685-01A1
    Organization: MATREGENIX; City/State: BOSTON, MA; Project number: 1R41HL184685-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 314211; Administering IC: National Heart Lung and Blood Institute; Project title: Sustained 9-cis Retinoic Acid-Eluting Nanofiber Scaffolds for Enhanced Lymphatic Regeneration and Lymphedema Treatment; Organization type: Domestic For-Profits
  • Jun 19, 2026 · NIH RePORTER 5R44DE035026-02
    Organization: MATREGENIX; City/State: BOSTON, MA; Project number: 5R44DE035026-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1119000; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Enhancing Dental and Craniomaxillofacial Surgery Outcomes with Cost-Effective and Scalable Animal-Free Amino Acid-Based Membranes for Guided Bone Regeneration; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 1R41HL184685-01A1
Talus BioscienceNIH awarded $1.04M (SBIR Phase II 1R44TR005930-01A1, new, notice Jun 19, 2026).
Evidence (1 event)
  • Jun 19, 2026 · NIH RePORTER 1R44TR005930-01A1
    Organization: TALUS BIOSCIENCE, INC.; City/State: Seattle, WA; Project number: 1R44TR005930-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1035634; Administering IC: National Center for Advancing Translational Sciences; Project title: Deployment of an AI platform to accelerate transcription factor drug development; Organization type: Domestic For-Profits
Jun 19, 2026NIH RePORTER 1R44TR005930-01A1
OrlucentNIH awarded $1.56M (SBIR Phase II 1R44CA306680-01A1, new, notice Sep 3, 2026).
Evidence (1 event)
  • Sep 3, 2026 · NIH RePORTER 1R44CA306680-01A1
    Organization: ORLUCENT, INC.; City/State: Los Gatos, CA; Project number: 1R44CA306680-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1556529; Administering IC: National Cancer Institute; Project title: Development of Manufacturing Controls for ORL1: A Fluorescent Imaging Agent for In Vivo Molecular Imaging of Melanomas; Organization type: Domestic For-Profits
Sep 3, 2026NIH RePORTER 1R44CA306680-01A1
Xosomix LLCNIH awarded $349K (SBIR Phase I 1R43AG102280-01, new, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 1R43AG102280-01
    Organization: XOSOMIX LLC; City/State: SAN DIEGO, CA; Project number: 1R43AG102280-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 349359; Administering IC: National Institute on Aging; Project title: Extracellular Vesicle encapsulated Adeno-associated virus (EV-AAV)-mediated delivery of Neurotrophic factor-α1(NF- α1)/Carboxypeptidase E (CPE) gene (EV-AAV-CPE) as a therapy for Alzheimer's Disease.; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 1R43AG102280-01
Vizlitics Inc.NIH awarded $1.15M (SBIR Phase II 5R44CA281547-03, continuation, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 5R44CA281547-03
    Organization: VIZLITICS INC.; City/State: CHAPPAQUA, NY; Project number: 5R44CA281547-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 1145004; Administering IC: National Cancer Institute; Project title: VIPCare: Virtual Predictive Care workflow with EHR integrated surveillance for optimalfollow-up care management for Cancer Patients; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 5R44CA281547-03
MAIA BiotechnologyNIH awarded $770K (SBIR Phase II 5R44CA309843-02, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44CA309843-02
    Organization: MAIA BIOTECHNOLOGY, INC.; City/State: CHICAGO, IL; Project number: 5R44CA309843-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 770168; Administering IC: National Cancer Institute; Project title: Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44CA309843-02
Rithim Biologics Inc.NIH awarded $769K (SBIR Phase II 5R44HL172541-03, continuation, notice Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · NIH RePORTER 5R44HL172541-03
    Organization: RITHIM BIOLOGICS, INC.; City/State: WOODBINE, MD; Project number: 5R44HL172541-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 768857; Administering IC: National Heart Lung and Blood Institute; Project title: Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 5R44HL172541-03
Gradient Medical, Inc.NIH awarded $1.15M (STTR Phase II 5R42CA275587-03, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R42CA275587-03
    Organization: GRADIENT MEDICAL, INC.; City/State: Raleigh, NC; Project number: 5R42CA275587-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1150000; Administering IC: National Cancer Institute; Project title: Commercialization of Algorithmic Non-thermal Ablation Technology for the Treatment of Inoperable Tumors; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R42CA275587-03
ContralineNIH awarded $829K (SBIR Phase II 5R44HD115509-03, continuation, notice Sep 2, 2026).
Evidence (1 event)
  • Sep 2, 2026 · NIH RePORTER 5R44HD115509-03
    Organization: CONTRALINE, INC.; City/State: CHARLOTTESVILLE, VA; Project number: 5R44HD115509-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 829377; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Development of ADAM Air: A Non-Hormonal Vas Occlusive Contraceptive Device; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 5R44HD115509-03
Exhalix, LLCNIH awarded $117K (SBIR Phase I 5R43DK143762-02, continuation, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 5R43DK143762-02
    Organization: EXHALIX, LLC; City/State: Albuquerque, NM; Project number: 5R43DK143762-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 116757; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Hydrogen Sulfide Delivery Technology for Organ Preservation Therapy; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 5R43DK143762-02
Cambium Oncology LLCNIH awarded $1.05M (SBIR Phase II 5R44CA285206-03, continuation, notice Jul 17, 2026).
Evidence (1 event)
  • Jul 17, 2026 · NIH RePORTER 5R44CA285206-03
    Organization: CAMBIUM ONCOLOGY LLC; City/State: ATLANTA, GA; Project number: 5R44CA285206-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1050003; Administering IC: National Cancer Institute; Project title: Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia; Organization type: Domestic For-Profits
Jul 17, 2026NIH RePORTER 5R44CA285206-03
Amydis DiagnosticsNIH awarded $1.11M (SBIR Phase II 5R44AG078075-03, continuation, notice Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · NIH RePORTER 5R44AG078075-03
    Organization: AMYDIS DIAGNOSTICS, INC.; City/State: La Jolla, CA; Project number: 5R44AG078075-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1107817; Administering IC: National Institute on Aging; Project title: Development of a topical tracer to detect TDP43 in ALS, LATE and FTD retinas for AI-powered disease insights; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 5R44AG078075-03
Immunyx Pharma USA Inc.NIH awarded $982K (SBIR Phase II 5R44DK145292-02, continuation, notice Aug 5, 2026).
Evidence (1 event)
  • Aug 5, 2026 · NIH RePORTER 5R44DK145292-02
    Organization: IMMUNYX PHARMA USA INC.; City/State: NEW YORK, NY; Project number: 5R44DK145292-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 981715; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of IMYX-3 for the Treatment of Ulcerative Colitis; Organization type: Domestic For-Profits
Aug 5, 2026NIH RePORTER 5R44DK145292-02
Perlara PBCNIH awarded $692K (SBIR Phase II 5R44GM161192-02, continuation, notice Aug 20, 2026).
Evidence (1 event)
  • Aug 20, 2026 · NIH RePORTER 5R44GM161192-02
    Organization: PERLARA, PBC; City/State: Alameda, CA; Project number: 5R44GM161192-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 692113; Administering IC: National Institute of General Medical Sciences; Project title: REMIT (Rescue Mitochondrial Therapeutics): Unlocking Broad-Spectrum Mitochondrial Rescuers; Organization type: Domestic For-Profits
Aug 20, 2026NIH RePORTER 5R44GM161192-02
Armida Labs, Inc.NIH awarded $1.09M (SBIR Phase II 5R44CA277917-03, continuation, notice Sep 2, 2026).
Evidence (1 event)
  • Sep 2, 2026 · NIH RePORTER 5R44CA277917-03
    Organization: ARMIDA LABS, INC.; City/State: SAN DIEGO, CA; Project number: 5R44CA277917-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 1088000; Administering IC: National Cancer Institute; Project title: Targeting pancreatic cancer metastases with Targefrin; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 5R44CA277917-03
Atsena Therapeutics, Inc.NIH awarded $731K (SBIR Phase II 5R44EY037156-02, continuation, notice Sep 1, 2026); 1 role open.
Evidence (1 event)
  • Sep 1, 2026 · NIH RePORTER 5R44EY037156-02
    Organization: ATSENA THERAPEUTICS, INC.; City/State: DURHAM, NC; Project number: 5R44EY037156-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 731026; Administering IC: National Eye Institute; Project title: Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1; Organization type: Domestic For-Profits
Sep 1, 2026NIH RePORTER 5R44EY037156-02
Vesteck, Inc.NIH awarded $624K (SBIR Phase II 5R44HL178318-02, continuation, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 5R44HL178318-02
    Organization: VESTECK, INC; City/State: Malvern, PA; Project number: 5R44HL178318-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 624389; Administering IC: National Heart Lung and Blood Institute; Project title: Endovascular Suturing Device for Augmentation of Endograft Fixation During Endovascular Repair of Abdominal Aortic Aneurysm to Reduce Reinterventions Due to Endograft Migration or Type 1a Endoleak; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 5R44HL178318-02
neuro42NIH awarded $1.47M (SBIR Phase II 5U44NS136026-03, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5U44NS136026-03
    Organization: NEURO42, INC.; City/State: SAN FRANCISCO, CA; Project number: 5U44NS136026-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1465731; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Portable Intraoperative MRI for Neurosurgery; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5U44NS136026-03
OrlanceNIH awarded $1M (SBIR Phase II 4R44AI186932-02, extension, notice Aug 31, 2026); 2 NIH awards totaling $1.3M in the last 12 months.
Evidence (2 events)
  • Aug 31, 2026 · NIH RePORTER 4R44AI186932-02
    Organization: ORLANCE, INC.; City/State: SEATTLE, WA; Project number: 4R44AI186932-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens; Organization type: Domestic For-Profits
  • Aug 14, 2026 · NIH RePORTER 5R41AI195068-02
    Organization: ORLANCE, INC.; City/State: SEATTLE, WA; Project number: 5R41AI195068-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 298837; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals; Organization type: Domestic For-Profits
Aug 31, 2026NIH RePORTER 4R44AI186932-02
New Health Sciences, Inc.NIH awarded $984K (SBIR Phase II 5R44HL178006-02, continuation, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 5R44HL178006-02
    Organization: NEW HEALTH SCIENCES, INC.; City/State: Lexington, MA; Project number: 5R44HL178006-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 984232; Administering IC: National Heart Lung and Blood Institute; Project title: Efficacy of Hypoxic Red Blood Cells Processed with the Hemanext ONE® System in Patients with Sickle Cell Anemia; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R44HL178006-02
Function TherapeuticsNIH awarded $200K (SBIR Phase I 5R43NS143450-02, continuation, notice Sep 18, 2026).
Evidence (1 event)
  • Sep 18, 2026 · NIH RePORTER 5R43NS143450-02
    Organization: FUNCTION THERAPEUTICS, INC.; City/State: MILWAUKEE, WI; Project number: 5R43NS143450-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 200070; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain; Organization type: Domestic For-Profits
Sep 18, 2026NIH RePORTER 5R43NS143450-02
ImmunoBlue, LLCNIH awarded $1.11M (STTR Phase II 5R42CA287488-03, continuation, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 5R42CA287488-03
    Organization: IMMUNOBLUE, LLC; City/State: Baltimore, MD; Project number: 5R42CA287488-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1106515; Administering IC: National Cancer Institute; Project title: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 5R42CA287488-03
Nest Health Tech Inc.NIH awarded $791K (STTR Phase II 5R42HG013908-03, continuation, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 5R42HG013908-03
    Organization: NEST GENOMICS; City/State: ALBANY, CA; Project number: 5R42HG013908-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 790626; Administering IC: National Human Genome Research Institute; Project title: Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 5R42HG013908-03
Zylo TherapeuticsNIH awarded $300K (STTR Phase I 5R41AI188793-02, continuation, notice Sep 2, 2026).
Evidence (1 event)
  • Sep 2, 2026 · NIH RePORTER 5R41AI188793-02
    Organization: ZYLO THERAPEUTICS, INC.; City/State: GREENVILLE, SC; Project number: 5R41AI188793-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis; Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 5R41AI188793-02
BaebiesNIH awarded $1M (SBIR Phase II 5R44AI188680-03, continuation, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 5R44AI188680-03
    Organization: BAEBIES, INC.; City/State: DURHAM, NC; Project number: 5R44AI188680-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 5R44AI188680-03
TREKKA TherapeuticsNIH awarded $283K (STTR Phase I 5R41DE034604-02, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5R41DE034604-02
    Organization: TREKKA THERAPEUTICS, LLC; City/State: SAINT PAUL, MN; Project number: 5R41DE034604-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 283223; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Nanodroplet Infused Analgesic-Wafer for Transmucosal Opioid-free Treatment of Subacute Oral Pain; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R41DE034604-02
Rerx Therapeutics, Inc.NIH awarded $1.31M (SBIR Phase II 5R44DK142483-02, continuation, notice Jul 6, 2026).
Evidence (1 event)
  • Jul 6, 2026 · NIH RePORTER 5R44DK142483-02
    Organization: RERX THERAPEUTICS, INC; City/State: BERKELEY, CA; Project number: 5R44DK142483-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 1307195; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Evaluation of novel small molecule targeting lipid and energy homeostasis for treating obesity; Organization type: Domestic For-Profits
Jul 6, 2026NIH RePORTER 5R44DK142483-02
SPOC BiosciencesNIH awarded $815K (SBIR Phase II 5R44OD024970-04, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5R44OD024970-04
    Organization: SPOC PROTEOMICS INC.; City/State: SCOTTSDALE, AZ; Project number: 5R44OD024970-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 815054; Administering IC: NIH Office of the Director; Project title: Tools and Methods for Producing High Quality Functional Protein Microarrays for Biomarker Discovery; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R44OD024970-04
PlurexaNIH awarded $770K (STTR Phase II 5R42DK136452-03, continuation, notice Aug 20, 2026).
Evidence (1 event)
  • Aug 20, 2026 · NIH RePORTER 5R42DK136452-03
    Organization: PLUREXA LLC; City/State: Seattle, WA; Project number: 5R42DK136452-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 770372; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Targeting Myosin to Treat Polycystic Kidney Disease; Organization type: Domestic For-Profits
Aug 20, 2026NIH RePORTER 5R42DK136452-03
Gryphon Bio Inc.NIH awarded $1.25M (SBIR Phase II 5R44NS130780-03, continuation, notice Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · NIH RePORTER 5R44NS130780-03
    Organization: GRYPHON BIO, INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 5R44NS130780-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1246138; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Novel sgp130-Fc Bioconjugates for TBI; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 5R44NS130780-03
Integrated Micro-Chromatography Systems, Inc.NIH awarded $699K (STTR Phase II 4R42GM163378-02, extension, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 4R42GM163378-02
    Organization: INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC.; City/State: IRMO, SC; Project number: 4R42GM163378-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 698612; Administering IC: National Institute of General Medical Sciences; Project title: Chemoenzymatic methods and reagents to access affordable (iso)globo- and(neo)lacto-glycosphingolipids; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 4R42GM163378-02
Eclipse Regenesis, Inc.NIH awarded $861K (SBIR Phase II 5R44DK127658-05, continuation, notice Aug 21, 2026).
Evidence (1 event)
  • Aug 21, 2026 · NIH RePORTER 5R44DK127658-05
    Organization: ECLIPSE ENTEROGENESIS, INC.; City/State: MENLO PARK, CA; Project number: 5R44DK127658-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 860948; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Outcomes study for the XL1 distraction enterogenesis device to improve nutrient absorption in short bowel syndrome patients; Organization type: Domestic For-Profits
Aug 21, 2026NIH RePORTER 5R44DK127658-05
Regenerative Medical Solutions IncNIH awarded $872K (SBIR Phase II 5R44DK133008-03, continuation, notice Aug 6, 2026).
Evidence (1 event)
  • Aug 6, 2026 · NIH RePORTER 5R44DK133008-03
    Organization: REGENERATIVE MEDICAL SOLUTIONS, INC.; City/State: CHICAGO, IL; Project number: 5R44DK133008-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 872115; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells; Organization type: Domestic For-Profits
Aug 6, 2026NIH RePORTER 5R44DK133008-03
Advanced Brain MonitoringNIH awarded $365K (SBIR Phase I 5R43AG094486-02, continuation, notice Jun 25, 2026).
Evidence (1 event)
  • Jun 25, 2026 · NIH RePORTER 5R43AG094486-02
    Organization: ADVANCED BRAIN MONITORING, INC.; City/State: CARLSBAD, CA; Project number: 5R43AG094486-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 365227; Administering IC: National Institute on Aging; Project title: Characterizing neurocognitive deficits in post-acute sequelae of COVID-19; Organization type: Domestic For-Profits
Jun 25, 2026NIH RePORTER 5R43AG094486-02
Obatala SciencesNIH awarded $150K (NIH grant 5R25AG078151-05, continuation, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 5R25AG078151-05
    Organization: OBATALA SCIENCES, INC.; City/State: NEW ORLEANS, LA; Project number: 5R25AG078151-05; Activity code: R25; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 150234; Administering IC: National Institute on Aging; Project title: Getting Regenerative Medical Biotech REDI to Age; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 5R25AG078151-05
Cryocrate LLCNIH awarded $316K (NIH grant 5R33CA302632-02, continuation, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 5R33CA302632-02
    Organization: CRYOCRATE, LLC; City/State: COLUMBIA, MO; Project number: 5R33CA302632-02; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 315827; Administering IC: National Cancer Institute; Project title: Novel Biocompatible, High-Throughput Cryopreservation Medium and Method for Enhanced Post-Thaw Migration and Cytotoxicity of NK Cells; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R33CA302632-02
Novoron Bioscience Inc.NIH awarded $1.25M (SBIR Phase II 5R44AG097355-02, continuation, notice Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · NIH RePORTER 5R44AG097355-02
    Organization: NOVORON BIOSCIENCE, INC.; City/State: SAN DIEGO, CA; Project number: 5R44AG097355-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1245237; Administering IC: National Institute on Aging; Project title: Human iPSC neural spheroids to screen for compounds that block tau propagation; Organization type: Domestic For-Profits
Jun 3, 2026NIH RePORTER 5R44AG097355-02
Livivos Inc.NIH awarded $786K (SBIR Phase II 5R44DK135225-03, continuation, notice Aug 5, 2026).
Evidence (1 event)
  • Aug 5, 2026 · NIH RePORTER 5R44DK135225-03
    Organization: LIVIVOS INC.; City/State: San Diego, CA; Project number: 5R44DK135225-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 785714; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Accurate Point of Care Liver Disease Diagnostics, Phase II; Organization type: Domestic For-Profits
Aug 5, 2026NIH RePORTER 5R44DK135225-03
Radiation Monitoring Devices, Inc.NIH awarded $846K (SBIR Phase II 5R44MH135525-03, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5R44MH135525-03
    Organization: RADIATION MONITORING DEVICES, INC.; City/State: WATERTOWN, MA; Project number: 5R44MH135525-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 845777; Administering IC: National Institute of Mental Health; Project title: Ultra-dense ceramic scintillator for BrainPET scanner; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R44MH135525-03
Navigation SciencesNIH awarded $181K (STTR Phase I 5R41CA306611-02, continuation, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 5R41CA306611-02
    Organization: NAVIGATION SCIENCES, INC.; City/State: BROOKLINE, MA; Project number: 5R41CA306611-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 181271; Administering IC: National Cancer Institute; Project title: Targeted Localization and Optimized Surgical Resection for Lung Cancer; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 5R41CA306611-02
5M Biomed, LLCNIH awarded $811K (STTR Phase II 5R42AG078718-03, continuation, notice Jun 25, 2026).
Evidence (1 event)
  • Jun 25, 2026 · NIH RePORTER 5R42AG078718-03
    Organization: 5M BIOMED, LLC; City/State: JOHNS CREEK, GA; Project number: 5R42AG078718-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 811413; Administering IC: National Institute on Aging; Project title: Development of "Imagnostix": A Liquid Biopsy System for Alzheimer's Disease; Organization type: Domestic For-Profits
Jun 25, 2026NIH RePORTER 5R42AG078718-03
Bioprovar CorporationNIH awarded $349K (SBIR Phase II 5U44AG074105-03, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5U44AG074105-03
    Organization: BIOPROVAR CORPORATION; City/State: HOUSTON, TX; Project number: 5U44AG074105-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 349073; Administering IC: National Institute on Aging; Project title: An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5U44AG074105-03
LifeBio Inc.NIH awarded $1.03M (SBIR Phase II 5R44AG069566-04, continuation, notice Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · NIH RePORTER 5R44AG069566-04
    Organization: LIFEBIO INC; City/State: MARYSVILLE, OH; Project number: 5R44AG069566-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1029947; Administering IC: National Institute on Aging; Project title: LifeBio Memory: Development of a reminiscence therapy online platform with machine learning to increase engagement; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 5R44AG069566-04
Embiosys Inc.NIH awarded $870K (SBIR Phase II 5R44CA310518-02, continuation, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 5R44CA310518-02
    Organization: EMBIOSYS INC.; City/State: North Andover, MA; Project number: 5R44CA310518-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 870482; Administering IC: National Cancer Institute; Project title: CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 5R44CA310518-02
Cellsight Technologies, Inc.NIH awarded $883K (SBIR Phase II 5R44AG094397-02, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5R44AG094397-02
    Organization: CELLSIGHT TECHNOLOGIES, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44AG094397-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 882921; Administering IC: National Institute on Aging; Project title: Imaging intracerebral and systemic T cell immunity in patients with Alzheimer's disease using 18F-F-AraG; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5R44AG094397-02
ADvantage TherapeuticsNIH awarded $1.25M (SBIR Phase II 5R44AG091827-02, continuation, notice Jun 3, 2026).
Evidence (1 event)
  • Jun 3, 2026 · NIH RePORTER 5R44AG091827-02
    Organization: ADVANTAGE THERAPEUTICS, INC; City/State: MIAMI, FL; Project number: 5R44AG091827-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1249368; Administering IC: National Institute on Aging; Project title: AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies; Organization type: Domestic For-Profits
Jun 3, 2026NIH RePORTER 5R44AG091827-02
Reelin Therapeutics, Inc.NIH awarded $241K (STTR Phase I 5R41AG094356-02, continuation, notice Aug 14, 2026).
Evidence (1 event)
  • Aug 14, 2026 · NIH RePORTER 5R41AG094356-02
    Organization: REELIN THERAPEUTICS, INC.; City/State: SAN DIEGO, CA; Project number: 5R41AG094356-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 241313; Administering IC: National Institute on Aging; Project title: Identification of next generation gamma-secretase modulators for Alzheimer's disease; Organization type: Domestic For-Profits
Aug 14, 2026NIH RePORTER 5R41AG094356-02
Glycyx MOR, Inc.NIH awarded $1.05M (SBIR Phase II 5R44CA306565-02, continuation, notice Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · NIH RePORTER 5R44CA306565-02
    Organization: GLYCYX MOR, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44CA306565-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1047803; Administering IC: National Cancer Institute; Project title: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1); Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 5R44CA306565-02
QuantumBioNIH awarded $684K (SBIR Phase II 4R44GM163476-02, extension, notice Aug 20, 2026).
Evidence (1 event)
  • Aug 20, 2026 · NIH RePORTER 4R44GM163476-02
    Organization: QUANTUMBIO, INC.; City/State: State College, PA; Project number: 4R44GM163476-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 684417; Administering IC: National Institute of General Medical Sciences; Project title: Addressing Structural Disorder and Conformational Heterogeneity in Modern Therapeutic Modalities: A Unified X-ray/Cryo-EM QM/MM Ensemble Refinement Toolkit with Enhanced Density-Driven MD; Organization type: Domestic For-Profits
Aug 20, 2026NIH RePORTER 4R44GM163476-02
Evoq Therapeutics, Inc.NIH awarded $1M (SBIR Phase II 5R44AI192013-02, continuation, notice Aug 20, 2026).
Evidence (1 event)
  • Aug 20, 2026 · NIH RePORTER 5R44AI192013-02
    Organization: EVOQ THERAPEUTICS, INC.; City/State: ANN ARBOR, MI; Project number: 5R44AI192013-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: NanoDiscs for Immune Modulation in Celiac Disease; Organization type: Domestic For-Profits
Aug 20, 2026NIH RePORTER 5R44AI192013-02
EndomimeticsNIH awarded $665K (SBIR Phase II 5R44NS110114-04, continuation, notice Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · NIH RePORTER 5R44NS110114-04
    Organization: ENDOMIMETICS, LLC; City/State: BIRMINGHAM, AL; Project number: 5R44NS110114-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 665292; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Enhanced endothelialization of nanomatrix coated flow diverter for intracranial aneurysms; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 5R44NS110114-04
Cytoagents, Inc.NIH awarded $936K (SBIR Phase II 5R44CA295189-02, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44CA295189-02
    Organization: CYTOAGENTS, INC.; City/State: PITTSBURGH, PA; Project number: 5R44CA295189-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 936370; Administering IC: National Cancer Institute; Project title: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44CA295189-02
Jaan BiotherapeuticsNIH awarded $1.57M (SBIR Phase II 5R44HL180034-02, continuation, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 5R44HL180034-02
    Organization: JAAN BIOTHERAPEUTICS, INC.; City/State: SAN DIEGO, CA; Project number: 5R44HL180034-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1571571; Administering IC: National Heart Lung and Blood Institute; Project title: Heart Muscle Regeneration; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 5R44HL180034-02
Translucence Biosystems, Inc.NIH awarded $1.31M (SBIR Phase II 5R44AG090130-02, continuation, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 5R44AG090130-02
    Organization: TRANSLUCENCE BIOSYSTEMS, INC.; City/State: Irvine, CA; Project number: 5R44AG090130-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1307377; Administering IC: National Institute on Aging; Project title: Brain-Wide Quantification of Blood-Brain Barrier Penetrating Antibody Therapeutics; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 5R44AG090130-02
Artiam Bio Inc.NIH awarded $280K (STTR Phase I 5R41AG090138-02, continuation, notice Jun 19, 2026).
Evidence (1 event)
  • Jun 19, 2026 · NIH RePORTER 5R41AG090138-02
    Organization: ARTIAM BIO INC.; City/State: CARY, NC; Project number: 5R41AG090138-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 279513; Administering IC: National Institute on Aging; Project title: Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine Model; Organization type: Domestic For-Profits
Jun 19, 2026NIH RePORTER 5R41AG090138-02
NovoMedixNIH awarded $356K (SBIR Phase I 1R43HL182659-01A1, new, notice Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · NIH RePORTER 1R43HL182659-01A1
    Organization: NOVOMEDIX, INC.; City/State: SAN DIEGO, CA; Project number: 1R43HL182659-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 355963; Administering IC: National Heart Lung and Blood Institute; Project title: Novel small molecule for the prevention and treatment of DMD cardiomyopathy; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 1R43HL182659-01A1
Callahan-Young LLCNIH awarded $962K (SBIR Phase II 5R44AG079736-03, continuation, notice Jul 10, 2026).
Evidence (1 event)
  • Jul 10, 2026 · NIH RePORTER 5R44AG079736-03
    Organization: CALLAHAN-YOUNG LLC; City/State: RALEIGH, NC; Project number: 5R44AG079736-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 962046; Administering IC: National Institute on Aging; Project title: Evaluating the Health Benefits of Jigsawdio: A Novel Multisensory Jigsaw Puzzle-based Intervention for Alzheimer's Disease and Related Dementias; Organization type: Domestic For-Profits
Jul 10, 2026NIH RePORTER 5R44AG079736-03
Matrisome BioNIH awarded $1.01M (SBIR Phase II 5R44CA298532-02, continuation, notice Aug 7, 2026).
Evidence (1 event)
  • Aug 7, 2026 · NIH RePORTER 5R44CA298532-02
    Organization: MATRISOME BIO, INC.; City/State: Cambridge, MA; Project number: 5R44CA298532-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1013647; Administering IC: National Cancer Institute; Project title: Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer; Organization type: Domestic For-Profits
Aug 7, 2026NIH RePORTER 5R44CA298532-02
Rush River Research Corp.NIH awarded $991K (SBIR Phase II 5R44MD018239-03, continuation, notice May 25, 2026).
Evidence (1 event)
  • May 25, 2026 · NIH RePORTER 5R44MD018239-03
    Organization: RUSH RIVER RESEARCH CORPORATION; City/State: ELLSWORTH, WI; Project number: 5R44MD018239-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 991050; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Modernized Culturally Sensitive Family Medical History Tool; Organization type: Domestic For-Profits
May 25, 2026NIH RePORTER 5R44MD018239-03
Natsar Pharmaceuticals, Inc.NIH awarded $615K (SBIR Phase II 5R44CA295155-02, continuation, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 5R44CA295155-02
    Organization: NATSAR PHARMACEUTICALS, INC.; City/State: ELLICOTT CITY, MD; Project number: 5R44CA295155-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 615189; Administering IC: National Cancer Institute; Project title: Drug development of RK-33 for breast cancer treatment; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 5R44CA295155-02
Wavely DiagnosticsNIH awarded $992K (SBIR Phase II 5R44MD018225-04, continuation, notice Jun 9, 2026).
Evidence (1 event)
  • Jun 9, 2026 · NIH RePORTER 5R44MD018225-04
    Organization: WAVELY DIAGNOSTICS, INC.; City/State: SEATTLE, WA; Project number: 5R44MD018225-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 991676; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Improving Rural Access to Pediatric Health Care with Accurate Telehealth Diagnosis of Acute Otitis Media via Wide Scale Use of Smartphone Acoustic Reflectometry; Organization type: Domestic For-Profits
Jun 9, 2026NIH RePORTER 5R44MD018225-04
Indoor BiotechnologiesNIH awarded $717K (NIH grant 5R01AI077653-16, continuation, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 5R01AI077653-16
    Organization: INDOOR BIOTECHNOLOGIES; City/State: CHARLOTTESVILLE, VA; Project number: 5R01AI077653-16; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 716893; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Antigenic determinants of asthma-associated allergens for design of immunotherapy; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 5R01AI077653-16
Golden HelixNIH awarded $945K (SBIR Phase II 5R44HG013456-03, continuation, notice Aug 6, 2026).
Evidence (1 event)
  • Aug 6, 2026 · NIH RePORTER 5R44HG013456-03
    Organization: GOLDEN HELIX, INC.; City/State: BOZEMAN, MT; Project number: 5R44HG013456-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 945358; Administering IC: National Human Genome Research Institute; Project title: Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options; Organization type: Domestic For-Profits
Aug 6, 2026NIH RePORTER 5R44HG013456-03
Anekabio LLCNIH awarded $246K (STTR Phase I 5R41NS143585-02, continuation, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 5R41NS143585-02
    Organization: ANEKABIO LLC; City/State: GAINESVILLE, FL; Project number: 5R41NS143585-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 245560; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development and Validation of Efficacy Biomarkers for QTE Therapy in Friedreich's Ataxia; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 5R41NS143585-02
RespireRx PharmaceuticalsNIH awarded $1.5M (SBIR Phase II 5R44NS143576-02, continuation, notice Sep 14, 2026).
Evidence (1 event)
  • Sep 14, 2026 · NIH RePORTER 5R44NS143576-02
    Organization: RESPIRERX PHARMACEUTICALS INC.; City/State: GLEN ROCK, NJ; Project number: 5R44NS143576-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1499869; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 5R44NS143576-02
Nuvox Pharma, LLCNIH awarded $1.06M (SBIR Phase II 5R44CA298498-02, continuation, notice Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · NIH RePORTER 5R44CA298498-02
    Organization: NUVOX PHARMA, LLC; City/State: TUCSON, AZ; Project number: 5R44CA298498-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1057531; Administering IC: National Cancer Institute; Project title: Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 5R44CA298498-02
NeOnc TechnologiesNIH awarded $1.03M (STTR Phase II 5R42CA246902-04, continuation, notice Sep 14, 2026); 3 NIH awards totaling $2.44M in the last 12 months.
Evidence (3 events)
  • Sep 14, 2026 · NIH RePORTER 5R42CA246902-04
    Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 5R42CA246902-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1033906; Administering IC: National Cancer Institute; Project title: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas; Organization type: Domestic For-Profits
  • Jul 16, 2026 · NIH RePORTER 6R41CA271879-02
    Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 6R41CA271879-02; Activity code: R41; Fiscal year: 2025; Award notice date: 2026-07-16; FY total cost (award amount): 399998; Administering IC: National Cancer Institute; Project title: Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia; Organization type: Domestic For-Profits
  • Jul 15, 2026 · NIH RePORTER 6R42CA246902-03
    Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 6R42CA246902-03; Activity code: R42; Fiscal year: 2025; Award notice date: 2026-07-15; FY total cost (award amount): 1007612; Administering IC: National Cancer Institute; Project title: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas; Organization type: Domestic For-Profits
Sep 14, 2026NIH RePORTER 5R42CA246902-04
ShasqiNIH awarded $1.14M (SBIR Phase II 5R44CA306491-02, continuation, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 5R44CA306491-02
    Organization: SHASQI, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44CA306491-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1142054; Administering IC: National Cancer Institute; Project title: CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 5R44CA306491-02
Luminary TherapeuticsNIH awarded $587K (SBIR Phase II 5R44CA278021-03, continuation, notice Sep 10, 2026).
Evidence (1 event)
  • Sep 10, 2026 · NIH RePORTER 5R44CA278021-03
    Organization: LUMINARY THERAPEUTICS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44CA278021-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 586799; Administering IC: National Cancer Institute; Project title: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies; Organization type: Domestic For-Profits
Sep 10, 2026NIH RePORTER 5R44CA278021-03
Jericho Sciences, LLCNIH awarded $314K (STTR Phase I 5R41AI195177-02, continuation, notice Aug 11, 2026).
Evidence (1 event)
  • Aug 11, 2026 · NIH RePORTER 5R41AI195177-02
    Organization: JERICHO SCIENCES, LLC; City/State: SPRINGFIELD, VA; Project number: 5R41AI195177-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Translational Development of a Small Molecule for the Treatment of HBV Infection; Organization type: Domestic For-Profits
Aug 11, 2026NIH RePORTER 5R41AI195177-02
Seacoast Science, Inc.NIH awarded $508K (SBIR Phase II 5R44OH012498-03, continuation, notice Aug 17, 2026).
Evidence (1 event)
  • Aug 17, 2026 · NIH RePORTER 5R44OH012498-03
    Organization: SEACOAST SCIENCE, INC.; City/State: CARLSBAD, CA; Project number: 5R44OH012498-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 508352; Administering IC: National Institute for Occupational Safety and Health; Project title: Auto-calibrating, Air Quality Monitoring System; Organization type: Domestic For-Profits
Aug 17, 2026NIH RePORTER 5R44OH012498-03
Lo Biosciences, IncNIH awarded $1.02M (SBIR Phase II 5R44PS005271-03, continuation, notice Aug 13, 2026).
Evidence (1 event)
  • Aug 13, 2026 · NIH RePORTER 5R44PS005271-03
    Organization: LO BIOSCIENCES, INC.; City/State: ROCKVILLE, MD; Project number: 5R44PS005271-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1022051; Administering IC: National Center for HIVAIDS, Viral Hepatitis, STD, and TB Prevention; Project title: A novel remote blood separation device for at-home plasma collection for HIV-1 testing; Organization type: Domestic For-Profits
Aug 13, 2026NIH RePORTER 5R44PS005271-03
Mesa Science Associates, Inc.NIH awarded $866K (SBIR Phase II 5R44AI191943-02, continuation, notice Aug 10, 2026).
Evidence (1 event)
  • Aug 10, 2026 · NIH RePORTER 5R44AI191943-02
    Organization: MESA SCIENCE ASSOCIATES, INC.; City/State: FREDERICK, MD; Project number: 5R44AI191943-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 865895; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Cobinamide as a Cyanide Antidote: Completion of pre-IND Studies; Organization type: Domestic For-Profits
Aug 10, 2026NIH RePORTER 5R44AI191943-02
MyogenicaNIH awarded $701K (STTR Phase II 5R42AR083779-03, continuation, notice Jul 8, 2026).
Evidence (1 event)
  • Jul 8, 2026 · NIH RePORTER 5R42AR083779-03
    Organization: MYOGENICA INC.; City/State: SAINT PAUL, MN; Project number: 5R42AR083779-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 701471; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD; Organization type: Domestic For-Profits
Jul 8, 2026NIH RePORTER 5R42AR083779-03
DFH Pharma, IncNIH awarded $965K (SBIR Phase II 5R44AI155312-05, continuation, notice Aug 26, 2026).
Evidence (1 event)
  • Aug 26, 2026 · NIH RePORTER 5R44AI155312-05
    Organization: DFH PHARMA, INC.; City/State: GAITHERSBURG, MD; Project number: 5R44AI155312-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 965000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents; Organization type: Domestic For-Profits
Aug 26, 2026NIH RePORTER 5R44AI155312-05
Eitr Biologics, Inc.NIH awarded $1M (SBIR Phase II 5R44AI177179-03, continuation, notice Aug 27, 2026).
Evidence (1 event)
  • Aug 27, 2026 · NIH RePORTER 5R44AI177179-03
    Organization: EITR BIOLOGICS, INC.; City/State: SAN DIEGO, CA; Project number: 5R44AI177179-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure; Organization type: Domestic For-Profits
Aug 27, 2026NIH RePORTER 5R44AI177179-03
Eldec PharmaceuticalsNIH awarded $908K (STTR Phase II 4R42DK145320-02, extension, notice Aug 11, 2026).
Evidence (1 event)
  • Aug 11, 2026 · NIH RePORTER 4R42DK145320-02
    Organization: ELDEC PHARMACEUTICALS, INC.; City/State: Durham, NC; Project number: 4R42DK145320-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 907989; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel peptide therapeutics to treat cystic fibrosis-related diabetes; Organization type: Domestic For-Profits
Aug 11, 2026NIH RePORTER 4R42DK145320-02
Amplified SciencesNIH awarded $182K (NIH grant 1UH2CA318311-01, new, notice Sep 4, 2026).
Evidence (1 event)
  • Sep 4, 2026 · NIH RePORTER 1UH2CA318311-01
    Organization: AMPLIFIED SCIENCES INC; City/State: WEST LAFAYETTE, IN; Project number: 1UH2CA318311-01; Activity code: UH2; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 182018; Administering IC: National Cancer Institute; Project title: Validation of a Dysplasia Grading Assay for Precancerous Pancreatic Cystic Lesions; Organization type: Domestic For-Profits
Sep 4, 2026NIH RePORTER 1UH2CA318311-01
William D Shannon Consulting LLCNIH awarded $220K (NIH grant 1R03DA064869-01A1, new, notice Aug 18, 2026).
Evidence (1 event)
  • Aug 18, 2026 · NIH RePORTER 1R03DA064869-01A1
    Organization: WILLIAM D SHANNON CONSULTING, LLC; City/State: St Louis, MO; Project number: 1R03DA064869-01A1; Activity code: R03; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 220000; Administering IC: National Institute on Drug Abuse; Project title: Novel Statistical Methods for Analyzing fcMRI Data for Substance Use and Addiction Research; Organization type: Domestic For-Profits
Aug 18, 2026NIH RePORTER 1R03DA064869-01A1
Glytr Therapeutics, Inc.NIH awarded $1M (STTR Phase II 4R42CA302415-02, extension, notice Sep 16, 2026).
Evidence (1 event)
  • Sep 16, 2026 · NIH RePORTER 4R42CA302415-02
    Organization: GLYTR THERAPEUTICS, INC.; City/State: San Carlos, CA; Project number: 4R42CA302415-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1002331; Administering IC: National Cancer Institute; Project title: Maximizing GlyTR pan-cancer immunotherapy by enhancing target density; Organization type: Domestic For-Profits
Sep 16, 2026NIH RePORTER 4R42CA302415-02
Onconaut TherapeuticsNIH awarded $760K (STTR Phase II 4R42CA306378-02, extension, notice Aug 31, 2026).
Evidence (1 event)
  • Aug 31, 2026 · NIH RePORTER 4R42CA306378-02
    Organization: ONCONAUT THERAPEUTICS INC.; City/State: AURORA, CO; Project number: 4R42CA306378-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 760110; Administering IC: National Cancer Institute; Project title: CHD1Li Targeted Combinations with Chemotherapy to Address Unmet Needs in Colorectal Cancer Treatment; Organization type: Domestic For-Profits
Aug 31, 2026NIH RePORTER 4R42CA306378-02
Ioncologi Inc.NIH awarded $1.01M (STTR Phase II 4R42CA302331-02, extension, notice Sep 17, 2026).
Evidence (1 event)
  • Sep 17, 2026 · NIH RePORTER 4R42CA302331-02
    Organization: IONCOLOGI INC; City/State: GAINESVILLE, FL; Project number: 4R42CA302331-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1006593; Administering IC: National Cancer Institute; Project title: Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic; Organization type: Domestic For-Profits
Sep 17, 2026NIH RePORTER 4R42CA302331-02
Gigamune, Inc.NIH awarded $1M (SBIR Phase II 4R44CA310160-02, extension, notice Sep 9, 2026).
Evidence (1 event)
  • Sep 9, 2026 · NIH RePORTER 4R44CA310160-02
    Organization: GIGAMUNE, INC.; City/State: SAN FRANCISCO, CA; Project number: 4R44CA310160-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1000000; Administering IC: National Cancer Institute; Project title: A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma; Organization type: Domestic For-Profits
Sep 9, 2026NIH RePORTER 4R44CA310160-02
VeraMorph LLCNIH awarded $935K (SBIR Phase II 4R44CA306533-02, extension, notice Sep 11, 2026).
Evidence (1 event)
  • Sep 11, 2026 · NIH RePORTER 4R44CA306533-02
    Organization: VERAMORPH, LLC; City/State: NORWOOD, MA; Project number: 4R44CA306533-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 935236; Administering IC: National Cancer Institute; Project title: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer; Organization type: Domestic For-Profits
Sep 11, 2026NIH RePORTER 4R44CA306533-02
Mapp BiopharmaceuticalNIH awarded $993K (SBIR commercialization 5SB1AI191871-02, continuation, notice Aug 25, 2026).
Evidence (1 event)
  • Aug 25, 2026 · NIH RePORTER 5SB1AI191871-02
    Organization: MAPP BIOPHARMACEUTICAL, INC.; City/State: SAN DIEGO, CA; Project number: 5SB1AI191871-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 993435; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of highly potent human monoclonal for RSV immunoprophylaxis; Organization type: Domestic For-Profits
Aug 25, 2026NIH RePORTER 5SB1AI191871-02
Lectenz BioNIH awarded $1.04M (SBIR Phase II 4R44GM159548-02, extension, notice Aug 24, 2026).
Evidence (1 event)
  • Aug 24, 2026 · NIH RePORTER 4R44GM159548-02
    Organization: LECTENZ BIO, INC.; City/State: ATHENS, GA; Project number: 4R44GM159548-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1044652; Administering IC: National Institute of General Medical Sciences; Project title: Innovative glycan-specific reagents to accelerate the detection of disease biomarkers; Organization type: Domestic For-Profits
Aug 24, 2026NIH RePORTER 4R44GM159548-02
Gilgamesh PharmaNIH awarded $1.85M (NIH grant 6UG3DA060053-03, change of grantee, notice May 13, 2026).
Evidence (1 event)
  • May 13, 2026 · NIH RePORTER 6UG3DA060053-03
    Organization: GILGAMESH PHARMA INC; City/State: NEW YORK, NY; Project number: 6UG3DA060053-03; Activity code: UG3; Fiscal year: 2025; Award notice date: 2026-05-13; FY total cost (award amount): 1851123; Administering IC: National Institute on Drug Abuse; Project title: Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder; Organization type: Domestic For-Profits
May 13, 2026NIH RePORTER 6UG3DA060053-03
NeuroLuxNIH awarded $249K (SBIR Phase I 5R43MH143569-02, continuation, notice Sep 2, 2026).
Evidence (1 event)
  • Sep 2, 2026 · NIH RePORTER 5R43MH143569-02
    Organization: NEUROLUX, INC.; City/State: CHAMPAIGN, IL; Project number: 5R43MH143569-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 248550; Administering IC: National Institute of Mental Health; Project title: Development and Validation of a Compliant Reversible Actuator and Detector Leveraging Electrophysiology for Organoids (Organoid-CRADLE); Organization type: Domestic For-Profits
Sep 2, 2026NIH RePORTER 5R43MH143569-02
Oligomerix, IncNIH awarded $1.5M (SBIR Phase II 4R44AG091987-02, extension, notice Jun 16, 2026).
Evidence (1 event)
  • Jun 16, 2026 · NIH RePORTER 4R44AG091987-02
    Organization: OLIGOMERIX, INC; City/State: Bronx, NY; Project number: 4R44AG091987-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 1499525; Administering IC: National Institute on Aging; Project title: A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period; Organization type: Domestic For-Profits
Jun 16, 2026NIH RePORTER 4R44AG091987-02
Nuravax, Inc.NIH awarded $1.26M (SBIR Phase II 4R44AG091903-02, extension, notice Jul 21, 2026).
Evidence (1 event)
  • Jul 21, 2026 · NIH RePORTER 4R44AG091903-02
    Organization: NURAVAX, INC.; City/State: IRVINE, CA; Project number: 4R44AG091903-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 1257282; Administering IC: National Institute on Aging; Project title: Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers; Organization type: Domestic For-Profits
Jul 21, 2026NIH RePORTER 4R44AG091903-02
Verily Life SciencesNIH awarded $150K (NIH grant 3OT2OD037975-01S2, supplement, notice Jul 27, 2026); 83 roles open.
Evidence (1 event)
  • Jul 27, 2026 · NIH RePORTER 3OT2OD037975-01S2
    Organization: VERILY LIFE SCIENCES LLC; City/State: SOUTH SAN FRANCISCO, CA; Project number: 3OT2OD037975-01S2; Activity code: OT2; Fiscal year: 2026; Award notice date: 2026-07-27; FY total cost (award amount): 150359; Administering IC: NIH Office of the Director; Project title: SysBio FAIRplex: a FAIR PLatform for EXploration of Systems Biology; Organization type: Domestic For-Profits
Jul 27, 2026NIH RePORTER 3OT2OD037975-01S2
Oui Therapeutics, Inc.NIH awarded $967K (SBIR Phase II 4R44MH136888-03, extension, notice Jul 28, 2026).
Evidence (1 event)
  • Jul 28, 2026 · NIH RePORTER 4R44MH136888-03
    Organization: OUI THERAPEUTICS, INC; City/State: NEW HAVEN, CT; Project number: 4R44MH136888-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 966804; Administering IC: National Institute of Mental Health; Project title: Development and Evaluation of a Novel Digital Therapeutic for Adults with Post-Traumatic Stress Disorder; Organization type: Domestic For-Profits
Jul 28, 2026NIH RePORTER 4R44MH136888-03
Oleolive, Inc.NIH awarded $7K (STTR Phase I 3R41HL180136-01S1, supplement, notice Jul 22, 2026).
Evidence (1 event)
  • Jul 22, 2026 · NIH RePORTER 3R41HL180136-01S1
    Organization: OLEOLIVE, INC.; City/State: SHREVEPORT, LA; Project number: 3R41HL180136-01S1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 6500; Administering IC: National Heart Lung and Blood Institute; Project title: Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits
Jul 22, 2026NIH RePORTER 3R41HL180136-01S1
Resilient Lifescience, Inc.NIH awarded $1.02M (SBIR Phase II 4R44DA060643-02, extension, notice Aug 3, 2026).
Evidence (1 event)
  • Aug 3, 2026 · NIH RePORTER 4R44DA060643-02
    Organization: RESILIENT LIFESCIENCE, INC.; City/State: Pittsburgh, PA; Project number: 4R44DA060643-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1018701; Administering IC: National Institute on Drug Abuse; Project title: Developing a wearable medical device to detect opioid overdose; Organization type: Domestic For-Profits
Aug 3, 2026NIH RePORTER 4R44DA060643-02
PyrAmesNIH awarded $247K (NIH grant 4R33HL168741-03, extension, notice Aug 28, 2026).
Evidence (1 event)
  • Aug 28, 2026 · NIH RePORTER 4R33HL168741-03
    Organization: PYRAMES, INC.; City/State: CUPERTINO, CA; Project number: 4R33HL168741-03; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 246530; Administering IC: National Heart Lung and Blood Institute; Project title: Non-invasive, continuous blood pressure monitoring for prenatal maternal health; Organization type: Domestic For-Profits
Aug 28, 2026NIH RePORTER 4R33HL168741-03
Feedback